Doc Code: MFEE.C.AD
Document Description: Maintenance Fee Address Change

PTO/AIA/47 (11-21)
Approved for use through 11/30/2024. OMB 0651-0016
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

"FEE ADDRESS" INDICATION FORM

Address to:
Mail Stop Maintenance Fee
Director of the United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

-OR-

Fax to:
571-273-6500

INSTRUCTIONS: The issue fee must have been paid for the application(s) listed on this form. In addition, only an address represented by a Customer Number can be established as the fee address for maintenance fee purposes (hereafter, fee address). A fee address should be established when correspondence related to maintenance fees should be mailed to a different address than the correspondence address for the application.

When to check the first box below: If you have a Customer Number to represent the fee address.

When to check the second box below: If you have no Customer Number representing the desired fee address, in which case a completed Request for Customer Number (PTO/SB/125) must be attached to this form. For more information on Customer Numbers, see the Manual of Patent Examining Procedure (MPEP) § 403.

For the following listed application(s), please recognize as the "Fee Address" under the provisions of 37 CFR 1.363 the address associated with:

☑ Customer Number: 22827

OR

☐ The attached Request for Customer Number form (PTO/SB/125)

PATENT NUMBER (if known)	APPLICATION NUMBER
8,546,449	13/065,553

Completed by (check one):

☐ Applicant/Inventor

☑ Attorney or Agent of record 38,024 (Reg. No.)

☐ Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(c) (Form PTO/AIA/96) is enclosed or was filed on _____ (Date)

/Tim Cassidy/
Signature

Timothy A. Cassidy
Typed or printed name

864-271-1592
Requester's telephone number

06/08/2023
Date

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. If the assignee is a juristic entity, this form must be signed by a patent practitioner (attorney or agent) of record. Submit multiple forms if more than one signature is required, see below*.

☑ *Total of 1 forms are submitted

A Federal agency may not conduct or sponsor, and a person is not required to respond to, nor shall a person be subject to a penalty for failure to comply with an information collection subject to the requirements of the Paperwork Reduction Act of 1995, unless the information collection has a currently valid OMB Control Number. The OMB Control Number for this information collection is 0651-0016. Public burden for this form is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the information collection. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden to the Chief Administrative Officer, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 or email InformationCollection@uspto.gov. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.** SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Michael S. Harvey	Examiner:	N/A
Serial Number:	13/065,553	Group Art Unit:	1628
Filed:	04/16/2007	Customer Number:	22827
Confirmation No.:	2262	Deposit Account:	04-1403
Title:	Methods and compositions for the generation of peracetic acid on site at the point-of-use	Docket Number:	LZA-273

NOTIFICATION OF LOSS OF ENTITLEMENT TO SMALL ENTITY STATUS

U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Please be notified that the Applicant, ENVIRO TECH CHEMICAL SERVICES, INC., has lost its entitlement to small entity status for the above-captioned application.

The Office is invited and encouraged to telephone the undersigned if any issues remain after consideration of this notification.

Respectfully submitted,

DORITY & MANNING, P.A.

June 8, 2023
Date

/Tim Cassidy/
Timothy A. Cassidy
Registration Number: 38,024

Post Office Box 1449
Greenville, SC 29602
Telephone: (864) 271-1592
Facsimile: (864) 233-7342 - Fax

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on:

DATE: June 8, 2023

NAME: R. Taylor Holden

SIGNATURE: /rtaylor holden/

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
13/065,553	**06/08/2023 02:58:51 PM ET**	**8568/17669**

Title of Invention

Methods and compositions for the generation of peracetic acid on site at the point-of-use

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	8546449
CONFIRMATION #	2262	FILED BY	Taylor Holden
PATENT CENTER #	62233109	FILING DATE	03/24/2011
CUSTOMER #	–	FIRST NAMED INVENTOR	Michael S. Harvey
CORRESPONDENCE ADDRESS	AUDREY A. MILLEMANN, WEINTRAUB GENSHLEA CHEDIAK 11TH FLOOR, 400 CAPITOL MALL SACRAMENTO, CALIFORNIA 95814 UNITED STATES	AUTHORIZED BY	Tim Cassidy

Documents

TOTAL DOCUMENTS: 2

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
LZA-273_Change-of-EntityStatus_FeeAddress.PDF		2	-	361 KB
LZA-273_Change-of-EntityStatus_FeeAddress-SES.LOSS.pdf	(1-1)	1	Notification of loss of entitlement to small entity status	80 KB
LZA-273_Change-of-EntityStatus_FeeAddress-C.AD.pdf	(2-2)	1	Change of Address	247 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
LZA-273_Change-of-EntityStatus_FeeAddress.PDF	9C8D83063BC367D908D26FEC909C08FAE9B79E6E30B1F132D2C1FE7CE42150DF59D80B136F2B83C6FF9B50FE98A82A39EA29EECD11E6996F9E014F3D78BF1733
LZA-273_Change-of-EntityStatus_FeeAddress-SES.LOSS.pdf	0DC583BDB6771A3D86462124E422FE26C9D530AC8D652A7342ADD9469A8E02C59CC5B16C011D7771D433BECFE03C238E09BEFECF8B9ACF56940F03995C552456
LZA-273_Change-of-EntityStatus_FeeAddress-C.AD.pdf	B744C423B7492A4CFA8CCCA56F1E3C76A2AA3DD7BF52B81091DAA41351817A8CBA2DB1C331811A41ADFBE05D10A0042306E24749533725C894504726FC6AECF8

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
13/065,553	03/24/2011	Michael S. Harvey	8568/17669

CONFIRMATION NO. 2262

IMPROPER CPOA LETTER

AUDREY A. MILLEMANN
WEINTRAUB GENSHLEA CHEDIAK
11TH FLOOR
400 CAPITOL MALL
SACRAMENTO, CA 95814

OC000000137315040

Date Mailed: 02/06/2023

NOTICE REGARDING POWER OF ATTORNEY

This is in response to the power of attorney filed 01/24/2023. The power of attorney in this application is not accepted for the reason(s) listed below:

- The power of attorney is from an assignee and the statement required by 37 CFR 3.73(c) has not been received.

/zabraha/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

22827
DORITY & MANNING, P.A.
POST OFFICE BOX 1449
GREENVILLE, SC 29602-1449
UNITED STATES

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 005

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82A (07-13)
Approved for use through 03/31/2021. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE REGISTERED PRACTITIONERS

NOTE: This form is to be submitted with the Power of Attorney by Applicant form (PTO/AIA/82B) to identify the application to which the Power of Attorney is directed, in accordance with 37 CFR 1.5, unless the application number and filing date are identified in the Power of Attorney by Applicant form. If neither form PTO/AIA/82A nor form PTO/AIA82B identifies the application to which the Power of Attorney is directed, the Power of Attorney will not be recognized in the application.

Application Number	13/065553
Filing Date	03/24/2011
First Named Inventor	Michael S. Harvey
Title	Methods and compositions for the generation of peracetic acid on site at the point-of-use
Art Unit	1628
Examiner Name	Not Assigned
Attorney Docket Number	LZA-273 (LP3623US00)

SIGNATURE of Applicant or Patent Practitioner

Signature	/timothy a. cassidy/	Date (Optional)	
Name	Timothy A. Cassidy	Registration Number	38024
Title (if Applicant is a juristic entity)			
Applicant Name (if Applicant is a juristic entity)			

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. If more than one applicant, use multiple forms.

☑ *Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82B (07-13)
Approved for use through 03/31/2021. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY BY APPLICANT

I hereby revoke all previous powers of attorney given in the application identified in either the attached transmittal letter or the boxes below.

Application Number	Filing Date

(Note: The boxes above may be left blank if information is provided on form PTO/AIA/82A.)

☑ I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above: 22827

OR

☐ I hereby appoint Practitioner(s) named in the attached list (form PTO/AIA/82C) as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above. (Note: Complete form PTO/AIA/82C.)

Please recognize or change the correspondence address for the application identified in the attached transmittal letter or the boxes above to:

☐ The address associated with the above-mentioned Customer Number

OR

☐ The address associated with Customer Number: 22827

OR

☐ Firm or Individual Name	Dority & Manning, P.A.				
Address	PO Box 1449				
City	Greenville	State	SC	Zip	29602
Country	US				
Telephone	864-271-1592	Email	docketing@dority-manning.com		

I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):

ENVIRO TECH CHEMICAL SERVICES, INC.

☐ Inventor or Joint Inventor (title not required below)

☐ Legal Representative of a Deceased or Legally Incapacitated Inventor (title not required below)

☑ Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)

☐ Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the application or is concurrently being filed with this document) (provide signer's title if applicant is a juristic entity)

SIGNATURE of Applicant for Patent

The undersigned (whose title is supplied below) is authorized to act on behalf of the applicant (e.g., where the applicant is a juristic entity).

Signature	/Julie Gallucci/	Date (Optional)	1/19/23
Name	Julie Gallucci		
Title	President EnviroTech		

NOTE: Signature - This form must be signed by the applicant in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. If more than one applicant, use multiple forms.

☑ Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Acknowledgement Receipt

EFS ID:	47416316
Application Number:	13065553
International Application Number:	
Confirmation Number:	2262
Title of Invention:	Methods and compositions for the generation of peracetic acid on site at the point-of-use
First Named Inventor/Applicant Name:	Michael S. Harvey
Correspondence Address:	AUDREY A. MILLEMANN WEINTRAUB GENSHLEA CHEDIAK 11TH FLOOR 400 CAPITOL MALL SACRAMENTO CA 95814 US 9165586033 amillemann@weintraub.com
Filer:	Timothy A. Cassidy/Taylor Holden
Filer Authorized By:	Timothy A. Cassidy
Attorney Docket Number:	8568/17669
Receipt Date:	24-JAN-2023
Filing Date:	24-MAR-2011
Time Stamp:	10:32:24
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Power of Attorney	LZA-273_POA.PDF	381883 67b177a85e46b26df1c7bf47a8834164b7c41e96	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	381883		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/065,553	10/01/2013	8546449	8568/17669	2262

7590 09/11/2013

AUDREY A. MILLEMANN
WEINTRAUB GENSHLEA CHEDIAK
11TH FLOOR
400 CAPITOL MALL
SACRAMENTO, CA 95814

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment is 162 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

Michael S. Harvey, Modesto, CA;
Jonathan N. Howarth, Modesto, CA;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 010

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	13/065,553
Filing Date	March 24, 2011
First Named Inventor	Michael S. Harvey
Art Unit	1628
Examiner Name	Rei Tsang Shiao
Attorney Docket Number	8568/17669

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number / Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 2010/0196505 A1	08-05-2010	Kaiser	
		US- 2012/0165407 A1	06-28-2012	Gupta	
		US- 2012/0172441 A1	07-05-2012	Li	
		US- 7,919,122	~~11-29-2007~~ 04-2011	Okano et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Change(s) applied to document,
/R.M.L./
8/22/2013

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document / Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]

Examiner Signature	/Rei Tsang Shiao/	Date Considered	6/17/2013

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Exp. Mail EM 653467405 US

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OPAP MAY 16 2012 PATENT & TRADEMARK OFFICE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	13/065,553
Filing Date	March 24, 2011
First Named Inventor	Michael S. Harvey
Art Unit	4761
Examiner Name	
Attorney Docket Number	8568/17769

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 3,956,159	05-11-1976	Jones	
		US- 5,122,538	06-16-1992	Lokkesmoe, et al.	
		US- 5,977,403	11-02-1999	Byers	
		US- 6,171,551 B1	01-09-2001	Malchesky, et al.	
		US- 6,262,013 B1	07-17-2001	Smith, et al.	
		US- 6,387,236 B2	05-14-2002	Nordman, et al.	
		US- 7,012,154 B2 03	~~02-02~~-2006	Viney Ward, et al.	
		US- 7,723,083 B2	~~01-01-2009~~	DiCosimo, et al. 05-2010	
		US- 7,271,137 B2	~~05-26-2005~~	Tucker, et al. 09-2007	
		US- 2004/0245116 A1	12-09-2004	Ohsaka, et al.	
		US- 2005/0118940 A1	06-02-2005	Hilgren, et al.	
		US- ~~2007/0082832~~ A1	04-12-2007	DiCosimo, et al.	2009/0043123
		US- 2009/0175956 A1	07-09-2009	Buschmann, et al.	
		US- 2009/0043132 A1	02-12-2009	Copenhafer, et al.	
		US- 2009/0314652 A1	12-24-2009	Buschmann, et al.	
		US- 2010/0196505 A1	08-05-2010	Kaiser, et al.	
		US- 2010/0227000 A1	09-09-2010	Ames, et al.	
		US- 3,432,546	~~11-09-1964~~	Oringer, et al. 03-1969	
		US-			

Change(s) applied to document, /R.M.L./ 8/22/2013

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	1	EP 0 563 460 B1	07-01-1998	The Procter & Gamble Co.		
	2	WO 01/46519 A1	06-28-2001	Warwick International		
	3	WO 2008/140988 A1	11-20-2008	Danisco US Inc.		
	4	WO 2010/005607 A2	01-14-2010	Electron Research & Dev.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

7590 07/15/2013
AUDREY A. MILLEMANN
WEINTRAUB GENSHLEA CHEDIAK
11TH FLOOR
400 CAPITOL MALL
SACRAMENTO, CA 95814

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

Audrey A. Millemann	(Depositor's name)
/Audrey A. Millemann/	(Signature)
August 14, 2013	(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/065,553	03/24/2011	Michael S. Harvey	8568/17669	2262

TITLE OF INVENTION: Methods and compositions for the generation of peracetic acid on site at the point-of-use

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	$890	$300	$0	$1190	10/15/2013

EXAMINER	ART UNIT	CLASS-SUBCLASS
SHIAO, REI TSANG	1628	514-557000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).
☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list
(1) the names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 Audrey A. Millemann
2 Weintraub Tobin
3

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE: Enviro Tech Chemical Services, Inc.
(B) RESIDENCE: (CITY and STATE OR COUNTRY): Modesto, California

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:
☒ Issue Fee
☒ Publication Fee (No small entity discount permitted)
☐ Advance Order - # of Copies _____

4b. Payment of Fee(s): (Please first reapply any previously paid Issue fee shown above)
☐ A check is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☒ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number 501176 (enclose an extra copy of this form).

PTOL-85 (Rev. 02/11)

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 013

5. Change in Entity Status (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29

NOTE: Absent a valid certification of Micro Entity Status (see form PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

☐ Applicant asserting small entity status. See 37 CFR 1.27

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

☐ Applicant changing to regular undiscounted fee status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature /Audrey A. Millemann/ Date August 14, 2013

Typed or printed name Audrey A. Millemann Registration No. 44,942

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 014

Electronic Patent Application Fee Transmittal

Application Number:	13065553
Filing Date:	24-Mar-2011
Title of Invention:	Methods and compositions for the generation of peracetic acid on site at the point-of-use
First Named Inventor/Applicant Name:	Michael S. Harvey
Filer:	Audrey A. Millemann/Alma Martinez
Attorney Docket Number:	8568/17669

Filed as Small Entity

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Utility Appl Issue Fee	2501	1	890	890
Publ. Fee- Early, Voluntary, or Normal	1504	1	300	300

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**1190**

Electronic Acknowledgement Receipt

EFS ID:	16594464
Application Number:	13065553
International Application Number:	
Confirmation Number:	2262
Title of Invention:	Methods and compositions for the generation of peracetic acid on site at the point-of-use
First Named Inventor/Applicant Name:	Michael S. Harvey
Correspondence Address:	AUDREY A. MILLEMANN WEINTRAUB GENSHLEA CHEDIAK 11TH FLOOR 400 CAPITOL MALL SACRAMENTO CA 95814 US 9165586033 amillemann@weintraub.com
Filer:	Audrey A. Millemann/Alma Martinez
Filer Authorized By:	Audrey A. Millemann
Attorney Docket Number:	8568/17669
Receipt Date:	14-AUG-2013
Filing Date:	24-MAR-2011
Time Stamp:	20:39:45
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$1190

RAM confirmation Number	7865
Deposit Account	501176
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Issue Fee Payment (PTO-85B)	8568_17669_Fee_Transmittal.pdf	127470 271370c8522f3985b1b1b8e0562ccaafff8eb87f	no	2
Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	31552 577c00173dfa3072c771a65d6027779fbdeef491	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	159022		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

7590 07/15/2013

AUDREY A. MILLEMANN
WEINTRAUB GENSHLEA CHEDIAK
11TH FLOOR
400 CAPITOL MALL
SACRAMENTO, CA 95814

EXAMINER
SHIAO, REI TSANG

ART UNIT	PAPER NUMBER
1628	

DATE MAILED: 07/15/2013

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/065,553	03/24/2011	Michael S. Harvey	8568/17669	2262

TITLE OF INVENTION: Methods and compositions for the generation of peracetic acid on site at the point-of-use

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	$890	$300	$0	$1190	10/15/2013

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PTOL-85 (Rev. 02/11)

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 019

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

7590 07/15/2013
AUDREY A. MILLEMANN
WEINTRAUB GENSHLEA CHEDIAK
11TH FLOOR
400 CAPITOL MALL
SACRAMENTO, CA 95814

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/065,553	03/24/2011	Michael S. Harvey	8568/17669	2262

TITLE OF INVENTION: Methods and compositions for the generation of peracetic acid on site at the point-of-use

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	$890	$300	$0	$1190	10/15/2013

EXAMINER	ART UNIT	CLASS-SUBCLASS
SHIAO, REI TSANG	1628	514-557000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

❑ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

❑ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) the names of up to 3 registered patent attorneys or agents OR, alternatively,

(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1_____
2_____
3_____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ❑ Individual ❑ Corporation or other private group entity ❑ Government

4a. The following fee(s) are submitted:

❑ Issue Fee

❑ Publication Fee (No small entity discount permitted)

❑ Advance Order - # of Copies _____

4b. Payment of Fee(s): **(Please first reapply any previously paid issue fee shown above)**

❑ A check is enclosed.

❑ Payment by credit card. Form PTO-2038 is attached.

❑ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 020

5. **Change in Entity Status** (from status indicated above)

❑ Applicant certifying micro entity status. See 37 CFR 1.29	NOTE: Absent a valid certification of Micro Entity Status (see form PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
❑ Applicant asserting small entity status. See 37 CFR 1.27	NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
❑ Applicant changing to regular undiscounted fee status.	NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 021

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/065,553	03/24/2011	Michael S. Harvey	8568/17669	2262

7590 07/15/2013

AUDREY A. MILLEMANN
WEINTRAUB GENSHLEA CHEDIAK
11TH FLOOR
400 CAPITOL MALL
SACRAMENTO, CA 95814

EXAMINER	
SHIAO, REI TSANG	

ART UNIT	PAPER NUMBER
1628	

DATE MAILED: 07/15/2013

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 162 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 162 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

PTOL-85 (Rev. 02/11)

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 022

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 13/065,553	Applicant(s) HARVEY ET AL.	
	Examiner REI-TSANG SHIAO	Art Unit 1628	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to *amendment filed on 5/23/2013.*
   ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on_____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are *7-8, 10-25, 28-29, 32-33 and 39, now are 1-23.* As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov .
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

   Certified copies:

   a) ☐ All b) ☐ Some *c) ☐ None of the:
      1. ☐ Certified copies of the priority documents have been received.
      2. ☐ Certified copies of the priority documents have been received in Application No. ____ .
      3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: ____.

   Interim copies:

   a) ☐ All b) ☐ Some c) ☐ None of the: Interim copies of the priority documents have been received.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☒ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 5/23/13
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
4. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____ .
5. ☒ Examiner's Amendment/Comment
6. ☒ Examiner's Statement of Reasons for Allowance
7. ☐ Other ____.

/REI-TSANG SHIAO /
Primary Examiner, Art Unit 1628

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 024

DETAILED ACTION

1. Amendment of claims 7-8 and cancelation of claim 9 in the amendment filed on 5/23/2013 is acknowledged. Claims 1-8 and 10-91 are pending in the application.

EXAMINER'S AMENDMENT

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Audrey A. Millemann on June 17, 2013. The application has been amended as follows:

In claim 16, line 2, after "peroxide", delete "and the acetyl precursor", and insert ---triacetin--

In claim 17, line 2, after "peroxide", delete "and the acetyl precursor", and insert ---triacetin--

In claim 18, line 3, after "peroxide", delete "and the acetyl precursor", and insert ---triacetin--

In claim 19, line 1, after "wherein", delete "the acetyl precursor is triacetin"

Delete claims 1-6, 26-27, 30-31, 34-38 and 40-91.

Reasons for Allowance

3. The rejection of claims 7-8, 10-25, 28-29, 32-33 and 39 under 35 U.S.C. 112, first or second paragraph has been overcome in the amendment filed on 05/23/2013. Since claim 9 has been canceled, the reject ion of claim 9 under 35 U.S.C. 112, first or second paragraph has been obviated herein.

4. Claims 7-8, 10-25, 28-29, 32-33 and 39 are neither anticipated nor rendered obvious over the art of record, and therefore are allowable. A suggestion for modification of a reference to obtain the instant processes has not been found. Claims 7-8, 10-25, 28-29, 32-33 and 39 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance”.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rei-tsang Shiao whose telephone number is (571) 272-0707. The examiner can normally be reached on 8:30 AM - 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brandon Fetterolf, can be reached on (571)272-2919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information

for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/REI-TSANG SHIAO/

Rei-tsang Shiao, Ph.D.
Primary Examiner
Art Unit 1628

June 19, 2013

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 2262

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
13/065,553	03/24/2011 RULE	514	1628	8568/17669

APPLICANTS

Michael S. Harvey, Modesto, CA;
Jonathan N. Howarth, Modesto, CA;

** CONTINUING DATA **********

** FOREIGN APPLICATIONS **********

** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** ** SMALL ENTITY **
04/08/2011

Foreign Priority claimed	35 USC 119(a-d) conditions met	Verified and Acknowledged	Met after Allowance	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
☐ Yes ☑ No	☐ Yes ☑ No	/REI-TSANG SHIAO/ Examiner's Signature	☐ R.S. Initials	CA	1	91	11

ADDRESS

Audrey A. Millemann
Weintraub Genshlea Chediak
11th Floor
400 Capitol Mall
Sacramento, CA 95814
UNITED STATES

23

TITLE

Methods and compositions for the generation of peracetic acid on site at the point-of-use

FILING FEE RECEIVED	FEES: Authority has been given in Paper	
3271	No._____ to charge/credit DEPOSIT ACCOUNT No._____ for following:	☐ All Fees ☐ 1.16 Fees (Filing) ☐ 1.17 Fees (Processing Ext. of time) ☐ 1.18 Fees (Issue) ☐ Other _____ ☐ Credit

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	13/065,553
Filing Date	March 24, 2011
First Named Inventor	Michael S. Harvey
Art Unit	1628
Examiner Name	Rei Tsang Shiao
Attorney Docket Number	8568/17669

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number — Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 2010/0196505 A1	08-05-2010	Kaiser	
		US- 2012/0165407 A1	06-28-2012	Gupta	
		US- 2012/0172441 A1	07-05-2012	Li	
		US- 7,919,122	11-29-2007	Okano	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document — Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]

Examiner Signature	/Rei Tsang Shiao/	Date Considered	6/17/2013

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1809	(514/557).CCLS.	USPAT; USOCR	OR	OFF	2013/06/19 11:18

EAST Search History (Interference)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	6	(514/557).CCLS.	UPAD	OR	OFF	2013/06/19 11:18

6/19/2013 11:19:12 AM

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 030

Search Notes

Application/Control No.	Applicant(s)/Patent under Reexamination
13/065,553	HARVEY ET AL.
Examiner	**Art Unit**
REI-TSANG SHIAO	1628

SEARCHED			
Class	Subclass	Date	Examiner
514	557	6/19/2013	R.S.

INTERFERENCE SEARCHED			
Class	Subclass	Date	Examiner
514	**557**	**6/19/2013**	**R.S.**

SEARCH NOTES (INCLUDING SEARCH STRATEGY)		
	DATE	EXMR
EAST class/subclass	6/19/2013	R.S.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 031

Issue Classification	**Application/Control No.** 13/065,553	**Applicant(s)/Patent under Reexamination** HARVEY ET AL.
	Examiner REI-TSANG SHIAO	**Art Unit** 1628

ISSUE CLASSIFICATION

ORIGINAL		INTERNATIONAL CLASSIFICATION									
CLASS	SUBCLASS	CLAIMED					NON-CLAIMED				
514	557	A	61	K	31 /19					/	
CROSS REFERENCES											
CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)				/					/	
					/					/	
					/					/	
					/					/	
					/					/	
					/					/	

(Assistant Examiner) (Date)	/Rei-tsang Shiao/ 6/19/2013	**Total Claims Allowed: 23**
(Legal Instruments Examiner) (Date)	(Primary Examiner) (Date)	O.G. Print Claim(s): 1 / O.G. Print Fig.: NONE

☐ **Claims renumbered in the same order as presented by applicant** ☐ CPA ☐ T.D. ☐ R.1.47

Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1		31		61		91		121		151		181
	2	21	32		62		92		122		152		182
	3	22	33		63		93		123		153		183
	4		34		64		94		124		154		184
	5		35		65		95		125		155		185
	6		36		66		96		126		156		186
1	7		37		67		97		127		157		187
2	8		38		68		98		128		158		188
	9	23	39		69		99		129		159		189
3	10		40		70		100		130		160		190
4	11		41		71		101		131		161		191
5	12		42		72		102		132		162		192
6	13		43		73		103		133		163		193
7	14		44		74		104		134		164		194
8	15		45		75		105		135		165		195
9	16		46		76		106		136		166		196
10	17		47		77		107		137		167		197
11	18		48		78		108		138		168		198
12	19		49		79		109		139		169		199
13	20		50		80		110		140		170		200
14	21		51		81		111		141		171		201
15	22		52		82		112		142		172		202
16	23		53		83		113		143		173		203
17	24		54		84		114		144		174		204
18	25		55		85		115		145		175		205
	26		56		86		116		146		176		206
	27		57		87		117		147		177		207
19	28		58		88		118		148		178		208
20	29		59		89		119		149		179		209
	30		60		90		120		150		180		210

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 032

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Michael S. Harvey, et al.	)	
	)	
Serial No.: 13/065,553	)	Art Unit: 1628
	)	Examiner: Rei Tsang Shiao
Filing Date: March 24, 2011	)	
	)	
For: Methods and Compositions for the Generation of Peracetic Acid on Site at the Point-of-Use	)	
	)	

May 23, 2013
Sacramento, California 95814

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

This amendment is submitted in response to the non-final office action mailed on April 1, 2013.

Amendments to the claims begin on page 2 of this paper.

Remarks/Arguments begin on page 18 of this paper.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 033

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (withdrawn) - A hydrogen peroxide-acetyl precursor solution, comprising:

    a. aqueous hydrogen peroxide;

    b. a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide;

    c. a trace amount of peracetic acid; and

    d. water.

2. (withdrawn) - The solution of claim 1, wherein said liquid acetyl precursor is triacetin.

3. (withdrawn) - The solution of claim 2, wherein said aqueous hydrogen peroxide is about 23% to about 40% and said triacetin is about 20% to about 53%, and further wherein the mole ratio of said hydrogen peroxide to said triacetin is about 2.98:1 to about 12.84:1.

4. (withdrawn) - The solution of claim 3, wherein said aqueous hydrogen peroxide is about 27% and said triacetin is about 46%, and further wherein said mole ratio of said hydrogen peroxide to said triacetin is about 3.8:1.

5. (withdrawn) - A method of preparing a hydrogen peroxide-acetyl precursor solution, comprising:

    a. introducing a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide to a solution of aqueous hydrogen peroxide; and

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 034

b. allowing the liquid acetyl precursor and the solution of aqueous hydrogen peroxide to mix to form a hydrogen peroxide-acetyl precursor solution.

6. (withdrawn) - The composition of claim 5, wherein the liquid acetyl precursor is triacetin.

7. (Currently amended) A method of generating a non-equilibrium solution of peracetic acid, comprising:

a. providing water;

b. introducing a hydrogen peroxide-triacetin ~~acetyl precursor~~ solution to the water;

c. mixing the hydrogen peroxide-triacetin ~~acetyl precursor~~ solution and the water to form a mixture;

d. adding an aqueous source of an alkali metal or earth alkali metal hydroxide to the mixture; and

e. forming a reaction medium comprising a non-equilibrium solution of peracetic acid.

8. (Currently amended) The method of claim 7, further comprising, prior to step (b), a step of providing the hydrogen peroxide-triacetin ~~acetyl precursor~~ solution comprising: introducing triacetin ~~a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide~~ to a solution of aqueous hydrogen peroxide; and allowing the triacetin ~~liquid acetyl precursor~~ and the solution of aqueous hydrogen peroxide to mix to form the hydrogen peroxide-triacetin ~~acetyl precursor~~ solution.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 035

9. (Cancelled)

10. (original) - The method of claim 9, wherein the hydrogen peroxide-triacetin solution has a mole ratio of hydrogen peroxide to triacetin of about 2.98:1 to about 12.84:1.

11. (original) - The method of claim 7, wherein the provided water is an aqueous stream.

12. (original) - The method of claim 7, wherein the provided water is contained in a mixing tank or other vessel.

13. (original) - The method of claim 9, wherein the aqueous source of the alkali metal or earth alkali metal hydroxide is sodium hydroxide.

14. (original) - The method of claim 13, wherein the sodium hydroxide is about 1.82% to about 7.28%.

15. (original) - The method of claim 7, wherein step (d) is performed simultaneously with step (b).

16. (original) - The method of claim 7, further comprising allowing the reaction medium sufficient time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 036

17. (original) - The method of claim 16, wherein the time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid is about 30 seconds to about five minutes.

18. (original) - The method of claim 17, further comprising, after step (e), a step of sampling the reaction medium to determine the time required to maximize the amount of hydrogen peroxide and acetyl precursor that are converted into peracetic acid.

19. (original) - The method of claim 16, wherein the acetyl precursor is triacetin and the percent of triacetin that is converted into peracetic acid is about 40.9% to about 85.7%.

20. (original) - The method of claim 14, wherein the mole ratio of the sodium hydroxide to the hydrogen peroxide to the triacetin is about 4.2:3.8:1.

21. (original) - The method of claim 7, wherein steps (a) through (e) are performed on a continuous basis.

22. (original) - The method of claim 7, wherein steps (a) through (e) are performed on an intermittent basis.

23. (original) - The method of claim 7, wherein the peracetic acid solution is for immediate use.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 037

24. (original) - The method of claim 7, further comprising, after step (e), a step of adding a source of acid to stabilize the non-equilibrium solution of peracetic acid for storing and using throughout a working day.

25. (original) - The method of claim 7, wherein the peracetic acid solution is prepared on a site having a point-of-use.

26. (withdrawn) - A method of generating a non-equilibrium solution of peracetic acid for use on a site having a point-of-use of peracetic acid, comprising:

a. providing water on a site;

b. providing a hydrogen peroxide-acetyl precursor solution on the site having a point-of-use;

c. introducing the hydrogen peroxide-acetyl precursor solution to the water;

d. mixing the hydrogen peroxide-acetyl precursor solution and the water to form a mixture;

e. providing an aqueous source of an alkali metal or earth alkali metal hydroxide on the site having the point-of-use;

f. adding the aqueous source of the alkali metal or earth alkali metal hydroxide to the mixture; and

g. forming a reaction medium comprising a non-equilibrium solution of peracetic acid for use at the point-of-use of peracetic acid.

27. (withdrawn) - The method of claim 26, further comprising, prior to step (b), a step of providing the hydrogen peroxide-acetyl precursor solution comprising: introducing a liquid

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 038

acetyl precursor that is soluble in aqueous hydrogen peroxide to a solution of aqueous hydrogen peroxide; and allowing the liquid acetyl precursor and the solution of aqueous hydrogen peroxide to mix to form the hydrogen peroxide-acetyl precursor solution.

28. (original) - The method of claim 8, wherein the liquid acetyl precursor is triacetin defining a hydrogen peroxide-triacetin solution.

29. (original) - The method of claim 28, wherein the hydrogen peroxide-triacetin solution has a mole ratio of hydrogen peroxide to triacetin of about 2.98:1 to about 12.84:1.

30. (withdrawn) - The method of claim 26, wherein the provided water is an aqueous stream.

31. (withdrawn) - The method of claim 26, wherein the provided water is contained in a mixing tank or other vessel.

32. (original) - The method of claim 28, wherein the aqueous source of the alkali metal or earth alkali metal hydroxide is sodium hydroxide.

33. (original) - The method of claim 32, wherein the sodium hydroxide is about 1.82% to about 7.28%.

34. (withdrawn) - The method of claim 26, wherein step (d) is performed simultaneously with step (b).

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 039

35. (withdrawn) - The method of claim 26, further comprising allowing the reaction medium sufficient time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid.

36. (withdrawn) - The method of claim 35, wherein the time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid is about 30 seconds to about five minutes.

37. (withdrawn) - The method of claim 36, further comprising, after step (e), a step of sampling the reaction medium to determine the time required to maximize the amount of hydrogen peroxide and acetyl precursor that are converted into peracetic acid.

38. (withdrawn) - The method of claim 35, wherein the acetyl precursor is triacetin and the percent of triacetin that is converted into peracetic acid is about 40.9% to about 85.7%.

39. (original) - The method of claim 33, wherein the mole ratio of the sodium hydroxide to the hydrogen peroxide to the triacetin is about 4.2:3.8:1.

40. (withdrawn) - The method of claim 26, wherein steps (a) through (e) are performed on a continuous basis.

41. (withdrawn) - The method of claim 26, wherein steps (a) through (e) are performed on an intermittent basis.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 040

42. (withdrawn) - The method of claim 26, wherein the peracetic acid solution is for immediate use.

43. (withdrawn) - The method of claim 26, further comprising, after step (e), a step of adding a source of acid to stabilize the non-equilibrium solution of peracetic acid for storing and using throughout a working day.

44. (withdrawn) - The method of claim 26, wherein the peracetic acid solution is prepared on a site having a point-of-use.

45. (withdrawn) - A non-equilibrium solution of peracetic acid made by the method of claim 7 for use as a disinfectant or sanitizer.

46. (withdrawn) - The solution of claim 45 for clean-in-place pipeline and equipment cleaning.

47. (withdrawn) - The solution of claim 45 for use in washing fruits and vegetables.

48. (withdrawn) - The solution of claim 45 for use in the treatment of meat, poultry, and seafood.

49. (withdrawn) - A method for sanitizing a surface, which comprises generating a non-equilibrium solution of peracetic acid comprising:

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 041

peracetic acid, hydrogen peroxide, triacetin, 1,2,3-propanetriol, a source of an alkali metal or earth alkali metal hydroxide, and water.

50. (withdrawn) - A non-equilibrium solution of peracetic acid, comprising:

a. peracetic acid;

b. hydrogen peroxide;

c. triacetin;

d. 1,2,3-propanetriol;

e. an aqueous source of an alkali metal or earth alkali metal hydroxide; and

f. water.

51. (withdrawn) - The solution of claim 50, wherein said solution has a pH of about 11.2 to about 13.37.

52. (withdrawn) - The solution of claim 50, wherein said peracetic acid is about 1% to about 7.1%.

53. (withdrawn) - A method of generating a non-equilibrium solution of peracetic acid, comprising:

a. providing water;

b. introducing a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide and aqueous hydrogen peroxide to the water;

c. mixing the liquid acetyl precursor and the aqueous hydrogen peroxide with the water to form a mixture;

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 042

d. adding an aqueous source of an alkali metal or earth alkali metal hydroxide to the mixture; and

e. forming a reaction medium comprising a non-equilibrium solution of peracetic acid.

54. (withdrawn) - The method of claim 53, wherein the liquid acetyl precursor is triacetin defining a hydrogen peroxide-triacetin solution.

55. (withdrawn) - The method of claim 53, wherein the liquid acetyl precursor and the aqueous hydrogen peroxide are introduced simultaneously.

56. (withdrawn) - The method of claim 53, wherein the liquid acetyl precursor and the aqueous hydrogen peroxide are introduced sequentially with either one first.

57. (withdrawn) - The method of claim 53, wherein the provided water is an aqueous stream.

58. (withdrawn) - The method of claim 53, wherein the provided water is contained in a mixing tank or other vessel.

59. (withdrawn) - The method of claim 54, wherein the aqueous source of the alkali metal or earth alkali metal hydroxide is sodium hydroxide.

60. (withdrawn) - The method of claim 59, wherein the sodium hydroxide is about 1.82% to about 7.28%.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 043

61. (withdrawn) - The method of claim 53, wherein step (d) is performed simultaneously with step (b).

62. (withdrawn) - The method of claim 53, further comprising allowing the reaction medium sufficient time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid.

63. (withdrawn) - The method of claim 62, wherein the time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid is about 30 seconds to about five minutes.

64. (withdrawn) - The method of claim 63, wherein the acetyl precursor is triacetin and the percent of triacetin that is converted into peracetic acid is about 40.9% to about 85.7%.

65. (withdrawn) - The method of claim 60, wherein the mole ratio of the sodium hydroxide to the hydrogen peroxide to the triacetin is about 4.2:3.8:1.

66. (withdrawn) - The method of claim 53, wherein said steps (a) through (e) are performed on a continuous basis.

67. (withdrawn) - The method of claim 53, wherein said steps (a) through (e) are performed on an intermittent basis.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 044

68. (withdrawn) - A method of generating a non-equilibrium solution of peracetic acid on a site having a point-of-use, comprising:

a. providing water on a site;

b. providing a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide and aqueous hydrogen peroxide on the site having a point-of-use;

c. introducing the liquid acetyl precursor and the aqueous hydrogen peroxide to the water;

d. mixing the aqueous hydrogen peroxide and the liquid acetyl precursor with the water to form a mixture;

e. providing an aqueous source of an alkali metal or earth alkali metal hydroxide water on the site having the point-of-use;

f. adding the aqueous source of the alkali metal or earth alkali metal hydroxide to the mixture; and

g. forming a reaction medium comprising a non-equilibrium solution of peracetic acid for use at the point-of-use.

69. (withdrawn) - The method of claim 68, wherein the liquid acetyl precursor is triacetin.

70. (withdrawn) - The method of claim 68, wherein the aqueous source of the alkali metal or earth alkali metal hydroxide is sodium hydroxide.

71. (withdrawn) - The method of claim 70, wherein the sodium hydroxide is about 1.82% to about 7.28%.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 045

72. (withdrawn) - The method of claim 68, further comprising allowing the reaction medium sufficient time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid.

73. (withdrawn) - The method of claim 72, wherein the time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid is about 30 seconds to about five minutes.

74. (withdrawn) - The method of claim 68, further comprising, after step (g), a step of sampling the reaction medium to determine the time required to maximize the amount of hydrogen peroxide and acetyl precursor that are converted into peracetic acid.

75. (withdrawn) - The method of claim 72, wherein the acetyl precursor is triacetin and the percent of triacetin that is converted into peracetic acid is about 40.9% to about 85.7%.

76. (withdrawn) - The method of claim 71, wherein the mole ratio of the sodium hydroxide to the hydrogen peroxide to the triacetin is about 4.2:3.8:1.

77. (withdrawn) - An on site non-equilibrium peracetic acid generation system, comprising:

a first container comprising a first solution wherein said first solution comprises:

aqueous hydrogen peroxide;

a liquid acetyl precursor that is soluble in said aqueous hydrogen peroxide;

a trace amount of peracetic acid; and

water;

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 046

a second container comprising a second solution wherein said second solution comprises:

an aqueous source of an alkali metal or earth alkali metal hydroxide; and

means for mixing the first solution, water, and the second solution to generate a non-equilibrium peracetic acid solution.

78. (withdrawn) - A freely-flowable solid composition, comprising:

a. a liquid acetyl precursor;

b. a water-soluble solid source of hydrogen peroxide; and

c. a water-soluble solid source of alkalinity.

79. (withdrawn) - The composition of claim 78, wherein said liquid acetyl precursor is triacetin.

80. (withdrawn) - The composition of claim 79, wherein said triacetin is about 0.99% to about 8.45%.

81. (withdrawn) - The composition of claim 78, wherein said solid source of hydrogen peroxide is sodium percarbonate and is about 13% to about 54% of the total.

82. (withdrawn) - The composition of claim 78, wherein said solid source of alkalinity is about 24% to about 44% of the total.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 047

83. (withdrawn) - A method of making a solid composition for bleaching and stain removal, comprising:

forming a homogenous freely-flowable solid by blending a liquid acetyl precursor, a water-soluble solid source of hydrogen peroxide, and a water-soluble solid source of alkalinity.

84. (withdrawn) - The method of claim 83, wherein the liquid acetyl precursor is triacetin.

85. (withdrawn) - The method of claim 84, wherein the triacetin is about 0.99% to about 8.45%.

86. (withdrawn) - The method of claim 83, wherein the solid source of hydrogen peroxide is about 13% to about 54%.

87. (withdrawn) - The composition of claim 83, wherein the solid source of alkalinity is about 24% to about 44% of the total.

88. (withdrawn) - The method of claim 83, further comprising adding a metal chelating agent.

89. (withdrawn) - The method of claim 83, further comprising adding a surfactant.

90. (withdrawn) - The method of claim 83, further comprising adding a compound to sequester water hardness.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 048

91. (withdrawn) - The method of claim 83, further comprising adding an inert solid filler.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 049

Remarks/Arguments

Applicants respectfully traverse the rejections in the Office Action and request reconsideration.

I. Rejection Under 35 U.S.C. Section 112, First and Second Paragraphs

The Examiner has rejected claims 7-25, 28-29, 32, 33, and 39 under 35 U.S.C. section 112, first and second paragraphs, as not enabled and indefinite, respectively, in the use of the phrase "acetyl precursor." The Examiner has suggested that Applicants amend independent claim 7 to replace "acetyl precursor" with "triacetin" as claimed in dependent claim 9.

Applicants appreciate the Examiner's suggestion and have amended claim 7, as well as dependent claim 8, to replace "acetyl precursor" with "triacetin." Applicants have cancelled claim 9. Thus, all of the claims under examination include the limitation of triacetin. Applicants request that the rejections under section 112 be withdrawn.

Date: May 23, 2013

Respectfully submitted,

By: /Audrey A. Millemann/
Audrey A. Millemann (Reg. No. 44,942)
Attorney for Applicants
Weintraub Tobin Chediak Coleman Grodin
400 Capitol Mall, 11th floor
Sacramento, CA 95814
(916) 558-6033

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 050

Electronic Patent Application Fee Transmittal

Application Number:	13065553
Filing Date:	24-Mar-2011
Title of Invention:	Methods and compositions for the generation of peracetic acid on site at the point-of-use
First Named Inventor/Applicant Name:	Michael S. Harvey
Filer:	Audrey A. Millemann/Alma Martinez
Attorney Docket Number:	8568/17669

Filed as Small Entity

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
Submission- Information Disclosure Stmt	2806	1	90	90
		Total in USD ($)		**90**

Electronic Acknowledgement Receipt

EFS ID:	15860971
Application Number:	13065553
International Application Number:	
Confirmation Number:	2262
Title of Invention:	Methods and compositions for the generation of peracetic acid on site at the point-of-use
First Named Inventor/Applicant Name:	Michael S. Harvey
Correspondence Address:	Audrey A. Millemann Weintraub Genshlea Chediak 11th Floor 400 Capitol Mall Sacramento CA 95814 US 9165586033 amillemann@weintraub.com
Filer:	Audrey A. Millemann/Alma Martinez
Filer Authorized By:	Audrey A. Millemann
Attorney Docket Number:	8568/17669
Receipt Date:	23-MAY-2013
Filing Date:	24-MAR-2011
Time Stamp:	21:48:16
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$90

RAM confirmation Number	6869
Deposit Account	501176
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	8568_17669_Supplemental_IDS.pdf	58609 e3e77803f8cb0ca01ab1ab14975a35b80167e6ba	no	2
Warnings:					
Information:					
2	Information Disclosure Statement (IDS) Form (SB08)	8568_17669_Form1449.pdf	78266 3585baad2d1a4baa9a313baf8d848e0885b5ab2a3	no	1
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	Amendment/Req. Reconsideration-After Non-Final Reject	8568_17669_Amendment.pdf	517402 58624a9d3b25657a34dc0cccfde04e3d92e44b6e	no	18
Warnings:					
Information:					
4	Fee Worksheet (SB06)	fee-info.pdf	29872 176cde9ae7f748f1701cc93aa1f2b19c572699c8	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	684149		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Michael S. Harvey, et al.	)	
		)	
Serial No.:	13/065,553	)	Art Unit: 1628
		)	Examiner: Rei Tsang Shiao
Filing Date:	March 24, 2011	)	
		)	
For:	Methods and Compositions for the Generation of Peracetic Acid on Site at the Point-of-Use	)	

May 23, 2013
Sacramento, California 95814

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to Rules 1.97 and 1.98, Applicants submit herewith copies of patents, publications, or other information of which Applicants are aware, as listed on the accompanying Form 1449, which Applicants believe may be material to the examination of this application and with respect to which there may be a duty to disclose.

The filing of this supplemental information disclosure statement and accompanying Form 1449 shall not be construed as a representation that a search has been made (37 C.F.R. 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this supplemental information disclosure statement and accompanying Form 1449 shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 056

Date: May 23, 2013

Respectfully submitted,

By: /Audrey A. Millemann/
Audrey A. Millemann (Reg. No. 44,942)
Attorney for Applicants
Weintraub Tobin Chediak Coleman Grodin
400 Capitol Mall, 11th floor
Sacramento, CA 95814
(916) 558-6033

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 057

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	13/065,553
Filing Date	March 24, 2011
First Named Inventor	Michael S. Harvey
Art Unit	1628
Examiner Name	Rei Tsang Shiao
Attorney Docket Number	8568/17669

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 2010/0196505 A1	08-05-2010	Kaiser	
		US- 2012/0165407 A1	06-28-2012	Gupta	
		US- 2012/0172441 A1	07-05-2012	Li	
		US- 7,919,122	11-29-2007	Okano	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/06 (07-06)
Approved for use through 1/31/2007. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number	Filing Date	☐ To be Mailed
13/065,553	03/24/2011	

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY ☒ RATE ($)	SMALL ENTITY ☒ FEE ($)	OR	OTHER THAN SMALL ENTITY RATE ($)	OTHER THAN SMALL ENTITY FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A			N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	x $ =		OR	x $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	x $ =			x $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $250 ($125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT 05/23/2013

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE ($)	SMALL ENTITY ADDITIONAL FEE ($)	OR	OTHER THAN SMALL ENTITY RATE ($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	* 88	Minus	** 91	= 0	x $40 =	0	OR	x $ =	
Independent (37 CFR 1.16(h))	* 10	Minus	***11	= 0	x $210 =	0	OR	x $ =	
☐ Application Size Fee (37 CFR 1.16(s))									
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
					TOTAL ADD'L FEE	0	OR	TOTAL ADD'L FEE	

AMENDMENT

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)		RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	*	Minus	**	=	x $ =		OR	x $ =	
Independent (37 CFR 1.16(h))	*	Minus	***	=	x $ =		OR	x $ =	
☐ Application Size Fee (37 CFR 1.16(s))									
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
					TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

Legal Instrument Examiner:
/POLIN ANG/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/065,553	03/24/2011	Michael S. Harvey	8568/17669	2262

7590 04/01/2013

Audrey A. Millemann
Weintraub Genshlea Chediak
11th Floor
400 Capitol Mall
Sacramento, CA 95814

EXAMINER	
SHIAO, REI TSANG	
ART UNIT	PAPER NUMBER
1628	

MAIL DATE	DELIVERY MODE
04/01/2013	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 060

Office Action Summary	Application No.	Applicant(s)	
	13/065,553	HARVEY ET AL.	
	Examiner	Art Unit	
	REI-TSANG SHIAO	1628	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *3* MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *14 February 2013*.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

5)☒ Claim(s) *1-91* is/are pending in the application.

5a) Of the above claim(s) *1-6, 26-27, 30-31, 34-38, and 40-91* is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☒ Claim(s) *7-25,28,29,32,33 and 39* is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☐ Claim(s) _____ are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☒ The drawing(s) filed on *3/24/2011* is/are: a)☒ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)

2) ☒ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date *5/10/12*.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .

4) ☐ Other: _____.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 061

DETAILED ACTION

1. Applicant's remarks filed on February 14, 2013 are acknowledged. Claims 1-91 are pending in the application.

Responses to Election/Restriction

2. Applicant's election without arguments of Group III claim 7-25, 28-29, 32-33 and 39, in the reply filed on February 14, 2013 is acknowledged. Election of a compound triacetin of the acetyl precursor as the single species is also acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claims 1-91 are pending in the application. The scope of the invention of the elected subject matter is as follows.

Claim 7-25, 28-29, 32-33 and 39 are drawn to processes of making, and prosecuted in the case. Claims 1-6, 26-27, 30-31, 34-38, and 40-91 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention.

The requirement is still deemed proper and therefore is made FINAL.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 7-25, 28-29, 32-33 and 39 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the acetyl precursor represents triacetin, does not reasonably provide enablement for the acetyl precursor without limitation, see claim 7. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims. Dependent claims 8-25, 28-29, 32-33 and 39 are also rejected along with claim 7 under 35 U.S.C. 112, first paragraph.

In *In re Wands*, 8 USPQ2d 1400 (1988), factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described. They are:

1. the nature of the invention,
2. the state of the prior art,
3. the predictability or lack thereof in the art,
4. the amount of direction or guidance present,
5. the presence or absence of working examples,
6. the breadth of the claims,
7. the quantity of experimentation needed, and
8. the level of the skill in the art.

In the instant case:

The nature of the invention

The nature of the invention of claims 7-25, 28-29, 32-33 and 39 is drawn to processes of making peracetic acid solution, wherein the acetyl precursor is without limitation (i.e., no named compounds), see claim 7.

The state of the prior art and the predictability or lack thereof in the art

The state of the prior art is DiCosimo et al. US 2007/0082832. DiCosimo et al. '832 discloses a similar process for preparing peracetic acid solution, see column 27.

The amount of direction or guidance present and the presence or absence of working examples

The only direction or guidance present in the instant specification is the acetyl precursor representing triacetin, see pages 9-10 of the specification. There are no working examples present for "acetyl precursor" without limitation (i.e., no named compounds)" of the instant invention found in the specification.

The breadth of the claims

The breadth of the claims is the instant processes comprising any "acetyl precursor" without limitation (i.e., no named compounds).

The quantity of experimentation needed

The quantity of experimentation needed is undue experimentation. One of skill in the art would need to determine what “acetyl precursor” without limitation (i.e., no named compounds) would be used by the instant invention, if any.

The level of the skill in the art

The level of skill in the art is high. However, due to the unpredictability in the pharmaceutical art, it is noted that each embodiment of the invention is required to be individually assessed for physical characteristics to determine which acetyl precursor are used. Thus, the specification fails to provide sufficient support of the broad scope of the compounds of the instant claims for the “acetyl precursor”.

As a result necessitating one of skill to perform an exhaustive search for which “acetyl precursor”, can be prepared of the instant claims in order to practice the claimed invention. Thus, factors such as "sufficient working examples", "the level of skill in the art" and "predictability", etc. have been demonstrated to be sufficiently lacking in the instantly claimed compounds. In view of the breadth of the claim, the chemical nature of the invention, and the lack of working examples regarding the activity of the claimed “acetyl precursor” without limitation, one having ordinary skill in the art would have to undergo an undue amount of experimentation to use the invention commensurate in scope with the claims.

Genentech Inc. v. Novo Nordisk A/S (CA FC) 42 USPQ2d 1001, states that “ a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion'' and ''patent protection is granted in return for an enabling

disclosure of an invention, not for vague intimations of general ideas that may or may not be workable".

Therefore, in view of the Wands factors and *In re Fisher* (CCPA 1970) discussed above, to practice the claimed invention herein, a person of skill in the art would have to engage in undue experimentation, with no assurance of success. This rejection can be overcome by incorporation of the limitation “acetyl precursor” into claim 7 (i.e., see claim 9) respectively would obviate the rejection.

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

> The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 7-25, 28-29, 32-33 and 39 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 7 recites the limitation “acetyl precursor” without named specific compounds is indefinite and ambiguous, i.e., see line 3. It is unclear what the scope of “acetyl precursor” is. The “acetyl precursor” is from any organic compounds having multiple functionality. Such breath in view of the limited exemplification and the lack of scope of subject matter resulted from a search of the prior art indicated that the “scope” of claim 7 cannot be ascertained. In view of the high degree of unpredictability of the chemical art and “acetyl precursor” must be made available at the time the invention was made, i.e., filing of application, the broad scope cannot be supplemented with future discovery of new “acetyl precursor”. It is recommended that “acetyl precursor” be limited to the specific disclosure in the specification, i.e., triacetin of claim 9. Dependent

claims 8-25, 28-29, 32-33 and 39 are also rejected along with claim 7 under 35 U.S.C. 112, second paragraph.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rei-tsang Shiao whose telephone number is (571) 272-0707. The examiner can normally be reached on 8:30 AM - 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brandon Fetterolf, can be reached on (571)272-2919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/REI-TSANG SHIAO/

Rei-tsang Shiao, Ph.D.
Primary Examiner, Art Unit 1628

March 14, 2013

Notice of References Cited	Application/Control No. 13/065,553	Applicant(s)/Patent Under Reexamination HARVEY ET AL.	
	Examiner REI-TSANG SHIAO	Art Unit 1628	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2007/0082832	04-2007	DiCosimo et al.	510/305
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 069

Search Notes

Application/Control No.	Applicant(s)/Patent under Reexamination
13/065,553	HARVEY ET AL.
Examiner	**Art Unit**
REI-TSANG SHIAO	1628

SEARCHED			
Class	Subclass	Date	Examiner
514	557	3/14/2013	R.S.

INTERFERENCE SEARCHED			
Class	Subclass	Date	Examiner

SEARCH NOTES (INCLUDING SEARCH STRATEGY)		
	DATE	EXMR
STN, structure, inventor names	3/4/2013	R.S.
EAST class/subclass	3/14/2013	R.S.
PALM inventor names	3/14/2013	R.S.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 070

Exp. Mail EM 653467405 US

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OPAP MAY 18 2012 PATENT & TRADEMARK OFFICE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	13/065,553
Filing Date	March 24, 2011
First Named Inventor	Michael S. Harvey
Art Unit	1761
Examiner Name	
Attorney Docket Number	8568/17769

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 3,956,159	05-11-1976	Jones	
		US- 5,122,538	06-16-1992	Lokkesmoe, et al.	
		US- 5,977,403	11-02-1999	Byers	
		US- 6,171,551 B1	01-09-2001	Malchesky, et al.	
		US- 6,262,013 B1	07-17-2001	Smith, et al.	
		US- 6,387,236 B2	05-14-2002	Nordman, et al.	
		US- 7,012,154 B2	02-02-2006	Vineyward, et al.	
		US- 7,723,083 B2	01-01-2009	DiCosimo, et al.	
		US- 7,271,137 B2	05-26-2005	Tucker, et al.	
		US- 2004/0245116 A1	12-09-2004	Ohsaka, et al.	
		US- 2005/0118940 A1	06-02-2005	Hilgren, et al.	
		US- 2007/0082832 A1	04-12-2007	DiCosimo, et al.	
		US- 2009/0175956 A1	07-09-2009	Buschmann, et al.	
		US- 2009/0043132 A1	02-12-2009	Copenhafer, et al.	
		US- 2009/0314652 A1	12-24-2009	Buschmann, et al.	
		US- 2010/0196505 A1	08-05-2010	Kaiser, et al.	
		US- 2010/0227000 A1	09-09-2010	Ames, et al.	
		US- 3,432,546	11-03-1964	Oringer, et al.	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	1	EP 0 563 460 B1	07-01-1998	The Procter & Gamble Co.		
	2	WO 01/46519 A1	06-28-2001	Warwick International		
	3	WO 2008/140988 A1	11-20-2008	Danisco US Inc.		
	4	WO 2010/005607 A2	01-14-2010	Electron Research & Dev.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	13/065,553
Filing Date	March 24, 2011
First Named Inventor	Michael S. Harvey
Art Unit	~~4761~~ 1628
Examiner Name	R.T. Shiao
Attorney Docket Number	8568/17669

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	1	LEVENEUR, et al., "Interaction of Instrinsic Kinetics and Internal Mass...Acids," Chemical Engineering Science 64 (2009) pp.4101-4114	
	2	ROCHA, et al., "Rates of Formation of Peroxyacetic...Phosphates," Journal of Molecular Catalysis A: Chemical 186 (2002) pp. 127-133	
	3	CLARIANT CORP.,technical bulletin, "Peractive -The Clean and Clever Way of Bleaching," August 1999	
	4	MILNE, "Oxygen Bleaching Systems in Domestic Laundry," Journal of Surfactants and Detergents, Vol.1, No. 2 (April 1998) pp. 253-261	
	5	SAHA, et al., "Synthesis of Peroxyacetic Acid Using In Situ...Electrode," Electrochemistry Communications 5 (2003) pp.445-448	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	3/14/2013

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L6	3193	(514/557).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2013/03/14 15:54

EAST Search History (Interference)

< This search history is empty>

3/14/2013 3:54:37 PM
C:\Users\rshiao\Documents\EAST\Workspaces\default.wsp

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 073

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 2262

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
13/065,553	03/24/2011 RULE	514	1628	8568/17669

APPLICANTS

Michael S. Harvey, Modesto, CA;
Jonathan N. Howarth, Modesto, CA;

** CONTINUING DATA **********

** FOREIGN APPLICATIONS **********

** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** ** SMALL ENTITY **
04/08/2011

Foreign Priority claimed	35 USC 119(a-d) conditions met	Verified and Acknowledged	Met after Allowance	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
☐ Yes ☑ No	☐ Yes ☑ No	/REI-TSANG SHIAO/ Examiner's Signature	☐ R.S. Initials	CA	1	91	11

ADDRESS

Audrey A. Millemann
Weintraub Genshlea Chediak
11th Floor
400 Capitol Mall
Sacramento, CA 95814
UNITED STATES

TITLE

Methods and compositions for the generation of peracetic acid on site at the point-of-use

FILING FEE RECEIVED	FEES: Authority has been given in Paper	
3271	No._____ to charge/credit DEPOSIT ACCOUNT No._____ for following:	☐ All Fees ☐ 1.16 Fees (Filing) ☐ 1.17 Fees (Processing Ext. of time) ☐ 1.18 Fees (Issue) ☐ Other _____ ☐ Credit

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 074

Index of Claims

Application/Control No.	Applicant(s)/Patent under Reexamination
13/065,553	HARVEY ET AL.
Examiner	**Art Unit**
REI-TSANG SHIAO	1628

√	Rejected	–	(Through numeral) Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

Claim		Date
Final	Original	3/14/13
	1	N
	2	N
	3	N
	4	N
	5	N
	6	N
	7	√
	8	√
	9	√
	10	√
	11	√
	12	√
	13	√
	14	√
	15	√
	16	√
	17	√
	18	√
	19	√
	20	√
	21	√
	22	√
	23	√
	24	√
	25	√
	26	N
	27	N
	28	√
	29	√
	30	N
	31	N
	32	√
	33	√
	34	N
	35	N
	36	N
	37	N
	38	N
	39	√
	40	N
	41	N
	42	N
	43	N
	44	N
	45	N
	46	N
	47	N
	48	N
	49	N
	50	N

Claim		Date
Final	Original	3/14/13
	51	N
	52	N
	53	N
	54	N
	55	N
	56	N
	57	N
	58	N
	59	N
	60	N
	61	N
	62	N
	63	N
	64	N
	65	N
	66	N
	67	N
	68	N
	69	N
	70	N
	71	N
	72	N
	73	N
	74	N
	75	N
	76	N
	77	N
	78	N
	79	N
	80	N
	81	N
	82	N
	83	N
	84	N
	85	N
	86	N
	87	N
	88	N
	89	N
	90	N
	91	N
	92	
	93	
	94	
	95	
	96	
	97	
	98	
	99	
	100	

Claim		Date
Final	Original	
	101	
	102	
	103	
	104	
	105	
	106	
	107	
	108	
	109	
	110	
	111	
	112	
	113	
	114	
	115	
	116	
	117	
	118	
	119	
	120	
	121	
	122	
	123	
	124	
	125	
	126	
	127	
	128	
	129	
	130	
	131	
	132	
	133	
	134	
	135	
	136	
	137	
	138	
	139	
	140	
	141	
	142	
	143	
	144	
	145	
	146	
	147	
	148	
	149	
	150	

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 075

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Michael S. Harvey, et al.	)	
		)	
Serial No.:	13/065,553	)	Art Unit: 1628
		)	Examiner: Rei Tsang Shiao
Filing Date:	March 24, 2011	)	
		)	
For:	Methods and Compositions for the Generation of Peracetic Acid on Site at the Point-of-Use	)	

February 14, 2013
Sacramento, California 95814

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This response is submitted in reply to the Restriction Requirement mailed November 8, 2012. In response to the Examiner's requirement that applicants elect a group of claims, applicants provisionally elect Group III (Claims 7-25, 28-29, 32-33 and 39). In response to the Examiner's requirement that applicants must elect a species, applicants elect the species wherein the acetyl precursor is triacetin. In response to the Examiner's requirement that applicants identify the claims encompassing the elected species, applicants identify claim 9.

Claims 1-4 (designated Group I), Claims 5-6 (designated Group II), Claims 26-27, 30-31, 34-38 and 40-44 (designated Group IV), Claims 45-48 (designated Group V), Claim 49 (designated Group VI), Claims 50-52 (designated Group VII), Claims 53-67 (designated Group VIII), Claims 68-76 (designated Group IX), Claim 77 (designated Group X), Claims 78-82 (designated Group XI), and Claims 83-91 (designated Group

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 076

XII) are hereby withdrawn without prejudice for presentation in one or more later co-pending divisional applications.

Respectfully submitted,

Michael S. Harvey, et al.

By: /Audrey A. Millemann/
Audrey A. Millemann (Reg. No. 44,942)
Attorney for Applicants
Weintraub Tobin Chediak Coleman Grodin Law Corporation
400 Capitol Mall, Eleventh Floor
Sacramento, California 95814
916/558-6033

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 077

Electronic Patent Application Fee Transmittal

Application Number:	13065553
Filing Date:	24-Mar-2011
Title of Invention:	Methods and compositions for the generation of peracetic acid on site at the point-of-use
First Named Inventor/Applicant Name:	Michael S. Harvey
Filer:	Audrey A. Millemann
Attorney Docket Number:	8568/17669

Filed as Small Entity

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Extension - 3 months with $0 paid	2253	1	645	645

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
			Total in USD ($)	**645**

Electronic Acknowledgement Receipt	
EFS ID:	14966135
Application Number:	13065553
International Application Number:	
Confirmation Number:	2262
Title of Invention:	Methods and compositions for the generation of peracetic acid on site at the point-of-use
First Named Inventor/Applicant Name:	Michael S. Harvey
Correspondence Address:	Audrey A. Millemann Weintraub Genshlea Chediak 11th Floor 400 Capitol Mall Sacramento CA 95814 US 9165586033 amillemann@weintraub.com
Filer:	Audrey A. Millemann
Filer Authorized By:	
Attorney Docket Number:	8568/17669
Receipt Date:	14-FEB-2013
Filing Date:	24-MAR-2011
Time Stamp:	19:36:30
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$645

RAM confirmation Number	7176
Deposit Account	501176
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Response to Election / Restriction Filed	8568_17669_ResponsetoRestriction.pdf	66976 2dd726038fd9c6e10e30011614321e75fd4cf957	no	2
Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	29880 183da792facf69254d997dd57a3f32c3d5ca9139	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	96856		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/065,553	03/24/2011	Michael S. Harvey	8568/17669	2262

7590 11/08/2012

Audrey A. Millemann
Weintraub Genshlea Chediak
11th Floor
400 Capitol Mall
Sacramento, CA 95814

EXAMINER	
SHIAO, REI TSANG	
ART UNIT	PAPER NUMBER
1628	

MAIL DATE	DELIVERY MODE
11/08/2012	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 082

Office Action Summary	Application No.	Applicant(s)	
	13/065,553	HARVEY ET AL.	
	Examiner	Art Unit	
	REI-TSANG SHIAO	1628	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *24 March 2011.*

2a)☐ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

5)☒ Claim(s) *1-91* is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☐ Claim(s) _____ is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☒ Claim(s) *1-91* are subject to restriction and/or election requirement.

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

12)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

13)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

DETAILED ACTION

1. Claims 1-91 are pending in the application.

Election/Restriction

2. The Markush group set forth in the claims includes both independent and distinct inventions, and patentably distinct compounds (or species) within each invention. However, this application discloses and claims a plurality of patentably distinct inventions far too numerous to list individually. Moreover, each of these inventions contains a plurality of patentably distinct compounds, also far too numerous to list individually. For these reasons provided below, restriction to one of the following Groups is required under 35 U.S.C. 121, wherein a Group is a set of patentably distinct inventions of a broad statutory category (e.g. Compounds, Methods of Use, Methods of Making, etc.):

I. Claims 1-4, drawn to products, classified in class 514/252/206 with various subclasses. If this group is elected, applicants are requested to elect a single species (i.e., a liquid acetyl precursor) of the product for the search purpose.

II. Claims 5-6, drawn to processes of making, classified in class 514/252/206 with various subclasses. If this group is elected, applicants are requested to elect a single species (i.e., a liquid acetyl precursor) of the product for the search purpose.

III. Claims 7-25, 28-29, 32-33 and 39, drawn to processes of making, classified in class 514/252/206 with various subclasses. If this group is elected, applicants are requested to elect a single species (i.e., a hydrogen peroxide precursor) of the product for the search purpose.

IV. Claims 26-27, 30-31, 34-38 and 40-44, drawn to processes of making, classified in class 514/252/206 with various subclasses. If this group is elected, applicants are requested to elect a single species (i.e., hydrogen peroxide-acetyl precursor) of the product for the search purpose.

V. Claims 45-48, drawn to products, classified in class 514/252/206 with various subclasses. If this group is elected, applicants are requested to elect a single species (i.e., hydrogen peroxide precursor) of the product for the search purpose.

VI. Claim 49, drawn to methods of use, classified in class 514/252/206 with various subclasses. If this group is elected, applicants are requested to elect a single species of the product for the search purpose.

VII. Claims 50-52, drawn to products, classified in class 514/252/206 with various subclasses. If this group is elected, applicants are requested to elect a single species of the product for the search purpose.

VIII. Claims 53-67, drawn to processes of making, classified in class 514/252/206 with various subclasses. If this group is elected, applicants are requested to elect a single species (i.e., a liquid acetyl precursor) of the product for the search purpose.

IX. Claims 68-76, drawn to processes of making, classified in class 514/252/206 with various subclasses. If this group is elected, applicants are requested to elect a single species (i.e., a liquid acetyl precursor) of the product for the search purpose.

X. Claims 77, drawn to products, classified in class 514/252/206 with various subclasses. If this group is elected, applicants are requested to elect a single species of the product for the search purpose.

XI. Claims 78-82, drawn to products, classified in class 514/252/206 with various subclasses. If this group is elected, applicants are requested to elect a single species of the product for the search purpose.

XII. Claims 83-91, drawn to processes of making, classified in class 514/252/206 with various subclasses. If this group is elected, applicants are requested to elect a single species (i.e., a liquid acetyl precursor) of the product for the search purpose.

In accordance with the decisions in ***In re Harnisch***, 631 F.2d 716, 206 USPQ 300 (CCPA 1980); and ***Ex parte Hozumi***, 3 USPQ2d 1059 (Bd. Pat. App. & Int. 1984), restriction of a Markush group is proper where the compounds within the group either (1) do not share a common utility, or (2) do not share a substantial structural feature disclosed as being essential to that utility. In addition, a Markush group may encompass a plurality of independent and distinct inventions where two or more members are so unrelated and diverse that a prior art reference anticipating the claim with respect to one of the members would not render the other member(s) obvious under 35 U.S.C. 103.

Where an election of any one of Groups I-XII is made, an election of a single compound or species is further required. Moreover**,** an election of a single compound is further required including an exact definition of each subject matter, for example, a liquid acetyl precursor or hydrogen peroxide precursor. Should applicant traverse on the ground that the compounds are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the compounds to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C 103(a) of the other.

All compounds falling outside the class(es) and subclass(es) of the selected compound and any other subclass encompassed by the election above will be directed to nonelected subject matter and will be withdrawn from consideration under 35 U.S.C. 121 and 37 C.F.R. 1.142(b). Applicant may reserve the right to file divisional

applications on the remaining subject matter. The provisions of 35 U.S.C. 121 apply with regard to double patenting covering divisional applications.

Applicant is reminded that upon cancellation of claims to a non-elected invention, the inventors must be amended in compliance with 37C.F.R. 1.48(b) if one of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 C.F.R. 1.48(b) and by the fee required under 37CFR 1.17(i). If desired upon election of a single compound, applicants can review the claims and disclosure to determine the scope of the invention and can **set forth** a group of compounds which are so similar within the same inventive concept and reduction to practice. Markush claims must be provided with support in the disclosure for each member of the Markush group. See MPEP 608.01(p). Applicant should exercise caution in making a selection of a single member for each substituent group on the base molecule to be consistent with the written description.

Rationale Establishing Patentable Distinctiveness Within Each Group

Each invention set listed above is directed to or involves the use or making of compounds which are recognized in the art as being distinct from one another because of their diverse chemical structure, their different chemical properties, modes of action, different effects and reactive conditions (MPEP 806.04, MPEP 808.01). Additionally, the level of skill in the art is not such that one invention would be obvious over either of the other inventions, i.e. they are patentable over each other. Chemical structures which are similar are presumed to function similarly, whereas chemical structures that

are not similar are not presumed to function similarly. The presumption even for similar chemical structures though is not irrebuttable, but may be overcome by scientific reasoning or evidence showing that the structure of the prior art would not have been expected to function as the structure of the claimed invention. Note that in accordance with the holdings of Application of Papesch, 50 CCPA 1084, 315 F.2d 381, 137 USPQ 43 (CCPA 1963) and In re Lalu, 223 USPQ 1257 (Fed. Cir. 1984), chemical structures are patentably distinct where the structures are either not structurally similar, or the prior art fails to suggest a function of a claimed compound would have been expected from a similar structure.

The above Groups represent general areas wherein the inventions are independent and distinct, each from the other because of the following reasons:

Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

(a) the inventions have acquired a separate status in the art in view of their different classification;

(b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;

(c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);

(d) the prior art applicable to one invention would not likely be applicable to another invention;

(e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) **and (ii) identification of the claims encompassing the elected invention**.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention. Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rei-tsang Shiao whose telephone number is (571) 272-

0707. The examiner can normally be reached on 8:30 AM - 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brandon Fetterolf, can be reached on (571)272-2919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/REI-TSANG SHIAO/

Rei-tsang Shiao, Ph.D.
Primary Examiner, Art Unit 1628

November 02, 2012

Search Notes	Application/Control No.	Applicant(s)/Patent under Reexamination
	13/065,553	HARVEY ET AL.
	Examiner	Art Unit
	REI-TSANG SHIAO	1628

SEARCHED			
Class	Subclass	Date	Examiner

INTERFERENCE SEARCHED			
Class	Subclass	Date	Examiner

SEARCH NOTES (INCLUDING SEARCH STRATEGY)		
	DATE	EXMR
restriction	11/2/2012	R.S.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 092

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
13/065,553	03/24/2011	Michael S. Harvey	8568/17669

CONFIRMATION NO. 2262

Audrey A. Millemann
Weintraub Genshlea Chediak
11th Floor
400 Capitol Mall
Sacramento, CA 95814

PUBLICATION NOTICE

OC000000056789313

Title: Methods and compositions for the generation of peracetic acid on site at the point-of-use

Publication No.US-2012-0245228-A1
Publication Date:09/27/2012

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently http://www.uspto.gov/patft/.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Office of Public Records. The Office of Public Records can be reached by telephone at (703) 308-9726 or (800) 972-6382, by facsimile at (703) 305-8759, by mail addressed to the United States Patent and Trademark Office, Office of Public Records, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently http://pair.uspto.gov/. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Managment, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 093

05-14-12

IFW

Doc Code: TRAN.LET

Document Description: Transmittal Letter



PTO/SB/21 (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	239

Application Number	13/065,553
Filing Date	March 24, 2011
First Named Inventor	Michael S. Harvey
Art Unit	1761
Examiner Name	
Attorney Docket Number	8568/17669

ENCLOSURES *(Check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment/Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☑ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Reply to Missing Parts/ Incomplete Application
  - ☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
  - ☐ Landscape Table on CD
- ☐ After Allowance Communication to TC
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC **(Appeal Notice, Brief, Reply Brief)**
- ☐ Proprietary Information
- ☐ Status Letter
- ☑ Other Enclosure(s) (please identify below):
  1. 4 Foreign Patent
  2. 5 Non Patent Literature Documents
  3. Return card

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Weintraub Genshlea Chediak Tobin & Tobin		
Signature	Audrey A. Millemann		
Printed name	Audrey A. Millemann		
Date	May 10, 2012	Reg. No.	44,942

CERTIFICATE OF TRANSMISSION/MAILING Express Mail EM 653467405US

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as ... mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: express Mail Stop Amendment

Signature	Audrey A. Millemann		
Typed or printed name	Audrey A. Millemann	Date	May 10, 2012

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Michael S. Harvey, et al.	
Serial No.:	13/065,553	Art Unit: 1761
Filing Date:	March 24, 2011	
For:	Methods and Compositions for the Generation of Peracetic Acid on Site at the Point-of-Use	

May 10, 2012
Sacramento, California 95814

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to Rules 1.97 and 1.98, Applicants submit herewith copies of patents, publications, or other information of which Applicants are aware, as listed on the accompanying Form 1449, which Applicants believe may be material to the examination of this application and with respect to which there may be a duty to disclose.

The filing of this information disclosure statement and accompanying Form 1449 shall not be construed as a representation that a search has been made (37 C.F.R. 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement and accompanying Form 1449 shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

Respectfully submitted,

Michael S. Harvey, et al.

By: Audrey A. Millemann

Audrey A. Millemann (Reg. No. 44,942)
Attorney for Applicants
Weintraub Genshlea Chediak
Law Corporation
400 Capitol Mall, Eleventh Floor
Sacramento, California 95814
916/558-6033

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 096

Exp. Mail EM 653467405 US

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OPAP WB MAY 18 2012 PATENT & TRADEMARK OFFICE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	13/065,553
Filing Date	March 24, 2011
First Named Inventor	Michael S. Harvey
Art Unit	1761
Examiner Name	
Attorney Docket Number	8568/17769

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 3,956,159	05-11-1976	Jones	
		US- 5,122,538	06-16-1992	Lokkesmoe, et al.	
		US- 5,977,403	11-02-1999	Byers	
		US- 6,171,551 B1	01-09-2001	Malchesky, et al.	
		US- 6,262,013 B1	07-17-2001	Smith, et al.	
		US- 6,387,236 B2	05-14-2002	Nordman, et al.	
		US- 7,012,154 B2	02-02-2006	Vineyward, et al.	
		US- 7,723,083 B2	01-01-2009	DiCosimo, et al.	
		US- 7,271,137 B2	05-26-2005	Tucker, et al.	
		US- 2004/0245116 A1	12-09-2004	Ohsaka, et al.	
		US- 2005/0118940 A1	06-02-2005	Hilgren, et al.	
		US- 2007/0082832 A1	04-12-2007	DiCosimo, et al.	
		US- 2009/0175956 A1	07-09-2009	Buschmann, et al.	
		US- 2009/0043132 A1	02-12-2009	Copenhafer, et al.	
		US- 2009/0314652 A1	12-24-2009	Buschmann, et al.	
		US- 2010/0196505 A1	08-05-2010	Kaiser, et al.	
		US- 2010/0227000 A1	09-09-2010	Ames, et al.	
		US- 3,432,546	11-03-1964	Oringer, et al.	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	1	EP 0 563 460 B1	07-01-1998	The Procter & Gamble Co.		
	2	WO 01/46519 A1	06-28-2001	Warwick International		
	3	WO 2008/140988 A1	11-20-2008	Danisco US Inc.		
	4	WO 2010/005607 A2	01-14-2010	Electron Research & Dev.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete If Known	
Application Number	13/065,553
Filing Date	March 24, 2011
First Named Inventor	Michael S. Harvey
Art Unit	1761
Examiner Name	
Attorney Docket Number	8568/17669

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	1	LEVENEUR, et al., "Interaction of Instrinsic Kinetics and Internal Mass...Acids," Chemical Engineering Science 64 (2009) pp.4101-4114	
	2	ROCHA, et al., "Rates of Formation of Peroxyacetic...Phosphates," Journal of Molecular Catalysis A: Chemical 186 (2002) pp. 127-133	
	3	CLARIANT CORP.,technical bulletin, "Peractive -The Clean and Clever Way of Bleaching," August 1999	
	4	MILNE, "Oxygen Bleaching Systems in Domestic Laundry," Journal of Surfactants and Detergents, Vol.1, No. 2 (April 1998) pp. 253-261	
	5	SAHA, et al., "Synthesis of Peroxyacetic Acid Using In Situ...Electrode," Electrochemistry Communications 5 (2003) pp.445-448	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number
WO 01/46519 A1

(51) International Patent Classification[7]: D21C 9/16, C07C 407/00

(21) International Application Number: PCT/GB00/04876

(22) International Filing Date:
18 December 2000 (18.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9930175.6 22 December 1999 (22.12.1999) GB

(71) Applicant *(for all designated States except US)*: WARWICK INTERNATIONAL GROUP LIMITED [GB/GB]; Mostyn, Holywell, Flintshire CH8 9HE (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: WITHENSHAW, John, David [GB/GB]; Orchard House, Flint Road, Northop, Mold CH7 6BR (GB). SKETT, Matthew, Brian [GB/GB]; 10 Chester Close, Shotton, Deeside, Flintshire CH5 1AU (GB).

(74) Agents: GODDARD, David, John; Harrison Goddard Foote, Orlando House, 11c Compstall Road, Marple Bridge, Stockport SK6 5HH___ et al. (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/46519 A1

(54) Title: PEROXYACID DELIVERY PROCESS

(57) Abstract: In a peroxyacid delivery process for the continuous generation of peroxyacid from hydrogen peroxide solution (5) and bleach activator (10) mixed together in a tank (1), the pH of the mixture is adjusted by the addition or injection of an alkaline material (16) selected from the group consisting of sodium hydroxide, potassium hydroxide and magnesium oxide under vigorous mixing conditions such as are provided by an in-line mixer (14) within which the Froude number is at least 1. Preferably the output of mixer (14) is fed though a pipe (18), which may be coiled through a cooling tank (19) for heat dissipation, to provide a residence time of 4 to 25 minutes for completion of the reaction without degradation of the product, which may be used for pulp bleaching. Preferably an excess of hydrogen peroxide is present, and sequestrant (3) is incorporated in the peroxide-activator mixture.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 099

Peroxyacid Delivery Process

This invention relates to peroxyacid delivery processes, in particular to processes in which a peroxyacid is formed by the reaction of hydrogen peroxide solution with a bleach activator. Herein the term "peroxyacid" is intended to include the anion, the relative amounts of the two species being depending on the pH. The peroxyacid is useful for the bleaching of wood or non-wood pulp under alkaline conditions.

The invention also encompasses the formation and delivery of a bleaching solution that contains a mixture of peroxyacid and hydrogen peroxide by the reacting under alkaline conditions an agglomerate or crystalline tetraacetylethylenediamine, commonly known as as TAED, with excess hydrogen peroxide. The bleaching solution is useful for the bleaching of wood or non-wood pulp under alkaline conditions.

Oxygen based bleaching is used because of its environmental benefits and oxidising power. Hydrogen peroxide is increasingly being used in oxygen based pulp bleaching. It has been proposed to use peroxyacid, especially peracetic acid, as a bleach or disinfectant. Both the on site generation of peracetic acid from carboxylic acid and hydrogen peroxide and the distribution of distilled or equilibrium peracetic acid presents risks which many potential users find unacceptable.

It has been proposed to solve this problem by reacting hydrogen peroxide with a bleach activator to generate a peroxyacid based oxygen bleaching species *in situ* to facilitate pulp bleaching and delignification.

Peroxyacid delivery processes using bleach activators have generally formed the peroaxyacid in the presence of the substrate to be bleached or disinfected.

The "pre-reaction" of a bleach activator with hydrogen peroxide for the formation of peroxyacid is claimed in copending application PCT/GB/9903178. The TAED bleach activator is pre-reacted batchwise with hydrogen peroxide, adjusted to a suitable alkaline pH and then pumped to the point of use. Batch reactions require bulky equipment, especially for larger duty operations. Furthermore the creation of a

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 100

large batch of peroxyacid may result in wastage if a problem prevents it being used for bleaching within a few hours.

TAED is a fine white crystalline powder. Use of TAED powder in a pre-reaction with hydrogen peroxide to form a bleaching solution for use in a bleaching process is undesirable for a number of reasons. Firstly it would not have the required free flow properties to be dosed effectively from a hopper. Secondly it would require special equipment to control dust levels. Thirdly it would not mix well with hydrogen peroxide solution and would have poor dispersing dissolution characteristics. These problems can be overcome by use of an agglomerated product.

TAED powder may be agglomerated using one or more binders provided specifically for this purpose, a commonly used binder being sodium carboxymethylcellulose (CMC). Alternatively a binding function in a TAED bleaching composition may be provided by an additional component incorporated for other purposes, or by an appropriate treatment such as extrusion where no specific binder is present. For use in the present invention, a preferred agglomerated product contains at least 50% TAED, and typically it contains from about 80 to about 90% TAED with the remainder being made up of any binder or binder system and optional disintegration and dispersion aids, together with other minor components, such as pigments, colorants and sequestrants. Where no binder is specifically added for the purpose, more than 90% TAED may be present in the agglomerate.

Use of bleach activator agglomerates containing a sodium carboxymethylcellulose or other conventional binder for large-scale reactions leads to problems. Firstly, as is the case with sodium carboxymethylcellulose, the binder may be insoluble under the pH and temperature conditions under which agglomerates may need to be pre-reacted with the hydrogen peroxide solution. Secondly the binder may react with the caustic soda added to adjust the alkalinity of the pre-reaction mixture and/or the pulp. Additionally, suspension of agglomerates in peroxide can form scum, which is unacceptable for processes, such as pulp bleaching, where residual solid matter must be avoided. Conventional binders may give rise to poor bleaching and may even form coloured species under the extremes of one or more of temperature, pressure

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 101

and residence time encountered in some processes. It has also been found that agglomerates with conventional binder systems do not disperse fast enough or wet fast enough in the low ionic medium of a pre-reaction process.

It would be desirable to have a safe, continuous process for on site generation of peroxyacid with low capital cost and short residence time.

The present invention provides a peroxyacid delivery process for the continuous generation of peroxyacid from hydrogen peroxide solution and bleach activator characterised in that the pH of a mixture of hydrogen peroxide solution and bleach activator is adjusted by the addition or injection of an alkaline material selected from the group consisting of sodium hydroxide, potassium hydroxide and magnesium oxide under vigorous mixing conditions provided by an in-line mixer within which the Froude number is at least 1, or by another mixer or combination of mixers providing an equivalent speed and intimacy of mixing. Where magnesium oxide is mentioned, this encompasses the hydrated product, irrespective of whether this is defined as magnesium oxide or magnesium hydroxide.

A definition of the dimensionless densiometric Froude number is given by:

$$\text{Froude Number} = \frac{v^2}{g.L}$$

where:

v	=	Flow velocity (m/s)
g	=	gravitational acceleration (m/s2)
L	=	characteristic dimension of the system (m)
	=	$(\Delta\rho/\underline{\rho}).d_h\varepsilon^2)$
$\Delta\rho$	=	difference in density between components being mixed
$\underline{\rho}$	=	mean density of the components being mixed
d_h	=	hydraulic diameter of the mixing unit (m)
ε	=	void fraction of mixing unit.

In-line mixers can enable the injection of the alkaline material in an essentially enclosed part of the system under continuous flow conditions between the supply of

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 102

mixed hydrogen peroxide and activator and a continuous supply outlet for the peroxyacid containing product. Of particular and preferred use are static in-line mixers containing elements to result in turbulent mixing of the alkaline material and the mixed hydrogen peroxide and activator to give a Froude number of more than 4, preferably more than 10 and most preferably more than 20.

However, the invention encompasses the use of other types of in-line mixer, and of other mixers capable of being inserted between the supply of mixed hydrogen peroxide and activator and a continuous supply outlet for the peroxyacid containing product, including tank type mixers. If necessary, a single mixer giving a lower Froude number or equivalent effect may be used in association with one or more further mixers, e.g. supplementary kinetic or dynamic mixers or agitators to provide the requisite speed and intimacy of mixing. However, a single mixer is at present preferred.

In a preferred embodiment the alkaline material is sodium hydroxide. Addition of sodium hydroxide solution without sufficiently vigorous mixing causes gassing off of hydrogen peroxide and loss of yield of the peroxyacid. Adjustment of the pH to about 8 to about 9.5, e.g. by use of sufficient sodium hydroxide, is recommended for greater than 90% yield based on TAED.

Advantageously an excess of sodium hydroxide. which equates to at least to 1 part by weight sodium hydroxide to 4 parts by weight TAED is used. This gives a pH of greater than 8 and gives better peracetate anion yield, based on TAED, than in the case if less sodium hydroxide is used. Greater sodium hydroxide excesses up to and greater than 1 part by weight sodium hydroxide to 3 parts TAED or even 1 part sodium hydroxide to 2 parts TAED can also be used. The ideal yield for the peracetate anion production is preferably >85% TAED conversion and most preferably >90% TAED conversion (based on two acetyl groups released per TAED).

The reaction mixture is preferably pumped along a reaction pipe downstream of the vigorous mixer(s) with a residence time of between 4 and 25 min.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 103

The premixing of the bleach activator and the hydrogen peroxide solution can be done in any suitable continuous or semi-batch operation. Agglomeration of the activator facilitates accurate dosing and also allows for easy recovery from accidental spillage. The bleach activator may be any one or mixtures of more than one acetyl donor. The process is particularly suitable for use with agglomerated TAED.

Activators generating peracids other than peracetic acid may be used but are not preferred. Specific activators, which are available for use in the invention, are tetraacetylethylenediamine (TAED), pentaacetyl glucose (PAG), tetraacetylglycolouril (TAGU), N-acetyl caprolactam, N-benzoyl caprolactam and triacetylethanolamine. Of these TAED is preferred because it gives the most cost-effective release of acetyl groups: it releases two such groups per molecule.

Binders and dispersing systems for the TAED agglomerate may be selected to suit the process. Preferred agglomerates comprise: TAED; a water soluble binder or binder system, preferably polyvinyl alcohol (PVOH); a dispersing system comprising a wetting agent which is a low foaming and does not discolour on exposure to temperatures of up to 120°C and optionally a salt, preferably sodium acetate, which is highly soluble in hydrogen peroxide. The binder or binder system preferably comprises less than 1.2%, preferably less than 0.5% CMC, and most preferably none at all.

The agglomerate preferably comprises: a TAED agglomerate with average particle size in the range of 5 to 2000 micron having a binder or binder system comprising less than 1.2% preferably less than 0.5% CMC, most preferably none at all; and 2-8% of anionic surfactant which can be dried to a solid and other ingredients which are non precipitating over the pH range of 5-10, the binder or binder system further being completely compatible with the pulp bleaching process and preferably readily biodegradable. For processing reasons the agglomerate may comprise up to 1.2%, preferably 0.1 to 0.5% by weight based on the dry agglomerate of a co-binder, such as sodium carboxymethylcellulose (CMC). However, agglomerates without any CMC are preferred.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 104

Preferably the anionic surfactant is incorporated at a level of 1 to 6% by weight based on the dry agglomerate, most preferably about 2.5%.

Other additives such as flow aids, sequestrants, pH adjusting components, diluents and the like may also be included in the agglomerate if required. The inclusion of one or more sequestrants is particularly advantageous, as these enable any transition metals in the water and alkali used to adjust the pH to be rendered non-catalytic for the decomposition of the hydrogen peroxide. If they are not added as part of the agglomerate they may be added separately, or to the hydrogen peroxide.

The agglomerates may be manufactured using any process known to those skilled in the art e.g. mixing TAED powder and a solution of surfactant to form agglomerates and drying the agglomerates so formed.

The concentration of hydrogen peroxide in the pre-reaction mixture (prior to pH adjustment) is normally in the range of 0.1 to 60% preferably 0.2 to 30% w/v. A typical level will be 3%. The amount of bleach activator used in the pre-reaction mixture should be in the range 0.001 to 20 g/l based on the theoretical dose to dry pulp. When TAED is used as the bleach activator we have found that use of large concentrations of TAED leads to an undesirable exothermic reaction and the maximum concentration that should be used is 10%, preferably 5% and most preferably less than 2%.

An excess of hydrogen peroxide, over the acetyl groups that are released from the bleach activator, is used. The mole ratio of peroxide to releasable acetyl groups is preferably more than 2:1, more preferably at least 3:1, and most preferably at least 3.35:1. It may be 10:1 or more, but it is preferably no greater than 5:1, more preferably no greater than 4:1.

As the per-acetic anion release between TAED and hydrogen peroxide solution takes at least 4 minutes to release >90% per-acetic anion after addition of the sodium hydroxide (alkaline material) the bleaching solution is provided with a residence time of at least 4 minutes, preferably by being passed through a reaction pipe or other vessel. In the latter case, the residence time is conveniently adjusted to suit the flow

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 105

rate by adding or subtracting lengths of pipe. The residence time for the reaction pipe is preferably no more than about 25 minutes.

The process is adaptable to any location and the reaction pipe length can be adapted according to the distance from the dosing point, with bore and length of the reaction pipe and flow rate being conjointly selected to give the correct retention time.

The activator input feed rate may be controlled via a flow meter feedback loop to the feed system, e.g. a volumetric feeder. The control point or measurement point may be located near the outlet of the reaction pipe. A pH probe near the outlet of the reaction pipe may be used to control the input rate of the alkaline material, e.g. a concentrated sodium hydroxide solution, such as one with a weight concentration of more than 3, preferably more than 5, more preferably more than 10, still more preferably more than 20 and most preferably more than 40 weight percent (but preferably no more than 50 weight percent), or a magnesium oxide slurry.

Although a tank may be used to provide at least part of the reaction capacity downstream of the vigorous or in-line mixer if desired, the use of a reaction pipe may have advantages over a tank. As with the use of an in-line mixer, because the system is then enclosed, exposure of an operator to peracetic anion solution is reduced. Furthermore, making the reaction pipe into a coil and applying cooling to it can dissipate heat. In addition the use of a reaction pipe gives more control over residence time than would be obtained from a tank, thus enabling greater control over the bleach solution concentration at the exit from the reaction pipe and therefore the point of delivery to the bleaching process.

The addition of untreated water to the bleaching solution will introduce transition metal ions. These are able to catalyse the decomposition of hydrogen peroxide. Treating the water to remove the ions or to render them inactive is necessary. A preferred treatment is to use a sequestrant. Any sequestrant may be used, including EDTA, DTPA (diethylenetriamine penta-acetic acid) and other sequestrants that do not contain phosphorous, but a phosphonate stabiliser is preferred. Preferred sequestrants are selected from the group comprising pentamethylene phosphonic acid and diethylenetriamine penta-(methylene phosphonic acid). The ratio of sequestrant to water is in the range 1:100 to 1:10000 parts by weight.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 106

An advantage of a continuous peroxyacid generating system is that it eliminates the need for a specific acid addition step that previous batch systems have required to lower the pH of the solution in the batch tank. Nevertheless, if the necessity should ever arise, it is possible to add acid to the pulp bleaching tank.

A further advantage of generating the peroxyacid continuously is that it may easily be controlled because it is operating as a steady state reaction.

Another advantage of the continuous process is that it can easily be scaled up without using correspondingly larger mixing tanks, that may take up too much space to enable the equipment to be added into an existing manufacturing facility.

Further features and advantages of the invention will become clear upon a reading of the appended claims, to which the reader is referred, and to the following description made with reference to the accompanying drawing and examples in which:

Figure 1 is a schematic of a continuous peroxyacid generating system.

Figure 1 shows a batch make-up tank 1. The tank is fed with water along delivery pipe 2. Sequestrant is dosed from tank 3 along sequestrant supply pipe 4. Hydrogen peroxide is dosed from tank 5 along peroxide supply pipe 6. Valves 7, 8 and 9 control the water, sequestrant and peroxide supplies respectively. Agglomerated TAED is held in a hopper 10 and fed to the tank 1 via a screw feeder 11. The contents of tank 1 are kept in suspension and mixed using an agitator 12. The outlet from tank 1 is fed by pump 13 to in-line mixer 14. The in-line mixer is also fed through pump 15 with caustic soda solution from tank 16. A control unit 17 controls valves 7, 8 and 9, screw feeder 11, and pumps 13 and 15. The output from the in-line mixer 14 enters a reaction pipe 18 which may be made up of a series of pipes, some of which may be coiled to allow for them to be put into a secondary container 19 which may have a cooling system 20. The reaction pipe 18 is connected into the bleaching process at its end 21.

The continuous process operates as follows: the control unit 17 opens valve 7 to allow approximately 100 kg of water to enter the batch make-up tank 1 along supply pipe 2. At the same time 0.2kg of sequestrant is dosed along pipe 4 by opening valve

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 107

8 and agglomerated TAED also enters tank 1 from hopper 10 by operation of the screw feeder 11. This takes about 1 minute. Throughout the fill cycle the agitator 12 is in continuous operation. Towards the end of the cycle the hydrogen peroxide is dosed along line 6 when the controller 17 opens valve 9. At the end of this fill cycle the level in tank 1 is at its maximum. Pump 13 empties tank 1 continuously and at a defined lower level of liquid in tank 1, or a defined period of time, the fill cycle starts again. Alternatively in a modification continuous metering pumps deliver all the components on a continuous basis. In a more automated process for variable flow rates, the flow rate is sensed, for example near the output 21, and is used to control the continuous metering pumps.

The homogeneous mixture or suspension of TAED, hydrogen peroxide, water and sequestrant is continuously dosed by pump 13 through the in-line mixer 14 where sodium hydroxide is also dosed continuously via pump 15 in sufficient quantity to give the required pH at the end of the reaction, e.g. at or near the end 21 of pipe 18. Once an empirical relationship has been determined the controller 17 controls the sodium hydroxide delivery by controlling pump 15 according to the setting of pump 13 which in turn is set by the overall flow requirement. In an alternative process, pH is determined, for example at or near an end 21 of pipe 18, and is used to control pump 15.

The reaction requires at least 4 minutes after the in-line mixer to achieve greater than 85% TAED to peracetate anion conversion. This reaction time is achieved by pumping the mixture through reaction pipe 18. The length of the reaction pipe 18 is dependent on flow rate and pipe volume (pipe bore) and the required retention time.

The in-line mixer 14 creates turbulent flow, causing intimate mixing of the sodium hydroxide and the TAED/peroxide mixture which leads to the reaction progressing rapidly, no solids being visible immediately down stream of the in-line mixer. This contrasts sharply with the build up of solids that occurs in that area if the mixing element of the in-line mixer 14 is removed.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 108

Examples 1 to 11 In these Examples sodium hydroxide addition was controlled according to the amount of TAED being used. Examples 1 to 6 were to assess the optimum ratio of sodium hydroxide to TAED. These examples used a 200m long reaction pipe of suitable diameter to give the required retention time. Comparative Example 7 was carried out to test the effectiveness of the in-line mixer in the system and was a repeat of Example 6 with the mixing element removed from the in-line mixer so that the sodium hydroxide was added directly to the slurry with no mixing at all. Throughout, it could be seen that the system was not effective because rapid de-gassing was occurring during the reaction and TAED crystals could be seen in the samples. Comparative example 7 gave a low peracetate anion release. To investigate this further the dimensionless densiometric Froude number was calculated for Example 6 to be 6.6 which contrasted with the much lower Froude number of 0.64 Comparative calculated for Comparative Example 7.

Comparative Examples 10 and 11 were a repeat of Example 1 except that Comparative Example 10 used powdered uncoated TAED and Comparative Example 11 used a CMC bound TAED agglomerate traditionally used in detergent formulations. Comparative Example 10 was a very poor producer of peracetate anion because the TAED could not be entrained without high shear agitation. When this agitation was applied, severe foaming occurred in the make-up tank. Comparative Example 11 did not produce any peracetate anion because the agglomerate foamed during mixing and did not become entrained in the batch tank.

The results of Examples 1 to 11 are given in Table 1. PAR is peracetic anion release, measures against the theoretical release based on the amount of TAED used. The results show that a TAED to sodium hydroxide ratio of less than or equal to about 4 to 1 is required to achieve greater than 85% Peracetate anion generation.

Examples 12-15 To ensure that the Froude number had a significant effect on peracetic anion release more Examples with and without the in-line mixer (ILM) at different flow rates were carried out. The results are shown in Table 2. All these examples were carried out using a 200m reaction pipe.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 109

The peracid release at lower Froude numbers is less good than at higher Froude numbers. Using the in-line static mixer with an element designed to provide radial mixing increases the Froude number for a given flow rate (retention time).

5

Table 1

Example	NaOH Parts	TAED Parts	Retention Mins.	ILM	Temp °C	PH Ave.	PAR% Ave.
1	1	4	10	✓	17	8.69	90
2	1	5	10	✓	17	8.39	81
3	1	3	10	✓	17	9.06	92
4	1	4	12	✓	17	8.61	92
5	1	4	8	✓	17	8.46	91
6	1	4	8	✓	22	8.43	90
C7	1	4	10	X	17	8.82	77
8	1	24	6	✓	22	8.87	91
9	1	24	4	✓	17	8.93	87
C10	1	24	10	✓	17	9.58	69
C11	1	24	10	✓	17	-	0

Table 2

Example	Retention Mins	ILM	Froude Number	PAR% Ave
12	19	✓	1	66.1
13	19	X	0.18	51.9
14	6	✓	10.2	91.1
15	6	X	1.8	76.8

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 110

CLAIMS

1. A peroxyacid delivery process for the continuous generation of peroxyacid from hydrogen peroxide solution and bleach activator characterised in that the pH of a mixture of hydrogen peroxide solution and bleach activator is adjusted by the addition or injection of an alkaline material selected from the group consisting of sodium hydroxide, potassium hydroxide and magnesium oxide under vigorous mixing conditions provided by an in-line mixer within which the Froude number is at least 1, or by another mixer or combination of mixers providing an equivalent speed and intimacy of mixing.

2. A peroxyacid delivery process according to claim 1 in which said Froude number is greater than 4, preferably greater than 10 and most preferably greater than 20.

3. A peroxyacid delivery process according to claim 1 or claim 2 in which the reaction of the bleach activator and the hydrogen peroxide takes place in the presence of a sequestrant, preferably a phosphonate (phosphonic acid) stabiliser.

4. A peroxyacid delivery process according to any preceding claim in which after said addition or injection of alkaline material the reaction mixture is pumped along a pipe with a residence time of between 4 and 25 min.

5. A peroxyacid delivery process according any preceding claim in which the bleach activator is TAED.

6. A peroxyacid delivery process according to claim 5 in which the TAED is added as an agglomerate which contains at least 50 % by weight TAED.

7. A peroxyacid delivery process according to any preceding claim wherein the alkaline material is sodium hydroxide.

8. A peroxyacid delivery process according to claim 5 and claim 7, or claim 6 and claim 7, in which the weight ratio of sodium hydroxide to TAED is at least 1 to 4.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 111

INTERNATIONAL SEARCH REPORT

Inte onal Application No
PCT/GB 00/04876

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 D21C9/16 C07C407/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 D21C C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
CHEM ABS Data, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	C. LEDUC ET AL: APPITA J., vol. 51, no. 4, 1998, pages 306-310, XP000926194 whole document, in particular page 308, column 3 - page 309, column 1	1,5,7
A	EP 0 456 032 A (HOECHST JAPAN LTD) 13 November 1991 (1991-11-13) whole document	1,5,7

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 February 2001	07/03/2001

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Van Amsterdam, L

1

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. ..onal Application No
PCT/GB 00/04876

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 456032 A	13-11-1991	JP 4108192 A	09-04-1992
		CA 2041468 A	26-10-1991
		FI 911963 A	26-10-1991
		NO 911626 A	28-10-1991

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 0 563 460 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
01.07.1998 Bulletin 1998/27

(51) Int Cl.[6]: **C11D 3/39**

(21) Application number: **92200961.8**

(22) Date of filing: **03.04.1992**

(54) **Acidic activated bleaching composition**

Durch Säure aktivierte Bleichzusammensetzung

Composition de blanchiment activée par un acide

(84) Designated Contracting States:
DE ES FR GB IT

(43) Date of publication of application:
06.10.1993 Bulletin 1993/40

(73) Proprietor: **THE PROCTER & GAMBLE COMPANY**
Cincinnati, Ohio 45202 (US)

(72) Inventors:
- **Hardy, Frederick Edward**
  Ponteland, Newcastle upon Tyne NE20 9ES (GB)
- **Sclalla, Stefano (NMN)**
  I-00128 Rome (IT)
- **Scoccianti, Raffaele (NMN)**
  I-00153 Rome (IT)
- **Manfredi, Barbara (NMN)**
  I-00162 Rome (IT)

(74) Representative: **Canonici, Jean-Jacques et al**
Procter & Gamble European Technical Center N.V.
Temselaan 100
1853 Strombeek-Bever (BE)

(56) References cited:
EP-A- 0 125 781

- **DATABASE WPIL Section Ch, Derwent Publications Ltd., London, GB; Class D25, AN 87-045571 [07] & JP-A-62 001 794 (KAO CORP.)**
- **DATABASE WPIL Section Ch, Derwent Publications Ltd, London, GB; Class D25, AN 87-046869 [07] & JP-A-62 004 794 (KAO CORP.)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Printed by Jouve, 75001 PARIS (FR)

EP 0 563 460 B1

Description

Technical field

The present invention relates to bleaching compositions, mainly for use in laundry applications. The compositions according to the present invention, which comprise hydrogen peroxide as well as peracid precursors, are stable upon storage.

Background

Bleaching compositions using hydrogen peroxide have been extensively described in the art. Such hydrogen peroxide bleaches have an advantage over chlorine bleaches in that they are environmentally more compatible. Another advantage is that they are "milder" bleaches. This latter advantage is especially significant in laundry applications as hydrogen peroxide bleaches are safer to fabrics.

A major drawback of hydrogen peroxide bleaches is that they are less active than chlorine bleaches at low temperatures which are often encountered in modern laundering applications. Thus, hydrogen peroxide bleach activators have been developed and have been extensively described in the art. These activators are mainly transition metals or peracid precursors. Peracid precursors react with hydrogen peroxide to yield peracids. Peracids are the "activated" bleaching compounds which are efficient at low temperatures.

A problem which occurs in the formulation of such "activated" hydrogen peroxide bleaching compositions is the difficulty to obtain a composition which is both chemically and physically stable. Indeed, such compositions of the prior art are either turbid suspensions of insoluble activators with good chemical stability, or clear compositions with poor chemical stability which causes significant and undesired oxygen release.

It has now been found that this problem could be addressed by formulating a bleaching composition comprising hydrogen peroxide, an organic peracid precursor selected from a specific class, e.g. glycol and glycerin esters, and by formulating said composition in a narrow, acidic pH range. The mildly acidic pH range allows for adequate chemical stability of both the hydrogen peroxide and the organic peracid precursor. The activation of hydrogen peroxide trough the formation of a peracid is enhanced by the pH raise which occurs upon dilution in the wash water, especially when a detergent composition bringing further alkalinity is also present in the wash water.

Glycol esters have been often described as solvents in detergent and bleaching compositions. Such compositions are described for instance in US-A-3 956 159. These compositions have a pH of 6.5 and above.


JP-A-62252500 (abstract) discloses bleaching compositions which comprise a bleach activator, including triacetin. These compositions are formulated at neutral or weakly basic pH.

Bleaching compositions for various applications, comprising triacetin are also disclosed in JP-A-62001792, JP-A-62001794 JP-A-62001796, and JP-A-61042600 (abstracts).

EP-A-125 781 discloses bleaching compositions comprising hydrogen peroxide and a particular peroxyacid generator like for example 1,1,5-triacetoxypent-4-ene, 1,1,5,5-tetraacetoxy pentane, the corresponding butene and butane compounds, ethylidene benzoate acetate and bis (ethylidene acetate) adipate.


Summary of the invention

The compositions according to the present invention are clear aqueous bleaching compositions comprising hydrogen peroxide as well as an organic peracid precursor, characterized in that the compositions have a pH in the range of from 3.5 to 6, and that the organic peracid precursor is a compound according to the formula:




wherein x is 0 or 1, R_1, R_2, R_3 are independently selected from -H, -OH,

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 115



where R_4 is C_1-C_4 alkyl, with the proviso that at least two of R_1, R_2 or R_3 are




or mixtures thereof.


Detailed description of the invention

The compositions according to the present invention are clear aqueous liquid compositions which comprise hydrogen peroxide. Preferably, the compositions according to the present invention comprise from 0.5 % to 20 % by weight of the total composition of hydrogen peroxide, more preferably from 2 % to 15 %, most preferably from 4 % to 9%.


The compositions according to the present invention further comprise a specific organic peracid precursor according to the formula:



wherein x is 0 or 1, R_1, R_2, R_3 are independently selected from -H, -OH,



where R_4 is C_1-C_4 alkyl, with the proviso that at least two of R_1 R_2 or R_3 are



or mixtures thereof. All these compounds are well known chemicals which are commercially available or can be synthesized according to the chemical literature.

Preferred such peracid precursors for use in the compositions according to the present invention are selected from ethylene glycol diesters, triacetin and diacetin, or mixtures thereof. Particularly preferred compounds are triacetin and ethylene glycol diacetate. Tributyrin also displays excellent stability in the compositions according to the present invention but is less preferred because it is less soluble in the compositions according to the present invention.

The compositions according to the present invention typically comprise from 1 % to 15 % by weight of the total composition of such an organic peracid precursor, or mixtures thereof. The desired amount of organic peracid precursor can also be defined in relation to the amount of hydrogen peroxide in the composition. Accordingly, the compositions according to the present invention preferably comprise from 0.1 to 2 moles of organic peracid precursor per mole of hydrogen peroxide.

The compositions according to the present invention have a pH in the range of from 3.5 to 6, most preferably from 3.5 to 5, most preferably about 4. The pH of the composition can be adjusted and buffered with such chemicals as

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 116

organic and inorganic acids which are stable to oxidation, citric acid, sulphuric acid, sodium hydroxide, ammonia and amines. Preferred buffer for use in the compositions according to the present invention is citric acid. It is essential that the pH of the composition remains within the above range as said range is critical to ensure adequate chemical stability of the hydrogen peroxide and of the specific organic peracid precursors used in the compositions according to the present invention.

The compositions according to the present invention may comprise surfactants. Preferred surfactants for use herein are well known anionic surfactants such as alkyl benzene sulphonates and alkyl sulfates, and/or nonionic surfactants such as ethoxylated and/or propoxylated alcohols. All surfactants for use herein must be resistant to oxidation by peracids and hydrogen peroxide, and are preferably water-soluble. The compositions according to the present invention can comprise from 0% to 30% by weight of the total composition of surfactants, preferably from 0.5 % to 15 %, most preferably from 2 % to 8 %.

The compositions according to the present invention may further comprise peroxide stabilizers such as stannates, 8-hydroxyquinoline, pyrophosphates and phosphonates. Chelating agents may also be useful in the context of the present invention; suitable chelants include EDTA, NTA and DETPA, picolinic and dipicolinic acids and amino polyphosphonates, although some of these are poorly environmentally compatible. Radical scavengers can also be used herein, such as butylated hydroxy toluene and other hindered hydroxy benzenes, or sodium benzoate. Butylated hydroxy toluene is a highly preferred ingredient as it has been observed that it stabilizes the peracid precursors according to the present invention, as well as hydrogen peroxide.

The compositions according to the present invention can also comprise such optional ingredients as whitening agents, dyes, builders, thickeners, hydrotropes, perfumes, all of which need to be compatible with the mildly acidic pH and the oxidizing environment of the compositions according to the present invention.

The compositions according to the present invention are further illustrated in the following examples.

Examples

The following compositions are made by mixing together the listed ingredients in the listed proportions.

Ingredients:	% by weight:				
	I	II	III	IV	
Hydrogen peroxide	6.0	6.0	6.0	6.0	
Na alkyl sulphate	2.8	2.8	2.8	2.8	
Triacetin	4.0	5.0	4.0	4.0	
Citric acid	1.0	1.0	1.0	1.0	
Na Stannate	0.0015	0.0010	0.0015	0.0015	
Na hydroxide	pH 4	pH 4	pH 3.5	pH 5	pH 4
Water & minors			up to 100 %		


Ingredients:	% by weight:			
	V	VI	VII	VIII
Hydrogen peroxide	6.0	8.0	3.5	5.0
Na alkyl sulphate	2.8	2.0	4.0	3.5
Triacetin	-	3.0	5.0	-
Ethylene glycol diacetate	4.0	-	-	5.0
Citric acid	1.0	1.0	1.0	1.0
Na stannate	0.0015	0.0015	0.0010	0.0015
Na hydroxide	pH 4	pH 4	pH 4	pH 4
Water & minors			up to 100 %	

Claims


1. An aqueous bleaching composition comprising hydrogen peroxide and an organic peracid precursor, **characterized in** that the compositions have a pH in the range of from 3.5 to 6, and that the organic peracid precursor is a

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 117


compound according to the formula:



wherein x is 0 or 1, R_1, R_2, R_3 are independently selected from -H, -OH,



where R_4 is C_1-C_4 alkyl, with the proviso that at least two of R_1, R_2 or R_3 are



or mixtures thereof.

2. A composition according to claim 1 which has a pH in the range of from 3.5 to 5.

3. A composition according to claim 2 which has a pH of about 4.

4. A composition according to any of the preceding claims wherein the organic peracid precursor is selected from ethylene glycol diesters, triacetin, diacetin, or mixtures thereof.

5. A composition according to claim 4 wherein the organic peracid precursor is selected from triacetin and ethylene glycol diacetate.

6. A composition according to any of the preceding claims which comprises from 0.5 % to 20 % by weight of the total composition of hydrogen peroxide.

7. A composition according to any of the preceding claims which comprises from 1 % to 15 % by weight of the total composition of said organic peracid precursor.

8. A composition according to claim 6 which comprises from 0.1 to 2 moles of said organic peracid precursor per mole of hydrogen peroxide.

9. A composition according to any of the preceding claims which comprises from 0.5 % to 15 % by weight of the total composition of a surfactant.

10. A composition according to any of the preceding claims which comprises citric acid.


11. A composition according to any of the preceding claims which comprises butylated hydroxy toluene.

Patentansprüche


1. Wäßrige Bleichmittelzusammensetzung, umfassend Wasserstoffperoxid und einen organischen Persäurevorläu-

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 118


fer, dadurch gekennzeichnet, daß die Zusammensetzung ein pH im Bereich von 3,5 bis 6 aufweist und daß der organische Persäurevorläufer eine Verbindung der Formel



ist, worin x 0 oder list, R_1, R_2, R_3 unabhängig voneinander aus -H, -OH,



gewählt sind, worin R_4 ein C_1-C_4-Alkyl ist, mit der Maßgabe, daß mindestens zwei von R_1, R_2 oder R_3



sind; oder Mischungen hiervon.

2. Zusammensetzung nach Anspruch 1, welche einen pH im Bereich von 3,5 bis 5 aufweist.

3. Zusammensetzung nach Anspruch 2, welche einen pH von etwa 4 aufweist.

4. Zusammensetzung nach mindestens einem der vorangehenden Ansprüche, wobei der organische Persäurevorläufer aus Ethylenglycoldiestern, Triacetin. Diacetin oder Mischungen hiervon gewählt ist.

5. Zusammensetzung nach Anspruch 4, wobei der organische Persäurevorläufer aus Triacetin und Ethylenglycoldiacetat gewählt ist.

6. Zusammensetzung nach mindestens einem der vorangehenden Ansprüche, umfassend 0,5 bis 20 Gew.-% der gesamten Zusammensetzung an Wasserstoffperoxid.

7. Zusammensetzung nach mindestens einem der vorangehenden Ansprüche, umfassend 1-15 Gew.-% der gesamten Zusammensetzung des organischen Persäurevorläufers.

8. Zusammensetzung nach Anspruch 6, umfassend 0,1 bis 2 Mole des organischen Persäurevorläufers, pro Mol Wasserstoffperoxid.

9. Zusammensetzung nach mindestens einem der vorangehenden Ansprüche, umfassend 0,5 bis 15 Gew.-% der gesamten Zusammensetzung eines Tensids.

10. Zusammensetzung nach mindestens einem der vorangehenden Ansprüche, umfassend Zitronensäure.


11. Zusammensetzung nach mindestens einem der vorangehenden Ansprüche, umfassend butyliertes Hydroxytoluol.

Revendications


1. Composition de blanchiment aqueuse comprenant du peroxyde d'hydrogène et un précurseur de peracide orga-

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 119


nique, caractérisée en ce que les compositions ont un pH dans le domaine de 3,5 à 6, et en ce que le précurseur de peracide organique est un composé répondant à la formule:



dans laquelle x vaut 0 ou 1, R_1, R_2, R_3 sont choisis indépendamment parmi -H, -OH,



où R_4 est un groupe alkyle en C_1-C_4, à condition qu'au moins deux des radicaux R_1, R_2 et R_3 soient



ou leurs mélanges.

2. Composition selon la revendication 1, qui possède un pH dans le domaine de 3,5 à 5.

3. Composition selon la revendication 2, qui possède un pH d'environ 4.

4. Composition selon l'une quelconque des revendications précédentes, dans laquelle le précurseur de peracide organique est choisi parmi les diesters d'éthylèneglycol, la triacétine, la diacétine, ou leurs mélanges.

5. Composition selon la revendication 4, dans laquelle le précurseur de peracide organique est choisi parmi la triacétine et le diacétate d'éthylèneglycol.

6. Composition selon l'une quelconque des revendications précédentes, qui comprend de 0,5% à 20%, en poids de la composition totale, de peroxyde d'hydrogène.

7. Composition selon l'une quelconque des revendications précédentes, qui comprend de 1% à 15%, en poids de la composition totale, dudit précurseur de peracide organique.

8. Composition selon la revendication 6, qui comprend de 0,1 à 2 moles dudit précurseur de peracide organique par mole de peroxyde d'hydrogène.

9. Composition selon l'une quelconque des revendications précédentes, qui comprend de 0,5% à 15%, en poids de la composition totale, d'un tensioactif.

10. Composition selon l'une quelconque des revendications précédentes, qui comprend de l'acide citrique.

11. Composition selon l'une quelconque des revendications précédentes, qui comprend de l'hydroxytoluène butylé.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 120

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 November 2008 (20.11.2008)

PCT

(10) International Publication Number
WO 2008/140988 A1

(51) International Patent Classification:
C12N 9/16 (2006.01) *C12N 9/52* (2006.01)
C12N 9/50 (2006.01) *C11D 3/386* (2006.01)

(21) International Application Number:
PCT/US2008/062633

(22) International Filing Date: 5 May 2008 (05.05.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/917,252 10 May 2007 (10.05.2007) US

(71) Applicant *(for all designated States except US)*: **DANISCO US INC., GENENCOR DIVISION** [US/US]; 925 Page Mill Road, Palo Alto, California 94304 (US).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **BARNETT, Christopher C.** [US/US]; Danisco US Inc., Genencor Division, 925 Page Mill Road, Palo Alto, California 94304 (US).

(74) Agent: **JACOBSON, Jill A.**; Danisco US Inc., Genencor Division, 925 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(54) Title: STABLE ENZYMATIC PERACID GENERATING SYSTEMS




FIG. 1

(57) Abstract: The present invention provides stable compositions comprising a perhydrolase enzyme, a hydrogen peroxide source, and an ester substrate that efficiently generate aqueous peracid solutions. The generated peracid solutions are suitable for decontaminating and/or sanitizing a wide range of materials and equipment contaminated with pathogens or toxic chemicals. In one preferred embodiment, the stable composition comprises an acyl transferase enzyme, sodium percarbonate, and propylene glycol diacetate, and is stable for 30 days or longer. Upon addition to water, the composition is activated and generates an aqueous solution with a high ratio of peracetic acid to acetic acid.

WO 2008/140988 A1

STABLE ENZYMATIC PERACID GENERATING SYSTEMS

CROSS-REFERENCE TO RELATED APPLICATIONS

[01] This application claims the benefit of U.S. Provisional Application No. 60/917,252, filed on May 10, 2007, which is incorporated by reference herein in its entirety.

FIELD OF THE INVENTION

[02] The present invention relates to stable compositions comprising a perhydrolase enzyme, a hydrogen peroxide source, and an ester substrate that efficiently generate aqueous peracid solutions suitable for use in decontamination involving a wide variety of chemical and biological warfare materials, as well as for general surface cleaning and decontamination.

BACKGROUND OF THE INVENTION

[03] Peracids are widely accepted as a decontamination/disinfection agent. Most notably, peracetic acid (also known as "peroxyacetic acid" or "PAA") is employed widely, *inter alia,* for sterilization of items used in the food industry and in hospitals, as well as for decontamination of biohazards. PAA also can be used as a bleaching chemical in cleaning compositions and industrial processes such as bleaching of pulp. PAA poses relatively few disposal problems after use because it decomposes to compounds which are readily degraded in sewage treatment plants. It has a broad spectrum of activity against microorganisms, and is effective even at low temperatures.

[04] A number of non-enzymatic, chemical or electrochemical methods for preparing aqueous PAA solutions have been described in the prior art. See *e.g.,* U.S. Patent Nos. 6,677,477, 6,211,237, 6,171,551, 5,350,563, and 4,137,256, each of which is hereby incorporated by reference herein.

[05] The typical commercially available aqueous PAA solutions contain about 15% by weight PAA, about 14% by weight hydrogen peroxide, and 28% by weight acetic acid. The use of PAA solutions of this type causes, on account of their unpleasant corrosive and fire-accelerating properties, problems with regard to handling, storage, materials and transport. Thus, PAA has a large chemical "footprint" – meaning that safe production and use of this chemical requires an inordinate amount of energy and resources.

[06] Additionally, the higher ratio of acetic acid to PAA in these commercial solutions exacerbates problems related to the corrosion of stainless steel containers during the cleaning process. A lower ratio of acetic acid would reduce the need to further treat (*e.g.*, passivate) steel containers following cleaning with PAA.

[07] Some of these problems could be attenuated by the development of enzymatic systems for the *in situ* generation of peracids in aqueous solution. Enzymatic peracid generating systems provide numerous significant advantages due to the non-caustic characteristics of the water-based biochemical solvents, which allow users to safely use the system without fear of injury to themselves, their equipment, or the environment. In addition, there is a reduced logistical burden, as the enzyme systems are easily transported, easy to use, and require the use of much less water than traditional decontamination methods. Additionally, by-products of enzymatic peracid generating systems typically are biodegradable. For example, PAA decomposes spontaneously to acetic or propionic acid.

[08] PCT/US06/47022, filed December 8, 2006 (which is hereby incorporated by reference herein) discloses enzymes that efficiently generate aqueous peracid solution in sufficient quantity for use in a range of decontaminating and sanitizing applications. In some embodiments, PCT/US06/47022 discloses an acyl transferase enzyme from *Mycobacterium smegmatis* and variants that generate aqueous PAA solution when the enzyme is added to water along with percarbonate and propylene glycol diacetate (PGDA).

[09] Water soluble containers provide a convenient means for delivering pre-measured compositions into an aqueous solution. Such containers have been described for use with cleaning compositions in a number of U.S. patents. For example, U.S. Pat. No. 5,783,541 teaches a dishwashing composition disposed in a water soluble film, wherein the water soluble film is coated with a water dissolvable glue. U.S. Pat. No. 6,037,319, which teaches a water soluble sachet containing a cleaning composition containing an alcohol and hexylene glycol. U.S. Pat. No. 6,465,413 discloses laundering and dishwashing products contained in a water soluble film sachet, wherein the formulation comprises a granulated percarbonate compound mixed with and encapsulated in an encapsulating blend comprising sulfate, carboxy methyl cellulose and nonionic surfactant. U.S. Pat. No. 6,492,312 discloses a water soluble sachet comprising such a dishwashing composition along with a discrete particle that enhances cleaning in a dishwashing machine. US 20030199415 A1, teaches a cleaning system comprising a water soluble sachet containing a concentrate of a liquid

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 123

cleaning composition having excellent foam collapse properties and excellent grease cutting property.

[10] U.S. Pat. No. 7,052,520 discloses a water-permeable, but not water-soluble, article referred to as a "sachet" or "bio-bag", for use in an enzymatic fabric cleaning. This "bio-bag" does not dissolve in water but rather contains the enzyme-producing micro-organisms in such a manner that they cannot disperse from it into the wash water.

[11] Notwithstanding the above developments in the art, there remains a need for an enzymatic system for generating peracids that exhibits greater stability, greater ease of use, while lessening the storage, transport and overall chemical issues created by the use of this class of compounds in commercial decontamination applications.

SUMMARY OF THE INVENTION

[12] The present invention provides stable compositions, systems, and kits that enzymatically generate peracid in aqueous solution, and which can be used in a wide range of decontamination methods and applications.

[13] In some embodiments, the present invention provides stable compositions useful for generating peracid in aqueous solution, wherein said composition comprises: an enzyme with perhydrolase activity, a hydrogen peroxide source, and an ester substrate. These three active ingredients are activated by addition to water resulting in the generation of an aqueous peracid solution. It is a surprising result of the present invention that these compositions are highly stable prior to activation (*i.e.*, addition to water), wherein stability corresponds to the composition's ability to generate a peracid upon addition to water in an amount effective for use in sanitizing, disinfecting and/or decontaminating items. That is, the stable compositions of present invention retain their ability to generate peracid upon addition to water (*i.e.*, peracid generating activity) for at least 7 days, about 14 days, about 30 days, about 60 days, or longer.

[14] In some embodiments, the stable compositions include additional active ingredients such as additional enzymes, surfactants, detergent formulations, and/or cleaning compositions. However, in one preferred embodiment, the composition includes three active ingredients: an acyl transferase enzyme, the hydrogen peroxide source, and the ester substrate.

[15] In one preferred embodiment, the stable composition comprises the acyl transferase enzyme from *M. smegmatis* (MsAcT), sodium percarbonate, and propylene glycol diacetate (PGDA), wherein the enzyme and percarbonate are solids suspended in the liquid PGDA.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 124

In some embodiments, the perhydrolase enzyme comprises the amino acid sequence set forth in SEQ ID NO:1 or a variant or homologue thereof. In one embodiment, the perhydrolase enzyme is the S54V variant of SEQ ID NO:1.

[16] In one embodiment, the composition comprises from about 0.001% to about 1% by weight MsAcT, from about 35% to about 45% by weight sodium percarbonate, and from about 65% to about 55% by weight propylene glycol diacetate. Upon addition to water, the stable composition is activated and commences generating peracetic acid (PAA). The weight percent of PAA produced in water does not decrease significantly despite prior storage of the composition at ambient temperature for at least 7 days, about 14 days, about 30 days, about 60 days, or longer.

[17] In preferred embodiments, the resulting peracid aqueous solutions generated by the stable compositions are at least about 0.08%, 0.16%, 0.24%, 0.32%, 0.40%, or greater percentage by weight peracid. In embodiments of the stable composition that generate PAA, the resulting PAA aqueous solutions generated by the stable compositions are at least about 0.08%, 0.16%, 0.24%, 0.32%, 0.40%, or greater percentage by weight PAA. In one preferred embodiment, the PAA aqueous solution is at least about 0.16% PAA by weight.

[18] Additionally, the ratio of peracid to acid produced by the enzymatic activity of the stable composition added to water is at least about 2:1, 4:1, 5:1, 10:1, 20:1, or even greater. In embodiments of the stable composition that generate PAA, the ratio of PAA to acetic acid generated upon addition to water is at least about 2:1, 4:1, 5:1, 10:1, 20:1, or even greater.

[19] The present invention provides systems and kits for generating peracids in aqueous solution that based on the stable composition embodiments. Thus, in one embodiment the invention provides a system for generating peracetic acid in aqueous solution comprising any of the stable compositions of the present invention in a water soluble container. In some embodiments, the container is formed from a water soluble polymer, preferably a polyvinyl alcohol polymer. Generally, the water soluble container can be in any form, preferably a sachet, ampoule, capsule or sphere. In one preferred embodiment, the water soluble container is a sachet comprising a polyvinyl alcohol film.

[20] In another embodiment, the present invention provides a kit for decontamination comprising the packaged combination of: (a) a pre-measured amount of any of the stable compositions of the present invention in a sealed container, wherein the amount of the stable composition generates an aqueous solution of at least about 0.16% peracetic acid by weight upon addition to a set volume of water, and (b) instructions for use of the stable

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 125

composition. In one embodiment, the sealed container of the kit is large enough to hold at least twice said set volume of water. In another embodiment, the kit further comprises the stable composition packaged within a water soluble container that is packaged within said sealed container. In one preferred embodiment, the water soluble container is a sachet made of a polyvinyl alcohol film. In an alternative embodiment, the packaged combination of the kit further comprises the set volume of water in a second sealed container, and wherein the water is sterilized.

[21] Generally, the stable compositions of the present invention, and the systems and kits incorporating the stable compositions, can be used in various methods for preparing aqueous solutions for decontaminating, disinfecting, and/or sanitizing items. Thus, the present invention also provides methods for preparing a decontamination solution comprising adding the stable composition useful for generating peracetic acid to water and mixing for at least about 30 minutes, 20 minutes, 15 minutes, 10 minutes, or even fewer minutes.

[22] In some embodiments, the method for decontamination comprises: (a) providing a stable composition comprising an enzyme with perhydrolase activity, wherein said activity comprises a perhydrolysis to hydrolysis ratio of at least 2:1; a hydrogen peroxide source; and an ester substrate; and (b) adding said composition to water and mixing for at least 20 minutes, thereby generating an aqueous solution of at least about 0.16% peracetic acid by weight, and a pH less than about 9.0; and (c) exposing an item comprising a contaminant to said solution. In one embodiment, the solution of the stable composition includes no other ingredients capable of buffering the pH.

[23] In one preferred embodiment, the method for decontamination of the present invention comprises: (a) providing a stable composition comprising an acyl transferase enzyme, a hydrogen peroxide source, and propylene glycol diacetate; (b) adding said composition to water and mixing for at least 20 minutes, thereby generating an aqueous solution of at least about 0.16% peracetic acid by weight; and (c) exposing an item comprising a contaminant to said solution. In some embodiments of the method for preparing a solution, the stable composition provided comprises from about 0.001% to about 1% by weight MsAcT, from about 35% to about 45% by weight sodium percarbonate, and from about 65% to about 55% by weight propylene glycol diacetate.

[24] In one preferred embodiment of the methods, the stable composition is contained in a water soluble container and the container is added to the water. In one preferred

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 126

embodiment, the water soluble container is a sachet, ampoule, capsule or sphere, formed from a water soluble polymer, preferably a polyvinyl alcohol polymer.

[25] In various embodiments, the methods of the invention are useful against a wide range of contaminants including toxins selected from the group consisting of botulinum toxin, anthracis toxin, ricin, scombroid toxin, ciguatoxin, tetrodotoxin, mycotoxins, and any combination thereof; and pathogens selected from the group consisting of bacteria, viruses, fungi, parasites, prions, and any combination thereof. In one embodiment, the methods of the invention are useful against biofilms, including those formed by pathogens including but not limited to: *Pseudomonas aeruginosa*, *Staphylococcus aureus* (SRWC-10943), and *Listeria monocytogenes* (ATCC 19112).

[26] In various embodiments, the methods of the invention are useful for decontaminating and/or sanitizing a wide range of contaminated items including hard surfaces, fabrics, food, feed, apparel, rugs, carpets, textiles, medical instruments, veterinary instruments, pharmaceutical processing equipment, and biotechnology processing equipment. In one preferred embodiment, PAA solutions generated using the stable compositions of the present invention may be used to sanitize stainless steel equipment, including large reactors, used in pharmaceutical and biotechnology processes.

BRIEF DESCRIPTION OF THE DRAWINGS

[27] Figure 1 provides a graph showing the enzymatic generation of PAA from hydrogen peroxide or percarbonate.

[28] Figure 2 provides a graph showing the generation of PAA from glucose and propyleneglycol diacetate.

[29] Figure 3 provides a graph showing the generation of PAA at three different temperatures (21°C, 40°C, and 60°C).

[30] Figure 4 provides a graph showing the ability of the acetyl transferase enzyme to produce concentrated PAA.

DETAILED DESCRIPTION OF THE INVENTION

I. Overview

[31] The present invention provides stable compositions, systems, kits, that enzymatically generate peracids in aqueous solution, and which can be used in a wide range of decontamination methods and applications. The present invention is based in part on the surprising discovery that compositions comprising a perhydrolase enzyme, such as acyl transferase, a hydrogen peroxide source, and an ester substrate, such as propylene

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 127

glycol diacetate, are extremely stable prior to use. Indeed, compositions of these three components can be stable for at least 7 days, about 14 days, about 30 days, about 60 days, or longer, wherein stability corresponds to the ability to generate an effective amount of peracid upon addition to water.

[32] Peracids (*e.g.*, peracetic acid) are well-characterized decontamination agents that are accepted and approved for use in a wide range of applications. *In-situ* enzymatic peracetic acid generation in water, which occurs with a preferred embodiment of the stable composition, systems and kits of the present invention, is desirable as it is much safer than reactive chemical generation in solvents and requires much less volume. Thus, the present invention provides a stable composition that is convenient, simple to use, and highly effective for a wide range decontamination methods and techniques. For example, the stable compositions of the present invention may be used in decontaminating chemical and biological warfare materials, as well as for general surface cleaning and decontamination

[33] In one preferred embodiment, the stable composition comprises the acyl transferase enzyme, MsAcT from *M. smegmatis*, and sodium percarbonate as hydrogen peroxide source. In one embodiment, the composition comprises from about 0.001% to about 1% by weight MsAcT, from about 35% to about 45% by weight sodium percarbonate, and from about 65% to about 55% by weight propylene glycol diacetate.

[34] The stable composition of the present provides numerous advantages over currently used methods that utilize peracid for cleaning, disinfection and/or decontamination. Significantly, the composition is a stable "All-In-One" composition, wherein all of the ingredients are formulated together (*e.g.*, in a single container or package). Consequently, usage of the composition only requires adding the contents of a single container to water. Additionally, the present invention also provides the stable composition in a sealed water soluble container, which allows the further convenience of not having to even open a container. Instead, the composition in the water soluble container is added to water, thereby providing an aqueous solution convenient for decontamination use.

II. Definitions

[35] Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. For example, Singleton and Sainsbury, *Dictionary of Microbiology and*

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 128

Molecular Biology, 2d Ed., John Wiley and Sons, NY (1994); and Hale and Marham, *The Harper Collins Dictionary of Biology*, Harper Perennial, NY (1991) provide those of skill in the art with a general dictionaries of many of the terms used in the invention. Although any methods and materials similar or equivalent to those described herein find use in the practice of the present invention, the preferred methods and materials are described herein. Accordingly, the terms defined immediately below are more fully described by reference to the Specification as a whole. Also, as used herein, the singular terms "a," "an," and "the" include the plural reference unless the context clearly indicates otherwise. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively. It is to be understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary, depending upon the context in which they are used by those of skill in the art.

[36] It is intended that every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written herein. Every minimum numerical limitation given throughout this specification will include every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this specification will include every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.

[37] As used herein, the term "enzyme" refers to any protein that catalyzes a chemical reaction. The catalytic function of an enzyme constitutes its "activity" or "enzymatic activity." An enzyme typically is classified according to the type of catalytic function it carries out, *e.g.*, hydrolysis of peptide bonds.

[38] As used herein, the term "substrate" refers to a substance (*e.g.*, a chemical compound) on which an enzyme performs its catalytic activity to generate a product.

[39] A "perhydrolase" refers to an enzyme that is capable of catalyzing a perhydrolysis reaction that results in the production of a sufficiently high amount of peracid suitable for use in an application such as cleaning, bleaching, disinfection, or sterilization. Generally, a perhydrolase enzyme used in methods described herein exhibits a high perhydrolysis to hydrolysis ratio. In some embodiments, the perhydrolase comprises, consists of, or consists essentially of the *Mycobacterium smegmatis* perhydrolase amino acid sequence set forth in

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 129

SEQ ID NO: 1, or a variant or homolog thereof. In some embodiments, the perhydrolase enzyme comprises acyl transferase activity and catalyzes an aqueous acyl transfer reaction.

[40] A "peracid" is an organic acid of the formula RC(=O)OOH.

[41] "Perhydrolysis" or "perhydrolyze" refers to an enzymatic reaction that produces a peracid. In some embodiments, a peracid is produced by perhydrolysis of an ester substrate of the formula $R_1C(=O)OR_2$, where R_1 and R_2 are the same or different organic moieties, in the presence of hydrogen peroxide (H_2O_2).

[42] The phrase "source of hydrogen peroxide" includes hydrogen peroxide as well as the components of a system that can spontaneously or enzymatically produce hydrogen peroxide as a reaction product.

[43] The phrase "perhydrolysis to hydrolysis ratio" refers to the ratio of the amount of enzymatically produced peracid to the amount of enzymatically produced acid by a perhydrolase enzyme from an ester substrate under defined conditions and within a defined time.

[44] As used herein, the term "acyl" refers to an organic acid group, which is the residue of a carboxylic acid after removal of a hydroxyl (-OH) group (*e.g.*, ethanoyl chloride, CH_3CO-Cl, is the acyl chloride formed from ethanoic acid, CH_3CO-OH). The name of an individual acyl group is general formed by replacing the "-ic" of the acid by "-yl."

[45] As used herein, the term "acylation" refers to a chemical transformation in which an acyl (RCO-) group is substituted into a molecule, generally for an active hydrogen of an -OH group.

[46] As used herein, the term "transferase" refers to an enzyme that catalyzes the transfer of a functional group from one substrate to another substrate.

[47] As used herein, the term "enzymatic conversion" refers to the modification of a substrate or intermediate to a product, by contacting the substrate or intermediate with an enzyme. In some embodiments, contact is made by directly exposing the substrate or intermediate to the appropriate enzyme. In other embodiments, contacting comprises exposing the substrate or intermediate to an organism that expresses and/or excretes the enzyme, and/or metabolizes the desired substrate and/or intermediate to the desired intermediate and/or end-product, respectively.

[48] As used herein, "effective amount of enzyme" refers to the quantity of enzyme necessary to achieve the activity required in the specific application (*e.g.*, production of peracetic acid by acyl transferase for use in decontamination). Such effective amounts are readily ascertained by one of ordinary skill in the art and are based on many factors, such as

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 130

the particular enzyme variant used, the specific composition, the method of decontamination, the item to be decontaminated, and the like.

[49] As used herein, the term "stability" in reference to a substance (*e.g.*, an enzyme) or composition refers to its ability to maintain a certain level of functional activity over a period of time under certain environmental conditions. Furthermore, the term "stability" can be used in a number of more specific contexts referring to the particular environmental condition that is of interest. For example, "thermal stability" as used herein refers to the ability of a substance or composition to maintain its function (*i.e.*, not degrade) at increased temperature. A substantial change in stability is evidenced by at least about a 5% or greater increase or decrease (in most embodiments, it is preferably an increase) in the half-life of the functional activity being assayed, as compared to the activity present in the absence of the selected environmental conditions.

[50] As used herein, the term "chemical stability" as used in reference to an enzyme refers to the stability of the enzyme in the presence of chemicals that adversely affect its activity. In some embodiments, such chemicals include, but are not limited to hydrogen peroxide, peracids, anionic detergents, cationic detergents, non-ionic detergents, chelants, etc. However, it is not intended that the present invention be limited to any particular chemical stability level nor range of chemical stability.

[51] As used herein, "pH stability" refers to the ability of a substance (*e.g.*, an enzyme) or composition to function at a particular pH. Stability at various pHs can be measured either by standard procedures known to those in the art and/or by the methods described herein. A substantial change in pH stability is evidenced by at least about 5% or greater increase or decrease (in most embodiments, it is preferably an increase) in the half-life of the functional activity, as compared to the activity at the optimum pH. It is not intended that the present invention be limited to any pH stability level nor pH range.

[52] As used herein, "oxidative stability" refers to the ability of a substance (*e.g.*, an enzyme) or composition to function under oxidative conditions, *e.g.*, in the presence of an oxidizing chemical.

[53] As used herein, "oxidizing chemical" refers to a chemical that has the capability of bleaching. The oxidizing chemical is present at an amount, pH and temperature suitable for bleaching. The term includes, but is not limited to hydrogen peroxide and peracids.

[54] As used herein, the terms "purified" and "isolated" refer to the removal of contaminants from a sample. For example, an acyl transferase is purified by removal of

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 131

contaminating proteins and other compounds within a solution or preparation that are not acyl transferases.

[55] As used herein, the term "contaminant" refers to any substance which by its contact or association with another substance, material, or item makes it undesirable, impure, and/or unfit for use.

[56] As used herein, the term "a contaminated item" or "item in need of decontamination" refers to any item or thing in contact or associated with a contaminant and/or which needs to be decontaminated. It is not intended that the item be limited to any particular thing or type of item. For example, in some embodiments, the item is a hard surface, while in other embodiments, the item is an article of clothing. In yet additional embodiments, the item is a textile. In yet further embodiments, the item is used in the medical and/or veterinary fields. In some preferred embodiments, the item is a surgical instrument. In further embodiments, the item is used in transportation (*e.g.*, roads, runways, railways, trains, cars, planes, ships, etc.). In further embodiments, the term is used in reference to food and/or feedstuffs, including but not limited to meat, meat by-products, fish, seafood, vegetables, fruits, dairy products, grains, baking products, silage, hays, forage, etc. Indeed, it is intended that the term encompass any item that is suitable for decontamination using the methods and compositions provided herein.

[57] As used herein, the term "decontamination" refers to the removal of substantially all or all contaminants from a contaminated item. In some preferred embodiments, decontamination encompasses disinfection, while in other embodiments, the term encompasses sterilization. However, it is not intended that the term be limited to these embodiments, as the term is intended to encompass the removal of inanimate contaminants, as well as microbial contamination. (*e.g.*, bacterial, fungal, viral, prions, etc.).

[58] As used herein, the term "disinfecting" refers to the removal of contaminants from the surfaces, as well as the inhibition or killing of microbes on the surfaces of items. It is not intended that the present invention be limited to any particular surface, item, or contaminant(s) or microbes to be removed.

[59] As used herein, the term "sterilizing" refers to the killing of all microbial organisms on a surface.

[60] As used herein, the term "sporicidal" refers to the killing of microbial spores, including but not limited to fungal and bacterial spores. The term encompasses compositions that are effective in preventing germination of spores, as well as those compositions that render spores completely non-viable.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 132

[61] As used herein, the terms "bactericidal," "fungicidal," and "viricidal" refer to compositions that kill bacteria, fungi, and viruses, respectively. The term "microbiocidal" refers to compositions that inhibit the growth and/or replication of any microorganisms, including but not limited to bacteria, fungi, viruses, protozoa, rickettsia, etc.

[62] As used herein, the terms "bacteriostatic," "fungistatic," and "virostatic" refer to compositions that inhibit the growth and/or replication of bacteria, fungi, and viruses, respectively. The term "microbiostatic" refers to compositions that inhibit the growth and/or replication of any microorganisms, including but not limited to bacteria, fungi, viruses, protozoa, rickettsia, etc.

[63] As used herein, the term "cleaning composition" refers to compositions that find use in the removal of undesired compounds from items to be cleaned, such as fabric, dishes, contact lenses, other solid substrates, hair (shampoos), skin (soaps and creams), teeth (mouthwashes, toothpastes) etc. The term further refers to any composition that is suited for cleaning, bleaching, disinfecting, and/or sterilizing any object and/or surface. It is intended that the term includes, but is not limited to detergent compositions (*e.g.*, liquid and/or solid laundry detergents and fine fabric detergents; hard surface cleaning formulations, such as for glass, wood, ceramic and metal counter tops and windows; carpet cleaners; oven cleaners; fabric fresheners; fabric softeners; and textile and laundry pre-spotters, as well as dish detergents). The term further encompasses any materials/compounds selected for the particular type of cleaning composition desired and the form of the product (*e.g.*, liquid, gel, granule, or spray composition), as long as the composition is compatible with the acyl transferase, hydrogen peroxide source, PGDA, and any other enzyme(s) or substance used in the composition. The specific selection of cleaning composition materials is readily made by considering the surface, item or fabric to be cleaned, and the desired form of the composition for the cleaning conditions during use. Indeed, the term "cleaning composition" as used herein, includes unless otherwise indicated, granular or powder-form all-purpose or heavy-duty washing agents, especially cleaning detergents; liquid, gel or paste-form all-purpose washing agents, especially the so-called heavy-duty liquid (HDL) types; liquid fine-fabric detergents; hand dishwashing agents or light duty dishwashing agents, especially those of the high-foaming type; machine dishwashing agents, including the various tablet, granular, liquid and rinse-aid types for household and institutional use; liquid cleaning and disinfecting agents, including antibacterial hand-wash types, cleaning bars, mouthwashes, denture cleaners, car or carpet shampoos, bathroom cleaners; hair shampoos and hair-rinses; shower gels and foam baths

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 133

and metal cleaners; as well as cleaning auxiliaries such as bleach additives and "stain-stick" or pre-treat types.

[64] As used herein, the terms "detergent composition" and "detergent formulation" are used in reference to mixtures which are intended for use in a wash medium for the cleaning of soiled objects. In some preferred embodiments, the term is used in reference to laundering fabrics and/or garments (*e.g.*, "laundry detergents"). In alternative embodiments, the term refers to other detergents, such as those used to clean dishes, cutlery, etc. (*e.g.*, "dishwashing detergents"). It is not intended that the present invention be limited to any particular detergent formulation or composition. Indeed, it is intended that in addition to a perhydrolase enzyme, *e.g.*, an acyl transferase, the term encompasses detergents that contain surfactants, transferase(s), hydrolytic enzymes, oxido reductases, builders, bleaching agents, bleach activators, bluing agents and fluorescent dyes, caking inhibitors, masking agents, enzyme activators, antioxidants, and solubilizers.

[65] As used herein, the term "enzyme compatible," when used in the context of cleaning composition materials means that the materials do not reduce the enzymatic activity to such an extent that the relevant enzyme is not effective as desired during normal use situations.

[66] As used herein, "protein" refers to any composition comprised of amino acids and recognized as a protein by those of skill in the art. The terms "protein," "peptide" and polypeptide are used interchangeably herein. Wherein a peptide is a portion of a protein, those skilled in the art understand the use of the term in context. The terms "wild-type" and "native" are used to refer to proteins found in nature. In some embodiments, the wild-type protein's sequence is the starting point of a protein engineering project.

[67] As used herein, the terms "related protein" or "homologous protein" refer to proteins that are functionally and/or structurally similar (*i.e.*, have similar action and/or structure). It is intended that the term encompass the same or similar enzyme(s) (*i.e.*, in terms of structure and function) obtained from different species. It is not intended that the present invention be limited to related proteins from any particular source(s) or proteins related evolutionarily. In addition, the term related or homologous proteins encompasses tertiary structural homologs and primary sequence homologs. Thus, the terms include proteins with "variant" or "mutant" sequences relative to the wild-type sequence.

[68] As used herein, the term "derivative" refers to a protein which is derived from a parent protein by addition of one or more amino acids to either or both of the C- and N-terminal end(s), substitution of one or more amino acids at one or a number of different sites in the amino acid sequence, and/or deletion of one or more amino acids at either or

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 134

both C- and N- terminal end(s) and/or at one or more sites in the amino acid sequence, and/or insertion of one or more amino acids at one or more sites in the amino acid sequence. The preparation of a protein derivative is often achieved by modifying a DNA sequence that encodes a native protein, transformation of the modified DNA sequence into a suitable host, and expression of the modified DNA sequence to produce the derivative protein.

[69] Related (and derivative) proteins encompass "variant" proteins. Variant proteins differ from a parent protein and/or from one another by a small number of amino acid residues. In some embodiments, the number of different amino acid residues is any of about 1, 2, 3, 4, 5, 10, 20, 25, 30, 35, 40, 45, or 50. In some embodiments, variants differ by about 1 to about 10 amino acids.

[70] In some embodiments, related proteins, such as variant proteins, comprise any of at least about 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 99.5% amino acid sequence identity.

[71] As used herein, the term "analogous sequence" refers to a polypeptide sequence within a protein that provides a similar function, tertiary structure, and/or conserved residues with respect to a reference protein. For example, in epitope regions that contain an alpha helix or a beta sheet structure, replacement amino acid(s) in an analogous sequence maintain the same structural element. In some embodiments, analogous sequences are provided that result in a variant enzyme exhibiting a similar or improved function with respect to the parent protein from which the variant is derived.

[72] As used herein, "homologous protein" refers to a protein (*e.g.*, a perhydrolase enzyme) that has similar function (*e.g.*, enzymatic activity) and/or structure as a reference protein (*e.g.*, a perhydrolase enzyme from a different source). Homologs may be from evolutionarily related or unrelated species. In some embodiments, a homolog has a quaternary, tertiary and/or primary structure similar to that of a reference protein, thereby potentially allowing for replacement of a segment or fragment in the reference protein with an analogous segment or fragment from the homolog, with reduced disruptiveness of structure and/or function of the reference protein in comparison with replacement of the segment or fragment with a sequence from a non-homologous protein.

[73] As used herein, "wild-type," "native," and "naturally-occurring" proteins are those found in nature. The terms "wild-type sequence" refers to an amino acid or nucleic acid sequence that is found in nature or naturally occurring. In some embodiments, a wild-type sequence is the starting point of a protein engineering project, for example, production of variant proteins.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 135

III. Enzymatic Generation of Peracid in Aqueous Solution

[74] The stable compositions of the present invention comprise at least one enzyme as a component (*i.e.*, ingredient). Generally, the enzymes used in the present invention must have significant perhydrolase activity – *i.e.*, a catalytic activity that results in the formation of high amounts of peracid suitable for applications such as cleaning, bleaching, and disinfecting. The use of enzymes with perhydrolase activity for peracid generation is described in WO 05/056782, which is hereby incorporated by reference herein in its entirety.

[75] Typically, enzymatic perhydrolase activity is accompanied by hydrolase activity. Indeed, as discussed below, many hydrolase enzymes also act as perhydrolases in the presence of hydrogen peroxide. In particularly preferred embodiments, the enzymes of the present invention have very high ratio of perhydrolase to hydrolase activity, and thereby produce a high ratio of peracid relative to acid products (*e.g.*, ratio of peracid to acid of at least about 2:1, 5:1, 10:1, or greater). These high perhydrolysis to hydrolysis ratios of these distinct enzymes makes these enzymes suitable for use in a very wide variety of applications.

[76] In addition to having significant perhydrolase activity, the enzymes useful in the stable compositions of the present invention exhibit relatively low activity in dry or substantially water free conditions. In some embodiments, the enzyme component of the stable composition has less than about 1%, 0.5%, 0.2%, or less than about 0.1% activity (perhydrolase or hydrolase) when there is less about 1% water by weight present in the composition. In preferred embodiments, the enzyme exhibits less than about 0.1% activity when there is about 2% water by weight present or less.

[77] In some embodiments, the perhydrolase enzyme is naturally-occurring (*i.e.*, a perhydrolase enzyme encoded by a genome of a cell). In some embodiments, the perhydrolase enzyme comprises, consists of, or consists essentially of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 99.5% identical to the amino acid sequence of a naturally-occurring perhydrolase enzyme.

[78] In some embodiments, the perhydrolase enzyme has a perhydrolysis:hydrolysis ratio of at least 1.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 136

1. Acyl transferase enzymes – MsAcT from M. smegmatis

[79] In one embodiment, the present invention provides a stable composition comprising an acyl transferase capable of the enzymatic conversion of hydrogen peroxide and ester substrate to peracid in aqueous solution. In preferred embodiments, the stable compositions of the present invention use acyl transferase enzymes that produce very high perhydrolysis to hydrolysis ratios. High perhydrolysis to hydrolysis ratios means that these enzymes produce higher yields of peracid, making them more effective in generating decontamination solutions.

[80] An acyl transferase with a favorable perhydrolysis to hydrolysis ratio that makes it particularly well-suited for the present invention is the *M. smegmatis* acyl transferase (MsAcT). For example, MsAcT when used to enzymatically convert PGDA and hydrogen peroxide from percarbonate generates PAA product in at least 5:1 excess over acetic acid. Because the MsAcT produces a high ratio of PAA to acetic acid, the pH of the resulting aqueous peracid solution is able to remain at relatively low pH, less than about pH 10, about pH 9.0, about pH 8.5, about pH 8.0, or about pH 7.5. Such low pH PAA (or other peracid) aqueous solutions are considered non-corrosive (or at least substantially less corrosive) to metals than typical commercial PAA solutions which contain high levels of acetic acid.

[81] Additionally, the MsAcT is essentially inactive in the absence of water. The MsAcT enzyme requires a significant amount of water present (*i.e.*, relatively high degree of hydration) in order to exhibit perhydrolase or hydrolase activity. Typically, MsAcT and it variants exhibit less than about 1%, 0.5%, 0.2%, or less than about 0.1% activity (perhydrolase or hydrolases) when there is less about 1% water by weight present in the composition that includes the enzyme.

[82] The wild-type *M. smegmatis* acyl transferase is described in WO 05/056782, which is hereby incorporated by reference herein in its entirety. PCT/US06/47022, filed December 8, 2006, which also is incorporated by reference herein, discloses a number of MsAcT variants including S54V-MsAcT, and the use of the wild-type and variants to generate aqueous peracid solution when the enzyme is added to water along with a hydrogen peroxide source and an ester substrate (*e.g.*, propylene glycol diacetate (PGDA)).

[83] In some embodiments, the perhydrolase enzyme is a naturally occurring *M. smegmatis* perhydrolase enzyme. In some embodiments, a perhydrolase enzyme comprises, consists of, or consists essentially of the amino acid sequence set forth in SEQ ID NO:1 or a variant or homologue thereof. In some embodiments, a perhydrolase enzyme comprises, consists of, or consists essentially of an amino acid sequence that is at least about 80%,

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 137

85%, 90%, 95%, 97%, 98%, 99%, or 99.5% identical to the amino acid sequence set forth in SEQ ID NO:1.

[84] The amino acid sequence of *M. smegmatis* perhydrolase is shown below:

MAKRILCFGDSLTWGWVPVEDGAPTERFAPDVRWTGVLAQQLGADFEVIEEGLSA
RTTNIDDPTDPRLNGASYLPSCLATHLPLDLVIIMLGTNDTKAYFRRTPLDIALGMS
VLVTQVLTSAGGVGTTYPAPKVLVVSPPPLAPMPHPWFQLIFEGGEQKTTELARVY
SALASFMKVPFFDAGSVISTDGVDGIHFTEANNRDLGVALAEQVRSLL (SEQ ID NO:1)

[85] The corresponding polynucleotide sequence encoding *M. smegmatis* perhydrolase is:

5'-ATGGCCAAGCGAATTCTGTGTTTCGGTGATTCCCTGACCTGGGGCTGGGTCC
CCGTCGAAGACGGGGCACCCACCGAGCGGTTCGCCCCCGACGTGCGCTGGACC
GGTGTGCTGGCCCAGCAGCTCGGAGCGGACTTCGAGGTGATCGAGGAGGGACT
GAGCGCGCGCACCACCAACATCGACGACCCCACCGATCCGCGGCTCAACGGCG
CGAGCTACCTGCCGTCGTGCCTCGCGACGCACCTGCCGCTCGACCTGGTGATCA
TCATGCTGGGCACCAACGACACCAAGGCCTACTTCCGGCGCACCCCGCTCGACA
TCGCGCTGGGCATGTCGGTGCTCGTCACGCAGGTGCTCACCAGCGCGGGCGGCG
TCGGCACCACGTACCCGGCACCCAAGGTGCTGGTGGTCTCGCCGCCACCGCTGG
CGCCCATGCCGCACCCCTGGTTCCAGTTGATCTTCGAGGGCGGCGAGCAGAAGA
CCACTGAGCTCGCCCGCGTGTACAGCGCGCTCGCGTCGTTCATGAAGGTGCCGT
TCTTCGACGCGGGTTCGGTGATCAGCACCGACGGCGTCGACGGAATCCACTTCA
CCGAGGCCAACAATCGCGATCTCGGGGTGGCCCTCGCGGAACAGGTGCGGAGC
CTGCTGTAA-3' (SEQ ID NO:2)

2. Variant Acyl Transferase Enzymes

[86] It is not intended that the stable compositions of the present invention be limited to including wild type *M. smegmatis* acyl transferase. In alternative embodiments, an acyl transferase can be used that is a homolog or engineered variant of the MsAcT acyl transferase. In further preferred embodiments, a monomeric hydrolase is engineered to produce a monomeric or multimeric enzyme that has better acyl transferase activity than the native monomeric enzyme. In some particularly preferred embodiments, the variant comprises the substitution S54V of MsAcT (referred to herein as "S54V-MsAcT" or the "S54V variant" or "variant S54V").

[87] In other embodiments, the acyl transferase used in the stable composition is one of the variant enzymes or homologs disclosed and described in WO 05/056782.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 138

[88] In some embodiments, the perhydrolase enzyme comprises one or more substitutions at one or more amino acid positions equivalent to position(s) in the *M. smegmatis* perhydrolase amino acid sequence set forth in SEQ ID NO:1. In some embodiments, the perhydrolase enzyme comprises any one or any combination of substitutions of amino acids selected from M1, K3, R4, I5, L6, C7, D10, S11, L12, T13, W14, W16, G15, V17, P18, V19, D21, G22, A23, P24, T25, E26, R27, F28, A29, P30, D31, V32, R33, W34, T35, G36, L38, Q40, Q41, D45, L42, G43, A44, F46, E47, V48, I49, E50, E51, G52, L53, S54, A55, R56, T57, T58, N59, I60, D61, D62, P63, T64, D65, P66, R67, L68, N69, G70, A71, S72, Y73, S76, C77, L78, A79, T80, L82, P83, L84, D85, L86, V87, N94, D95, T96, K97, Y99F100, R101, R102, P104, L105, D106, I107, A108, L109, G110, M111, S112, V113, L114, V115, T116, Q117, V118, L119, T120, S121, A122, G124, V125, G126, T127, T128, Y129, P146, P148, W149, F150, I153, F154, I194, and F196.

[89] In some embodiments, the perhydrolase enzyme comprises one or more of the following substitutions at one or more amino acid positions equivalent to position(s) in the *M. smegmatis* perhydrolase amino acid sequence set forth in SEQ ID NO:1: L12C, Q, or G; T25S, G, or P; L53H, Q, G, or S; S54V, L A, P, T, or R; A55G or T; R67T, Q, N, G, E, L, or F; K97R; V125S, G, R, A, or P; F154Y; F196G.

[90] In some embodiments, the perhydrolase enzyme comprises a combination of amino acid substitutions at amino acid positions equivalent to amino acid positions in the *M. smegmatis* perhydrolase amino acid sequence set forth in SEQ ID NO:1: L121 S54V; L12M S54T; L12T S54V; L12Q T25S S54V; L53H S54V; S54P V125R; S54V V125G; S54V F196G; S54V K97R V125G; or A55G R67T K97R V125G.

[91] Several methods are known in the art that are suitable for generating variants of the acyl transferase enzymes of the present invention, including but not limited to site-saturation mutagenesis, scanning mutagenesis, insertional mutagenesis, random mutagenesis, site-directed mutagenesis, and directed-evolution, as well as various other recombinatorial approaches.

[92] In some embodiments, acyl transferases useful with the present invention include engineered variants within the SGNH-hydrolase family of proteins. In some preferred embodiments, the engineered proteins comprise at least one or a combination of the following conserved residues: L6, W14, W34, L38, R56, D62, L74, L78, H81, P83, M90, K97, G110, L114, L135, F180, G205. In alternative embodiments, these engineered proteins comprise the GDSL-GRTT and/or ARTT motifs. In further embodiments, the

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 139

enzymes are multimers, including but not limited to dimers, octamers, and tetramers. In yet additional preferred embodiments, the engineered proteins exhibit a perhydrolysis to hydrolysis ratio that is greater than about 1:1, 2:1, 5:1, or even 10:1.

[93] An amino acid residue of an acyl transferase is equivalent to a residue of *M. smegmatis* acyl transferase if it is either homologous (*i.e.*, having a corresponding position in either the primary and/or tertiary structure) or analogous to a specific residue or portion of that residue in *M. smegmatis* acyl transferase (*i.e.*, having the same or similar functional capacity to combine, react, and/or chemically interact).

[94] In some embodiments, in order to establish homology to primary structure, the amino acid sequence of an acyl transferase is directly compared to the *M. smegmatis* acyl transferase primary sequence and particularly to a set of residues known to be invariant in all acyl transferases for which sequence is known. After aligning the conserved residues, allowing for necessary insertions and deletions in order to maintain alignment (*i.e.*, avoiding the elimination of conserved residues through arbitrary deletion and insertion), the residues equivalent to particular amino acids in the primary sequence of *M. smegmatis* acyl transferase are defined. In preferred embodiments, alignment of conserved residues conserves 100% of such residues. However, alignment of greater than 75% or as little as 50% of conserved residues is also adequate to define equivalent residues. In preferred embodiments, conservation of the catalytic serine and histidine residues are maintained.

[95] Conserved residues are used to define the corresponding equivalent amino acid residues of *M. smegmatis* acyl transferase in other acyl transferases (*e.g.*, acyl transferases from other *Mycobacterium* species, as well as any other organisms).

[96] In some embodiments, the following residues of *M. smegmatis* acyl transferase are modified: Cys7, Asp10, Ser11, Leu12, Thr13, Trp14, Trp16, Pro24, Thr25, Leu53, Ser54, Ala55, Thr64, Asp65, Arg67, Cys77, Thr91, Asn94, Asp95, Tyr99, Val125, Pro138, Leu140, Pro146, Pro148, Trp149, Phe150, Ile153, Phe154, Thr159, Thr186, Ile192, Ile194, and Phe196. However, it is not intended that the present invention be limited to sequence that are modified at these positions. Indeed, it is intended that the present invention encompass various modifications and combinations of modifications.

[97] In some embodiments, some of the residues identified for substitution, insertion or deletion are conserved residues whereas others are not. The acyl transferase mutants of the present invention include various mutants, including those encoded by nucleic acid that comprises a signal sequence. In some embodiments of acyl transferase mutants that are

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 140

encoded by such a sequence are secreted by an expression host. In some further embodiments, the nucleic acid sequence comprises a homolog having a secretion signal.

[98] Characterization of wild-type and mutant proteins is accomplished via any means suitable and is preferably based on the assessment of properties of interest. For example, pH and/or temperature, as well as detergent and /or oxidative stability is/are determined in some embodiments of the present invention. Indeed, it is contemplated that enzymes having various degrees of stability in one or more of these characteristics (pH, temperature, proteolytic stability, detergent stability, and/or oxidative stability) will find use. In still other embodiments, acyl transferases with low peracid degradation activity are selected.

3. Other Enzymes

[99] Although acyl transferase from *M. smegmatis* (MsAcT) is used in one preferred embodiment of the stable compositions, any perhydrolase enzyme obtained from any source which in the presence of hydrogen peroxide converts an ester substrate into mostly peracid may be used in the present invention. In preferred embodiments, the enzyme exhibit a perhydrolysis to hydrolysis ratio that is greater than about 2:1, 5:1, or even 10:1. Consequently, the ratio of peracid to acid product is greater than about 2:1, 5:1, or even 10:1, and the pH of the resulting aqueous peracid solution is able to remain relatively low, *e.g.*, less than about pH 10, about pH 9.0, about pH 8.5, about pH 8.0, or about pH 7.5.

[100] In addition to the acyl transferase enzymes, various hydrolases have perhydrolase activity that makes them useful as enzymes in the compositions of the present invention. Thus, hydrolases useful in the present invention include but are not limited to: carboxylate ester hydrolase, thioester hydrolase, phosphate monoester hydrolase, and phosphate diester hydrolase which act on ester bonds; a thioether hydrolase which acts on ether bonds; and α-amino-acyl-peptide hydrolase, peptidyl-amino acid hydrolase, acyl-amino acid hydrolase, dipeptide hydrolase, and peptidyl-peptide hydrolase which act on peptide bonds. Such hydrolase(s) find use alone or in combination with MsAcT or another perhydrolase. Preferable among them are carboxylate ester hydrolase, and peptidyl-peptide hydrolase.

[101] Other suitable hydrolases include: (1) proteases belonging to the peptidyl-peptide hydrolase class (*e.g.*, pepsin, pepsin B, rennin, trypsin, chymotrypsin A, chymotrypsin B, elastase, enterokinase, cathepsin C, papain, chymopapain, ficin, thrombin, fibrinolysin, renin, subtilisin, aspergillopeptidase A, collagenase, clostridiopeptidase B, kallikrein, gastrisin, cathepsin D, bromelin, keratinase, chymotrypsin C, pepsin C, aspergillopeptidase B, urokinase, carboxypeptidase A and B, and aminopeptidase); (2) carboxylate ester

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 141

hydrolase including carboxyl esterase, lipase, pectin esterase, and chlorophyllase; and (3) enzymes having high perhydrolysis to hydrolysis ratios. Especially effective among them are lipases, as well as esterases that exhibit high perhydrolysis to hydrolysis ratios, as well as protein engineered esterases, cutinases, and lipases, using the primary, secondary, tertiary, and/or quaternary structural features of the perhydrolases of the present invention.

[102] Additionally, it is contemplated that the stable compositions of the present invention may comprise additional enzymes. It is contemplated that by using combinations of enzymes, there will be a concurrent reduction in the amount of chemicals needed. The additional enzymes include but are not limited to: microbial cell wall-degrading and glycoprotein-degrading enzymes, lysozyme, hemicellulases, peroxidases, proteases, cellulases, xylanases, lipases, phospholipases, esterases, cutinases, pectinases, keratinases, reductases, oxidases, phenoloxidases, lipoxygenases, ligninases, pullulanases, tannases, pentosanases, malanases, ß-glucanases, arabinosidases, hyaluronidase, chondroitinase, laccase, endoglucanases, PNGases, amylases, etc., as well as mixtures thereof. In some embodiments, enzyme stabilizers may also be included in the stable composition.

[103] It is not intended that the present invention be limited to any specific enzyme for the generation of hydrogen peroxide, as any enzyme that generates H_2O_2 and acid with a suitable substrate finds use in the methods of the present invention. For example, lactate oxidases from *Lactobacillus* species which are known to create H_2O_2 from lactic acid and oxygen find use with the present invention. Indeed, one advantage of the methods of the present invention is that the generation of acid reduces the pH of a basic solution to the pH range in which the peracid is most effective in bleaching (*i.e.*, at or below the pKa).

[104] Other enzymes (*e.g.*, alcohol oxidase, ethylene glycol oxidase, glycerol oxidase, amino acid oxidase, etc.) that can generate hydrogen peroxide also find use with ester substrates in combination with the acyl transferase or other perhydrolase enzymes of the present invention to generate peracids. Enzymes that generate acid from substrates without the generation of hydrogen peroxide also find use in the present invention. Examples of such enzymes include, but are not limited to proteases. Thus, as described herein, the present invention provides definite advantages over the currently used methods and compositions for decontaminant formulation and use, as well as various other applications.

[105] In addition, oxidases find use in the present invention, including carbohydrate oxidases selected from the group consisting of aldose oxidase (IUPAC classification EC1.1.3.9), galactose oxidase (IUPAC classification EC1.1.3.9), cellobiose oxidase

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 142

(IUPAC classification EC1.1.3.25), pyranose oxidase (IUPAC classification EC1.1.3.10), sorbose oxidase (IUPAC classification EC1.1.3.11) and/or hexose oxidase (IUPAC classification EC1.1.3.5), glucose oxidase (IUPAC classification EC1.1.3.4) and mixtures thereof.

[106] Indeed, it is contemplated that any suitable oxidase can be used in the present invention that follows the equation:

Enzyme + reduced substrate → oxidized substrate + H_2O_2.

4. Hydrogen Peroxide Source

[107] The present invention provides a stable composition comprising a hydrogen peroxide source. In some embodiments, the hydrogen peroxide source is a solid compound that generates hydrogen peroxide upon addition to water. Such compounds include adducts of hydrogen peroxide with various inorganic or organic compounds, of which the most widely employed is sodium carbonate perhydrate, also referred to as sodium percarbonate.

[108] Inorganic perhydrate salts are one preferred embodiment of hydrogen peroxide source. Examples of inorganic perhydrate salts include perborate, percarbonate, perphosphate, persulfate and persilicate salts. The inorganic perhydrate salts are normally the alkali metal salts.

[109] Other hydrogen peroxide adducts useful in the compositions of the present invention include adducts of hydrogen peroxide with zeolites, or urea hydrogen peroxide.

[110] The hydrogen peroxide source compounds may be included as the crystalline and/or substantially pure solid without additional protection. For certain perhydrate salts however, the preferred executions of such granular compositions utilize a coated form of the material which provides better storage stability for the perhydrate salt in the granular product. Suitable coatings comprise inorganic salts such as alkali metal silicate, carbonate or borate salts or mixtures thereof, or organic materials such as waxes, oils, or fatty soaps.

[111] In some embodiments, the present invention provides a stable composition wherein the hydrogen peroxide source is an enzymatic hydrogen peroxide generation system. In one preferred embodiment, the enzymatic hydrogen peroxide generation system comprises an oxidase and its substrate. Suitable oxidase enzymes include, but are not limited to: glucose oxidase, sorbitol oxidase, hexose oxidase, choline oxidase, alcohol oxidase, glycerol oxidase, cholesterol oxidase, pyranose oxidase, carboxyalcohol oxidase, L-amino acid oxidase, glycine oxidase, pyruvate oxidase, glutamate oxidase, sarcosine

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 143

oxidase, lysine oxidase, lactate oxidase, vanillyl oxidase, glycolate oxidase, galactose oxidase, uricase, oxalate oxidase, and xanthine oxidase.

[112] In some embodiments, the hydrogen-peroxide generating compounds and enzyme systems can be combined into the stable composition in their substantially pure form. In alternative embodiments, they may be combined with other components such as surfactants, sequestrants, builders, pH regulators, buffers, stabilizers, processing additives or any other known components of washing compositions, sanitising compositions, disinfecting compositions or bleach additives. In one embodiment, the stable composition comprises a detergent.

[113] Other compounds and enzymatic systems useful as hydrogen peroxide sources in the stable compositions of the present invention include but are not limited those described in U.S.S.N. 10/581,014, which is hereby incorporated by reference herein.

5. Ester Substrates and Peracids

[114] It is not intended that the stable compositions of the present invention be limited to ingredients that generate only peracetic acid. Stable compositions may also be prepared that produce any of a wide range of peracids useful for cleaning, disinfecting, and decontaminating.

[115] Pernonanoic acids, as well as peracids made from long chain fatty acids (*i.e.*, C10-C18) or longer chains, may be generated from All-In-One compositions prepared according to the teachings of the present invention. In some preferred embodiments, the peracid is selected from peracetic acid, perproprionic, perbutanoic, perpentanoic, and perhexanoic acid, and pernonanoic acid.

[116] According to the present invention, a stable All-In-One composition for generating a specific peracid compound upon addition to water requires the use of an ester substrate that upon enzymatic conversion results in the desired peracid. Thus, in some embodiments, the ester substrate is a stable ester of an acid selected from the list consisting of: acetic acid, propionic acid, butanoic acid, pentanoic acid, hexanoic acid, nonanoic acid, formic acid, butyric acid, valeric acid, caproic acid, caprylic acid, decanoic acid, dodecanoic acid, myristic acid, palmitic acid, stearic acid, and oleic acid. In additional embodiments, triacetin, tributyrin, neodol esters, and/or ethoxylated neodol esters serve as ester substrates for peracid formation. Thus, exemplary acetic ester substrates include but are not limited to: methyl acetate, ethyl acetate, propyl acetate, triacetin (1, 3-diacetyloxypropan-2-yl acetate), and propylene glycol diacetate.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 144

[117] In a preferred embodiment, the ester substrate is a stable alcohol ester of an acid the enzymatic conversion of which results in the desired peracid. Thus, in one preferred embodiment, the ester substrate is any poly-alcohol ester compound, *e.g.*, a poly-ol diester such as PGDA. In another preferred embodiment, the ester substrate is a diol-diester compound.

[118] A wide range of ester substrates for perhydrolase enzymes (*e.g.*, acyl transferase) useful in the compositions of the present invention are disclosed in WO 05/056782, which is hereby incorporated by reference herein in its entirety.

[119] The ester substrates useful in the stable compositions of the present invention may be in either solid or liquid form. Generally, the ester substrate should be dry or substantially free of water that can activate the enzyme component of the composition. In preferred embodiments, the ester substrate includes less about 5%, less than about 1%, less than about 0.5%, less than about 0.1%, or even a lower percentage by weight of water.

[120] In some embodiments, the ester substrate is a stable liquid at room temperature, for example, propylene glycol diacetate (PGDA). In some embodiments, the ester substrate is a stable liquid, in which the enzyme and hydrogen peroxide source components of the stable composition do not dissolve. In preferred embodiments, the ester substrate is substantially free of water, thereby minimizing any activation of the enzyme and/or the hydrogen peroxide source in the composition prior to its use.

6. Adjunct Materials and Additional Components

[121] Additional components find use in the formulations of the present invention. Although it is not intended that the formulations of the present invention be so limited, various components are described herein. Indeed, while such components are not essential for the purposes of the present invention, the non-limiting list of adjuncts illustrated hereinafter are suitable for use in the instant compositions and may be desirably incorporated in certain embodiments of the invention, for example to assist or enhance cleaning performance, for treatment of the substrate to be cleaned, or to modify the aesthetics of the cleaning composition as is the case with perfumes, colorants, dyes or the like. It is understood that such adjuncts are in addition to the enzymes of the present invention, hydrogen peroxide and/or hydrogen peroxide source and material comprising an ester moiety. The precise nature of these additional components, and levels of incorporation thereof, will depend on the physical form of the composition and the nature of

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 145

the cleaning operation for which it is to be used. Suitable adjunct materials include, but are not limited to, surfactants, builders, chelating agents, dye transfer inhibiting agents, deposition aids, dispersants, corrosion inhibitors, additional enzymes, and enzyme stabilizers, catalytic materials, bleach activators, bleach boosters, preformed peracids, polymeric dispersing agents, clay soil removal/anti-redeposition agents, brighteners, suds suppressors, dyes, perfumes, structure elasticizing agents, carriers, hydrotropes, processing aids and/or pigments. In addition to the disclosure below, suitable examples of such other adjuncts and levels of use are found in U.S. Patent Nos. 5,576,282, 6,306,812, and 6,326,348, herein incorporated by reference. The aforementioned adjunct ingredients may constitute the balance of the cleaning compositions of the present invention.

[122] In some embodiments, the enzyme system of the present invention further comprises enzymes that remove any residual peracid and/or H_2O_2 after decontamination has been achieved. Such enzymes include but are not limited to catalases and/or hydrolytic enzymes.

[123] Importantly, the present invention provides means for effective cleaning, bleaching, and disinfecting over broad pH and temperature ranges. In some embodiments, the pH range utilized in this generation is 4-12. In some alternative embodiments, the temperature range utilized is between about 5° and about 90°C. The present invention provides advantages over the presently used systems (*See e.g.*, EP Appln. 87-304933.9) in that bleaching is possible at the optimum pH of peracid oxidation, as well as providing bleaching at neutral pH, acidic pHs, and at low temperatures.

IV. Preparation and Use of Stable Compositions for Generating Peracid Solutions

[124] One key advantage of the stable compositions of the present invention is that they are "All-In-One" formulations where all the ingredients are in one container. These stable All-In-One compositions also have the advantage of easy preparation simply by combining the ingredients (*e.g.*, enzyme, hydrogen peroxide source, and ester substrate) in a suitable vessel or container. The order of mixing the ingredients is not particularly important and generally the various ingredients can be added sequentially.

[125] In some embodiments, all of the ingredients of the composition are solids which are simply combined by mixing. In other embodiments, at least one of the ingredients, typically the ester substrate, is a liquid, and preparation is by mixing the dry solid ingredients into the liquid.

[126] Preferably, the stable composition is prepared using solid forms of enzyme(s) and hydrogen peroxide generating compound(s) and mixing them so they are

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 146

suspended in a liquid form of substrate ester compound. In one preferred embodiment, the stable composition of the present invention comprises an acyl transferase enzyme, a hydrogen peroxide source, and the liquid ester substrate, PGDA.

[127] In one preferred embodiment, the solid ingredients may be combined in a "dry formulation" (*e.g.*, acyl transferase enzyme + percarbonate) which is then added to a liquid ester substrate so as to create a suspension. *See e.g.*, preparation of the All-In-One composition disclosed herein in Example 9.

[128] In one preferred embodiment, the solid ingredients of the stable composition are used as-is. For example, granules or powder of sodium percarbonate (*i.e.*, straight out of a commercially obtained reagent jar) are combined in a container with crude solid or granules of acyl transferase, then added to the liquid PGDA to create a suspension. In alternative embodiments, the solid ingredients can be treated prior to combining with each other, or prior to addition to any liquid phase. Examples of such treatments could include encapsulation of enzyme granules and/or peroxide generating compounds in order to inhibit activity during storage, or effect slower release over time after addition to water.

[129] Generally, the stability of the composition is highly dependent on preventing any enzymatic conversion of the substrate, and/or generation of hydrogen peroxide, prior to use. In embodiments where all of the composition ingredients are in solid form, this is accomplished primarily by keeping the mixed ingredients dry or substantially water-free (*i.e.*, less than about 2%, 1%, or 0.5% water by weight). Even relatively small amounts of water that can allow enzyme activity and/or hydrogen peroxide generation to occur should be avoided in order to maximize stability of the All-In-One composition. Consequently, in some embodiments the stable composition further comprises a dessicant or drying agent (*e.g.*, zeolite compound, molecular sieves, etc.).

[130] In one embodiment, the enzyme(s) is incorporated into the stable composition in the form of granules or a spray-dried coating of enzyme-containing crude extract. In other embodiments, the enzyme(s) used in the composition is substantially purified and in a granular, spray-dried, lyophilized, or otherwise dry solid form. In some embodiments, enzyme granules are used which have been formulated so as to contain an enzyme protecting agent and a dissolution retardant material (*i.e.*, material that regulates the dissolution of granules during use).

[131] The present invention can be employed in connection with any number of processes for making dry enzyme granules or dry formulations of hydrogen peroxide source compounds, such as Enzoguard® (Genencor International Inc., Rochester, N.Y.) described

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 147

in U.S. Pat. No. 5,324,649, (which is hereby incorporated by reference herein), or Savinase granules (Novo Nordisk, Denmark), among others. Other exemplary dry formulation processes for enzymes or other compounds which can be used to make the compositions of the present invention include those disclosed in, U.S. Pat. Nos. 4,106,991. 4,689,297, 5,814,501, 5,879,920, 6,248,706, 6,413,749, 6,534,466, or PCT publications WO 97/12958, WO 99/32613, WO 01/29170, and those techniques described in "Enzymes in Detergency," ed. Jan H. van Ee, et al., Chpt. 15, pgs. 310-312 (Marcel Dekker, Inc., New York, N.Y. (1997)); each of which is hereby incorporated by reference herein.

[132] The amounts of hydrogen peroxide source and ester substrate used in the stable composition depends on the specific compounds used as well as the enzyme and final concentration of peracid. Generally, the enzymatic generation of a peracid requires an equimolar amount of hydrogen peroxide and the corresponding ester substrate compound. Consequently, in one preferred embodiment the weight percentage of each of the hydrogen peroxide source and the substrate depends on the formula weight of the specific compounds and is selected so that there are equimolar amounts of hydrogen peroxide and substrate.

[133] The enzyme is incorporated into the composition as much as required according to the purpose. Generally, enzyme should preferably be incorporated in an amount of 0.00001 to 5 weight percent, and more preferably 0.02 to 3 weight percent. Where crude enzyme is used, the granules are added to the stable composition in such an amount that the purified enzyme is 0.001 to 50 weight percent in the granules. Relatively smaller amounts by weight are used with increasing enzyme purity. The granules are used in an amount of 0.002 to 20 and preferably 0.1 to 10 weight percent. Ultimately, specific amounts of enzyme will depend to some extent on the particular enzyme's empirically determined activity for a particular peracid application.

[134] For example, in one preferred embodiment, the stable composition comprises the acyl transferase enzyme from *M. smegmatis* (MsAcT), sodium percarbonate, and propylene glycol diacetate (PGDA), wherein the enzyme and percarbonate are solids suspended in the liquid PGDA, and whereby upon addition to water, the stable composition is capable of generating at least about 0.16% by weight peracetic acid solution. Because of the high ratio of PAA to acetic acid produced by the composition, an aqueous solution of 0.16% by weight PAA has a pH about 8.6. In some embodiments, longer mixing/reaction times for the composition in water can result in even higher levels of PAA (*e.g.*, 0.18% by weight) with lower pH (*e.g.*, about pH 8.0).

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 148

[135] In this embodiment, the composition is prepared by mixing a dry formulation of enzyme and percarbonate into the liquid PGDA. The resulting stable composition is a liquid suspension preferably comprising: from about 0.001% to about 1% by weight MsAcT, from about 35% to about 45% by weight sodium percarbonate, and from about 65% to about 55% by weight propylene glycol diacetate. The stability of this liquid suspension is demonstrated by the fact that the weight percent of peracetic acid it produces in a set amount of water does not decrease significantly despite prior storage of the composition at ambient temperature for at least 7 days, about 14 days, about 30 days, about 60 days, or longer.

[136] The use of the stable compositions of the present invention to prepare an aqueous solution is straightforward: simply add the composition to an appropriate amount of water and stir. Generally, only purified (*e.g.*, MilliQ water), distilled, sterilized and/or deionized water is used. Thus, the present invention also provides a method for preparing a peracid solution comprising adding the stable composition to water and mixing for at least about 30 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, or even fewer minutes. In some embodiments, the method of preparation comprises: (a) providing a stable composition comprising an enzyme with perhydrolase activity, wherein said activity comprises a perhydrolysis to hydrolysis ratio of at least 2:1; a hydrogen peroxide source; and an ester substrate; and (b) adding said composition to water and mixing for at least 20 minutes, thereby generating an aqueous solution of at least about 0.16% peracetic acid by weight, and a pH less than about 9.0. In one embodiment, the composition and the water comprise no other ingredients capable of buffering the pH.

[137] In preferred embodiments, the method of preparation comprises: (a) providing a stable composition comprising an acyl transferase enzyme, a hydrogen peroxide source, and propylene glycol diacetate; and (b) adding said composition to water and mixing for at least 20 minutes, thereby generating an aqueous solution of at least about 0.16% peracetic acid by weight.

[138] It is contemplated that in addition to pure water, the stable compositions can be used in various aqueous systems, including those that have a large percentage of water (*e.g.*, more than about 85%, or more than about 95% water), as well as those with lower percentages of water (*e.g.*, less than about 85%). Alternative embodiments are contemplated where the stable composition is added to aqueous buffer solutions, and/or solutions comprising other ingredients such as surfactants, cleaning compositions, or detergent formulations. In such embodiments, the other ingredients included in the aqueous

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 149

solution can affect the catalytic activity of the peracid generating enzyme. Adjustments to the enzyme concentration, stirring time, temperature, and/or other parameters related to the use of the stable composition are within the knowledge of, or may be determined empirically by, one of ordinary skill in the art.

[139] Generally, the stable compositions of the present invention are intended to be used by adding to water at typical ambient temperatures of about 18°C to about 25°C, or about 20°C to about 22°C. In some applications, however, it may be preferred to use the stable compositions at lower or higher temperatures. The stable compositions are capable of functioning over wide temperature ranges (*e.g.*, from about 5°C to about 90°C; from about 16°C to about °60C; and from about 20°C to about 37°C). Generally, the functional temperature range is dependent on the ability of the enzyme to maintain sufficient activity. Thus, in one embodiment, the present invention contemplates a stable composition comprising wild-type or engineered enzymes with high thermal stability.

[140] Furthermore, the present invention provides systems and kits for generating peracids in aqueous solution that based on the stable composition embodiments. Thus, in one embodiment the invention provides a system for generating peracetic acid in aqueous solution comprising any of the stable compositions of the present invention in a water soluble container. In some embodiments, the container is formed from a water soluble polymer, preferably a polyvinyl alcohol polymer. Generally, the water soluble container can be in any form, preferably a sachet, ampoule, capsule or sphere. In one preferred embodiment, the water soluble container is a sachet comprising a polyvinyl alcohol film.

V. Water Soluble Containers

[141] Water soluble containers useful for delivering the stable compositions of the present invention can be in the form of a sachet, a capsule, or other blow-molded shapes, an injected molded ampoule, or other injection-molded shapes, or rotationally-molded spheres or capsules are formed from a water soluble thermoplastic resin.

[142] Water soluble plastics which may be useful for forming the container include low molecular weight and/or chemically modified polylactides; such polymers have been produced and sold under the name HEPLON™ (Chronopol, Inc.).

[143] In one embodiment, the water soluble containers useful with the present invention comprise melt processable polyvinyl alcohol resins (PVA). Such resins include VINEX™; (Texas Polymer Services, Inc.) and MONOSOL™ film (ChrisCraft Film). Any number or

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 150

combination of PVA resins can be used. Such water soluble polymers are described in *e.g.*, U.S. Patent Nos. 6,956,070, 7,022,656, and 7,067,575, each of which is hereby incorporated by reference herein.

[144] Typical resin properties are:

[145] 1. Glass Transition Temperature (°C) = 28 to 38; preferred is 28 to 33.

[146] 2. Weight Average Molecular Weight (Mw) = 15,000 to 95,000; preferred is 55,000-65,000.

[147] 3. Number Average Molecular Weight (Mn) = 7,500 to 60,000; preferred is 27,000 to 33,000.

[148] In one embodiment, the poly(vinyl) alcohol resin used is MONOSOL™ 7030 or MONOSOL™ 8630.

[149] Blow molded capsules can be formed from the polyvinyl alcohol resin having a molecular weight of about 50,000 to about 70,000 and a glass transition temperature of about 28 to about 33°C. Pelletized resin and concentrate(s) are fed into an extruder. The extruder into which they are fed has a circular, oval, square or rectangular die and an appropriate mandrel. The molten polymer mass exits the die and assumes the shape of the die/mandrel combination. Air is blown into the interior volume of the extrudate while the extrudate contacts a pair of split molds. The molds control the final shape of the package. While in the mold, the package is filled with the appropriate volume of liquid. The mold quenches the plastic. The liquid is contained within the interior volume of the blow molded package.

[150] An injection molded ampoule or capsule is formed from the poly(vinyl) alcohol resin having a molecular weight of about 50,000 to about 70,000 and a glass transition temperature of about 28 to 38°C. Pelletized resin and concentrate(s) are fed to the throat of a reciprocating screw, injection molding machine. The rotation of the screw pushes the pelletized mass forward while the increasing diameter of the screw compresses the pellets and forces them to contact the machine's heated barrel. The combination of heat, conducted to the pellets by the barrel and frictional heat, generated by the contact of the pellets with the rotating screw, melts the pellets as they are pushed forward. The molten polymer mass collects in front of the screw as the screw rotates and begins to retract to the rear of the machine. At the appropriate time, the screw moves forward forcing the melt through the nozzle at the tip of the machine and into a mold or hot runner system which feeds several molds. The molds control the shape of the finished package. The package may be filled

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 151

with liquid either while in the mold or after ejection from the mold. The filling port of the package is heat sealed after filling is completed. This process may be conducted either in-line or off-line.

[151] A rotationally molded sphere or capsule is formed from the poly(vinyl) alcohol resin having a molecular weight of about 50,000 to about 70,000 and a glass transition temperature of about 28 to 38°C. Pelletized resin and concentrate are pulverized to an appropriate mesh size, typically 35 mesh. A specific weight of the pulverized resin is fed to a cold mold having the desired shape and volume. The mold is sealed and heated while simultaneously rotating in three directions. The powder melts and coats the entire inside surface of the mold. While continuously rotating, the mold is cooled so that the resin solidifies into a shape which replicates the size and texture of the mold. After rejection of the finished package, the liquid is injected into the hollow package using a heated needle or probe after filling, the injection port of the package is heat sealed.

[152] Other suitable resins useful for water soluble containers of the present invention include polyethylene oxides (*e.g.*, POLYOX™; Union Carbide, Inc.) and cellulose derived water soluble carbohydrates (*e.g.*, METHOCEL™; Dow Chemical, Inc.). Typically, the cellulose derived water soluble polymers are not readily melt processable.

[153] In some embodiments, the water soluble container is a sachet. In one particularly preferred embodiment, the sachet may be formed from PVA film. Such PVA film sachets are commercially available (Solupak, Ltd., UK).

[154] Generally, PVA film sachets useful with the present invention may be commercially obtained (*e.g.*, from Solupak, Ltd., UK), or may be manufactured using polymer film manufacturing techniques well-known in the art. For example, the pelletized, pre-dried, melt processable PVA resin, is fed to a film extruder. The feed material may also contain pre-dried color concentrate which uses a PVA carrier resin. Other additives, similarly prepared, such as antioxidants, UV stabilizers, anti-blocking additives, etc. may also be added to the extruder. The resin and concentrate are melt blended in the extruder. The extruder die may consist of a circular die for producing blown film or a coat hanger die for producing cast film. Circular dies may have rotating die lips and/or mandrels to modify visual appearance and/or properties.

[155] Typical PVA film properties useful for the water-soluble sachets of the present invention include:

1. Tensile strength (125 mil, break, 50% RH) = 4,700 to 5,700 psi.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 152

2. Tensile modulus (125 mil, 50% RH) = 47,000 to 243,000 psi; preferred range is 140,000 to 150,000 psi.

3. Tear resistance (mean) (ASTM-D-199 gm/ml) = 900-1500.

4. Impact strength (mean) (ASTM-D-1709, gm) = 600-1,000.

5. 100% Elongation (mean) (ASTM-D-882, psi) = 300-600.

6. Oxygen transmission (1.5 mil, 0% RH, 1 atm) = 0.0350 to 0.450 cc/100 sq. in./24 h.

7. Oxygen transmission (1.5 mil, 50% RH, 1 atm) = 1.20 to 1.50 cc/100 sq. in./24 h.

8. 100% modulus (mean) (ASTM-D-882, psi) = 1000-3000.

9. Solubility (sec) (MSTM-205,75°F.) disintegration=1-15; dissolution =10-30.

[156] The extruded film is slit to the appropriate width and wound on cores. Each core holds one reel of film. The reels of slit film are fed to either a vertical form, fill, seal machine (VFFS) or a horizontal form, fill, seal machine (HFFS). The Form, Fill, Seal machine (FFS) makes the appropriate sachet shape (cylinder, square, pillow, oval, etc.) from the film and seals the edges longitudinally (machine direction seal). The FFS machine also makes an end seal (transverse direction seal) and fills the appropriate volume of non-aqueous liquid above the initial transverse seal. The FFS machine then applies another end seal. The liquid is contained in the volume between the two end seals.

[157] In one embodiment, the PVA film used is MONOSOL™ having a weight average molecular weight range of about 55,000 to 65,000 and a number average molecular weight range of about 27,000 to 33,000.

VI. Kits

[158] The stable compositions of the invention described herein are particularly amenable to packaging in various kits. In one embodiment, the present invention provides a kit for decontamination comprising a pre-measured amount of any of the stable compositions described herein, wherein the stable composition comprises a perhydrolasae enzyme, a hydrogen peroxide source, and an ester substrate, and wherein the amount of the stable composition generates an aqueous solution of at least about 0.16% peracid by weight upon addition to a set volume of water, in suitable packaging. In some embodiments, the kit further comprises instructions for use of the stable composition in a method for decontamination as described herein. Instructions may be provided in printed form or in the form of an electronic medium such as a floppy disc, CD, or DVD, or in the form of a website address where such instructions may be obtained.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 153

[159] In one preferred embodiment, the stable composition is provided in a water soluble sealed container. In one preferred embodiment, the water soluble container of the kit is in the form of a sachet, a capsule, an ampoule, spheres formed from a water soluble thermoplastic resin, or other injection-molded shapes. In some embodiments, the water soluble sealed container is made of a water soluble polymer material selected from the group consisting of: polyvinyl alcohol, polyethylene oxides, cellulose derived water soluble carbohydrates, and polyactides. In one preferred embodiment, the water soluble container of the kit is a sachet made of a polyvinyl alcohol film.

[160] In one embodiment of the kit, kit further comprises a mixing container (or vessel) with a volume large enough to hold at least twice said set volume of water. In this embodiment, the mixing container may be a disposable bucket or beaker, optionally sterilized, that optionally contains a magnetic stir bar in the container along with the stable composition.

[161] In one embodiment, a sealed container comprising the stable composition is packaged inside the mixing container of the kit. Thus, usage of such a kit requires merely adding water to the mixing container with stirring.

[162] In another embodiment, the kit further comprises a set volume of water in a sealed container. In one embodiment, the water in the sealed container is sterilized. In one embodiment, the kit comprises the stable composition in a first sealed container and water in a second sealed container.

[163] In another embodiment, the kit includes a stirring device (*e.g.*, a spoon, or similar implement) and/or a magnetic stir bar packaged in the kit, but outside the sealed container. In other embodiments, the kit further comprises a separate package containing a composition for neutralizing the peracid solution after use.

VII. Methods and Uses for Sanitizing, Disinfecting and/or Decontaminating

[164] The stable compositions of the present invention (and related systems and kits incorporating these compositions) can be used in a range of methods for decontaminating, disinfecting, and/or sanitizing items.

[165] In some embodiments, the method for decontamination of the present invention comprises: (a) providing a stable composition comprising an enzyme with perhydrolase activity, wherein said activity comprises a perhydrolysis to hydrolysis ratio of at least 2:1; a hydrogen peroxide source; and an ester substrate; and (b) adding said composition to water and mixing for at least 20 minutes, thereby generating an aqueous solution of at least about

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 154

0.16% peracetic acid by weight, and a pH less than about 9.0; and (c) exposing an item comprising a contaminant to said solution.

[166] In one preferred embodiment, the method for decontamination of the present invention comprises: (a) providing a stable composition comprising an acyl transferase enzyme, a hydrogen peroxide source, and propylene glycol diacetate; (b) adding said composition to water and mixing for at least 20 minutes, thereby generating an aqueous solution of at least about 0.16% peracetic acid by weight; and (c) exposing an item comprising a contaminant to said solution. In some embodiments of the method for preparing a solution, the stable composition provided comprises from about 0.001% to about 1% by weight MsAcT, from about 35% to about 45% by weight sodium percarbonate, and from about 65% to about 55% by weight propylene glycol diacetate.

[167] Depending on the specific type of contaminant to be removed, the step of exposing the item to the peracid solution may be performed over a wide range of time scales. For example, in certain sanitizing procedures exposure times as short as about 30 seconds, 1 minute, 5 minutes or 10 minutes may be sufficient. However, in other applications (*e.g.*, removal of biofilms), it may be necessary to expose the item for considerably longer periods of time, such as about 30 minutes, 1 hour, 6 hours, 12 hours, 24 hours, or even longer, in order to achieve adequate level of decontamination.

[168] Similarly, the temperature of the peracid solution during the exposure step may be adjusted depending on the particular type of contaminant. In a preferred embodiment, the exposure temperature is the ambient temperature at which the solution is prepared, *i.e.*, typically about 18-25°C. In other embodiments, higher temperatures may be used to facilitate the decontamination process. Generally, higher temperatures will accelerate the reactivity of the peracid solution thereby accelerating the decontamination process. Thus, in some embodiments, the exposure step may be carried out with the peracid solution at about 30°C, 37°C, 45°C, 50°C, 60°C, 75°C, 90°C or even higher.

[169] In one preferred embodiment of the methods, the stable composition is contained in a water soluble container and the container is added to the water. In one preferred embodiment, the water soluble container is a sachet, ampoule, capsule or sphere, formed from a water soluble polymer, preferably a polyvinyl alcohol polymer.

[170] In various embodiments, the methods of decontamination using the stable compositions are useful against a wide range of contaminants including toxins selected from the group consisting of botulinum toxin, anthracis toxin, ricin, scombroid toxin, ciguatoxin,

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 155

tetrodotoxin, mycotoxins, and any combination thereof; and pathogens selected from the group consisting of bacteria, viruses, fungi, parasites, prions, and any combination thereof. For example, the methods disclosed herein may be used for decontamination of materials contaminated with materials including but not limited to toxic chemicals, mustard, VX, *B. anthracis* spores, *Y. pestis*, *F. tularensis*, fungi, and toxins (*e.g.*, botulinum, ricin, mycotoxins, etc.), as well as cells infected with infective virions (*e.g.*, flaviviruses, orthomyxoviruses, paramyxoviruses, arenaviruses, rhabdoviruses, arboviruses, enteroviruses, bunyaviruses, etc.). In some particularly preferred embodiments, the at least one pathogen is selected from *Bacillus spp., B. anthracis, Clostridium spp., C. botulinum*, *C. perfringens*, *Listeria spp.*, *Pseudomonas spp.*, *Staphylococcus spp.*, *Streptococcus spp.*, *Salmonella spp.*, *Shigella spp.*, *E. coli*, *Yersinia spp.*, *Y. pestis*, *Francisella spp.*, *F. tularensis*, *Camplyobacter ssp.*, *Vibrio spp.*, *Brucella spp.*, *Cryptosporidium spp.*, *Giardia spp.*, *Cyclospora spp.*, and *Trichinella spp.*

[171] A biofilm is a collection of microorganisms embedded in a matrix of extracellular polymeric substances and various organic and inorganic compounds. Although some biofilms may contain a single species of microorganism, typically biofilms comprise not only different species of microorganisms but different types of microorganisms, for example algae, protozoa, bacteria and others. It has been found that one of the characterizing features of biofilms is that the microorganisms therein act cooperatively or synergistically. Empirically it has been found that microorganisms living in a biofilm are better protected from biocides than microorganisms living outside a biofilm. Thus, removal of pathogenic biofilms represents a particularly difficult problem in decontaminating and/or sanitizing equipment .

[172] The peracid solutions generated using the stable compositions of the present invention and the methods of their use are effective at decontaminating biofilms. In one embodiment, the stable composition made be used to generate a peracid solution useful to remove biofilms, including those formed by one or more pathogenic bacteria selected from the group consisting of: *Bacillus spp., B. anthracis, Clostridium spp., C. botulinum, C. perfringens*, *Listeria spp.*, *Pseudomonas spp.*, *Staphylococcus spp.*, *Streptococcus spp.*, *Salmonella spp.*, *Shigella ssp.*, *E. coli*, *Yersinia spp.*, *Y. pestis*, *Francisella spp.*, *F. tularensis*, *Camplyobacter ssp.*, *Vibrio spp.*, *Brucella spp.*, *Cryptosporidium spp.*, *Giardia spp.*, *Cyclospora spp.*, *Trichinella spp.*, and any combination thereof. In one preferred embodiment, a peracid solution made by the methods of the present invention may be used to decontaminate biofilms selected from group consisting of: *Pseudomonas aeruginosa*,

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 156

Staphylococcus aureus (SRWC-10943), *Listeria monocytogenes* (ATCC 19112), and any combination thereof.

[173] In one preferred embodiment, pathogenic biofilms comprising bacterial cultures of *Pseudomonas spp., Staphylococcus spp.,* and/or *Listeria spp.*, contaminating stainless steel equipment can be substantially removed (*i.e.*, ~ 500-1000-fold reduction) by exposure to a 0.16% by weight PAA solution (generated from the stable composition) at 45°C for 45 minutes.

[174]

[175] In various embodiments, the methods of decontamination using the stable compositions are useful for decontaminating a wide range of contaminated items including hard surfaces, fabrics, food, feed, apparel, rugs, carpets, textiles, medical instruments, veterinary instruments, sanitize, and stainless steel items and equipment, including large reactors, used in pharmaceutical and biotechnology processes.

[176] The peracid solutions generated enzymatically using the stable compositions of the present invention are particularly well-suited for cleaning stainless steel items and equipment because the ratio of peracid to corresponding acid generated in aqueous solution is much higher than found in commercial solutions. For example, a PAA solution generated using the stable composition of S54V-MsAcT, percarbonate, and PGDA, will have a ratio of PAA to acetic acid of approximately 10:1. Commercial PAA solutions typically have more acetic acid than PAA and may even have the reversed ratio (1:10). The increased ratio of PAA to acetic acid reduces, or completely obviates, the need to carry out further passivating treatments of the stainless steel item or equipment following the PAA treatment. Thus, in some embodiments, peracid solutions generated using the stable compositions of the present invention may be used to sanitize stainless steel items and equipment, including large reactors, used in pharmaceutical and biotechnology processes. In preferred embodiments, the peracid solutions may be used to sanitize stainless steel items and equipment in a single-step, without the need for any further treatment of the steel with a passivating agent.

[177] In still further embodiments, the present invention finds use in decontamination of food and/or feed, including but not limited to vegetables, fruits, and other food and/or feed items. Indeed, it is contemplated that the present invention will find use in the surface cleaning of fruits, vegetables, eggs, meats, etc. Indeed, it is intended that the present invention will find use in the food and/or feed industries to remove contaminants from

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 157

various food and/or feed items. In some particularly preferred embodiments, methods for food and/or feed decontamination set forth by the Food and Drug Administration and/or other food safety entities, as known to those of skill in the art find use with the present invention.

[178] In still further preferred embodiments, the item in need of decontamination is selected from hard surfaces, fabrics, food, feed, apparel, rugs, carpets, textiles, medical instruments, and veterinary instruments. In some particularly preferred embodiments, the food is selected from fruits, vegetables, fish, seafood, and meat. In some still further preferred embodiments, the hard surfaces are selected from household surfaces and industrial surfaces. In some particularly preferred embodiments, the household surfaces are selected from kitchen countertops, sinks, cupboards, cutting boards, tables, shelving, food preparation storage areas, bathroom fixtures, floors, ceilings, walls, and bedroom areas. In some alternative embodiments, the industrial surfaces are selected from food processing areas, feed processing areas, tables, shelving, floors, ceilings, walls, sinks, cutting boards, airplanes, automobiles, trains, and boats.

EXAMPLES

[179] The following examples are provided in order to demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

[180] In the experimental disclosure which follows, the following abbreviations apply: °C (degrees Centigrade); RT (room temperature); rpm (revolutions per minute); H_2O (water); dH_2O (distilled water); HCl (hydrochloric acid); aa (amino acid); bp (base pair); kb (kilobase pair); kD (kilodaltons); gm (grams); µg and ug (micrograms); mg (milligrams); ng (nanograms); µl and ul (microliters); ml (milliliters); mm (millimeters); nm (nanometers); µm and um (micrometer); M (molar); mM (millimolar); µM and uM (micromolar); U (units); V (volts); MW (molecular weight); sec (seconds); min(s) (minute/minutes); hr(s) (hour/hours); $MgCl_2$ (magnesium chloride); NaCl (sodium chloride); OD_{420} (optical density at 420 nm); PAGE (polyacrylamide gel electrophoresis); EtOH (ethanol); LB (Luria broth); LA (Luria agar); PBS (phosphate buffered saline [150 mM NaCl, 10 mM sodium phosphate buffer, pH 7.2]); SDS (sodium dodecyl sulfate); Tris (tris(hydroxymethyl)aminomethane); w/v (weight to volume); v/v (volume to volume); wt % (weight percent); PGDA (1,2-propylene glycol diacetate); PAA (peracetic acid); Per (perhydrolase); *per* (perhydrolase gene); Ms (*M. smegmatis*); MsAcT (*M. smegmatis* acyl transferase); S54V-MsAcT or S54V

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 158

variant (*M. smegmatis* acyl transferase variant comprising the S54V substitution); MS (mass spectroscopy); Dial (Dial Brands, Inc., Scottsdale, AZ); Kemira (Kemira Industrial Chemicals, Helsingborg, Sweden); EM Science (EM Science, Gibbston, NJ); HP (Hewlett-Packard, Palo Alto, CA); ICN (ICN Pharmaceuticals, Inc., Costa Mesa, CA); Dial (Dial, Corp., Scottsdale, AZ); Pierce (Pierce Biotechnology, Rockford, IL); Amicon (Amicon, Inc., Beverly, MA); ATCC (American Type Culture Collection, Manassas, VA); Amersham (Amersham Biosciences, Inc., Piscataway, NJ); Becton Dickinson (Becton Dickinson Labware, Lincoln Park, NJ); BioRad (BioRad, Richmond, CA); Difco (Difco Laboratories, Detroit, MI); GIBCO BRL or Gibco BRL (Life Technologies, Inc., Gaithersburg, MD); MIDI (MIDI Labs, Newark, DE); Sigma or Aldrich (Sigma-Aldrich Inc., St. Louis, MO); Sorvall (Sorvall Instruments, a subsidiary of DuPont Co., Biotechnology Systems, Wilmington, DE); Agilent (Agilent Technologies, Palo Alto, CA); Minolta (Konica Minolta, Ramsey, NJ); and Zeiss (Carl Zeiss, Inc., Thornwood, NY).

EXAMPLE 1

Killing Curve for *B. subtilis* Spores by Peracetic Acid (PAA)

[181] In this Example, experiments conducted to determine the killing curve of peracetic acid (PAA) and PAA in conjunction with detergent (commercially available PUREX® [Dial] was used in this Example) for *B. subtilis* spores. In these experiments, the *B. subtilis* spores were prepared as known in the art (*See e.g.*, Siccardi *et al.*, J. Bacteriol., 121:13-19 [1975]). Assays were carried out in duplicate in 96-well, round bottomed microtiter plates (Costar) with peracetic acid (32 wt % in acetic acid; Aldrich). The PAA was serially diluted in either 50 mM KPO_4 buffer, pH 7.1 ("Buffer"), or in a 1:500 dilution of Purex (original formula; Dial) in the same buffer ("Buffer + Det") in a total volume of 50 µl. The amount of PAA added to the assay was 0, 0.4, 4 or 40 mM. A volume of 5 µl of the spore suspension, containing 10^9 -10^{10} spores, was then added to each well and the assay incubated for 15 min at RT. Ice cold LB (150 µl) (*See e.g.*, Sambrook *et al.*, "Molecular Cloning: A Laboratory Manual", Second Edition (Cold Spring Harbor), [1989]) was then added to each well, mixed, and 100 µl transferred to a fresh 96-well plate. Serial dilutions of each solution were made (in a total volume of 100 µl/well). A volume of 5 µl of each dilution was spotted onto LA plates (Sambrook *et al.*, *supra*), and incubated at 37°C for 17-24 h. Colonies were counted and the % spore killing was determined relative to the respective controls (buffer alone or buffer + detergent, without peracid). The results are presented in Table 1, as an average of duplicates from one experiment. However, the experiment was done twice in

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 159

duplicate with similar results. Based on these results, PAA in the range of about 4 to about 40 mM was determined to be sufficient to kill *B. subtilis* spores in 15 min.

Table 1: Killing of *B. subtilis* Spores by PAA

	Buffer		Buffer + Detergent	
[PAA] (mM)	Spores/ml	% Spore Killing	Spores/ml	% Spore Killing
0	$1.8x10^9$	0	$1.6 x10^9$	0
0.4	$2.4x10^8$	86.4	$1.7 x10^9$	0.05
4	$1.6x10^8$	90	$2.4 x10^8$	86.4
40	0	100	0	100

EXAMPLE 2

Enzymatic Generation of PAA

[182] In this Example, three methods for generation of PAA by acyl transferase are described. In one method, at least one acyl transferase (wild-type or variant) is combined with at least one ester substrate, and hydrogen peroxide in a buffer or detergent, with or without one or more surfactants. In an alternative method, at least one acyl transferase (wild-type or variant), at least one ester substrate, and sodium percarbonate (or other source of H_2O_2) are combined in a buffer or detergent, with or without one or more other surfactants. In yet a further method, at least one acyl transferase (wild-type or variant) is combined with glucose oxidase and glucose, in a concentration sufficient to generate an amount of PAA with which to kill spores in buffer or detergent. In some formulations, one or more other surfactants are also included. Other enzymes that generate H_2O_2 also find use in this system, including oxidases, oxidoreductases (*e.g.*, glyerol oxidase or hexose oxidase). In some preferred embodiments, a co-factor independent alcohol oxidase is used.

Determination of PAA Concentration

[183] In these experiments, methods known in the art were used to determine the concentration of PAA (*See e.g.*, Pinkernell *et al.*, Analyst, 122:567-571 [1997]). In this ABTS assay, 100 µl of the solution to be analyzed was added to 1 ml of 125 mM potassium citrate buffer, pH 5.0, containing 1.0 mM 3-ethylbenzthiazoline-6-sulfonic acid (ABTS) and 50 uM KI, and allowed to incubate at RT for 3 minutes. The absorbance was measured at 420 nm in a HP 8452A Diode Array Spectrophotomer and compared to a standard curve prepared using authentic standard. The enzymatic reactions to form PAA were initiated with addition of enzyme and conducted at RT. Aliquots were withdrawn from the reactions at the indicated times and analyzed for PAA concentration. The sodium percarbonate used in

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 160

these experiments was obtained from Kemira and the hydrogen peroxide was obtained from EM Science.

Comparison of PAA Enzymatically Generated from H_2O_2 or Sodium Percarbonate

[184] A solution of 39 mM sodium percarbonate (sodium carbonate peroxyhydrate, Technical grade 85%, yielding 100 mM effective H_2O_2; Kemira) was prepared in 320 mM KPO_4 pH 7.1. After dissolution of the solid percarbonate, the resulting solution had a pH of 7.6. To compare the enzymatic production of PAA from prepared H_2O_2 (32 wt %, Aldrich) or H_2O_2 formed from percarbonate under identical pH conditions, two reactions were prepared. One reaction contained 100 mM H_2O_2 in 320 mM KPO_4, pH 7.6, 100 mM 1,2-propylene glycol diacetate (Aldrich), and 2 ppm variant S54V. The absolute concentration of H_2O_2 was assumed from the value stated on the label and not confirmed by analysis. The second reaction contained 39 mM sodium percarbonate in 320 mM KPO_4, pH 7.1, 100 mM 1,2-propylene glycol diacetate, and 2 ppm S54V. The reactions were initiated by the addition of the enzyme. Samples were withdrawn at the times indicated and the concentration of PAA determined as described in Example 1.

[185] The results for PGDA as substrate are shown in Figure 1. As indicated in Figure 1, the progress of the reaction and final concentration of PAA is similar in both cases.

[186] In order to study the use of different propyl alcohol acetate ester substrates, the generation of PAA was carried out using the same general method described above for PGDA, but using either propyl acetate or triacetin as the ester substrate. It was observed that these other two ester substrates also reacted in the system with S54V-MsAcT to make PAA. The relative conversion rate to PAA for the three ester substrates was observed to be: PGDA > triacetin > propyl acetate.

EXAMPLE 3

Enzymatic Generation of PAA Kills *B. subtilis* Spores

[187] In this Example, experiments conducted to assess the killing ability of enzymatically generated PAA tested with *B. subtilis* spores are described. Based on the results obtained in the experiments described in Examples 1 and 2, a range of 4 to 40 mM PAA was determined to be sufficient to demonstrate killing of spores of *B. subtilis* I-168. In these experiments, spore killing was assessed in buffer, as well as in detergent.

Spore Killing in Buffer

[188] In this experiment, sodium percarbonate was used as the source of H_2O_2. The final solution contained: 100 mM 1,2-propylene glycol diacetate, 2 ppm S54V variant, 39 mM

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 161

sodium percarbonate (Technical grade 85%; yielding 100 mM effective H_2O_2) in 320 mM KPO_4 pH 7.1 in a total volume of 800 µl. This mix (yield 40 mM PAA) was serially diluted to give additional mixes that yielded 4.9, 9.9 and 20.5 mM PAA. A mix with only 400 mM KPO_4 pH 7.1 was used to determine total spore counts in the absence of PAA. The mixes were allowed to incubate at room temperature for 3 min. A volume of 180 µl of each of the mixes was then dispensed into duplicate wells of a round-bottomed 96-well plate (Costar) that contained 20 µl of the spore suspension used in Example 1, to yield a total volume of 200 µl in each well. The liquid was gently pipetted 4-5 times to ensure mixing of the components. The mixes were incubated with the spores for a further 15 or 30 minutes at room temperature. At the 15 and 30 minute time points, 20 µl were removed from each of the wells, added to wells in a fresh 96-well plate and serially diluted in LB to 10^{-7} in a total volume of 100 µl. A volume of 5 µl from each dilution of each spore mixture was spotted onto an LA plate, allowed to dry and then incubated overnight at 37°C. Also at the 15 and 30 min time points, an appropriate volume was removed from each well and diluted sufficiently in dH_2O to yield a measurable amount of PAA using the ABTS assay on scale with a standard, as described in Example 1. Results of these assays are shown in Table 2. The results of the spore killing are presented as an average of the duplicates.

Table 2: Use of MsAcT System to Generate PAA to Kill *B. subtilis* Spores in Buffer

[PAA] (mM) (Theoretical)	[PAA] Generated (mM) (15 min)	Spores/ml 15 min	%Spore Killing 15 min	[PAA] Generated (mM) (30 min)	Spores/ml 30 min	%Spore Killing 30 min
0	0	$1.5x10^9$	0	0	$1.5 x10^9$	0
4.9	2.2	$9 x10^8$	40	2.4	$9.4 x10^8$	37
9.9	6.1	$1 x10^8$	93.3	7.1	$5 x10^7$	96.7
20.5	15	$4.4 x10^4$	99.997	18	0	100
39.5	35	0	100	41	0	100

Spore Killing in Detergent.

[189] The experiment was repeated exactly as described except that a 1:500 dilution of Purex in 320 mM KPO_4 pH 7.1, was used in place of the buffer. The results are presented in Table 3 (average of duplicates). Controls included various reaction components in 400 mM KPO_4 pH 7.1 buffer: 2 ppm S54V variant, 2 ppm S54V variant with 39 mM percarbonate, 100 mM 1,2-propylene glycol diacetate, 100 mM 1,2-propylene glycol diacetate with 39 mM sodium percarbonate, 39 mM sodium percarbonate. All these treatments gave equivalent levels of spores/ml after a 30 min incubation, except sodium percarbonate alone ($1x10^9$ spores/ml vs $5x10^9$ spores/ml for other controls). This decrease was not seen with

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 162

sodium percarbonate in combination with other components and was certainly not as dramatic as the killing seen by the mixture of all 3 components at comparable levels (100% killing).

Table 3: Use of MsAcT System to Generate PAA to Kill *B. subtilis* Spores in Detergent

[PAA] (mM) (Theoretical)	[PAA] Generated (mM) (15 min)	Spores/ml 15 min	%Spore Killing 15 min	[PAA] Generated (mM) (30 min)	Spores/ml 30 min	%Spore Killing 30 min
0	0	$2x10^9$	0	0	$2x10^9$	0
4.9	3.7	$2x10^9$	0	3.3	$5x10^8$	75
9.9	8.9	$1.7x10^9$	91.5	8.1	$4x10^7$	98
20.5	19.6	$3x10^5$	99.99	18.9	0	100
39.5	44.5	0	100	40.4	0	100

EXAMPLE 4

Enzymatic Generation of PAA to Kill *Trichoderma reesei* Spores

[190] In this Example, experiments conducted to assess the killing ability of PAA on T. *reesei* spores are described. *T. reesei* spores were prepared by growing the strain for approximately 4 days on Potato Dextrose (PDA) media at 30°C. When the plate was approximately 75% covered by fungal growth, it was incubated at room temperature for several days until there was confluent growth. The spores were scraped off the plate using a cotton-tipped swab, resuspended in 1 ml of 10% glycerol and frozen at –80°C until used. Prior to use in the spore killing assay, the spore suspension was thawed, the spores pelleted by centrifugation, washed twice with 1 ml dH_2O, and resuspended in 1 ml of dH_2O. The spore killing experiments were carried out as described in Example 3, except that 20 µl of the fungal spore preparation were added to the wells of the 96-well plate instead of the *Bacillus* spores. Also, the mixes were made up such that the amount of PAA generated was 40, 13.3, 4.4 and 1.5 mM. The dilutions of the 15 and 30 minute incubations were plated on PDA media. The actual amount of PAA generated was determined as described in Example 1, at the 15 and 30 minute time points. The results are presented in Table 4. These results indicate that fungal spores were killed by PAA generated by the MsAcT system and at a lower level of PAA than the *B. subtilis* spores.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 163

Table 4. Use of MsAcT System to Generate PAA to Kill *Trichoderma reesei* Spores

[PAA] Generated (mM) (Theoretical)	[PAA] Generated (mM) 15 min	Spores/ml 15 min	%Spore Killing 15 min	[PAA] Generated (mM) 30 min	Spores/ml 30 min	%Spore Killing 30 min
0	0	$2x10^{10}$	0	0	$2x10^{7}$	0
1.5	0.41	$2x10^{5}$	99.99	0.3	$2x10^{5}$	99.99
4.4	2.1	0	100	2.2	0	100
13.3	10	0	100	8.5	0	100
40	42	0	100	38	0	100

EXAMPLE 5
PAA Production from Glucose and PGDA

[191] In this Example, experiments to assess the amount of peracetic acid produced from glucose and propyleneglycol diacetate are described. A 15 ml solution was prepared containing 50 mM KPO_4 pH 7.1 with 60 mM glucose, and 20 mM 1,2-propylene glycol diacetate (Aldrich). The solution was continuously sparged with air and stirred at room temperature. The reaction to generate H_2O_2 was initiated by the addition of 100 Units of glucose oxidase (Oxygen HP, Genencor International) and allowed to proceed for 1 hr. A sample was withdrawn and tested for PAA before the addition of 2 ppm S54V variant, to initiate the production of PAA from the formed H_2O_2. The results are presented in Figure 2. Further samples were withdrawn at the times indicated in Figure 2, and the concentration of PAA determined as described above. No PAA was detected before the addition of enzyme and approximately 9.5 mM PAA was produced from the 20 mM 1,2-propylene glycol diacetate and the H_2O_2 produced from the glucose/ glucose oxidase reaction.

EXAMPLE 6
Generation of PAA by MsAcT at Different Temperatures

[192] In this Example, experiments were conducted to assess the generation of peracetic acid by MsAcT at different temperatures are described. Such generation provides means to resolve problems associated with storage instability of PAA at various temperatures. In these experiments, MsAcT is used to generate PAA over a range of temperatures from about 20°C to about 60°C. In some experiments, temperatures such as 21°C, 40°C, and 60°C are used.

[193] In these experiments, three reactions were prepared, consisting of 320 mM KPO_4 pH 7.1, 100 mM 1,2-propylene glycol diacetate (Aldrich), and 100 mM sodium percarbonate. The reactions were equilibrated at 21°C, 40°C and 60°C, and then initiated by the addition

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 164

of S54V variant to a final concentration of 2 ppm. The results are presented in Figure 3. Samples were withdrawn at the times indicated in the Figure, and the concentration of PAA determined as described above. These results indicate that the enzyme system is functional at least up to 60°C.

EXAMPLE 7

Generation of Concentrated Peracetic Acid by MsAcT

[194] In this Example experiments were conducted to determine the ability of MsAcT to generate a concentrated solution of peracetic acid. These experiments were conducted in order to address the potential benefit of preparing a concentrated peracetic acid solution which is suitable for dosing or dilution into different solutions for use. In this experiment the reaction contained 50 mM KPO_4, 2 M H_2O_2 (EM Science), 2 M 1,2-propylene glycol diacetate (Aldrich), and the S54V variant to a final concentration of 160 ppm. The reaction was vortexed occasionally to mix the reactants, as they were not miscible at this concentration. Mixing was conducted at room temperature. The results are shown in Figure 4. Samples were diluted at the indicated times and the peracetic acid concentration was determined as described above.

EXAMPLE 8

An Enzymatic PAA Generating System With High Sporicidal Activity

[195] This example illustrates the effectiveness of a 0.16% by weight peracetic acid (PAA) solution, generated using a three component formulation of the S54V mutant of the acyl transferase enzyme from *M. smegmatis* (S54V-MsAcT), 1,2-propylene glycol diacetate (PGDA) (as ester substrate), and sodium percarbonate (as hydrogen peroxide source), in a number of EPA approved decontamination assays.

Materials and Methods

[196] Preparation of 250 mL PAA test solution: A dry formulation was made up in 15 mL conical tubes, each containing from about 1.20 g to about 1.30 g sodium percarbonate, and from about 26.0 mg to about 31.9 mg of granules of S54V-MsAcT enzyme. For each dry formulation tube, a separate 15 mL conical tube was prepared containing 1.8 mL of the ester substrate, propylene glycol diacetate (PGDA). One dry formulation tube was packaged with one PGDA tube in a single zip lock bag. The contents of one zip lock bag (*i.e.*, one dry formulation tube and one PGDA tube) constituted one unit for generation of 0.16% PAA upon addition to 250 mL of water.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 165

[197] PAA test solution was prepared by adding the dry formulation from one unit into 250 mL of room temperature sterilized deionized water until fully dissolved. Some of the 250 mL test solution was used to rinse any residual dry formulation from the tube into the solution. Then the tube of PGDA liquid from was added to the stirring 250 mL solution and once again, some of the solution was used to rinse any residual PGDA from the tube into the solution. The PAA test solution was then allowed to stir for 20 minutes. The PAA test solution was homogeneous by visual inspection. It was used within two hours of preparation.

[198] Preparation of 2000 mL PAA test solution: A dry formulation was made up in 15 mL conical tubes, each containing from about 9.6 g to about 9.8 g sodium percarbonate, and from about 216 mg to about 226 mg of granules of S54V-MsAcT enzyme. For each dry formulation sample, a separate 15 mL conical tube was prepared containing 1.8 mL of the ester substrate, propylene glycol diacetate (PGDA). One dry formulation tube was packaged with one PGDA tube in a single zip lock bag. The contents of one zip lock bag it (*i.e.*, one dry formulation tube and one PGDA tube) constituted one unit for generation of 0.16% PAA upon addition to 2000 mL of water.

[199] Preparation of the 2000 mL PAA test solution was the same as described above for the 250 mL test solution except for the larger amounts of dry formulation, PGDA liquid and water.

[200] Assay 1: Germicidal and Detergent Sanitizing Action

[201] PAA test solutions were prepared according to the 250 mL recipe above. A suspension of either *Staphylococcus aureus* (ATCC 6538) or *Escherichia coli* (ATCC 11229) cells was exposed to the PAA test solution for either 30 seconds or 60 seconds. Following exposure, an aliquot was transferred to the neutralizing subculture medium (Letheen broth + 0.1% sodium thiosulfate + 0.01% catalase) and assayed for survivors utilizing pour plating techniques and Tryptone glucose extract agar (TGEA). Appropriate numbers control, purity, sterility, viability, and neutralization controls also were performed.

[202] Assay 2: Inanimate Non-Food Contact Surface Sanitizing Efficacy

[203] PAA test solutions were prepared according to the 250 mL recipe above. A film of bacterial cells dried on a surface of a glass slide carriers. Four different lots of eight slides were prepared using two different bacteria: *Staphylococcus aureus* (ATCC 6538) and *Enterobacter aerogenes* (ATCC 13048). Five of the contaminated slides were exposed to the PAA test solution for either two minutes or five minutes at 18.0°C. After exposure, the

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 166

neutralizing subculture medium (Letheen broth + 0.1% sodium thiosulfate + 0.01% catalase) was added to each jar containing the glass slide carrier and the PAA test solution, and the solution was assayed for survivors. Three control slides from each lot were not exposed to a water solution and similarly treated with neutralizing subculture medium.

[204] Assay 3: AOAC Germicidal Efficacy - Use-Dilution Method

[205] PAA test solutions were prepared according to the 2000 mL recipe above. A film of bacterial cells was dried on the surface of a lot of 30 stainless steel carrier items. Three different lots were prepared using three different bacteria: *Pseudomonas aeruginosa* (ATCC 15442), *Staphylococcus aureus* (ATCC 6538), and *Salmonella choleraesuis* (ATCC 10708). Each of the contaminated items was exposed to the PAA test solution for either 5 minutes or 10 minutes at room temperature (20.0°C). After exposure, the items were transferred to vessels containing neutralizing subculture medium (Letheen broth + 0.1% sodium thiosulfate + 0.01% catalase) and assayed for surviving bacteria. Appropriate purity, viability, carrier item sterility, neutralizing subculture medium sterility, viability, neutralization confirmation and carrier population controls also were performed.

[206] Assay 4: AOAC Sporicidal Efficacy:

[207] PAA test solutions were prepared according to the 250 mL recipe above. A suspension of *Bacillus subtilis* (ATCC 19659) spores was dried on a lot of 30 Dacron sutures. A suspension of *Clostridium sporogenes* (ATCC 3584) was dried on a lot of 30 porcelain penicylinders. Each of the contaminated items was exposed to the PAA test solution for either 2 hours or 5.5 hours at room temperature (20.0°C). After exposure, the items were transferred to vessels containing neutralizing subculture medium (thiolglycollate medium + 0.1% sodium thiosulfate + 0.01% catalase) and assayed for surviving bacteria. Appropriate HCl, viability, purity, sterility, contaminated item quantitation, and neutralization controls also were performed.

Results

[208] Assay 1: The PAA test solution demonstrated > 99.999% reduction of either *Staphylococcus aureus* (ATCC 6538) or *Escherichia coli* (ATCC 11229) after only a 30 second exposure at 20.0°C.

[209] Assay 2: The PAA test solution demonstrated > 99.9% reduction of either *Staphylococcus aureus* (ATCC 6538) or *Enterobacter aerogenes* (ATCC 13048) on glass slides following two-minute (or five minute) exposure at 18.0°C.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 167

[210] Assay 3: Five minute exposure of the contaminated stainless steel carrier items to the PAA test solution resulted in no demonstrated growth in any of 30 subculture tubes of any of *Pseudomonas aeruginosa* (ATCC 15442), *Staphylococcus aureus* (ATCC 6538), and *Salmonella choleraesuis* (ATCC 10708). One of 30 items exposed for ten minutes to the PAA solution did exhibit growth of *Pseudomonas aeruginosa* (ATCC 15442), however there was no demonstrated growth for any of the other bacteria in any of the ten minute exposure subculture tubes.

[211] Assay 4: No demonstrated growth of *Bacillus subtilis* (ATCC 19659) in any of the 30 primary subcultures and no growth in any of the 30 secondary subcultures when tested using contaminated Dacron sutures exposed to the PAA solution for 2 hours or 5.5 hours at 20.0°C. Similarly, no demonstrated growth of *Clostridium sporogenes* (ATCC 3584) in any of the 30 primary subcultures and no growth in any of the 30 secondary subcultures when tested using contaminated porcelain penicylinders exposed to the PAA solution for 2 hours or 5.5 hours at 20.0°C.

Conclusions

[212] The 0.16% PAA solution generated using a three component formulation of S54V-MsAcT enzyme, propylene glycol diacetate (as ester substrate), and sodium percarbonate (as peroxide source), was highly effective in all four EPA approved disinfection/decontamination assays tested. The Germicidal and Detergent Sanitizing Action of Disinfectants test results show greater that 99.999% effectiveness against *Staphylococcus aureus* and *Escherichia coli*. The Standard Test Method for Efficacy of Sanitizers Recommended for Inanimate Non-Food Contact Surfaces test results show greater than 99.9% effectiveness against *Stapylococcus aureus* and *Enterobacter aerogenes*. The AOAC Use-Dilution Method test results showed 100% effectiveness against *Staphylococcus aureus*, *Salmonella choleraesius*, and 96.7% effectiveness against *Pseudomonas aeruginosa*. The Sporicidal Activity of Disinfectants (AOAC) assay demonstrated 100% efficacy of the PAA solution against *Bacillus subtilis* and *Clostridium sporogenes* spores.

EXAMPLE 9

A Stable "All-In-One" PAA Generating Composition With High Sporicidal Activity

[213] This example illustrates the preparation, and stability over time, of an "All-In-One" composition of S54V-MsAcT enzyme and sodium percarbonate in the liquid ester substrate,

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 168

propylene glycol diacetate. The example also illustrates the use of this composition to generate a 0.16 % by weight PAA solution.

Materials and Methods

[214] All-in-One Composition: To a tube of the dry formulation (containing 1.22 g of sodium percarbonate and 28.0 mg of S54V-MsAcT granules) prepared as described in Example 8 was added 1.8 mL of PGDA liquid.

[215] Activation and Assay of All-in-One Composition: The All-in-One composition as prepared above was added to 250 mL of deionized water with stirring. Two additional PAA solutions were prepared according to the 250 mL and 2000 mL recipes described above in Example 8.

[216] At t = 20 minutes, the pH of each of these three solutions was measured and found to be 10.3. Also at t = 20 minutes, a 20 µL aliquot was taken from each of the three solutions and added to 980 µL of 125 mM sodium citrate, pH 5.0. These three diluted samples were then assayed for PAA concentration using the ABTS assay described above.

[217] Stability Study: Two additional All-in-One composition samples were prepared. One was maintained for 4 days before being activated in 250 mL water and assaying for PAA concentration. The other was maintained for 33 days at room temperature before being activated in 250 mL water and assaying for PAA concentration. For comparison, samples were prepared as in Example 8 with the dry formulation components maintained separately from the liquid PGDA component for the same 4 day and 33 day periods at room temperature before being activated in water.

[218] Variable PAA Generating Compositions: A set of five All-in-One compositions with variable amounts of sodium percarbonate were prepared to demonstrate the ability to vary the concentration of PAA generated over a range between about 60% and 160% of the standard composition. The five All-in-One composition samples were made up according to amounts listed in Table 5.

TABLE 5

Sample #	Sodium percarbonate (g)	Enzyme (mg)	PGDA (mL)
1	0.768	30.7	1.8
2	1.003	30.9	1.8
3	1.251	29.6	1.8
4	1.501	28.7	1.8
5	2.009	30.5	1.8

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 169

[219] These five samples were then added to 250 mL deionized water with stirring at ambient temperature (20°C). Sample aliquots for assay were taken at 10, 20, and 30 minutes. PAA concentration was assayed using the ABTS assay in a microtiter plate.

[220] Sporicidal Efficacy Assay: An All-In-One composition was prepared containing 1.37 g sodium percarbonate, 33.30 mg S54V-MsAcT, mixed with 1.80 mL PGDA in a 15.0 mL conical tube. The composition was added to sterile deionized water with stirring for 20 minutes. 10 mL of the resulting PAA test solution was placed into each of four 25 x 150 mm tubes. These tubes were placed in a 20°C incubator and allowed to come to temperature. Using sterile forceps, five penicylinders, contaminated with *B. subtilis*, or five suture loops, contaminated with *B. subtilis,* were added to each tube. After the addition of all of the cylinders or sutures to each solution, a period of five minutes was allowed to make time for later removal from the tubes. After a contact time of one hour at 20°C, the penicylinders or sutures were removed, each to a separate tube of 10 mL fluid thioglycollate medium (Difco Cat. # 225650) using bent sterile plastic needles (tips bent aseptically while inside the bag into a hook). After completing transfer to the primary tube of thiolglycollate medium, the cylinders and sutures were transferred to a fresh tube of thioglycollate medium (10 mL) and incubated for 21 days at 37°C. If no growth was observed after 21 days, the tubes were heat-shocked at 80°C and re-incubated for an additional 72 hours at 37 °C. Nineteen to twenty replicates were run.

Results

[221] The All-in-One composition when activated in 250 mL of water with stirring for 20 minutes generated a solution with 0.18% peracid. The 250 mL and 2000 mL recipes prepared in the same assay yielded solutions with 0.17% and 0.17% peracid, respectively.

[222] The solutions prepared with the All-in-One composition maintained for 4 days and 33 days at room temperature generated 100% of the expected concentration of peracid. Similarly, the solutions prepared using the separate dry formulation and liquid components yielded essentially 100% of their expected PAA concentration.

[223] The five All-in-One composition samples prepared with varying amounts sodium percarbonate yielded a range of PAA concentrations from 0.11% to 0.33% at the 20 minute time point that constitutes the standard usage conditions. Thus, the All-in-One composition can be "tuned" to provide a desired PAA concentration within a specified range. In this particular example, the concentration of PAA generated ranged from 19-51 mM, which was

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 170

28.5 – 76.5 mM H_2O_2 ($Na_2CO_3 \cdot 1.5H_2O_2$). The maximum conversion rate of H_2O_2 was 61.7% observed for sample 5 at t = 30 minutes. Based on this, a desired amount of PAA can be achieved by adjusting the percarbonate level or the PGDA level, or both.

[224] The All-in-One composition made with 1.37 g sodium percarbonate, 33.30 mg S54V-MsAcT, mixed with 1.80 mL PGDA in 250 mL water exhibited no failures in sporicidal efficacy for the *B. subtilis* contaminated sutures and penicylinders.

Conclusions

[225] An "All-in-One" composition containing all three components for enzymatic PAA generation in a single tube can be used to generate an effective PAA decontamination solution (0.16%) equally as well as formulations where the dry components are stored separate from the liquid PGDA ester substrate. Remarkably, the All-in-One composition exhibited stability with 0% loss of performance in PAA generation even after 33 days at room temperature before activating in water. Moreover, the PAA solutions prepared using the "All-in-One" composition showed high levels of sporicidal efficacy equivalent to the separate dry and liquid component formulations when assayed on contaminated sutures and porcelain penicylinders.

[226] Furthermore, it was found that the All-in-One composition can be "tuned" by varying the amount of sodium percarbonate used so as to generate PAA concentrations ranging from about 0.11% to 0.33%.

EXAMPLE 10
Use of Water Soluble Sachet for Delivery of An All-In-One PAA Generating Composition

[227] This example illustrates the preparation and use of an All-In-One composition for PAA generation formulated in a water-soluble sachet.

Materials and Methods

[228] Water soluble polyvinyl alcohol (PVA) sachets were obtained from Solupak Ltd. (Manchester, UK). Ten of these sachets were prepared for use with the All-In-One composition by filling each with 7.5 g of PGDA, 4.8 g of sodium percarbonate and 110 mg of the acyl transferase S54V-MsAcT. Each sachet was then sealed using a heat sealer.

[229] Sachets were shipped from the UK to the US, resulting in a transit time of 7 days before use. Upon receipt, a sachet was dissolved in 2000 mL of purified water (MilliQ) at 21°C. The pH and PAA concentration of the 2000 mL solution was measured at selected

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 171

time points over 50 minute time course. PAA was assayed using the ABTS in citrate assay, as described above.

Results

[230] The sachet dissolved in the 2000 mL solution as expected delivering the All-In-One composition and resulting in the following PAA concentrations and pH values listed in Table 6.

TABLE 6

Time (min)	PAA (wt. %)	pH
0.00	0.02	5.20
5.00	0.02	10.10
10.00	0.04	10.19
15.00	0.08	9.78
20.00	0.12	9.37
25.00	0.14	8.97
30.00	0.16	8.62
50.00	0.18	8.12

[231] As shown above, the sachet delivery system performed as scaled. It generated the targeted PAA concentration and gave a typical pH profile, with a pH of 8.6 being generated at 20 minutes (the proposed dissolution time), which is a pH range generally considered as non-corrosive.

Conclusions

[232] The All-In-One composition is stable and can be delivered to solution effectively in a water soluble polyvinyl alcohol sachet. The resulting PAA concentrations and pH values of the solution after 30 minutes that are equivalent to those observed without the sachet.

[233] All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

[234] Having described the preferred embodiments of the present invention, it will appear to those ordinarily skilled in the art that various modifications may be made to the disclosed embodiments, and that such modifications are intended to be within the scope of the present invention.

[235] Those of skill in the art readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 172

inherent therein. The compositions and methods described herein are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. It is readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

[236] The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

[237] The invention has been described broadly and generically herein. Each of the narrower species and sub generic groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 173

CLAIMS

I claim:

1. A composition comprising a perhydrolase enzyme, a hydrogen peroxide source, and an ester substrate, wherein said composition generates a peracid when mixed with water, and wherein said composition retains peracid generating activity for a time period of at least about 7 days.

2. The composition of claim 1, wherein the ester substrate is a liquid and the perhydrolase enzyme and hydrogen peroxide source are solids suspended in the liquid.

3. The composition of claim 1, wherein the peracid is selected from peracetic acid, pernonanoic acid, perpropionic acid, perbutanoic acid, perpentanoic acid, and perhexanoic acid.

4. The composition of claim 4, wherein the peracid is peracetic acid.

5. The composition of claim 1, wherein the ester substrate is propylene glycol diacetate.

6. The composition of claim 1, wherein the perhydrolase enzyme comprises the amino acid sequence set forth in SEQ ID NO:1.

7. The composition of claim 1, wherein the perhydrolase enzyme is the S54V variant of SEQ ID NO:1.

8. The composition of claim 1, wherein the hydrogen peroxide source is a hydrogen peroxide generating compound selected from sodium percarbonate, sodium perborate, and urea hydrogen peroxide.

9. The composition of claim 8, wherein the hydrogen peroxide source is sodium percarbonate.

10. The composition of claim 1, wherein the composition comprises about 0.001% to about 1% by weight perhydrolase enzyme, about 35% to about 45% by weight sodium percarbonate, and about 55% to about 65% by weight propylene glycol diacetate.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 174

11. The composition of claim 1, wherein the hydrogen peroxide source is an enzymatic hydrogen peroxide generation system comprising an oxidase and its substrate.

12. The composition of claim 11, wherein the oxidase is selected from glucose oxidase, sorbitol oxidase, hexose oxidase, choline oxidase, alcohol oxidase, glycerol oxidase, cholesterol oxidase, pyranose oxidase, carboxyalcohol oxidase, L-amino acid oxidase, glycine oxidase, pyruvate oxidase, glutamate oxidase, sarcosine oxidase, lysine oxidase, lactate oxidase, vanillyl oxidase, glycolate oxidase, galactose oxidase, uricase, oxalate oxidase, and xanthine oxidase.

13. The composition of claim 1, further comprising at least one additional enzyme selected from proteases, cellulases, amylases, and microbial cell wall degrading enzymes.

14. The composition of claim 1, wherein the composition further comprises at least one surfactant.

15. A method for preparing a decontamination solution comprising adding the composition of any of claims 1 to 14 to water and mixing for at least about 20 minutes.

16. A method for decontamination comprising:

(a) providing a composition according to any of claims 1 to 14;

(b) adding said composition to water and mixing, thereby generating an aqueous peracid solution;

(c) exposing an item comprising a contaminant to said solution.

17. The method of claim 16, wherein the composition is contained in a water soluble container.

18. The method of claim 18, wherein the container is a sachet made of polyvinyl alcohol film.

19. The method of claim 16, wherein the water is sterilized.

20. The method of claim 16, wherein said exposing comprises exposing said item to said solution at high temperature.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 175

21. The method of claim 16, wherein said contaminant comprises a toxin selected from botulinum toxin, anthracis toxin, ricin, scombroid toxin, ciguatoxin, tetrodotoxin, mycotoxins, and any combination thereof.

22. The method of claim 16, wherein said contaminant comprises a pathogen selected from bacteria, viruses, fungi, parasites, prions, and any combination thereof.

23. The method of claim 22, wherein said pathogen is selected *Bacillus spp., B. anthracis, Clostridium spp., C. botulinum, C. perfringens, Listeria spp., Staphylococcus spp., Streptococcus spp., Salmonella spp., Shigella ssp., E. coli, Yersinia spp., Y. pestis, Francisella spp., F. tularensis, Camplyobacter ssp., Vibrio spp., Brucella spp., Cryptosporidium spp., Giardia spp., Cyclospora spp.*, and *Trichinella spp.*

24. The method of claim 16, wherein said item is selected from hard surfaces, fabrics, food, feed, apparel, rugs, carpets, textiles, medical instruments, and veterinary instruments.

25. A system comprising a water soluble container comprising a stable composition according any of claims 1 to 15.

26. The system of claim 25, wherein said container is a sachet, ampoule, capsule, or sphere.

27. The system of claim 26, wherein the water soluble container is made of a water soluble polymer material polyvinyl alcohol, polyethylene oxides, cellulose derived water soluble carbohydrates, and polylactides.

28. A method for preparing a decontamination solution comprising adding system of claim 26 to water and mixing.

29. A kit for decontamination comprising the stable composition of any of claims 1 to 15 in packaging.

30. The kit of claim 29, wherein the composition is in a water soluble container.

31. The kit of claim 30, wherein the water soluble container is a sachet, ampoule, capsule, or sphere.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 176

32. The kit of claim 30, wherein the water soluble container is made of a water soluble polymer material selected from polyvinyl alcohol, polyethylene oxides, cellulose derived water soluble carbohydrates, and polylactides.

33. The kit of claim 29, further comprising an empty mixing container for mixing said composition with water.

34. The kit of claim 29, further comprising water in a sealed container, wherein the water is sterilized.

35. The kit of claim 29, further comprising instructions for use in a method according to claim 16.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 177



100mM PGD, 2ppm S54V,
320 mM KPO4,
PAA (mM)
Time (min)
100 mM H2O2
100 mM Percarb
0
10
20
30
40
50
60
0
20
40
60

FIG. 1



20mM PGD, 60mM Glc, 6.7U/ml GO,
2ppm S54V, 50 mM KPO4, pH 7.1
PAA (mM
Time (min)
0
2
4
6
8
10
0
20
40
60
80

FIG. 2



100mM PGD, 100mM PC,
2ppm S54V, 320 mM KPO4, pH 7.1
PAA (mM)
Time (min)
21C
40C
60C

FIG. 3



Propylene glycol diacetate, 2 M; H2O2, 2 M;
S54V, 160 ppm; K2PO4, 50 mM
PAA (mM)
Time (min)
AcT reaction
No enzyme control

FIG. 4

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2008/062633

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12N9/16 C12N9/50 C12N9/52 C11D3/386

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, Sequence Search, EMBASE, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/056782 A (GENENCOR INT [US]; PROCTER & GAMBLE [US]; AMIN NEELAM S [US]; BOSTON M) 23 June 2005 (2005-06-23) Whole document, in particular p.33, 69-70, 72-73, 125, 134, 139, 155	1-35
P,X	WO 2007/133263 A (GENENCOR INT [US]; CERVIN MARGUERITE A [US]; WHITED GREGG [US]) 22 November 2007 (2007-11-22) Whole document, in particular p.9, l.20-21	1-35
X	WO 2007/044667 A (DU PONT [US]; DICOSIMO ROBERT [US]; PAYNE MARK S [US]; WAGNER LORRAINE) 19 April 2007 (2007-04-19) Whole document, in particular p.17-18	1-5,8-35

-/--

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
7 October 2008	20/10/2008

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Roscoe, Richard

Form PCT/ISA/210 (second sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2008/062633

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006/119060 A (DU PONT [US]; DICOSIMO ROBERT [US]; PAYNE MARK SCOTT [US]; HANN EUGENI) 9 November 2006 (2006-11-09) Whole document, in particular p15, 26	1-5,8-35
X	WO 2007/044666 A (DU PONT [US]; DICOSIMO ROBERT [US]; WAGNER LORRAINE [US]) 19 April 2007 (2007-04-19) Whole document, in particular p.13-14	1-5,8-35
A	CARBONI-OERLEMANS C ET AL: "Hydrolase-catalysed synthesis of peroxycarboxylic acids: Biocatalytic promiscuity for practical applications" JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 126, no. 2, 1 November 2006 (2006-11-01), pages 140-151, XP002460370 ISSN: 0168-1656 the whole document	
A	NATTERMANN H ET AL: "Efficient killing of anthrax spores using aqueous and alcoholic peracetic acid solutions" BUNDESGESUNDHEITSBLATT GESUNDHEITSFORSCH.GESUNDHEITSSCHUTZ, SPRINGER, BERLIN, DE, vol. 48, no. 8, 1 August 2005 (2005-08-01), pages 939-950, XP019319123 ISSN: 1437-1588 the whole document	

Form PCT/ISA/210 (continuation of second sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2008/062633

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005056782 A	23-06-2005	BR PI0417233 A	06-03-2007
		CA 2547709 A1	23-06-2005
		CN 1981035 A	13-06-2007
		EP 1689859 A2	16-08-2006
		MX PA06005652 A	17-08-2006
		US 2008145353 A1	19-06-2008
WO 2007133263 A	22-11-2007	AU 2006343548 A1	22-11-2007
		EP 1954814 A2	13-08-2008
WO 2007044667 A	19-04-2007	NONE	
WO 2006119060 A	09-11-2006	CN 101166828 A	23-04-2008
		EP 1877566 A1	16-01-2008
		US 2007042924 A1	22-02-2007
WO 2007044666 A	19-04-2007	EP 1941048 A2	09-07-2008

Form PCT/ISA/210 (patent family annex) (April 2005)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 January 2010 (14.01.2010)

PCT

(10) International Publication Number
WO 2010/005607 A2

(51) International Patent Classification:
C25B 3/00 (2006.01) *C25B 9/00* (2006.01)
C25B 15/08 (2006.01)

(21) International Application Number:
PCT/US2009/037651

(22) International Filing Date:
19 March 2009 (19.03.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/037,821 19 March 2008 (19.03.2008) US

(71) Applicant *(for all designated States except US)*: **ELTRON RESEARCH & DEVELOPMENT, INC.** [US/US]; 4600 Nautilus Court South, Boulder, CO 80301-3241 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BUSCHMANN, Wayne, E.** [US/US]; 9261 Wexford Road, Boulder, CO 80303 (US). **DEL NEGRO, Andrew, S.** [US/US]; 12576 Maria Circle, Broomfield, CO 80020 (US). **BRYANT, Patrick, S.** [US/US]; 19407 W. 52nd Drive, Golden, CO 80403 (US).

(74) Agent: **CHAPMAN, Gary, B.**; GREENLEE, WINNER AND SULLIVAN, P.C., 4875 Pearl East Circle, Suite 200, Boulder, CO 80301 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: PRODUCTION OF PEROXYCARBOXYLIC ACIDS




Fig. 5

(57) Abstract: Provided are various methods, systems and reactors for producing peroxycarboxylic acid compositions, such as non-equilibrium compositions of peracetic acid, for example. The methods and systems relate to electrolytic generation of hydrogen peroxide or peroxide ions in a reactor, wherein the generated materials are reacted with an acetyl donor to form peracetic acid. In an embodiment, a source of alkali metal ions is provided to an anode chamber such that the ratio of concentrations of the alkali metal ions to protons in the anode chamber of a reactor is greater than 1.

WO 2010/005607 A2

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 184

PRODUCTION OF PEROXYCARBOXYLIC ACIDS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. provisional application 61/037,821 filed March 19, 2008, which is incorporated by reference in its entirety herein to the extent not inconsistent with the disclosure herein.

BACKGROUND OF THE INVENTION

[0002] Rapid, on-site production of peracetic acid (PAA) from safe, non-hazardous feedstocks is an enabling technology for facilities and applications where bulk storage and handling of hazardous materials is not permissible or where the consumption time exceeds the shelf life of bulk peracetic acid. Small quantity users of peracetic acid will especially benefit from on-site generation due to the impracticalities (hazardous and unstable) of distributing small quantities of peracetic acid.

[0003] Various methods for on-site peracetic acid production are known in the art. Disadvantages of such known methods are, among others, (1) the long reaction or cure times required to produce equilibrium concentrations of peracetic acid solutions; (2) costs of shipping, handling, and storage, (3) limited shelf life of concentrated acids, bases, and peroxides, which are all corrosives and hazardous materials; (4) cost of shipping large quantities of water containing merchant hydrogen peroxide; (5) the presence of stabilizers or contaminants originating from merchant hydrogen peroxide; (6) relatively low production rates or excessive equipment size and cost associated with direct electrochemical production of peracetic acid with gas diffusion electrode reactor technologies; (7) inability to recycle supporting electrolyte salts back into the production process. In addition, the practice of combining bulk chemical constituents obtained from merchant suppliers to produce non-equilibrium peroxycarboxylic acid solutions, including peracetic acid is incapable of producing the compositions provided herein. Processes and related devices provided herein eliminate these disadvantages and other disadvantages associated with shipping, storing and handling concentrated merchant peracetic acid.

[0004] U.S. Pat. Nos. 6,566,574, 6,723,890 and 7,271,137 all relate to compositions for neutralization or decontamination of chemical or biological toxins prepared by chemical mixing of various components including a reactive compound which can be hydrogen peroxide. U.S. Pat. No. 6,723,890 relates to an aqueous decontamination formulation comprising: a cationic surfactant; a cationic hydrotrope;

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 185

certain reactive compounds (including hydrogen peroxide); a fatty alcohol having a concentration from greater than 1 wt. % to 2 wt %; and water. U.S. Pat. No. 7,271,137 relates to an aqueous decontamination formulation for use in disinfection and sterilization, consisting of (by weight percentage): 0.5-60% reactive compound selected from the group consisting of nucleophilic compounds and oxidizing compounds, which can be hydrogen peroxide; 1-10% water-soluble bleaching activator which can be monoacetin, diacetin, or triacetin, among other acetyl compounds, and; 3-30% of inorganic base which can comprise potassium acetate.

[0005] U.S. Pat. No.7,235,252, Preto et al. relates to a system for rapid preparation, just before use, of organic peroxyacids, in a hydroalcoholic environment, by mixing separately stored first and second reactants, where the first reactant includes an acyl donating group and the second reactant is in the solid state and comprises a peroxide anion source, a biocidal agent including at least one linear or branched aliphatic and/or aromatic alcohol, and a stabilizing buffer component suitable for keeping the second reactant at a desired pH value.

[0006] U.S. Pat. No. 5,505,740 (Kong et. al) describes a method for in-situ formation of peroxyacid using peroxyacid precursor, a source of hydrogen peroxide and a source for delayed release of acid for a bleaching product (wash solution) and a method of removing soil from fabrics. In the method of Kong et al. the aqueous wash solution is initially raised to a relatively high pH level (e.g., 9.5) to enhance production of the peroxyacid in the aqueous solution, followed by lowering the pH of the aqueous solution by, for example, the delayed release of acid, to enhance bleach performance. The source of the delayed release of acid may be an acid of delayed solubility, an acid coated with a low solubility agent or an acid generating species, or an acid independent of the bleaching product employed.

[0007] U.S. Pat. No. 5,122,538, Lokkesmoe et al, (Ecolab) relates to a process to generate peroxy acid sanitizing and bleaching compositions at the point-of-use. The process comprising introducing hydrogen peroxide and a carboxylic acid into a reactor and contacting the hydrogen peroxide and carboxylic acid in the presence of a sulfonic acid resin and in the substantial absence of active metal ions to form an aqueous peroxy acid composition at concentrations up to 20 wt %.

[0008] British Pat. Pub. No. GB 1,456,592 relates to a bleaching composition having both encapsulated bleaching granules and agglomerated pH-adjustment granules acid. The bleaching granules comprise an organic peroxy acid compound stabilized by salt(s) of strong acids and water of hydration, encapsulated in a fatty

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 186

alcohol coating. The pH-adjustment granules comprise a water-soluble alkaline buffer yielding pH 7-9 agglomerated with a suitable adhesive material to yield the desired solubility delay. Preferred peroxyacid compounds are diperisophthalic acid, diperazelaic acid, diperadipic acid, monoperoxyisophthalic acid, monosodium salt of diperoxyterephthalic acid, 4-chlorodiperoxyphthalic acid, p-nitroperoxy benzoic acid, and m-chloroperoxy benzoic acid.

[0009] U.S. Pat. No. 6,569,286 and published PCT No. WO0019006 (App. No. WO1999GB03178) relate to a process for bleaching of wood and non-wood pulp. In this process an agglomerate containing, among others, a bleach activator (e.g., tetraacetylethylenediamine, TAED) and a peroxide soluble binder (e.g., polyvinyl alcohol) is added to a dilute solution of hydrogen peroxide. The components are allowed to react and the pH of the resulting mixture is chemically adjusted to a suitable alkaline pH and the pulp is contacted with the resulting solution. The patent notes the use of an ion-selective barrier or membrane between the anodic and cathodic chambers of the electrolysis unit of Figure 1 therein. The barrier between the anodic and cathodic chambers in the device of Figure 1 is described as "a cation exchange membrane, which permits migration of protons (H^+) between the two chambers," and as a separation between electrolytes in the two chambers.

[0010] The above processes differ from the processes provided herein, at least in part, in that they are all based on mixing chemical precursors with no electrochemical production or electrochemical pH adjustment components.

[0011] Peracids can be produced in electrochemical cells or reactors by establishing a potential difference across electrodes immersed in electrically-conducting fluid and introducing appropriate reactant materials. For example, U.S. Pat. No. 6,387,238 (Merk et al.) (corresponding to WO 01/10215 or JP-T-2003-506120) relates to a method for preparing an antimicrobial solution containing peracetic acid in which hydrogen peroxide or peroxide ions are formed electrolytically and the hydrogen peroxide or peroxide ions are then reacted with an acetyl donor to form peracetic acid.

[0012] U.S. Pat. No. 6,949,178 (Tennakoon et al.) discloses a process and apparatus for the preparation of peroxyacetic acid at the cathode of an electrolytic cell having an ionically conducting membrane in intimate contact between an anode and a gas diffusion cathode. The method comprises supplying an aqueous organic acid solution to the anode, supplying a source of oxygen to the cathode, and generating peroxyacid at the cathode.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 187

[0013] European Patent EP1469102 (Ohsaka et al.) relates to a process and apparatus for electrolytically producing peracetic acid from acetic acid or acetate and an oxygen-containing gas using an electrolytic cell incorporating a gas diffusion electrode in the presence of a solid acid catalyst.

[0014] U.S. provisional application 61/019,825, filed Jan. 8, 2008 and U.S application 12/350,866, filed Jan. 8, 2009 relate to frozen non-equilibrium peroxycarboxylic acid compositions useful as antimicrobial ice.

SUMMARY OF THE INVENTION

[0015] The invention provides improved methods of production of peroxycarboxylic acids and peroxycarboxylic acid containing solutions for various applications that utilize non-equilibrium peroxycarboxylic acids. The invention also provides improved compositions comprising peroxycarboxylic acids made by the methods herein.

[0016] In an embodiment, various processes for producing peroxycarboxylic acids, such as peracetic acid are provided. The production is particularly useful for on-site production of peracetic acid. Additionally, the peroxycarboxylic acid solutions produced, including peracetic acid solutions, have non-equilibrium compositions, such as characterized by high peroxycarboxylic acid (POA) and water to carboxylic acid (CA) and hydrogen peroxide (H_2O_2) ratios. In an aspect, the ratio of $[POA][H_2O]/[CA][H_2O_2]$ is ≥ 10, ≥ 100, ≥ 1000, ≥ 10,000. In another aspect the ratio of $[POA]:[H_2O_2]$ is: ≥ 1, ≥ 5, ≥ 10, ≥ 100, when the [POA]:[CA] concentration ratio is ≥ 1.

[0017] More specifically, peracetic acid solutions of this invention have non-equilibrium compositions such as characterized by high peracetic acid (PAA) and water (H_2O) to acetic acid (AA) and hydrogen peroxide (H_2O_2) ratios. In an aspect, the ratio of $[PAA][H_2O]/[AA][H_2O_2]$ is ≥ 10, ≥ 100, ≥ 1000, ≥ 10,000. In another aspect the ratio of $[PAA]:[H_2O_2]$ is: ≥ 1, ≥ 5, ≥ 10, ≥ 100 when the [PAA]:[AA] concentration ratio is ≥ 1. The non-equilibrium PAA solutions are economically competitive to equilibrium peracetic acid solutions commercially produced ("merchant") and having typically maximum weight peracetic acid content of between 5% and 35%, where $[PAA][H_2O]/[AA][H_2O_2]$ ratios are typically between 1.8 and 2.5.

[0018] A particular advantage of the use of non-equilibrium peroxycarboxylic acid is that solutions having concentrations of less than about 10 g/L peroxycarboxylic acid can be produced economically. This is particularly the case with non-equilibrium PAA. For example, making dilute solutions (<10 g/L) of equilibrium PAA is not cost-effective

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 188

because in dilute solutions equilibrium favors the formation of hydrogen peroxide and acetic acid over PAA requiring high ratios of feed chemicals to obtain the desired PAA product at low concentration. Therefore, the cost of feed chemicals is much lower for non-equilibrium PAA relative to equilibrium PAA at low concentrations of PAA. Another advantage of non-equilibrium peroxycarboxylic acid is that the feed chemicals (hydrogen peroxide and acyl donor (or acetyl donor)) are significantly less hazardous than those of high concentration equilibrium solutions. This results in safer storage and handling for the end user.

[0019] In an aspect, processes disclosed herein utilize an electrochemical reactor that produces electrolytic hydrogen peroxide (H_2O_2) and/or peroxycarboxylic acid solutions of controlled pH and composition. Typical H_2O_2 concentrations of use in the process examples and made by various reactor systems include, but are not limited to, from 0.01% up to 0.1% (1000 mg/L), or from 0.01% up to 0.5% (5000 mg/L), or from 0.01% up to 5% (50,000 mg/L). Electrolytically produced peroxide solution is reacted with an acyl or acetyl donor to generate peroxycarboxylic acid. In an embodiment, the generated peroxycarboxylic acid is peracetic acid.

[0020] In an aspect, various processes are provided for producing peroxycarboxylic acids such as 2-hydroxyperbenzoic acid (peroxysalicylic acid) and other substituted derivatives of peroxybenzoic acids. The production is particularly useful for on-site production of peroxybenzoic acids. Additionally, produced peroxybenzoic acid solutions have non-equilibrium compositions such as characterized by high peroxybenzoic acid (PBA) and water (H_2O) to benzoic acid (BA) and hydrogen peroxide (H_2O_2) ratios. In an aspect, the ratio of $[PBA][H_2O]/[BA][H_2O_2]$ is ≥ 10, ≥ 100, ≥ 1000, $\geq 10{,}000$, thus making them economically competitive to commercial peroxybenzoic acid sources, while eliminating the hazards and costs of shipping and storing organic peroxides such as peroxybenzoic acids. In specific embodiments, solutions of peroxycarboxylic acids of this invention are solutions in water. In other specific embodiments, solutions of peroxycarboxylic acids are solutions in aqueous solvents which are mixtures of water and a water miscible organic solvent, such as a lower alcohol, and in particular ethanol. In an aspect, processes disclosed herein utilize an electrochemical reactor that produces electrolytic hydrogen peroxide (H_2O_2) solutions of controlled pH and composition. Typical H_2O_2 concentrations of use in the process examples and made by various reactor systems include, but are not limited to, from 0.01% up to 0.1% (1000 mg/L), or from 0.01% up to 0.5% (5000 mg/L), or from 0.01% up to 5% (50,000 mg/L). Electrolytically produced peroxide solution is reacted with an

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 189

acyl donor, such as 2-hydroxybenzoic acid ethyl ester (salicylic acid ethyl ester, ethyl salicylate), to generate peroxybenzoic acids. In an embodiment, the generated peroxycarboxylic acid is peroxysalicylic acid.

[0021] In an aspect, the acyl or acetyl donor is not in contact with an electrode of the reactor. Instead, the donor is placed in a chamber that does not contain an electrode. Examples of such chambers include, but are not limited to, a chamber that is external to the reactor and a chamber that is internal to the reactor, but is not in direct fluid contact with the electrodes. In this aspect, "not in direct fluid contact" refers to membranes that separate the central chamber from each of the cathode and anode chambers so that the central chamber contains "post-processed" peroxycarboxylixc acid product. Such systems provide a number of benefits, such as not electrolyzing the acyl or acetyl donor, POA or PAA product or H_2O_2 to inactive forms, improved process monitoring and process control, thereby achieving higher yields and reliability compared to conventional electrochemical POA (particularly PAA) production. Additional advantages include, but are not limited to, preserving the as-formed [POA]:[H_2O_2] ratio, access to the acyl or acetyl donor(s), POA or PAA components and mixture for monitoring and replenishing as necessary, and ability to reliably control end product characteristics.

[0022] In an aspect, the acyl or acetyl donor is not in contact with a cathode of the reactor. For example, the donor is placed in a chamber that contains an anode. Such a system provides the benefits of not electrolyzing the POA or PAA product to inactive forms, improved process monitoring and process control, thereby achieving higher yields and reliability compared to conventional electrochemical POA or PAA production. Additional advantages include, but are not limited to, increasing the [POA]:[H_2O_2] ratio, reducing concentration of acyl or acetyl donor byproduct, and ability to reliably control end product characteristics.

[0023] The peracid production rate and yield amount depends on the reactor system and operating conditions including, but not limited to, concentration of reactants, temperature, pH, reactor materials such as membranes, electrodes, operating voltage, electrolyte composition and concentration, added chemical stabilizers, flow-rates, delivery rate and mechanism of supply of oxygen-containing gas, etc. The process may be operated in batch mode. The process may be operated in continuous mode. The process may be semi-batch or semi-continuous mode. Generated peroxycarboxylic acid-containing solutions are pH adjusted by either chemical and/or electrolytic methods, the latter allowing electrolyte ions to be recovered back into the electrolytic

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 190

peroxide production process, thereby facilitating continuous or semi-continuous operating modes. The pH adjustment may be automatic or semi-automated such as by feedback control and flowloops where caustic flow-stream output may be at least partially introduced into a feedstock stream.

[0024] The peroxycarboxylic acid product solution produced by any of these processes can be formed very rapidly and on-demand with non-equilibrium compositions making it more convenient, efficient, and cost effective while being safer to handle at relatively low (point of use) concentrations compared to concentrated peroxycarboxylic acid products having equilibrium compositions.

[0025] In an embodiment, the processes and device systems for performing the processes provide one or more of: (1) Electrochemical production of a caustic hydrogen peroxide solution where the solution pH, concentration of peroxide, and ratio of hydroxide to peroxide are controlled by the electrolytic reactor process by flowstream manipulation, residence time, mixing methods, ion selection and concentration, and other parameter control as known in the art; (2) Reaction of the electrolytic caustic hydrogen peroxide solution with an acyl or acetyl donor to rapidly produce non-equilibrium peroxycarboxylic acid solutions that may optionally include additional additives (such as electrolytes, stabilizers, buffers, alcohols, etc.); (3) The pH of the resulting peroxycarboxylic acid solution, particularly peracetic acid, may optionally be adjusted to lower pH (including, but not limited to pH ≤ 7, pH ≤ 6, or 1.5 ≤ pH ≤ 4.5) by either a chemical means of mixing acid with the solutions or electrolytically adjusting the pH in the same apparatus used to produce the electrolytic caustic hydrogen peroxide solution (e.g., and optionally a combination of the two pH adjustment methods); (4) Recovery of electrolyte cations liberated during pH adjustment of the peroxycarboxylic acid solutions for recycle of electrolyte cations back into the electrolytic caustic hydrogen peroxide production process; (5) Feedstocks for this process are electricity, an oxygen-containing gas, water, an electrolyte salt, and an acyl or acetyl donor.

[0026] There are a large number of known acyl or acetyl donors including, but not limited to, diacetin, triacetin, acetylsalicylic acid, tetraacetylethylenediamine. In an aspect, the acyl donor is not a carboxylic acid, but instead is a donor that provides for a non-reversible chemical reaction with hydrogen peroxide to form the corresponding peroxycarboxylic acid. In a more specific aspect, the acetyl donor is not acetic acid, but instead is a donor that provides for a non-reversible chemical reaction with hydrogen peroxide to form peracetic acid. The reaction between the acetyl donor and hydrogen peroxide is accelerated at alkaline pH, and in some embodiments, preferably between

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 191

$10 \leq pH \leq 13$. The acetyl donor or mixture of donors may be in liquid or solid form or dissolved in a solvent when reacted with a solution of hydrogen peroxide, preferably at alkaline pH, to form peracetic acid. The resulting peracetic acid product may then be used as made or its pH adjusted to a desirable level. Additionally, a peroxide stabilizer may be added before, during, or after combination of the acetyl donor with hydrogen peroxide.

[0027] In an embodiment, the electrochemically produced caustic hydrogen peroxide solution is chemically reacted with an acyl or acetyl donor (and other additives if desired). Next, the pH of the resulting peroxycarboxylic acid solution is adjusted electrolytically and/or chemically if desired (for product stabilization or pH requirements of the end use application). During the electrolytic product pH adjustment process or after chemical pH adjustment, the cations liberated by neutralization of caustic are electrolytically separated and recovered back into the electrochemical caustic hydrogen peroxide production process. This electrolytic recycling of cations reduces or eliminates the need for additional electrolyte salt feedstock. The operating conditions of the electrochemical process are also adjusted to optimize the caustic hydrogen peroxide solution pH and hydroxide to peroxide ratio prior to reaction with the acyl or acetyl donor, whereby the chemical reaction rate and yield of peroxycarboxylic acid is maximized. Depending on the specific reactor and system, parameters of interest include return flow-rates of feedback loops, residence time in mixing or reactor chambers, electrolyte concentrations, any one or more feedstock parameters or compositions, including electrolytes, stabilizers, co-solvents, pH adjusters, pH buffers.

[0028] In another embodiment, sequential physical mixing of bulk chemicals is used to generate peroxycarboxylic acid in situ. This alternative physical mixing approach includes the steps of (1) mixing a base with hydrogen peroxide to produce a caustic peroxide solution; (2) mixing the caustic peroxide solution with an acyl donor (e.g. an acetyl donor) to produce a non-equilibrium peroxycarboxylic acid solution; (3) adjusting the pH of the resulting peroxycarboxylic acid solution with acid (for product stabilization or pH requirements of the end use application). The required feedstocks for this process in an automated system are electricity, water, merchant hydrogen peroxide, base (such as sodium or potassium hydroxide or acetate), acyl donors (e.g., acetyl donors), and acid (such as sulfuric or acetic acid).

[0029] In an embodiment, the invention is an electrolytic reactor for carrying out any of the processes disclosed herein. Depending on the particular process, the reactor may be a two-chamber or a three-chamber reactor. In an aspect, a mixing chamber is

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 192

integrated within the reactor for mixing an acyl donor (e.g., an acetyl donor) with a caustic hydrogen peroxide solution, wherein the chamber is electrically isolated from the cathode and anode. In an aspect, the reactor and process provides PAA production without a need for distillation. As required, various flowloops for introducing feedstock, feedback lines for pH control, and output lines for collecting POA (e.g., PAA) product solution are incorporated.

[0030] In another embodiment, provided is a method for making a peroxycarboxylic acid composition by electrolytically generating alkaline hydrogen peroxide or peroxide ions in a reactor comprising a cathode chamber having a cathode, an anode chamber having an anode and at least one cation exchange membrane separating said chambers. A source of alkali metal ions is provided to the anode chamber such that the ratio of concentrations of alkali metal ions to protons formed in the anode chamber is greater than 1 and the predominant cations transported through the at least one cation exchange membrane are alkali metal ions. Hydrogen peroxide or peroxide ions are reacted with an acetyl donor to form peracetic acid in a mixing chamber that is electrically isolated from the anode and cathode of the reactor to produce the peroxycarboxylic acid composition comprising alkali metal ions.

[0031] In an aspect, the source of alkali metal ions is a salt added to said anode chamber, or is the peroxycarboxylic acid composition formed in the method, wherein at least a portion of the composition is recycled to the anode chamber.

[0032] In another aspect, any of the methods provided herein relate to the source of alkali metal ions being added directly to the anode chamber.

[0033] In an embodiment, any of the methods provided herein use a two chamber reactor, such as an anode chamber and a cathode chamber. In an embodiment, any of the methods provided herein use a reactor comprising a central chamber between the anode and cathode chambers and separated from each of the chambers by at least one cation exchange membrane and the source of alkali metal ions is added to the anode chamber, the central chamber or both. Optionally, the alkaline hydrogen peroxide or peroxide ions has a pH greater than or equal to 10 and less than or equal to 13.

[0034] Any of the methods provided herein optionally have an alkaline hydrogen peroxide or peroxide ions with a pH greater than or equal to 10 and less than or equal to 13.

[0035] In another aspect, any of the methods provided herein relate to a reacting step that further comprises introducing one or more acetyl donors to the mixing chamber; and introducing the electrolytically generated alkaline hydrogen peroxide or

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 193

peroxide ions from a cathode chamber of the reactor to the mixing chamber, thereby generating the peracetic acid composition. Any of the methods provided herein further comprise introducing to the reactor a peroxide stabilizer, an electrolyte salt or both. In an aspect, any of the methods provided herein relate to a peroxycarboxylic acid composition formed having a pH that is less than or equal to 8.

[0036] Further provided are methods related to specific ratio of concentrations, such as molar ratios, of alkali metal ions to protons formed in the anode chamber. In an aspect, provided are ratios in the anode chamber that are greater than or equal to 3; between about 3 and 4, inclusive; and greater than or equal to 10, for example.

[0037] In another embodiment, any of the methods provided herein further comprise introducing the peroxycarboxylic acid composition from the mixing chamber to the reactor, adjusting the pH of the peroxycarboxylic acid composition by electrodialysis, and removing the peroxycarboxylic acid composition from the reactor to obtain a peroxycarboxylic acid product solution, wherein the peroxycarboxylic acid product solution has a pH that is less than or equal 8, and optionally wherein the ratio of concentrations of alkali metal ions to protons formed in the anode chamber is greater than or equal to 3, or greater than or equal to 10.

[0038] Also provided are methods for making a peroxycarboxylic acid composition by electrolytically generating hydrogen peroxide or peroxide ions in an electrochemical reactor having an anode chamber having an anode and a cathode chamber having a cathode and at least one cation exchange membrane separating the anode and cathode chambers. Hydrogen peroxide or peroxide ions are reacted with an acyl or acetyl donor to form peroxycarboxylic acid, wherein the peroxycarboxylic acid is formed in a mixing chamber that is electrically isolated from the anode and cathode. A salt is introduced into the reactor and an alkaline electrolyte solution produced by electrodialysis of the salt introduced to the reactor. The alkaline caustic electrolyte solution adjusts the pH of the hydrogen peroxide or peroxide ions to a pH that is greater than or equal to 9.5 and less than or equal to 13.

[0039] In an aspect, the method further comprises adding a source of alkali metal cations to an anode chamber of the reactor. In an embodiment of this aspect, the ratio of concentrations of alkali metal ions to protons in the anode chamber is greater than or equal to 1; greater than or equal to 3, greater than or equal to 3 and less than or equal to 4; or greater than or equal to 10.

[0040] In another aspect, the reactor has a catholyte solution containing the generated hydrogen peroxide or peroxide ions, and the method further comprises,

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 194

controlling the reactor catholyte pH, wherein the catholyte pH is greater than or equal to 10 and less than or equal to 13; and/or controlling a peroxide to hydroxide ratio in the catholyte solution, wherein the ratio is greater than or equal to 0.5:1 and less than or equal to 5:1 or between about 0.5:1 and 2:1. Optionally, the controlling steps comprise balancing transfer rates of alkali metal cations and acid protons introduced to the catholyte solution.

[0041] In an aspect, the ratio of concentrations of alkali metal ions to protons formed in the anode chamber is greater than 1, the alkaline hydrogen peroxide or peroxide ions has a pH greater than or equal to 10 and less than or equal to 13, and the peroxycarboxylic acid composition has a pH less than or equal to 8.

[0042] In another aspect, the peroxycarboxylic acid composition is introduced to an anode chamber of the reactor, thereby lowering said peracetic acid composition pH by electrodialysis and lowering the hydrogen peroxide concentration.

[0043] Any of the methods provided herein further comprise introducing at least a portion of the peroxycarboxylic acid composition from the anode chamber to the mixing chamber by an acidic anolyte loop, thereby providing additional pH regulation of the peroxycarboxylic acid composition.

[0044] In an aspect, any of the methods relate to a peroxycarboxylic acid that is peracetic acid. In another aspect, any of the methods relate to a peroxycarboxylic acid that is a substituted derivative of peroxybenzoic acid. In another aspect, any of the methods are for making a peroxycarboxylic acid that is a non-equilibrium composition.

[0045] Also provided is an electrochemical reactor for generating peroxycarboxylic acid compositions, comprising an anode positioned within an anode chamber; a cathode positioned within a cathode chamber for producing alkaline hydrogen peroxide catholyte solution; at least one cation exchange membrane separating the anode and cathode chambers; an optional central chamber between the cathode and anode chambers and separated from each of the chambers by at least one cation exchange membrane; a mixing chamber electrically isolated from the anode and cathode for receiving an acyl donor; a mixing chamber conduit for supplying a caustic catholyte solution to the mixing chamber; a peroxycarboxylic acid (POA) composition conduit for introducing POA made in the mixing chamber to the reactor, wherein the POA composition conduit is operably connected to the anode chamber or the optional central chamber; and a reactor outlet for removing from the reactor at least a portion of the POA formed in the reactor. In an embodiment, the removed POA is in a solution of lower pH than the POA made in the mixing chamber

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 195

[0046] In an aspect, the reactor further comprises an acidic anolyte loop that operably connects the reactor outlet to the POA composition conduit, thereby providing rapid pH adjustment to the POA made in said mixing chamber. In another aspect, the mixing chamber is positioned either external to the reactor or internal to the reactor.

[0047] Without wishing to be bound by any particular theory, there can be discussion herein of beliefs or understandings of underlying principles relating to the invention. It is recognized that regardless of the ultimate correctness of any mechanistic explanation or hypothesis, an embodiment of the invention can nonetheless be operative and useful.

BRIEF DESCRIPTION OF THE DRAWINGS

[0048] **FIG. 1** is a flow-chart summary of one embodiment of a PAA-producing process, where produced PAA is fed into the reactor, such as into a central chamber (for a three-chamber reactor) or anode chamber (for a two-chamber reactor).

[0049] **FIG. 2** is a flow-chart summary of one embodiment of a PAA-producing process, where produced PAA is not fed into the reactor, but instead is used directly such as for caustic applications like. A base-containing source or acid-containing source may be used as desired to control the output PAA pH.

[0050] **FIG. 3** is a schematic illustration of a three-chamber electrolytic reactor for peracetic acid generation.

[0051] **FIG. 4** is a schematic illustration of a two-chamber electrolytic reactor for peracetic acid generation, wherein the generated peracetic acid is passed over the anode as anolyte solution to shift pH from caustic to acid.

[0052] **FIG. 5** is a schematic illustration of a two-chamber electrolytic reactor for peracetic acid generation, wherein the generated peracetic acid is dosed into an acidic anolyte loop to rapidly shift the pH from caustic to acid.

[0053] **FIG. 6** is a schematic illustration of a two-chamber electrolytic reactor for peracetic acid generation, wherein the generated peracetic acid is directly isolated or used without subsequent interaction with the reactor.

[0054] **Fig. 7** is a schematic diagram of preferred dosing and mixing of materials in generator process, excluding the electrolytic reactor.

[0055] **Fig. 8** is a graph of concentration of peracetic acid with time to determine the degradation rate in the absence of peroxide stabilizers. The average half life of the peracetic acid in the product solution was 10 days. The decay curve was approximately linear. See Example 10.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 196

[0056] **Fig. 9** is a graph of concentration of peracetic acid to determine the degradation rate in the absence of peroxide stabilizers. The average half life of the peracetic acid in the solutions was 1.8 hours. The decay curve was approximately linear as illustrated.

DETAILED DESCRIPTION OF THE INVENTION

[0057] "Acyl donor" refers to a material which supplies an acyl donor for reacting with the hydrogen peroxide or peroxide ions to form a solution which includes a peroxycarboxylic acid. In a specific embodiment, an "acyl donor" refers to a material which supplies an acetyl donor for reacting with the hydrogen peroxide or peroxide ions to form a solution which includes peracetic acid.

[0058] "Acetyl donor" refers to a material which supplies an acetyl donor for reacting with the hydrogen peroxide or peroxide ions to form a solution which includes peracetic acid. The composition of the acetyl donor source for use in a commercial reactor system may be composed of an acetyl donor compound, optionally containing more than one type of acetyl donor compound, optionally containing an electrolyte salt, optionally containing a peroxide stabilizer, optionally containing a base, optionally containing an acid, optionally containing a solvent (water, alcohols, organic). Examples of acetyl donors include, but are not limited to O-acetyl donors (--O--C(O)CH_3), such as acetin, diacetin, triacetin, acetylsalicylic acid, (β)-D-glucose pentaacetate, cellulose (mono and tri) acetate, D-mannitol hexaacetate, sucrose octaacetate, and acetic anhydride. N-acetyl donors (--N--C(O)CH_3) may also be used, such as N,N,N'N'-tetraacetylethylenediamine (TAED), N-acetyl glycine, N-acetyl-DL-methionine, 6-acetamidohexanoic acid, N-acetyl-L-cysteine, 4-acetamidophenol, and N-acetyl-L-glutamine. Examples of acyl donors

[0059] "Peroxycarboxylic acids" (POA, also referred to in the art as peracids, peroxyacids, or percarboxylic acids) include, but are not limited to, peracetic acid (peroxyacetic acid), peroxybenzoic acid (perbenzoic acid) and substituted forms of peroxybenzoic acid; di-peroxymalonic acid, di-peroxysuccinic acid, di-peroxyglutaric acid, di-peroxyadipic acid; all isomeric forms of each of peroxypropionic acid, peroxybutanoic acid, peroxyhexanoic acid, peroxydodecanoic acid, and peroxylactic acid; and peroxycarboxylic acid derivatives of amides, carbohydrates, saccharides, polysaccharides, cellulose, fatty acids and surfactants. Peroxyacetic acid (PAA) is a representative peroxycarboxylic acid (POA). Methods and compositions herein which

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 197

are exemplified with PAA can be practiced in general with any one or more peroxycarboxylic acids (POA).

[0060] "POA composition" or more specifically 'PAA composition" refers to the POA, or more specifically the PAA, made and released from the mixing chamber. "POA product solution" or more specifically "PAA product solution" refers to POA, or more specifically PAA, removed from the reactor, such as a POA or PAA composition that has been introduced to the reactor. In an embodiment, the POA product solution has a pH that is lower than the POA composition that is introduced to the reactor. In an aspect the POA product solution, specifically the PAA product solution has a pH ≤ 8, pH ≤ 7, pH ≤ 6, or 1.5 ≤ pH ≤ 4.5.

[0061] "Reactor" refers to an electrolytic chamber that uses electricity, water and oxygen to generate a reactant such as hydrogen peroxide for producing PAA. Suitable reactors are known in the art (see, e.g., U.S. Pat. Nos. 6,387,238, 6,949,178; U.S. Pub. No. 2007/0074975, each of which are hereby incorporated by reference, such as for reactor design and materials) and are disclosed herein. Some common features of such reactors are outlined in **FIGs. 3-6** and include electrodes and electrode-containing chambers, membranes, inputs for reactants, and a power supply.


[0062] "Not in contact" refers to a reactant material that is placed in a chamber that is isolated from the electrode (cathode and anode) chambers, such as a mixing chamber. In processes disclosed herein, this refers to acetyl donors in a mixing chamber that is physically separated from the electrode chambers.

[0063] "Caustic" refers to basic pH solutions. In an aspect the pH is greater than about 9, greater than 10, or greater than and equal to 10 and less than and equal to 13. In an aspect, the hydrogen peroxide-containing catholyte solution is caustic, such as pH ≥ 9, pH ≥ 10, or 9.5 ≤ pH ≤ 13 and is introduced to the acetyl donor containing source to generate PAA.

[0064] "Equilibrium" and "non-equilibrium". "Equilibrium PAA" is most commonly produced by mixing hydrogen peroxide, acetic acid, water and an acid catalyst. The mixture is allowed to "cure" for several days at which time the mixture reaches steady state equilibrium.

[0065] In aqueous solution peracetic acid is in a chemical equilibrium with acetic acid, hydrogen peroxide and water. This equilibrium is represented in the following Equation (1):


Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 198



(1)

[0066] For example, a higher concentration of reactants is required to produce a higher concentration of peracetic acid. Conversely, a higher concentration of water will drive the reaction backwards, which means dilute solutions have very low peracetic acid equilibrium concentrations and mostly contain water and unused starting materials.

[0067] The molar concentration ratio of products versus reactants gives an equilibrium ratio often referred to as the equilibrium constant as shown in the following Equation (2A):



(2A)

[0068] For equilibrium peracetic acid solutions this equilibrium constant typically ranges between 1.8 and 2.5. [See "Organic Peroxides," Daniel Swern, Editor; Wiley-Interscience, New York, 1970-72 (3 volume series)]. As used herein, in certain aspects "nonequilibrium peracetic acid solutions" refer to PAA solutions having equilibrium constants greater than 10, greater than 100, greater than 1000, and greater than 10,000. Equilibrium solutions of peroxycarboxylic other than peracetic acid are known in the art and equilibrium constants for the generic equilibrium equation:

$$\frac{[RCO\text{-}O\text{-}OH] \times [H_2O]}{[RCO\text{-}OH] \times [H_2O_2]} = \text{equilibrium constant} \qquad (2B)$$

are known in the art or can be determined by methods well-known in the art.

An example of typical equilibrium compositions commercially produced and distributed in bulk is 5-35% by weight peracetic acid, up to 30% hydrogen peroxide, up to 40% acetic acid and the balance being water. The weight ratio of hydrogen peroxide to peracetic acid to acetic acid in the merchant products ranges between 4.6:1:1.3 (5-6% PAA equilibrium product) and 1:5.4:6.2 (35% PAA equilibrium product). Using only the $[H_2O_2]$:[PAA] ratio is an oversimplified definition for distinguishing equilibrium from non-equilibrium peracetic acid solutions in that it does not represent the acetic acid constituent involved with the equilibrium constant.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 199

"Non-equilibrium" refers to chemical mixtures that do not provide an equilibrium constant value, such as provided by Equation (2A) for peracetic acid solutions, that is between about 1.8 and 2.5 or for Equation (2B) where the specific equilibrium constant depends upon the R group. Accordingly, a non-equilibrium PAA solution is optionally described as having an equilibrium constant typically as calculated by Equation (2) that is not between 1.8 and 2.5. In an aspect, the nonequilibrium PAA is defined as those solutions having an equilibrium constant of greater than 10, greater than 100, greater than 1000, and greater than 10,000.

[0069] In specific embodiments, herein the non-equilibrium PAA solutions include those in which the ratio of hydrogen peroxide to PAA is less than 2, those in which this ratio is less than 1 and to those in which this ratio is 0.5 or less. Non-equilibrium PAA solutions of this invention include those in which the concentration of PAA is less than 200 mg/L, those in which this concentration is 100 mg/L or less, those in which the concentration is 50 mg/L or less, those in which the concentration is 10 mg/L or less and those in which the concentration is 5 mg/L or less.

[0070] Current practice in cleaning, disinfection and water treatment applications is distribution of bulk PAA solutions delivered and stored in vented drums until use. This is typically sold as equilibrium solutions with PAA concentrations of 5-6%, 15% or 35% in the presence of excess hydrogen peroxide and acetic acid with water making up the balance.

[0071] Alternatively, large quantities of equilibrium PAA can be produced on-site by blending concentrated hydrogen peroxide and acetic acid in water. Sulfuric acid may also be added as a catalyst to accelerate the equilibration. The blended solution is allowed to 'cure' for at least 6-10 days while reaching chemical equilibrium prior to use. The cure time increases with decreasing concentration of either starting material and is several weeks or longer at very low point-of-use concentrations. Most applications using peracetic acid (with the exception of pulp bleaching) are regulated to use less than 170 mg/L concentrations for hard surface cleaning and less than 80 mg/L for contact with produce and often less than 10 mg/L for water treatment.

[0072] As an example of the drawback to producing low concentration equilibrium solutions, a 200 mg/L concentration of peracetic acid in an equilibrium solution would contain 4000 mg/L hydrogen peroxide and 35,000 mg/L acetic acid that is unused starting material (equilibrium constant = 2.05). In contrast, non-equilibrium peracetic acid solutions can contain 200 mg/L peracetic acid, 200 mg/L hydrogen peroxide and 160 mg/L acetic acid (equilibrium constant = 9315). Therefore to directly produce low


Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 200

concentrations of peracetic acid rapidly and economically on-site, a non-equilibrium product is required.

[0073] Conventional non-equilibrium peracetic acid solutions are commercially produced in bulk by distillation of equilibrium peracetic acid solutions and storing the non-equilibrium distillate near its freezing point to minimize decomposition and re-equilibration during storage. Equilibrium peracetic acid solutions are produced by reacting concentrated hydrogen peroxide with concentrated acetic acid in a 1-20% sulfuric acid solution where the sulfuric acid acts as an acid catalyst to make the reaction occur rapidly. The non-equilibrium peracetic acid produced is distilled from the reaction mixture and stored near its freezing point to minimize decomposition. This method of producing non-equilibrium peracetic acid is not practical for smaller users due to the operating skill required for such a production process, the use of concentrated hazardous materials, and the explosion hazard created by distillation of concentrated peroxides.

[0074] Alternatively, non-equilibrium peracetic acid solutions can be chemically produced by an irreversible, non-equilibrium reaction of hydrogen peroxide with an acetyl donor in a solvent such as, but not limited to, water. One typical example of this reaction using acetylsalicylic acid as the acetyl donor is given in Equation (3). Typically caustic pH (pH >10) is used to accelerate the reaction since the hydrogen peroxide anion is a much better nucleophile than hydrogen peroxide. The reaction pH can be adjusted with an appropriate base (proton acceptors such as hydroxide or amines for example).


[0075] Both the hydrogen peroxide anion and hydroxide anion compete in the reaction with the acetyl donor, the former producing peracetic acid and the latter producing acetic acid. The percent conversion of the acetyl donor to peracetic acid is maximized by optimizing the hydrogen peroxide to hydroxide ratio mixing method and reaction time. In embodiments, the processes provided herein adjust the hydrogen peroxide to hydroxide ratio, such as ratios of 1:2, 1:1.5, 1:1, 1.5:1, 2:1, greater than 2:1. In the example given below, up to 85% of the acetyl donor is converted to peracetic acid.



acetylsalicylic acid salicylic acid (3)

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 201

[0076] Both the hydrogen peroxide anion and hydroxide anion compete in the reaction with the acyl donor, the former producing a peroxycarboxylic acid and the latter producing a carboxylic acid. The percent conversion of the acyl donor to peroxycarboxylic acid is maximized by optimizing the hydrogen peroxide to hydroxide ratio, mixing method and reaction time. In embodiments, the processes provided herein adjust the hydrogen peroxide to hydroxide ratio, such as ratios of 1:2, 1:1.5, 1:1, 1.5:1, 2:1, greater than 2:1. In the example given below, up to 85% of the acyl donor, salicylic acid ethyl ester, is converted to a peroxycarboxylic acid and preferably greater than 85% of the acyl donor is converted to peroxycarboxylic acid. In the example given below, the peroxysalicylic acid may be used, for example, as a biocide, an epoxidation agent for alkenes, or a polymerization agent, catalyst or initiator. In the example given below, the acyl donor byproduct is ethanol, which may be used as a co-solvent component or biocidal component of a product solution.



salicylic acid ethyl ester peroxysalicylic acid (3.5)

[0077] An example of a non-equilibrium reaction solution in the above Equation (3) is combining 1.1 g/L hydrogen peroxide adjusted to pH 12.0 with sodium hydroxide and reacted with 10 g/L acetylsalicylic acid. The product solution contains 0.32 g/L hydrogen peroxide and 1.9 g/L peracetic acid with 85% conversion of the acetylsalicylic acid. This product has a non-equilibrium hydrogen peroxide to peracetic acid ratio of 0.17, more than ten times lower than for merchant equilibrium products.

[0078] At alkaline pH (pH >7.5), the peracetic acid is unstable and decomposes to oxygen and acetic acid and/or acetate anion over time at a much higher rate than at lower pH. Alternatively, the acetyl donor byproduct may further react with the peracetic acid in the presence of alkaline pH causing its decomposition or consumption with acetic acid and oxygen as the byproducts. Therefore, the adjustment of the pH to neutral (pH 7) or acidic (pH <7) is often desired for stabilization and storage.

[0079] At alkaline pH ($7.5 \leq pH \leq 10.5$), near the pKa of peracetic acid (pKa = 8.2), peracetic acid is least stable. Decomposition of peracetic acid is greatly accelerated in this pH range due to a self reaction between the protonated and deprotonated (anion) forms of peracetic acid leading to the evolution of oxygen. The electronic state of oxygen evolved by this mechanism is thought to be singlet oxygen,

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 202

which is more reactive than triplet oxygen and enhances bleaching and oxidation power. [See Jörg Hoffmann, Gerard Just, Wilhelm Pritzkow, Harald Schmidt, Journal Praktische Chemie/Chemiker-Zeitung, Vol. 334, Iss. 4, pp 293-297 (1992)].

[0080] The above self-reaction decomposition process may be inhibited by rapid adjustment of the solution pH from alkaline (pH>10.5) to acidic (pH <7), and the yield of peracetic acid is increased by increasing the rate of pH adjustment.

[0081] As disclosed herein, the above self-reaction decomposition process at alkaline pH ($7.5 \leq pH \leq 10.5$) may also be inhibited by addition of an appropriate peroxide stabilizer without adjusting the pH out of this range.

[0082] The invention may be further understood by the following non-limiting examples. All references cited herein are hereby incorporated by reference to the extent not inconsistent with the disclosure herewith. Although the description herein contains many specificities, these should not be construed as limiting the scope of the invention, but as merely providing illustrations of some of the presently preferred embodiments of the invention. For example, the scope of the invention should be determined by the appended claims and their equivalents, rather than by the examples given.

[0083] Flow-charts of exemplary processes of the invention for production of POA (and PAA) are provided in **FIGS. 1-2**. In **FIG. 1**, electrolytically produced caustic H_2O_2 is removed from the cathode chamber of electrolysis device and mixed with an acyl or acetyl donor to generate POA solutions. POA composition from the mixing chamber is introduced into a reactor chamber, thereby providing further processing capability. For example, the POA product removed from the reactor can have a precisely user-controlled pH level. The introduction location will depend on the particular reactor, and could range from a central chamber (in a three-chamber system) to an anode chamber (in a two-chamber system), as described herein. Alternatively, **FIG. 2** illustrates an embodiment where the POA composition is used "directly."

EXAMPLE 1: Non-Equilibrium PAA production Using a Three-Chamber Reactor

[0084] **FIG. 3** schematically illustrates a process of the invention for generating peracetic acid and other peroxyacids using an electrolytic reactor that generates hydrogen peroxide and caustic (base) from electricity, water, oxygen, electrolyte salts and acetyl donors or peroxyacid donors.

[0085] The electrolytic reactor in this example is composed of three flow chambers, one containing an anode (anode chamber), one containing a cathode (cathode chamber) and one disposed in between (central chamber) that does not contain an electrode. The three chambers are separated by cation exchange

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 203

membranes where the one adjacent to the anode chamber is designated as the anode membrane and the one adjacent to the cathode is the cathode membrane. The anode and cathode electrodes are connected to a power supply (not shown). External to the electrolytic reactor is a mixing device where the caustic hydrogen peroxide solution produced at the cathode is mixed with the acetyl donor containing solution to generate PAA.

[0086] The general operating principal of electrolytic reactor is summarized in the following equations (4)-(6). The mixing chamber in the illustrated embodiments is optionally incorporated within the reactor, so long as the chamber interior volume is electrically "isolated" from the cathode and anode chambers. The two electron reduction of oxygen in the presence of water at a cathode surface that supplies electrons to the reaction produces hydroxide and hydrogen peroxide anions. Balancing the electrons consumed and ionic charge generated at the cathode is oxidation of water at the anode, which releases two molar equivalents of electrons and generates ½ molar equivalent of oxygen (O_2) and two molar equivalents of protons. To complete the electrolytic process, the protons migrate under the influence of the applied electric field gradient from the anode chamber to the cathode chamber through the cation exchange membranes and solution contained in the central chamber. The protons, upon arrival to the cathode chamber, ion pair with the hydroxide and hydrogen peroxide anions forming water and hydrogen peroxide.

(4) cathode reaction: $O_2 + H_2O + 2e^- \longrightarrow HOO^- + HO^-$

(5) anode reaction: $H_2O \longrightarrow 2H^+ + 1/2\ O_2 + 2e^-$

(6) ion pairing: $2H^+$ (from anode reaction) + $HOO^- + HO^- \longrightarrow HOOH + HOH$ (in catholyte)

[0087] If, on the other hand, the protons migrating from the anode are partially or completely captured and replaced with alkali metal cations (e.g., sodium and/or potassium ions) then the alkali metal cations will instead migrate to the cathode chamber under the influence of the electric field gradient. The alkali metal cations will then ion pair with the hydroxide and hydrogen peroxide anions forming caustic (sodium or potassium hydroxide) and sodium hydrogen peroxide or potassium hydrogen peroxide in the equations (7)-(9) below.

(7) cathode reaction: $O_2 + H_2O + 2e^- \longrightarrow HOO^- + HO^-$

(8) anode reaction: $H_2O \longrightarrow 2H^+ + 1/2\ O_2 + 2e^-$

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 204

(9) ion pairing (in catholyte): $2Na^+$ (from anolyte electrolyte or central chamber electrolyte)+ $HOO^- + HO^- \longrightarrow HOONa + HONa$

[0088] The source of alkali metal cations can be in the form of a salt (sulfate, phosphate, acetate, citrate, bicarbonate, bisulfate etc.) or base (NaOH, KOH, NaOOH, KOOH, etc.) or caustic hydrogen peroxide product from the reactor or caustic peracetic acid product. In a preferred embodiment, the source of alkali metal cations is the caustic peracetic acid product. The alkali metal cation source may comprise in whole or in part the anode solution or central chamber solution. The protons generated at the anode are captured by ion pairing with the above listed anions whereby some or all of the alkali metal cations are liberated and become mobile charge carriers (ionized and mobile in solution and through a membrane) that migrate under the influence of the electric field gradient to the cathode.

[0089] In an aspect, any of the systems and methods described herein are further characterized in terms of a molar ratio (also referred herein as a "concentration ratio") of ions in the anolyte solution, and more specifically of the anolyte solution in the anode chamber. In an aspect, the molar ratio of alkali metal ions (e.g., Na^+ or K^+) to protons (e.g., H^+) in the anode chamber is greater than 1, greater than 3, or is greater than 10. As discussed, there are many different means for generating alkali metal ions. An important feature provided herein is preferentially increasing alkali metal ions in the anode chamber to provide a buffer so that amount of available protons is minimized.

[0090] In an embodiment for Na^+/H^+ Molar ratio (or K^+/H^+ Molar ratio) in the anolyte solution for a two chamber reactor configuration and Nafion® as the membrane: The Na^+/H^+ ratio should be greater than 1 to have useful alkaline hydrogen peroxide production Faradaic efficiency; preferably the Na^+/H^+ ratio is greater than 3 for greater alkaline hydrogen peroxide production efficiency; and ideally this ratio is greater than 10 for the highest alkaline hydrogen peroxide production efficiencies. (There are no efficiency limitations created by the ratio being in greater excess.) The higher the Na^+/H^+ ratio, the greater proportion of sodium transport through the membrane over protons to support the production of alkaline hydrogen peroxide.

[0091] If so desired, one may reduce this ratio to ca. 3-4 to allow some amount of acid protons to be transported through the membrane from the anolyte to the catholyte. This may be advantageous in some cases to reduce the concentration of hydroxide in the catholyte, thereby increasing the efficiency of the conversion yield of the acetyl donor to the peroxycarboxylic acid when the acetyl donor is mixed with the alkaline

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 205

hydrogen peroxide solution. The reaction of excess hydroxide with an acetyl donor simply produces the carboxylic acid.

[0092] It is understood that these ratios refer to steady-state systems and that there may be a start-up period of time, such as during continuous mode operation where there is a periodic recycling of a reagent such as peroxycarboxylic acid, where steady state has not been achieved and that the ratio is less than 1. In an aspect, the ratios provided herein intend to refer to the ratio achieved during steady state conditions after the start-up period.

[0093] By the above mechanism the cations supplied, for example, to the central chamber solution (or alternatively to the anode chamber solution) are transported to the cathode solution under the influence of the electric field gradient. This process is herein referred to as "electrodialysis". By the above mechanism, the alkali metal cations present in a process' cathode solution can be recycled back into an unprocessed cathode solution by passing the processed cathode solution through the central chamber. By the above mechanism, the alkali metal cations present in a processed cathode solution mixed with an acetyl donor to produce peracetic acid may be recycled back into the unprocessed cathode solution by passing the processed cathode solution mixed with an acetyl donor through the central chamber. By the above mechanism, the alkali metal cations present in a cathode solution mixed with a peroxyacid donor to produce a peroxyacid can be recycled back into the cathode solution by passing the cathode solution through the central chamber. A process utilizing one or more of these recycling steps is referred to herein as a "continuous process." A continuous process need not run continuously, but instead refers to this recycling and can be interrupted as needed and supplemented with one or more substituents such as a top-up of water or one or more other reagents. Accordingly, any of the processes or systems described is performed in continuous mode.

[0094] When there is more than one type of mobile charge carrier in the system the relative concentrations of each charge carrier type reaching the cathode can be controlled. For example, adjusting the concentration of alkali metal source in the central chamber solution and/or adjusting the type of anion in the central chamber solution will adjust the ratio and/or mobility of protons versus alkali metal cations reaching the cathode chamber. This in turn adjusts the ratio of ion pairing between protons, alkali metal cations, hydroxide, and peroxide anions.

[0095] Protons will preferentially ion pair with the stronger base, hydroxide in this case, to form water thereby reducing the hydroxide concentration more rapidly than the

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 206

peroxide anion concentration (hydrogen peroxide is a weak acid with a pK_a of 11.6). Reducing the hydroxide to peroxide ratio is desirable to maximize the chemical conversion of the acetate or peroxyacid donor to the desired peracetic acid or peroxyacid product instead of the corresponding carboxylic acid. As noted, the hydroxide competes for reaction with the acetyl donor to produce acetic acid.

[0096] The process illustrated in **FIG. 3** is summarized by the flow-charts of **FIG. 1**. **FIG. 1** reflects an embodiment where: (1) A caustic hydrogen peroxide product is electrolytically produced at the cathode. (2) The caustic hydrogen peroxide product is removed from the reactor and (3) mixed with a source of acetyl donors or peroxyacid donors (single or mixture) and optionally salts and/or peroxide stabilizers to form a solution containing peracetic acid or other peroxyacids. (4) The peracetic acid or peroxyacid containing solution formed in step (3) is then passed back through a different flow chamber in the electrolytic reactor disposed between the anode and cathode flow chambers, partitioned from the cathode and anode flow chambers by ion exchange membranes. During passage of the peracetic acid or peroxyacid containing solution through the central flow chamber of the reactor alkali metal cations are transported by electrodialysis through the cathode membrane and recycled back into the caustic hydrogen peroxide solution production process at the cathode. Alkali metal cations are removed from the peracetic acid or peroxyacid containing solution and are replaced by acid protons produced by electrolytic oxidation of water at the anode and transported through the anode membrane by the applied electric field gradient. This ion transport and electrodialysis process lowers the pH of the peracetic acid or peroxyacid containing solution to a suitable pH range, preferably pH 7 or lower, where peracetic acid and peroxyacids are most stable.

[0097] **FIG. 2** summarizes another embodiment, where step (4) involving the peracetic acid or peroxyacid containing solution formed in step (3) being used directly for an application requiring elevated pH, such as a pH greater than 11 in some embodiments (example of such an application is pulp bleaching). A salt electrolyte containing alkali metal cations is added to the anolyte or central chamber solutions to provide the cations required by the above process to produce caustic peroxide at the cathode.

[0098] There are several useful features related to this example, including: (1) preventing the acetyl donor from contacting an electrode of the reactor where the acetyl donor may be electrolytically degraded or deactivated or the acetyl donor may foul the electrode surface; (1a) preventing the acyl donor from contacting an electrode of the

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 207

reactor where the acetyl donor may be electrolytically degraded or deactivated or the acyl donor may foul the electrode surface; (2) producing peracetic acid or peroxycarboxylic acids from electrolytically generated hydrogen peroxide and hydrogen peroxide ions from stable precursors, non-toxic precursors, and non-hazardous precursors on-site and on-demand; (3) producing peracetic acid or peroxycarboxylic acids from electrolytically generated hydrogen peroxide and hydrogen peroxide ions in the absence of an electrode so that all peroxide species are preserved in the product stream; (4) producing peracetic acid or peroxycarboxylic acids from electrolytically generated hydrogen peroxide and hydrogen peroxide ions in the absence of a cathode so that all peracetic acid and peroxycarboxylic acids are preserved in the product stream; (5) producing peracetic acid or peroxycarboxylic acids from electrolytically generated hydrogen peroxide and hydrogen peroxide ions in the presence of an anode so that hydrogen peroxide concentration may be decreased in the product stream; (6) producing alkaline electrolyte from a salt rather than adding alkaline chemical feedstocks; (7) controlling the catholyte pH and peroxide to hydroxide ratio by balancing the transfer rates of alkali metal cations and acid protons through the cathode membrane into the catholyte where the cation transfer is driven primarily by electrodialysis; (8) adjusting the pH of the peracetic acid products using electrodialysis to replace alkali metal cations with acid protons generated at the anode; (9) recovering alkali metal cations from the peracetic acid or peroxyacid products using electrodialysis to transfer cations to the catholyte where they are recycled back into the process for producing caustic (alkaline) hydrogen peroxide. An advantage of keeping the acetyl donor and peracetic acid product out of contact with an electrode include avoiding electrolysis of the acetyl donor or PAA product or H_2O_2 to inactive forms. Advantages of passing the alkaline PAA product solution through the reactor (central or anode chambers) include automated pH adjustment without the use of bulk chemicals and recovery of alkali metal ions back into the process (minimizes consumables). Advantages of passing the alkaline PAA product through the anode chamber include automated pH adjustment without the use of bulk chemicals; recovery of alkali metal ions back into the process (thereby minimizing the amount of consumables introduced to the reactor); reduction of the H_2O_2 concentration (thereby minimizing corrosivity of PAA product); and reduction of the acetyl donor byproduct concentration (thereby reducing organic content).

[0099] Additionally, the materials in the reactor system that are contacted by peracetic acid or peroxyacids are preferably compatible and do not cause significant

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 208

degradation of the peroxyacid products (this includes reactive or catalytic materials, leachable materials, material degradation byproducts, etc.). The materials of the reactor system that are contacted by caustic peracetic acid or peroxyacids products should be compatible and not cause significant degradation of the caustic peroxyacid products (this includes reactive or catalytic materials, leachable materials, material degradation byproducts, etc.). These materials include fluid lines, mixing devices, wetted pump parts, gaskets, membranes, wetted reactor body parts, flow frames, other objects contained within the reactor (screens, fibers, ion exchange resins, particles, etc.) fluid reservoirs, storage tanks, valves, fittings, meters, sensors, etc.

[00100] Preferred metals and metal alloys compatible as wetted parts in the reactor system include stainless steel (austenitic alloys), titanium, zirconium, Inconel alloys, Hastelloy alloys. Preferred plastics, elastomers, rubbers and polymers compatible as wetted parts in the reactor system include polypropylene, polysulfone, polyvinylchloride (PVC), chlorinated polyvinylchloride (CPVC), Teflon(R), polytetrafluoroethylene (PTFE), polyvinyldifluoride (PVDF, Kynar), Kel-F, polymethyl methacrylate resins (acrylics), acrylonitrile butadiene styrene (ABS) resins, ethylene propylene diene M-class (EPDM), Viton fluoroelastomers (composed of at least two of the following: hexafluoroethylene, vinylidene fluoride, tetrafluoroethylene, and perfluoromethylvinlyethers).

[00101] Preferred cathode materials include carbon-based materials such as graphite, carbon fiber, carbon felt, graphite felt, carbon black, activated carbon, carbon aerogels, and carbon nanotubes having native surfaces or surfaces modified with carbon oxides, catalytic organic molecules, catalytic metals and/or metal oxides, halogenated surfaces, thermoplastics (e.g., PTFE), electropolymers (e.g., polypyrrole, polypyridine) and combinations thereof appropriate for the electrochemical reduction of oxygen to peroxide, peroxide ions, and peroxide radicals. In an embodiment preferred cathode materials include metal-based materials such as nickel, stainless steel alloys, Inconel alloys coated with graphite, graphene, carbon black, activated carbon, carbon aerogels, carbon nanotubes, thermoplastics, carbonized thermoplastics, gold, palladium, platinum, iridium and alloys and their respective oxide forms; or specific metal oxides such as oxides of the lanthanides and mixtures of two or more of the metal oxides such as cerium oxide, copper oxide, manganese oxide, iron oxide, silver oxide, nickel oxide, palladium oxide, platinum oxide, iridium oxide.

[00102] Preferred anode materials include titanium, anodized titanium supported metal oxides such as iridium oxide, doped iridium oxides, lanthanum oxides and

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 209

platinized titanium. In a preferred embodiment, the anode is a dimensionally stable anode (DSA) comprising a titanium supported electrocatalyst.

[00103] Preferred membrane materials include ion exchange resin membranes and microporous membrane products composed of preferred plastics and polymer resins compatible with the process solutions. In a preferred embodiment the membrane is a Nafion(R) ion exchange membrane.

[00104] Wetted parts of the reactor system are treated prior to generation of peroxide species. All wetted surfaces are washed with a degreasing fluid such as Blue Gold(TM) or alcohol (e.g., methanol, ethanol, isopropanol) to remove organic materials and soils followed by rinsing with demineralized water. Wetted stainless steel parts are passivated with citric acid or nitric acid at concentrations of at least 5 wt% in warm water heated to at least 35 degrees Centigrade followed by rinsing with demineralized water. Membranes are pre-treated by soaking in alkaline hydrogen peroxide overnight. Any wetted surfaces in contact with peroxycarboxylic acids may also be pre-soaked in alkaline peracetic acid to remove or extract any reactive materials that can react with and consume peroxycarboxylic acid products. Electrodes are prepared according to procedures specific for each particular electrode type and material.

[00105] The mixing device for the acetyl donors indicated schematically in Figure 3 (as well as in Figures 4-6) to mix the acetyl or acyl donor materials with the alkaline hydrogen peroxide solution to promote their reaction to produce peroxycarboxylic acids. Several approaches and apparatus may be used to carry out the mixing. Approaches include active mixing, passive mixing, induction, and injection methods. Apparatus effective in this invention include mechanically stirred tanks, centrifugal mixers, centrifugal pumps, static mixers, eductors, venturi mixers, and injector tubes and nozzles. The acetyl or acyl donor may be introduced to such apparatus by means of dosing pumps, metering pumps, peristaltic pumps, gravity feed, solenoid valve feed, rotary valve feed, and pressure driven feed mechanisms utilizing pneumatic or hydraulic driving forces. The mixture of alkaline hydrogen peroxide and acetyl or acyl donor is provided a reaction time (also called residence time or dwell time or cure time) in the mixing apparatus that allows the formation of the peroxyacetic acid product to occur. The reaction time is preferably adjusted to maximize peroxycarboxylic acid yield prior to pH adjustment, stabilization or use. After the selected reaction time, the peroxyacetic acid product is circulated or passed through the central reactor chamber in Figure 3, (or circulated or passed through the central reactor chamber in Figures 4 and 5, or not passed through the reactor in Figure 6)

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 210

[00106] An advantage of the acetyl or acyl donor dosing and mixing approach is the ability to use materials in the form of a solid, liquid, dispersion, suspension or combination of such forms. The acetyl or acyl donor may also have limited or minimal solubility in alkaline hydrogen peroxide solution and be mixed as a two-phase system until reaction has occurred. Alternatively, an organic cosolvent may be dosed into the mixture to increase solubility.

[00107] In a preferred embodiment an acetyl or acyl donor in liquid form is injected into an alkaline hydrogen peroxide solution flowing through a venturi mixer followed by a cure time set by the residence time spent traveling through a transfer line of an appropriate length, Figure 7. The resulting peroxycarboxylic acid solution is transferred to the anode of the reactor to adjust the product pH, recover electrolyte, and lower the residual hydrogen peroxide concentration.

[00108] In an embodiment the acetyl or acyl donor is sparingly soluble in alkaline hydrogen peroxide solution resulting in a two phase mixture or dispersion of immiscible liquids. In an embodiment the acetyl or acyl donor dissolution rate is slow in alkaline hydrogen peroxide solution resulting in a two phase mixture, dispersion or suspension.

[00109] In an embodiment the peroxycarboxylic acid product is soluble in alkaline hydrogen peroxide solution. In an embodiment the peroxycarboxylic acid product is soluble in acidic solution. In an embodiment the peroxycarboxylic acid product is soluble in water. In an embodiment the peroxycarboxylic acid product is not soluble in the alkaline or acidified product fluid and is recovered as a separate phase by an appropriate means such as precipitation, centrifugation, hydrocyclone separation or filtration.

[00110] In an embodiment the acetyl or acyl donor byproduct is soluble in alkaline hydrogen peroxide solution. In an embodiment the acetyl or acyl donor byproduct is soluble in acidic solution. In an embodiment the acetyl or acyl donor byproduct is soluble in water. In an embodiment the acetyl or acyl donor byproduct is sparingly soluble in alkaline hydrogen peroxide solution resulting in a two phase mixture or dispersion of immiscible liquids. In an embodiment the acetyl or acyl donor byproduct is not soluble in the alkaline or acidified product fluid and is recovered as a separate phase by an appropriate means such as precipitation, centrifugation, hydrocyclone separation or filtration.

[00111] Figure 7 indicates three possible locations for makeup electrolyte to enter the generator system. "Makeup Electrolyte Location 1" represents addition of electrolyte into the catholyte solution reservoir either directly or carried in the makeup water.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 211

"Makeup Electrolyte Location 2" represents addition of electrolyte into the anolyte solution reservoir or anode circulation loop through the reactor. "Makeup Electrolyte Location 3" represents addition of electrolyte into the mixing stage where the catholyte solution and acetyl or acyl donor materials are mixed. Alternatively, the makeup electrolyte may be combined with the acetyl or acyl donor as a single input into the mixing stage.

[00112] The makeup electrolyte may be in the form of a solid, liquid, solution or suspension. Preferred methods of adding solid makeup electrolyte to the generator system include solid chemical feeders such as augers or rotary valve mechanisms. Preferred mechanisms of adding liquid makeup electrolyte (solution, liquid suspension) include chemical feeders such as dosing pumps, peristaltic pumps, gravity, pressure and vacuum.

EXAMPLE 2: Batch mode operation

[00113] A cathode starting solution consisting of 1.42 g sodium sulfate in 2.0 L of deionized water is added to the catholyte reservoir. An anode solution consisting of 5.56 mL concentrated sulfuric acid in 1.0 L of deionized water is added to the anolyte reservoir. A central chamber solution consisting of 14.2 g sodium sulfate in 1.0 L of deionized water is added to the central chamber reservoir. All three solutions are circulated through their respective flow chambers, as summarized in **FIG. 3**.

[00114] The circulating catholyte solution is oxygenated while a current density of 300 A/m^2 is applied to the electrodes for 3 hours using a digital DC power supply operated in current control mode. Hydrogen peroxide and caustic (NaOH) is produced in the catholyte solution giving a cathode product containing 2.04 g/L H_2O_2 at pH 11.4 at which time the reactor is turned off. The sodium ion concentration measured in the central chamber solution is depleted from the starting concentration of 4.39 g/L to a final concentration of 1.83 g/L. The catholyte product solution and central chamber solution are drained from the reactor.

[00115] 2.0 L of catholyte product is mixed in a separate container with 11.69 g of acetylsalicylic acid and 10.65 g sodium acetate trihydrate and this mixture is stirred for 15 minutes. This final mixture is added to the central chamber reservoir. A new catholyte starting solution of 1.42 g sodium sulfate in 2.0 L of deionized is added to the catholyte reservoir.

[00116] The reactor is restarted and all three solutions (anolyte, catholyte and central chamber) are circulated through their respective flow chambers. The circulating catholyte solution is oxygenated while a current density of 300 A/m^2 is applied to the

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 212

electrodes for 1 hour. Hydrogen peroxide and caustic (NaOH) is produced in the catholyte solution. The central chamber solution (or peracetic acid product solution) contains 1.3 g/L peracetic acid, and salicylic acid and acetate byproducts at a pH of 4.4. The sodium ion concentration measured in the central chamber solution is depleted from the starting concentration of 2.53 g/L to a final concentration of 1.67 g/L.

[00117] In another batch operation example, a cathode starting solution of 1.42 g sodium sulfate in 2.0 L of deionized water is added to the catholyte reservoir. An anode solution of 5.56 mL concentrated sulfuric acid in 1.0 L of deionized water is added to the anolyte reservoir. A central chamber solution of 51.7 g sodium acetate trihydrate in 2.0 L of deionized water is added to the central chamber reservoir. All three solutions are circulated through their respective flow chambers as provided in **FIG. 3**.

[00118] The circulating catholyte solution is oxygenated while a current density of 300 A/m^2 was applied to the electrodes for 4 hours using a digital DC power supply operated in current control mode. Hydrogen peroxide and caustic (NaOH) is produced in the catholyte solution giving a cathode product containing 2.86 g/L H_2O_2 at pH 12.3 at which time the reactor is turned off. The sodium ion concentration measured in the central chamber solution is depleted from the starting concentration of 4.15 g/L to a final concentration of 1.22 g/L. The catholyte product solution and central chamber solution are drained from the reactor.

[00119] 2.0 L of catholyte product is mixed in a separate container with 27.50 g of acetylsalicylic acid and 14.40 g sodium acetate trihydrate and this mixture is stirred for 15 minutes. This final mixture is added to the central chamber reservoir. A new catholyte starting solution of 1.42 g sodium sulfate in 2.0 L of deionized is added to the catholyte reservoir.

[00120] The reactor is restarted and all three solutions (anolyte, catholyte and central chamber) are circulated through their respective flow chambers. The circulating catholyte solution is oxygenated while a current density of 300 A/m^2 is applied to the electrodes for 1 hour. Hydrogen peroxide and caustic (NaOH) is produced in the catholyte solution. The central chamber solution (or peracetic acid product solution) contains 2.7 g/L peracetic acid, less than 0.4 g/L hydrogen peroxide, and salicylic acid and acetate byproducts at a pH of 5.4. The sodium ion concentration measured in the central chamber solution is depleted from the starting concentration of 4.89 g/L to a final concentration of 4.00 g/L.

[00121] Continuous mode. In other embodiments the batch production process is modified to work as a continuous production process by drawing off a constant stream

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 213

of catholyte product directly from the catholyte circulation loop, passing the catholyte product through a mixer (mixing chamber) that is dosed with the acetyl donor, and then passing the mixture through the central chamber with the proper residence time in a single pass. A makeup water stream to the catholyte solution replenishes the catholyte product draw-down volume in the process. This process is illustrated in **FIG. 3**

[00122] **FIGs. 4-6** illustrate various two-chamber embodiments, and are further discussed as Examples 3-5.

EXAMPLE 3: Two-chamber, pH shift of PAA composition

[00123] **FIG. 4** is a two-chamber configuration, wherein the caustic PAA composition is passed over the anode as anolyte solution to shift the pH from caustic to acid. Sodium and/or potassium cations are recovered back into the cathode process.

EXAMPLE 4: Two-chamber, rapid pH shift by acidic anolyte loop

[00124] **FIG. 5** is a two-chamber configuration, wherein the caustic PAA product is dosed into an acidic anolyte loop to very rapidly shift the pH from caustic to acid. Cations (such as sodium and/or potassium, for example) are recovered back into the cathode process.

EXAMPLE 5: Two-chamber, direct use of caustic PAA composition

[00125] **FIG. 6** is a two-chamber configuration, wherein the caustic PAA product is used directly. Sodium and/or potassium cations are not recovered back into the cathode process. Sodium or potassium feedstock is added in the form of sodium or potassium hydroxide in the 'base containing source.'

[00126] Alternatively, the sodium or potassium feedstock is added as a salt or hydroxide into the anode loop to produce caustic hydrogen peroxide, as in the previous example, to be mixed with the acetyl donor.

[00127] The caustic PAA is particularly useful for bleaching in applications such as pulp and paper and textiles.

EXAMPLE 6: Batch operation, 2-chamber reactor using triacetin donor

[00128] A cathode starting solution of 1.42 g sodium sulfate in 2.0 L of deionized water is added to the catholyte reservoir. An anode solution of 10.62 mL of 30% peracetic acid and 0.71 g sodium sulfate in 1.0 L of deionized water is adjusted to pH

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 214

11.2 with sodium hydroxide and added to the anolyte reservoir. Catholyte and anolyte solutions are circulated through their respective flow chambers.

[00129] The circulating catholyte solution is oxygenated while a current density of 300 A/m^2 is applied to the electrodes for 4 hours using a digital DC power supply operated in current control mode. Hydrogen peroxide and caustic (NaOH) is produced in the catholyte solution giving a cathode product containing 3.32 g/L H_2O_2 at pH 11.6 at which time the reactor is turned off. The sodium ion concentration measured in the anolyte solution is depleted from the starting concentration of 3.06 g/L to a final concentration of 0.130 g/L. The anolyte solution is drained from the reactor.

[00130] 1.0 L of catholyte product is transferred to the empty anolyte reservoir. To this solution is added 3.05 mL of triacetin and this mixture is stirred for 15 minutes. This mixture contained 2.09 g/L peracetic acid and 2.13 g/L hydrogen peroxide and approximately 1.46 g/L sodium ion concentration. 1.0 L of deionized water is added to the remaining catholyte solution in the catholyte reservoir.

[00131] The reactor is restarted and the catholyte and anolyte solutions are circulated through their respective flow chambers. The circulating catholyte solution is oxygenated while a current density of 300 A/m^2 is applied to the electrodes for 1.5 hours. Hydrogen peroxide and caustic (NaOH) is produced in the catholyte solution. The anolyte solution (or peracetic acid product solution) contains 1.14 g/L peracetic acid and 0.26 g/L hydrogen peroxide at a pH of 3.6. The sodium ion concentration measured in the anolyte product solution is 0.409 g/L.

EXAMPLE 7: Dependence of PAA decomposition during pH, temperature adjustment (3-Chamber Reactor).

[00132] For all three exemplary data sets below, PAA solutions are prepared by dissolving the appropriate volume of H_2O_2 (30%), along with 3.55 g of anhydrous sodium sulfate (0.05M) in 500 mL of deionized water. The pH is adjusted to 11.4 with sodium hydroxide pellets. Triacetin is then added via volumetric pipette. The solution is stirred for 15 minutes and the PAA concentration determined by titration with sodium thiosulfate to give the initial yields shown in Table 1. The pH of the solution is then adjusted by circulation through the central chamber of the electrolytic cell run at 3.0A. Once the pH turns acidic, a final yield of PAA is determined by titration.

[00133] Dependence of PAA decomposition on temperature during pH adjustment (2-Chamber – PAA solutions prepared as above) is summarized in TABLE 2.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 215

[00134] High concentration solution of caustic PAA can be diluted before pH adjustment to minimize loss (PAA solutions prepared as above) is summarized in TABLE 3.

[00135] Without being bound by any particular theory, there are proposed reasons for loss of PAA yield during pH adjustment. PAA losses during pH adjustment are due to (1) auto-decomposition of the peracetic acid species, which is accelerated at high pH and (2) decomposition by a self reaction between peracetic acid anion and peracetic acid, which is accelerated near the pKa of peracetic acid of 8.2 [Jörg Hoffmann, Gerard Just, Wilhelm Pritzkow, Harald Schmidt, Journal für Praktische Chemie/Chemiker-Zeitung, Vol. 334, Iss. 4, pp 293-297 (1992)]. PAA in the pH range between approximately 7.5 and 10.5 is particularly sensitive to decomposition unless there is a suitable stabilizer present such as salicylic acid or acetylsalicylic acid, phosphonic acid derivatives, Dequest®, 1-hydroxyethylidene-1,1-diphosphonic acid (HEDP), or others. Accordingly, in some embodiments the pH of the cathode products is above about 10.5, thereby minimizing this decomposition affect.

[00136] The use of a peroxide stabilizer such as Dequest® provides a stabilizing effect to PAA in the pH range where decomposition is accelerated as summarized in Table 4.

[00137] Caustic peroxide solutions are prepared at pH 11.4. Triacetin and Dequest® are added and the solutions stirred for fifteen (15) minutes. The pH is then adjusted with glacial acetic acid and the solutions stirred for an additional sixty (60) minutes.

EXAMPLE 8: pH adjustment in anode chamber of reactor with the use of Dequest® stabilizer.

[00138] An aqueous solution is made containing 6.68 mL H_2O_2 (30%) and 7.1 g sodium sulfate dissolved in 1 L total volume of deionized H_2O. The pH is adjusted to 11.41 with NaOH pellets. 4.0 mL of triacetin is added to this solution along with 0.29 g of Dequest®. The solution is stirred for 10 minutes and the resulting solution contains 2090 ppm PAA at pH 10.6. 500 mL of this PAA solution is circulated through the anode chamber while a cathode starting solution of 1.42 g sodium sulfate in 2.0 L of deionized water is circulated through the cathode chamber. The circulating catholyte solution is oxygenated while a current density of 300 A/m^2 is applied to the electrodes. After 30 minutes of electrolysis the anolyte solution contains 1900 ppm PAA at a pH of 4.5. The PAA concentration decreases by 9% during the pH adjustment in the reactor. This loss

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 216

is in contrast to what is typically near a 30% loss without the use of a stabilizer at comparable PAA concentration as summarized in Tables 1 and Table 3.

Example 9- Continuous operation, 2-chamber reactor using triacetin donor

[00139] The continuous production system has two stages of operation. The first stage is the startup stage during which the internal process fluids are brought up to steady state operating conditions including pH, electrolyte strength, solution volume, hydrogen peroxide concentration, sodium hydroxide concentration, and peracetic acid concentration. The second stage is the continuous production stage during which peracetic acid product solution is generated at a constant rate, pH and composition.

[00140] For the startup stage of system operation, a cathode starting solution of 7.22 g sodium sulfate in 7.0 L of deionized water is added to the catholyte reservoir **(Figure 5)**. An anode starting solution of 58.5 g sodium sulfate and 67.5 g sodium acetate in 2.0 L of deionized water is added to the anolyte reservoir. Catholyte and anolyte solutions are circulated through their respective flow chambers in the reactor.

[00141] The circulating catholyte solution is oxygenated with 1.0 L/min oxygen gas at the cathode feed pressure of ca. 18 psig while a current density of 420-480 A/m^2 is applied to the electrodes for using a switch mode DC power supply operated in voltage control mode. Hydrogen peroxide and caustic (NaOH) are produced in the catholyte solution, until the catholyte solution contains 6.0-7.0 g/L H_2O_2 at approximately pH 11.5.

[00142] A catholyte solution makeup water source is turned on at a rate of 20 mL/min. The makeup water source is tap water passed through an ion exchange water softening cartridge prior to entering the catholyte reservoir. Sodium sulfate is added to the catholyte solution at a rate of ca. 0.04 g/min. Simultaneously, a side-stream of the catholyte solution is drawn from the catholyte reservoir at a rate of 20 mL/min into which triacetin is dosed at a rate of 0.16 g/min. The catholyte-triacetin mixture is passed through a coil of Teflon tubing having a residence time of ca. 3 min, after which the mixture flows into the anolyte reservoir. Anolyte solution is drawn from the anolyte reservoir through an overflow tube at a rate of ca. 20 mL/min. After the peracetic acid in the anolyte solution reaches a steady state concentration of 4 g/L the startup stage of system operation is complete.

[00143] The continuous production stage of system operation commences by maintaining the steady-state conditions achieved with the operating conditions achieved by the completion of the startup stage. The continuous production stage of system operation produces a non-equilibrium peracetic acid solution drawn at a continuous rate

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 217

of 20 mL/min from the anolyte reservoir having average active ingredient concentrations of 4.2 g/L peracetic acid and 0.4 g/L hydrogen peroxide.

Example 10- Continuous operation, 2-chamber reactor using triacetin donor

[00144] For the startup stage of system operation a cathode starting solution of 7.22 g sodium sulfate in 7.0 L of deionized water is added to the catholyte reservoir. An anode starting solution of 1.42 g sodium sulfate and 135.5 g sodium acetate in 2.0 L of deionized water is added to the anolyte reservoir. Catholyte and anolyte solutions are circulated through their respective flow chambers in the reactor.

[00145] The circulating catholyte solution is oxygenated with 1.0 L/min oxygen gas at the cathode feed pressure of ca. 18 psig while a current density of 210-220 A/m^2 is applied to the electrodes for using a switch mode DC power supply operated in voltage control mode. Hydrogen peroxide and caustic (NaOH) are produced in the catholyte solution, until the catholyte solution contains 2.0-2.2 g/L H_2O_2 at approximately pH 11.5.

[00146] A catholyte solution makeup water source is turned on at a rate of 50 mL/min. The makeup water source is tap water passed through an ion exchange water softening cartridge prior to entering the catholyte reservoir. Sodium sulfate is added to the catholyte solution at a rate of ca. 0.04 g/min. Simultaneously, a side-stream of the catholyte solution is drawn from the catholyte reservoir at a rate of 50 mL/min into which triacetin is dosed at a rate of 0.13 g/min. The catholyte-triacetin mixture is circulated in a small reservoir having a residence time of ca. 20 min, after which the mixture passes through an overflow tube into the anolyte reservoir. Anolyte solution is drawn from the anolyte reservoir through an overflow tube at a rate of ca. 50 mL/min. After the peracetic acid in the anolyte solution reaches a steady state concentration of 0.9 g/L the startup stage of system operation is complete.

[00147] The continuous production stage of system operation commences by maintaining the steady-state conditions achieved with the operating conditions achieved by the completion of the startup stage. The continuous production stage of system operation produces a non-equilibrium peracetic acid solution drawn at a continuous rate of 50 mL/min from the anolyte reservoir having average active ingredient concentrations of 0.95 g/L peracetic acid and 0.15 g/L hydrogen peroxide.

[00148] Detailed product composition analyses was conducted on two different peracetic acid production runs in the continuous operation, 2-chamber reactor using triacetin donor similar to that described above, see Table 5. Peracetic acid and hydrogen peroxide concentrations were determined by established titration methods.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 218

Acetic acid and glycerol concentrations were determined by HPLC, sodium ion concentration was measured with a sodium ISE, and pH was measured with a bench top pH meter.

[00149] Three peracetic acid product samples collected from the anolyte reservoir of the continuous operation, 2-chamber reactor using triacetin as the acetyl donor were placed in three separate darkened HDPE bottles and stored at room temperature in darkness. At time zero and various times thereafter, the concentration of peracetic acid was measured in each of the three solution samples to determine the degradation rate in the absence of peroxide stabilizers. The average half life of the peracetic acid in the product solution was 10 days. The decay curve was approximately linear as illustrated in Fig. 8.

[00150] Two samples of the catholyte-triacetin mixture collected immediately upstream of the anolyte reservoir of the continuous operation, 2-chamber reactor using triacetin as the acetyl donor were placed in two separate darkened HDPE bottles and stored at room temperature in darkness. At time zero and various times thereafter, the concentration of peracetic acid was measured in each of the three solution samples to determine the degradation rate in the absence of peroxide stabilizers. The average half life of the peracetic acid in the solutions was 1.8 hours. The decay curve was approximately linear as illustrated in Fig. 9I

Example 11- Continuous operation, 2-chamber reactor using salicylic acid ethyl ester donor

[00151] For the startup stage of system operation a cathode starting solution of 7.22 g sodium sulfate in 7.0 L of deionized water is added to the catholyte reservoir. An anode starting solution of 120 g sodium sulfate in 2.0 L of deionized water is added to the anolyte reservoir. Catholyte and anolyte solutions are circulated through their respective flow chambers in the reactor.

[00152] The circulating catholyte solution is oxygenated with 1.0 L/min oxygen gas at the cathode feed pressure of ca. 18 psig while a current density of 420-480 A/m^2 is applied to the electrodes using a switch mode DC power supply operated in voltage control mode. Hydrogen peroxide and caustic (NaOH) is produced in the catholyte solution until the catholyte solution contains 6.0-7.1 g/L H_2O_2 at approximately pH 11.5. The startup stage of the system is complete when the hydrogen peroxide concentration reaches the desired steady-state concentration.

[00153] The continuous production stage of system operation commences by supplying catholyte solution makeup water at a rate of 20 mL/min. The makeup water

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 219

source is tap water passed through an ion exchange water softening cartridge prior to entering the catholyte reservoir. Sodium sulfate is added to the catholyte solution at a rate of ca. 0.04 g/min. Simultaneously, a side-stream of the catholyte solution is drawn from the catholyte reservoir at a rate of 20 mL/min into which salicylic acid ethyl ester is dosed at a rate of 0.95 g/min. The catholyte-salicylic acid ethyl ester mixture is passed through a coil of Teflon tubing having a residence time of ca. 3 min, after which the mixture flows into the anolyte circulation circuit outfitted with a solids separation apparatus such as a filter, centrifugal separator or settling tank. The acidified persalicylic acid precipitates from solution and is recovered from the anolyte circuit as a solid. Anolyte solution is drawn from the anolyte reservoir through an overflow tube at a rate of ca. 20 mL/min and recycled back into the catholyte makeup water or discharged.

Example 12- Continuous operation, 2-chamber reactor using n-butylmalonic acid diethyl ester donor

[00154] The continuous production system has two stages of operation. The first stage is the startup stage during which the internal process fluids are brought up to steady state operating conditions including pH, electrolyte strength, solution volume, hydrogen peroxide concentration, sodium hydroxide concentration, and peracetic acid concentration. The second stage is the continuous production stage during which peracetic acid product solution is generated at a constant rate, pH and composition.

[00155] For the startup stage of system operation a cathode starting solution of 7.22 g sodium sulfate in 7.0 L of deionized water is added to the catholyte reservoir. An anode starting solution of 120 g sodium sulfate in 2.0 L of deionized water is added to the anolyte reservoir. Catholyte and anolyte solutions are circulated through their respective flow chambers in the reactor.

[00156] The circulating catholyte solution is oxygenated with 1.0 L/min oxygen gas at the cathode feed pressure of ca. 18 psig while a current density of 420-480 A/m^2 is applied to the electrodes for using a switch mode DC power supply operated in voltage control mode. Hydrogen peroxide and caustic (NaOH) is produced in the catholyte solution until the catholyte solution contains 6.0-7.0 g/L H_2O_2 at approximately pH 11.5.

[00157] A catholyte solution makeup water source is turned on at a rate of 20 mL/min. The makeup water source is tap water passed through an ion exchange water softening cartridge prior to entering the catholyte reservoir. Sodium sulfate is added to the catholyte solution at a rate of ca. 0.04 g/min. Simultaneously, a side-stream of the catholyte solution is drawn from the catholyte reservoir at a rate of 20 mL/min into which n-butylmalonic acid diethyl ester is dosed at a rate of 0.62 g/min. The catholyte-triacetin

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 220

mixture is passed through a coil of Teflon tubing having a residence time of ca. 3 min, after which the mixture flows into the anolyte reservoir. Anolyte solution is drawn from the anolyte reservoir through an overflow tube at a rate of ca. 20 mL/min. After the n-butyl-diperoxymalonic acid in the anolyte solution reaches a steady state concentration of approximately 14.8 g/L the startup stage of system operation is complete.

[00158] The continuous production stage of system operation commences by maintaining the steady-state conditions achieved with the operating conditions achieved by the completion of the startup stage. The continuous production stage of system operation produces a non-equilibrium n-butyl-diperoxymalonic acid solution drawn at a continuous rate of 20 mL/min from the anolyte reservoir having average active ingredient concentrations of 14.8 g/L the n-butyl-diperoxymalonic acid, 6.4 g/L n-butylmalonic acid, 13.1 g/L ethanol and 0.4 g/L hydrogen peroxide.

[00159] When a group of substituents is disclosed herein, it is understood that all individual members of that group and all subgroups, including any isomers, enantiomers, and diastereomers of the group members, are disclosed separately. When a Markush group or other grouping is used herein, all individual members of the group and all combinations and subcombinations possible of the group are intended to be individually included in the disclosure. A number of specific groups of variable definitions have been described herein. It is intended that all combinations and subcombinations of the specific groups of variable definitions are individually included in this disclosure. Compounds described herein may exist in one or more isomeric forms, e.g., structural or optical isomers. When a compound is described herein such that a particular isomer, enantiomer or diastereomer of the compound is not specified, for example, in a formula or in a chemical name, that description is intended to include each isomers and enantiomer (e.g., cis/trans isomers, R/S enantiomers) of the compound described individual or in any combination. Additionally, unless otherwise specified, all isotopic variants of compounds disclosed herein are intended to be encompassed by the disclosure. For example, it will be understood that any one or more hydrogens in a molecule disclosed can be replaced with deuterium or tritium. Isotopic variants of a molecule are generally useful as standards in assays for the molecule and in chemical and biological research related to the molecule or its use. Isotopic variants, including those carrying radioisotopes, may also be useful in diagnostic assays and in therapeutics. Methods for making such isotopic variants are known in the art. Specific names of compounds are intended to be exemplary, as it is known that one of ordinary skill in the art can name the same compounds differently.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 221

[00160] Molecules disclosed herein may contain one or more ionizable groups [groups from which a proton can be removed (e.g., -COOH) or added (e.g., amines) or which can be quaternized (e.g., amines)]. All possible ionic forms of such molecules and salts thereof are intended to be included individually in the disclosure herein. With regard to salts of the compounds herein, one of ordinary skill in the art can select from among a wide variety of available counterions those that are appropriate for preparation of salts of this invention for a given application. In specific applications, the selection of a given anion or cation for preparation of a salt may result in increased or decreased solubility of that salt.

[00161] Every formulation or combination of components described or exemplified herein can be used to practice the invention, unless otherwise stated.

[00162] Whenever a range is given in the specification, for example, a temperature range, a time range, a pH range, or a composition or concentration range, all intermediate ranges and subranges, as well as all individual values included in the ranges given are intended to be included in the disclosure. The upper and lower limits of the range may themselves be included in the range. It will be understood that any subranges or individual values in a range or subrange that are included in the description herein can be excluded from the claims herein.

[00163] All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. References cited herein are incorporated by reference herein in their entirety to indicate the state of the art as of their publication or filing date and it is intended that this information can be employed herein, if needed, to exclude specific embodiments that are in the prior art. For example, when composition of matter are claimed, it should be understood that compounds known and available in the art prior to Applicant's invention, including compounds for which an enabling disclosure is provided in the references cited herein, are not intended to be included in the composition of matter claims herein.

[00164] As used herein, "comprising" is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. As used herein, "consisting of" excludes any element, step, or ingredient not specified in the claim element. As used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. The broad term comprising is intended to encompass the narrower consisting essentially of and the even narrower consisting of. Thus, in any recitation herein of a phrase "comprising one or more claim

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 222

element" (e.g., "comprising A and B), the phrase is intended to encompass the narrower, for example, "consisting essentially of A and B" and "consisting of A and B." Thus, the broader word "comprising" is intended to provide specific support in each use herein for either "consisting essentially of" or "consisting of." The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein.

[00165] One of ordinary skill in the art will appreciate that starting materials, catalysts, reagents, synthetic methods, purification methods, analytical methods, and assay methods, other than those specifically exemplified can be employed in the practice of the invention without resort to undue experimentation. All art-known functional equivalents, of any such materials and methods are intended to be included in this invention. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by examples, preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

[00166] All references cited herein are hereby incorporated by reference to the extent that there is no inconsistency with the disclosure of this specification. Some references provided herein are incorporated by reference to provide details concerning sources of starting materials; alternative starting materials, reagents, methods of synthesis, purification methods, and methods of analysis, reactor systems; as well as additional uses of the invention. For example, U.S. Pub 2007/0074975 (Published April 5, 2007) is hereby specifically incorporated by reference for electrochemical reactors and related methods, including systems and processes for hydrogen peroxide production. Provisional application no. 61/019,825 filed January 8, 2008 is incorporated by reference, and in particular for non-equilibrium compositions of peroxycarboxylic acid and hydrogen peroxide in water, non-equilibrium peracetic acid compositions and processes for producing these non-equilibrium mixtures.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 223

TABLE 1

Triacetin (mL)	H_2O_2(30%) (mL)	Initial caustic PAA Yield (ppm)	PAA Yield after pH adjustment (ppm)	% loss
1	1.67	760	684	10
2	3.34	1710	1330	22
2	5.01	1900	1330	30

TABLE 2

Anolyte solution Temp.	Triacetin (mL)	H_2O_2(30%) (mL)	Initial caustic PAA Yield (ppm)	PAA Yield after pH adjustment (ppm)	% loss
>30 C	1.25	4.58	1520	950	37
ice bath cooled	1.25	4.58	1520	1330	12

TABLE 3

Triacetin (mL)	H_2O_2(30%) (mL)	Initial caustic PAA Yield (ppm)	Diluted caustic PAA conc. (ppm)	PAA Yield after pH adjustment (ppm)	% loss
3.71	13.4	5890	589	475	19
2	5.01	1900	not diluted	1330	30

10

TABLE 4: Dequest Stabilization (500 mL) reaction mixtures#

Triacetin (mL)	H_2O_2 (30%) (mL)	Dequest® (g)	Initial Caustic PAA Yield (ppm)	Adjusted pH	PAA concentration after 60 min (ppm)	% loss of PAA
2.0	6.68	0	3116	9.16	418	86.6
2.0	6.68	0.044	3268	9.42	3230	1.2
2.0	6.68	0.088	3230	9.36	3192	1.2
2.0	6.68	0.176	3344	9.59	3230	3.4

TABLE 5

Peracetic acid product composition from continuous 2-chamber reactor using triacetin as feedstock		
Constituent	Trial 1 Concentration	Trial 2 Concentration
peracetic acid	950 mg/L	950 mg/L
hydrogen peroxide	212 mg/L	170 mg/L
acetic acid	1560 mg/L	1500 mg/L
glycerol	1120 mg/L	1110 mg/L
sodium	348 mg/L	NA
pH	3.40	NA

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 224

We claim:

1. A method for making a peroxycarboxylic acid composition, said method comprising:

    a. electrolytically generating alkaline hydrogen peroxide or peroxide ions in a reactor comprising a cathode chamber having a cathode, an anode chamber having an anode and at least one cation exchange membrane separating said chambers;

    b. providing a source of alkali metal ions to said anode chamber such that the ratio of concentrations of alkali metal ions to protons formed in the anode chamber is greater than 1 and the predominant cations transported through the at least one cation exchange membrane are alkali metal ions; and

    c. reacting said hydrogen peroxide or peroxide ions with an acetyl donor to form peracetic acid in a mixing chamber that is electrically isolated from said anode and cathode of the reactor to produce the peroxycarboxylic acid composition comprising alkali metal ions.

2. The method of claim 1 wherein the source of alkali metal ions is a salt added to said anode chamber.

3. The method of claim 1 wherein the source of alkali metal ions is the peroxycarboxylic acid composition formed in step c wherein at least a portion of said composition is recycled to the anode chamber.

4. The method of any one of claims 1-3 wherein the source of alkali metal ions is added directly to the anode chamber.

5. The method of any one of claims 1-3 wherein the reactor further comprises a central chamber between the anode and cathode chambers and separated from each of said chambers by at least one cation exchange membrane and said source of alkali metal ions is added to said anode chamber, said central chamber or both.

6. The method of any one of claims 1-3 wherein the reactor further comprises a central chamber between the anode and cathode chambers and separated from

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 225

each of said chambers by at least one cation exchange membrane and said source of alkali metal ions is added to said anode chamber, said central chamber or both and wherein the alkaline hydrogen peroxide or peroxide ions has a pH greater than or equal to 10 and less than or equal to 13.

7. The method of any one of claims 1-3 wherein the alkaline hydrogen peroxide or peroxide ions has a pH greater than or equal to 10 and less than or equal to 13.

8. The method of claim 1, wherein said reacting step further comprises

   a. introducing one or more acetyl donors to said mixing chamber; and

   b. introducing said electrolytically generated alkaline hydrogen peroxide or peroxide ions from a cathode chamber of said reactor to said mixing chamber, thereby generating said peracetic acid composition.

9. The method of any one of claims 1-3 or 8, further comprising introducing to the reactor a peroxide stabilizer, an electrolyte salt or both.

10. The method of any one of claims 1-3 wherein the peroxycarboxylic acid composition formed has a pH that is less than or equal to 8.

11. The method of any one of claims 1-3 wherein the ratio of concentrations of alkali metal ions to protons formed in the anode chamber is greater than or equal to 3.

12. The method of any one of claims 1-3 wherein the ratio of concentrations of alkali metal ions to protons formed in the anode chamber is between about 3 and 4, inclusive.

13. The method of any one of claims 1-3 wherein the ratio of concentrations of alkali metal ions to protons formed in the anode chamber is greater than or equal to 10.

14. The method of any one of claims 1-3 or 8 further comprising:

   a. introducing said peroxycarboxylic acid composition from said mixing chamber to said reactor;

   b. adjusting the pH of said peroxycarboxylic acid composition by electrodialysis; and

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 226

c. removing said peroxycarboxylic acid composition from said reactor to obtain a peroxycarboxylic acid product solution, wherein said peroxycarboxylic acid product solution has a pH that is less than or equal 8.

15. The method of any one of claims 1-3 or 8 further comprising:

a. introducing said peroxycarboxylic acid composition from said mixing chamber to said reactor;

b. adjusting the pH of said peroxycarboxylic acid composition by electrodialysis; and

c. removing said peroxycarboxylic acid composition from said reactor to obtain a peroxycarboxylic acid product solution, wherein said peroxycarboxylic acid product solution has a pH that is less than or equal 8 and wherein the ratio of concentrations of alkali metal ions to protons formed in the anode chamber is greater than or equal to 3.

16. The method of any one of claims 1-3 or 8 further comprising:

a. introducing said peroxycarboxylic acid composition from said mixing chamber to said reactor;

b. adjusting the pH of said peroxycarboxylic acid composition by electrodialysis; and

c. removing said peroxycarboxylic acid composition from said reactor to obtain a peroxycarboxylic acid product solution, wherein said peracetic acid product solution has a pH that is less than or equal 8 and wherein the ratio of concentrations of alkali metal ions to protons formed in the anode chamber is greater than or equal to 10.

17. A method for making a peroxycarboxylic acid composition, said method comprising:

a. electrolytically generating hydrogen peroxide or peroxide ions in an electrochemical reactor having an anode chamber having an anode and a cathode chamber having a cathode and at least one cation exchange membrane separating the anode and cathode chambers;

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 227

b. reacting said hydrogen peroxide or peroxide ions with an acyl or acetyl donor to form peroxycarboxylic acid, wherein said peroxycarboxylic acid is formed in a mixing chamber that is electrically isolated from said anode and said cathode;

c. introducing a salt into said rector; and

d. producing an alkaline electrolyte solution by electrodialysis of the salt introduced to said reactor, wherein said electrolyte solution adjusts the pH of said hydrogen peroxide or peroxide ions to a pH that is greater than or equal to 9.5 and less than or equal to 13.

18. The method of claim 17, further comprising adding a source of alkali metal cations to an anode chamber of said reactor.

19. The method of claim 18, wherein the ratio of concentrations of alkali metal ions to protons in said anode chamber is selected from the group consisting of: greater than or equal to 1; greater than or equal to 3, greater than or equal to 3 and less than or equal to 4; and greater than or equal to 10.

20. The method of claim 17, wherein said reactor has a catholyte solution containing said generated hydrogen peroxide or peroxide ions, said method further comprising:

a. controlling said reactor catholyte pH, wherein said catholyte pH is greater than or equal to 10 and less than or equal to 13; and/or

b. controlling a peroxide to hydroxide ratio in said catholyte solution, wherein said ratio is greater than or equal to 0.5:1 and less than or equal to 5:1.

wherein said controlling steps comprise balancing transfer rates of alkali metal cations and acid protons introduced to said catholyte solution.

21. The method of any of claims 1 and 18, wherein the ratio of concentrations of alkali metal ions to protons formed in the anode chamber is greater than 1, the alkaline hydrogen peroxide or peroxide ions has a pH greater than or equal to 10 and less than or equal to 13; and the peroxycarboxylic acid composition has a pH less than or equal to 8.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 228

22. The method of claim 17, wherein said peroxycarboxylic acid composition is introduced to an anode chamber of said reactor, thereby lowering said peracetic acid composition pH by electrodialysis and lowering said hydrogen peroxide concentration.

23. The method of any one of claims 1-3, 8 or 17 further comprising:

    a. introducing at least a portion of said peroxycarboxylic acid composition from said anode chamber to said mixing chamber by an acidic anolyte loop, thereby providing additional pH regulation of said peroxycarboxylic acid composition.

24. The method of any one of claims 1-3, 8 or 17 where the peroxycarboxylic acid is peracetic acid.

25., The method of any one of claims 1-3, 8 or 17 where the peroxycarboxylic acids is a substituted derivative of peroxybenzoic acid.

26. The method of any of claims 1-3, 8 and 17, wherein said peroxycarboxylic acid is a non-equilibrium composition.

27. An electrochemical reactor for generating peroxycarboxylic acid compositions, said reactor comprising:

    a. an anode positioned within an anode chamber;

    b. a cathode positioned within a cathode chamber for producing alkaline hydrogen peroxide catholyte solution;

    c. at least one cation exchange membrane separating said anode and cathode chambers;

    d. an optional central chamber between said cathode and anode chambers and separated from each of said chambers by at least one cation exchange membrane;

    e. a mixing chamber electrically isolated from said anode and cathode for receiving an acyl donor;

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 229

f. a mixing chamber conduit for supplying said catholyte solution to said mixing chamber;

g. a peroxycarboxylic acid (POA) composition conduit for introducing POA made in said mixing chamber to said reactor, wherein said POA composition conduit is operably connected to said anode chamber or said optional central chamber; and

h. a reactor outlet for removing from said reactor at least a portion of said POA formed in said reactor.

28. The reactor of claim 27 wherein said removed POA is in a solution of lower pH than said POA made in said mixing chamber

29. The reactor of any one of claims 27 or 28, further comprising:

a. an acidic anolyte loop that operably connects said reactor outlet to said POA composition conduit, thereby providing rapid pH adjustment to said POA made in said mixing chamber.

30. The reactor of any one of claims 27 or 28, wherein said mixing chamber is positioned either external to said reactor or internal to said reactor.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 230



(1)
Electrolytically produce caustic H_2O_2 product at the reactor cathode
(2)
Remove caustic H_2O_2 from cathode chamber
(3)
Mix caustic H_2O_2 with source of acetyl donors or peroxyacid donors to generate PAA solution or other peroxyacid solutions
(4)
Introduce the generated solution through a central (or anode) flow chamber in the reactor so that:
-alkali metal cations are transported by electrodialysis through the cathode membrane and recycled into the caustic H_2O_2 solution;
-removed alkali metal cations are replaced by acid protons produced at the anode and transported through the anode membrane under the applied electric field gradient
-resulting in lower pH of PAA or peroxyacid containing solution to stabilize outflow of PAA or peroxyacid containing solution
-processing over an anode removes residual H_2O_2 making a PAA solution less corrosive
-processing over an anode may reduce residual organic content from acetyl donor byproduct

Fig. 1



(1)
Electrolytically produce caustic H_2O_2 product at the reactor cathode
(2)
Remove caustic H_2O_2 from cathode chamber
(3)
Mix caustic H_2O_2 with source of acetyl donors or peroxyacid donors to generate PAA solution or other peroxyacid solutions
(4)
Directly use generated solution for applications requiring high pH, such as for textile bleaching or pulp bleaching
-add alkali metal cation (e.g., salt electrolyte) to anolyte or central chamber solutions to provide cations for generation of caustic peroxide at cathode
-add peroxide stabilizer to alkaline PAA or peroxyacid solution to inhibit decomposition of PAA or peroxyacid

Fig. 2



PAA Product Solution
PAA, AA, HOOH
donor byproduct
pH 7 or less
cathode membrane
makeup
water
makeup
water
O_2
anode
central
cathode
H^+
K^+
H^+
K^+
H^+
K^+
anode loop
H_2SO_4
$KHSO_4$
cathode products
KOOH, HOOH
KOH, pH 10-13
oxygen
source
anode membrane
PAA, KPAA,
KOAc, HOOH,
KOH,
donor byproduct
mixing device
acetyl donor
containing
source

Fig. 3



PAA Product Solution
PAA, AA, HOOH
donor byproduct
pH 7 or less
membrane
makeup
water
O_2
anode
cathode
H^+
K^+
H^+
K^+
H^+
K^+
cathode products
KOOH, HOOH
KOH, pH 10-13
oxygen
source
PAA, KPAA,
KOAc, HOOH,
KOH,
donor byproduct
mixing device
acetyl donor
containing
source

Fig. 4



PAA Product Solution
PAA, AA, HOOH
donor byproduct
pH 7 or less
membrane
makeup
water
O_2
anode
cathode
H^+
K^+
H^+
K^+
H^+
K^+
anode loop
pH 7 or less
cathode products
KOOH, HOOH
KOH, pH 10-13
oxygen
source
PAA, KPAA,
KOAc, HOOH,
KOH,
donor byproduct
mixing device
acetyl donor
containing
source

Fig. 5



membrane
makeup water
makeup water
O_2
anode
cathode
anode loop
H_2SO_4
H^+
H^+
H^+
cathode products
HOOH, pH <8
oxygen source
Caustic Product Solution
PAA, KPAA,
KOAc, HOOH,
KOH,
donor byproduct
mixing device
acetyl donor containing source
base containing source

Fig. 6



Makeup Water
Makeup Electrolyte, Location 3
transfer line coil
Makeup Electrolyte, Location 2
Catholyte Solution Reservoir
Optional Separation Stage
Anolyte Product Reservoir
Peroxycarboxylic Acid Products
Venturi or static mixer
Acetyl donor, Acyl donor Reservoir
Makeup Electrolyte, Location 1
insoluble materials or products
Optional Separation Stage

Fig. 7



PAA Decomposition (pH 2.0-3.0)
[PAA] (ppm)
4100
4000
3900
3800
3700
3600
3500
3400
0
20
40
60
time (hrs)
Series1
Series2
Series3
Average
Expon. (Average)
y = 3998e-0.0028x
R2 = 0.9812

Fig. 8



PAA decomposition (pH 11.0-12.0)
experiment 1
experiment 2
[PAA]
4500
4000
3500
3000
2500
2000
1500
1000
500
0
0
20
40
60
80
100
time (min)

Fig. 9

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRPART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
13/065,553	03/24/2011	1761	3271	8568/17669	91	11

CONFIRMATION NO. 2262

Audrey A. Millemann
Weintraub Genshlea Chediak
11th Floor
400 Capitol Mall
Sacramento, CA 95814

FILING RECEIPT

OC000000047044286

Date Mailed: 04/13/2011

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Applicant(s)

Michael S. Harvey, Modesto, CA;
Jonathan N. Howarth, Modesto, CA;

Power of Attorney:
Audrey Millemann--44942

Domestic Priority data as claimed by applicant

Foreign Applications (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.)

If Required, Foreign Filing License Granted: 04/08/2011

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 13/065,553**

Projected Publication Date: 09/27/2012

Non-Publication Request: No

Early Publication Request: No
**** SMALL ENTITY ****

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 239

Title

Methods and compositions for the generation of peracetic acid on site at the point-of-use

Preliminary Class

510

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 240

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number: 13/065,553

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY FEE($)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	165		N/A	
SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	270		N/A	
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	110		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	91 minus 20 =	* 71	x 26 =	1846	OR		
INDEPENDENT CLAIMS (37 CFR 1.16(h))	11 minus 3 =	* 8	x 110 =	880			
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $270 ($135 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			0.00			
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				0.00			
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	3271		TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT A	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT B	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.

02570
032411
U.S. PTO

PTO/SB/05 (08-08)
Approved for use through 09/30/2010. OMB 0651-0032
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	8568/17669	U.S. PTO 13/065553
First Inventor	Michael S. Harvey	03/24/2011
Title	Methods...Peracetic Acid...Use	
Express Mail Label No.	EV 419585747US	

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☑ **Fee Transmittal Form** (e.g., PTO/SB/17)
2. ☑ **Applicant claims small entity status.** See 37 CFR 1.27.
3. ☑ **Specification** [*Total Pages* 74]
   Both the claims and abstract must start on a new page
   (For information on the preferred arrangement, see MPEP 608.01(a))
4. ☑ **Drawing(s)** (*35 U.S.C. 113*) [*Total Sheets* 1]
5. **Oath or Declaration** [*Total Sheets* 7]
   a. ☑ Newly executed (original or copy)
   b. ☐ A copy from a prior application (37 CFR 1.63(d))
   (for continuation/divisional with Box 18 completed)
   i. ☐ DELETION OF INVENTOR(S)
   Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ **Application Data Sheet.** See 37 CFR 1.76
7. ☐ **CD-ROM or CD-R** in duplicate, large table or Computer Program *(Appendix)*
   ☐ Landscape Table on CD
8. **Nucleotide and/or Amino Acid Sequence Submission**
   (if applicable, items a. – c. are required)
   a. ☐ Computer Readable Form (CRF)
   b. Specification Sequence Listing on:
      i. ☐ CD-ROM or CD-R (2 copies); or
      ii. ☐ Paper
   c. ☐ Statements verifying identity of above copies

ADDRESS TO:

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

ACCOMPANYING APPLICATION PARTS

9. ☐ **Assignment Papers** (cover sheet & document(s))
   Name of Assignee _____
10. ☐ **37 CFR 3.73(b) Statement** *(when there is an assignee)* ☑ **Power of Attorney** (combined)
11. ☐ **English Translation Document** *(if applicable)*
12. ☐ **Information Disclosure Statement** (PTO/SB/08 or PTO-1449)
    ☐ Copies of citations attached
13. ☐ **Preliminary Amendment**
14. ☑ **Return Receipt Postcard** (MPEP 503)
    (Should be specifically itemized)
15. ☐ **Certified Copy of Priority Document(s)**
    (if foreign priority is claimed)
16. ☐ **Nonpublication Request** under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or equivalent.
17. ☐ Other: _____

18. If a CONTINUING APPLICATION, *check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:*


☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: .....

Prior application information: *Examiner* _____ *Art Unit:* _____

19. CORRESPONDENCE ADDRESS

☐ The address associated with Customer Number: _____ **OR** ☑ Correspondence address below

Name	Audrey A. Millemann				
Address	Weintraub Genshlea Chediak 400 Capitol Mall, 11th Floor				
City	Sacramento	State	CA	Zip Code	95814
Country	US	Telephone	916-558-6033	Email	amillemann@weintraub.com

Signature		Date	March 23, 2011
Name (Print/Type)	Audrey A. Millemann	Registration No. (Attorney/Agent)	44,942

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Exp. Mail EV 419585747 US

PTO/SB/17 (10-08)
Approved for use through 09/30/2010. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL
For FY 2009

☑ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT ($) 3271

Complete if Known	
Application Number	
Filing Date	
First Named Inventor	Michael S. Harvey
Examiner Name	
Art Unit	
Attorney Docket No.	8568/17669

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☑ Deposit Account Deposit Account Number: 501176 Deposit Account Name: Weitraub Genshlea Chediak

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☑ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, **except for the filing fee**

☑ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☑ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES Fee ($)	FILING FEES Small Entity Fee ($)	SEARCH FEES Fee ($)	SEARCH FEES Small Entity Fee ($)	EXAMINATION FEES Fee ($)	EXAMINATION FEES Small Entity Fee ($)	Fees Paid ($)
Utility	330	165	540	270	220	110	545
Design	220	110	100	50	140	70	
Plant	220	110	330	165	170	85	
Reissue	330	165	540	270	650	325	
Provisional	220	110	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee ($)	Small Entity Fee ($)
Each claim over 20 (including Reissues)	52	26
Each independent claim over 3 (including Reissues)	220	110
Multiple dependent claims	390	195

Total Claims	Extra Claims	Fee ($)	Fee Paid ($)
91 - 20 or HP =	71	x 26	= 1846

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee ($)	Fee Paid ($)
12 - 3 or HP =	8	x 110	= 880

HP = highest number of independent claims paid for, if greater than 3.

Multiple Dependent Claims Fee ($)	Multiple Dependent Claims Fee Paid ($)

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is $270 ($135 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee ($)	Fee Paid ($)
74 - 100 =	0	/ 50 = _____ (round up to a whole number)	x _____	= _____

4. OTHER FEE(S)

	Fees Paid ($)
Non-English Specification, $130 fee (no small entity discount)	
Other (e.g., late filing surcharge): _____	

SUBMITTED BY

Signature	Audrey A. Millemann	Registration No. (Attorney/Agent) 44,942	Telephone 916-558-6033
Name (Print/Type)	Audrey A. Millemann		Date March 23, 2011

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

METHODS AND COMPOSITIONS FOR THE GENERATION OF PERACETIC ACID ON SITE AT THE POINT-OF-USE

Michael S. Harvey and Jonathan N. Howarth

FIELD OF THE INVENITON

[0001] The invention relates to liquid compositions and methods of using the liquid compositions for the generation of a peroxyacetic acid sanitizer on site in proximity to the point-of-use. The invention also relates to a solid bleaching and stain removal composition.

BACKGROUND OF THE INVENTION

[0002] **A. Liquid PAA Disinfectants and Sanitizers**

[0003] Disinfectants and sanitizers based on peroxyacetic acid (PAA), also commonly known as peracetic acid, are used in the dairy, food and beverage processing industries for clean-in-place pipeline and equipment disinfecting and cleaning, for fruit and vegetable washing, and in the treatment of meat, poultry and seafood products. Peroxyacetic acid disinfectants are also used in the treatment of cooling water, process water, and municipal wastewater. Other uses include slime and biofilm removal in papermaking processes.

[0004] Peroxyacetic acid products are supplied as stable equilibrium ternary aqueous solutions of peroxyacetic acid, acetic acid, and hydrogen peroxide. They are prepared in advance of delivery, typically by reacting hydrogen peroxide with acetic acid in the presence of a mineral acid catalyst. Although some PAA is formed immediately, the PAA does not reach its maximum concentration until after several days. A metal chelating agent, such as hydroxyethylidene

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 245

diphosphonic acid (HEDP) or dipicolinic acid, is also introduced to suppress the transition metal cation catalyzed decomposition of peroxygen compounds. The PAA product is then placed in containers, such as totes, drums and pails, in preparation for shipment to the end user. Typical commercial products have concentrations of PAA of about 1-15% w/w, although a concentration of up to 30% is possible. However, the latter concentration product only finds captive use because of its extremely hazardous and explosive properties.

[0005] There are several problems with the use of equilibrium solutions of PAA. First, the low concentration of PAA (1-15%) means that most of the weight (85-99%) of the products consist of substantial amounts of inert ingredients, such as water, acetic acid, and hydrogen peroxide. This results in the need for larger product storage areas and causes increased transportation and handling costs. Second, the products are inefficient in the use of both hydrogen peroxide (hydrogen peroxide) and acetic acid (AA). To maintain adequate storage stability of the PAA, either hydrogen peroxide or AA must be present at a level on a weight percentage basis that is greater than the level of PAA, which increases raw material costs. Third, the presence of the HEDP or dipicolinic acid stabilizer limits the amount of PAA that can be applied to certain foodstuffs because the amount of HEDP or dipicolinic acid is regulated by the Food and Drug Administration (FDA). Fourth, the reaction between hydrogen peroxide and AA is quite slow in some cases, and typically requires several days' time before the PAA product can be tested for quality confirmation. Therefore, manufacturers of these products must store large inventories of the PAA product before it can be shipped to the end user. Fifth, for transportation purposes, equilibrium solutions that are greater than 6% PAA are considered to be dangerous products and must be labeled with the DOT marking "Organic Peroxide", Hazard Class 5.2, 8 (oxidizer, corrosive). If producers and end-users exceed the yearly threshold amount of just 6,666 lbs. of 15% PAA, they must file Risk Management Plans with both federal EPA and state

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 246

authorities. This is an arduous and time-consuming process. In addition, producers of equilibrium solutions of PAA that are over 6% PAA must obtain permitting by the local fire department and pay an extra hazardous material shipping fee when the product is shipped from their facility. On the other hand, there are much less stringent requirements for products that contain hydrogen peroxide, and all reporting, permitting and shipping restrictions are lifted for products that contain less than 27% hydrogen peroxide.

[0006] As a result of these problems, there have been various attempts to make non-equilibrium solutions of PAA on site, at the point-of-use. For example, U.S. patent no. 7,012,154 discloses a system in which AA, hydrogen peroxide, water, and sulfuric acid are fed to a jacketed reactor for the production of PAA. A wiped-film distillation column attached to the reactor condenses and isolates the pure PAA from the gas phase and immediately introduces it to the receiving water. This system suffers from a number of drawbacks. First, it is extremely capital intensive due to the high cost of the equipment, including the reactor, heater, pumps, distillation column, and computerized control system which ensures accurate metering of the reagents. Second, there are significant safety hazards associated with the production of pure PAA due to its explosive properties. Third, the equipment and synthesis process is very complex and requires knowledgeable and highly trained technicians to continuously operate and maintain the system in a safe and effective manner.

[0007] Other attempts to make non-equilibrium solutions of PAA at the point-of-use are based on electrolytic processes. U.S. patent nos. 6,171,551 and 6,387,236 disclose processes that employ a cell divided by an ion-exchange membrane in which PAA (and other oxidants including hydrogen peroxide and ozone) are produced in the anode compartment which consists of an aqueous solution of acetic acid or acetate salt. In addition to the high costs of electricity and electrolysis equipment, these processes also result in a very low yield of PAA from the

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 247

acetyl precursor. For example, the '551 patent reports that less than 14 ppm of PAA was produced after 90 minutes of electrolysis of a 490,000 ppm anolyte of aqueous potassium acetate. In addition, these processes are difficult to perform intermittently.

[0008] Other methods of generating non-equilibrium solutions of PAA on site, using electrolysis, are described in WIPO International Publication Nos. WO 2004/0245116 and WO 2008/140988, and U.S. Patent Application Publication No. 2009/0314652. These references disclose cation membrane-divided electrolysis cells and the use of gas diffusion electrodes to effect the cathodic reduction of oxygen gas to hydrogen peroxide under alkaline conditions. The hydrogen peroxide was then allowed to react with acetic acid or an acetyl precursor to form PAA in the bulk solution, whereupon the catholyte was directed to the acidic anode compartment of the cell to stabilize the PAA. This system suffers from several disadvantages. Due to the low solubility of oxygen in water (about 8 ppm maximum), the concentration of electroactive species is very low, which forces the cell to operate at low current density (amperage per surface area of electrode). In order to produce a meaningful amount of hydrogen peroxide, the cells must have a very large surface area. This requires high capital equipment costs and a very large footprint for the electrolysis equipment. Another disadvantage of this system is that it is very difficult to maintain steady-state conditions and simultaneously balance the feed of acetic acid or acetyl precursor to the cathode compartment with the concurrent withdrawal of acidified PAA solution from the anode compartment. This is because cations carrying the cell current through the cation exchange membrane are always hydrated so as the cations move through the membrane, they are accompanied by water molecules. As a result, the volume of the anolyte decreases and the volume of the catholyte increases, making the steady-state condition difficult to maintain. It is difficult to perform this process intermittently. Finally, this system can only be of economic value if the source of oxygen is air, which comprises 23% oxygen. However, the carbon dioxide

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 248

contained in air causes carbonates to precipitate, which impedes the flow of electrical current, limiting or eliminating the production of hydrogen peroxide, and hence, PAA.

[0009] Another method of making a non-equilibrium solution of PAA at the point-of-use is disclosed in WIPO International Publication No. WO 2008/140988 and U.S. Patent Application Publication Nos. 2009/0005590 and 2007/0082832. These references disclose biosynthetic methods of producing peracids from carboxylic acids and carboxylic acid esters. These methods involve the use of perhydrolase enzymes to catalyze the perhydrolysis of the carboxylic acid or ester into the peracid using a solid or liquid source of hydrogen peroxide. Although these methods can produce compositions containing up to 20 parts of peracid to one part of hydrogen peroxide, they are limited by the amount of peracid that can be produced before the perhydrolase enzyme is oxidized by the reactant products and ceases to function as intended. The highest concentration of peracid disclosed by these references was 0.16% (1,600 mg/L). However, peracid or PAA solutions that are produced with enzymes have limited appeal because they are very expensive to produce, and for regulatory reasons, the enzyme must be removed from the solution before the solution can be applied to food or hard surfaces for disinfection purposes. Removing the enzyme from the solution is not an easy task; thus, it is typically not done. Therefore, PAA solutions prepared by enzymatic methods are not suitable for the more broad commercial uses in the food, dairy, beverage, meat, and poultry industries, which are regulated by the FDA and the Environmental Protection Agency (EPA).

[0010] Another method of generating non-equilibrium PAA at its point-of-use requires substituting the traditional mineral acid catalyst with sulfonic acid ion-exchange resins, as disclosed in U.S. patent no. 5,122,538. A solution containing a 1.5:1 mole ratio of AA to hydrogen peroxide was passed through a column packed with a sulfonic acid ion-exchange resin and produced a solution of 15% PAA within 30 minutes. The method described in the '538

patent suffers from the limitation that it requires a large volume of expensive resin bed in order to be effective. Moreover, all existing ion exchange resin systems are limited by the fact the resin is subject to oxidative degradation by PAA and have a short limited lifespan.

[0011] Other attempts to produce non-equilibrium PAA solutions on site, at the point-of-use, for bleaching cellulosic materials have reacted hydrogen peroxide with acetic anhydride. For example, U.S. patent no. 3,432,546 discloses a process where hydrogen peroxide, acetic anhydride, and an ammonium hydroxide catalyst were metered to a tubular reactor to continuously produce a solution containing 3.25% PAA with a conversion of 78% hydrogen peroxide. However, the process generated measurable amounts of diacetyl peroxide (0.44%) which is an explosion hazard. Moreover, the reaction product would be unsuited for any application other than cellulosic bleaching purposes because there was no attempt to remove the ammonium hydroxide catalyst from the reaction medium. Ammonium hydroxide is an undesirable contaminant in PAA products that are used as disinfectants and sanitizers in the dairy, food, and beverage processing industries, and in PAA products used in fruit and vegetable washing and in the treatment of meat, poultry, and seafood.

[0012] Another process for generating non-equilibrium solutions of PAA on site, at the point-of-use was disclosed in U.S. Patent Application Publication No. 2009/0043132. This process utilized introduction of hydrogen peroxide into a sidestream of the water requiring treatment. This was followed by introducing acetic anhydride, whereupon PAA was generated *in-situ*. It was found that acetic anhydride preferentially reacted with hydrogen peroxide rather than undergo undesirable hydrolysis with water. Within 20 minutes, up to 3000 ppm of PAA was generated in the sidestream which was then reconstituted with the main body of water and diluted further. All processes that employ acetic anhydride suffer the limitation that acetic anhydride is expensive, very corrosive, an irritant, and highly flammable.

[0013] Yet another process for generating non-equilibrium solutions of PAA on site at the point-of-use is disclosed in WIPO International Publication No. WO 01/46519 A1. This process utilized the metering of an aqueous solution of hydrogen peroxide into an agitated tank and co-metering a solid dry source of tetraacetylethylenediamine (TAED) from a storage hopper using a screw feeder. The agitator kept the solid TAED suspended in the hydrogen peroxide solution which was then fed to an in-line static mixer where aqueous sodium hydroxide was introduced. The mixture was then directed through 200 meters of coiled tubing immersed in a cooling tank so that the temperature rise accompanying the exothermic reaction was contained. Upon exiting the coiled tubing, the mixture containing PAA could be directed to the water requiring treatment. Disadvantages of this approach include the difficulty of accurately metering a solid and a liquid simultaneously, and the high capital equipment cost of the metering system, electronic controllers, agitation tank, coiled tubular reactor, and the cooling system.

[0014] Thus, there is a need for a method to make non-equilibrium PAA on site at the point-of-use that addresses the above problems.

[0015] **B. Solid PAA Bleaches and Stain Removers**

[0016] PAA is also used in laundry bleaching applications where it is generated *in-situ* in the laundry wash water. The PAA is typically produced from a solid source of hydrogen peroxide, such as sodium percarbonate or sodium perborate. The hydrogen peroxide must be in the presence of a solid acetyl precursor, most typically, tetraacetylethylenediamine (TAED). When dissolved in laundry wash water, the TAED undergoes a perhydrolysis reaction with hydrogen peroxide to form PAA. TAED is the preferred acetyl precursor because it possesses low toxicity, is of low environmental impact, and is readily biodegradable. However, TAED-based laundry bleaches have several problems. First, of the four acetyl groups on TAED, only two are known to be available for perhydrolysis, making TAED an expensive acetyl precursor on

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 251

a weight basis. Second, TAED has low water solubility, especially at the cooler water temperature bleaching cycles that are less damaging to fabrics. This is a major drawback, as current consumer trends in energy conservation are towards bleaching laundry fabrics with cool temperature water, rather than heated water. Undissolved TAED in cool temperature water is less unavailable as an acetyl precursor for the dissolved source of hydrogen peroxide and can even deposit on fabrics, necessitating a separate rinse step to remove it. Third, over time, when exposed to high humidity, solid TAED can react with the solid source of hydrogen peroxide and the free water to form PAA, as well as degrade the activity, making it less effective over time. Because the PAA is volatile, it imparts an undesirable pungent odor to the product. Thus, there is a need for a solid, peroxygen bleach that overcomes the deficiencies of the TAED-containing bleaches.

SUMMARY OF THE INVENTION

[0017] In an embodiment, liquid compositions for use in generating non-equilibrium solutions of PAA are provided. These hydrogen peroxide-acetyl precursor solutions comprise a solution of aqueous hydrogen peroxide, a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide, a trace amount of peracetic acid, and water. A preferable acetyl precursor is triacetin, which displays an unexpectedly high solubility in hydrogen peroxide. These hydrogen peroxide-acetyl precursor solutions may be used for generating a non-equilibrium solution of peracetic acid for use as a disinfectant or sanitizer on a site having a point-of-use of peracetic acid.

[0018] The hydrogen peroxide-acetyl precursor solutions are advantageous in that they are formulated such that sufficient acetyl precursor can be dissolved in an amount of hydrogen peroxide that would fully perhydrolyze all of the acetyl groups of the acetyl precursor.

Moverover, the hydrogen peroxide component of these compositions is remarkably stable. These compositions overcome one or more problems of the known prior art, and are free of the regulatory reporting, permitting, and shipping restrictions that govern equilibrium PAA products.

[0019] In another embodiment, a method of preparing a hydrogen peroxide-acetyl precursor solution is provided. The method comprises introducing a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide to a solution of aqueous hydrogen peroxide; and allowing the acetyl precursor and the aqueous hydrogen peroxide to mix to form a hydrogen peroxide-acetyl precursor solution.

[0020] A further embodiment is a method of continuously or intermittently generating a non-equilibrium solution of peracetic acid on a site having a point-of-use of peracetic acid for use as a disinfectant or sanitizer. Water is provided on the site having the point-of-use. The water may be a flowing aqueous stream or it may be contained in a mixing tank or other vessel. A hydrogen peroxide-acetyl precursor solution is provided on the site having the point-of-use. In one embodiment, the liquid acetyl precursor is triacetin and the solution that is formed is a hydrogen peroxide-triacetin solution. The hydrogen peroxide-acetyl precursor solution may be prepared off site and then transported to the site having the point-of-use, or the acetyl precursor and the aqueous hydrogen peroxide may be transported to the site having the point-of-use and then used to prepare the hydrogen peroxide-acetyl precursor solution on the site. The hydrogen peroxide-acetyl precursor solution is then introduced to the water. Alternatively, and in another embodiment, the acetyl precursor and the aqueous hydrogen peroxide may be introduced to the water separately, either sequentially, with either one first, or simultaneously. The hydrogen peroxide-acetyl precursor solution and the water are mixed to form a mixture. An aqueous source of an alkali metal or earth alkali metal hydroxide, such as sodium hydroxide, is provided on the site having the point-of-use. The aqueous source of an alkali metal or earth alkali metal

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 253

hydroxide is added to the mixture. Alternatively, and in another embodiment, the aqueous source of alkali metal or earth alkali metal hydroxide may be added simultaneously with the hydrogen peroxide-acetyl precursor solution or with the acetyl precursor and the aqueous hydrogen peroxide, to the water. A reaction medium comprising a non-equilibrium solution of peracetic acid is formed. In the reaction medium, the hydrogen peroxide reacts with the acetyl precursor to form peracetic acid. Almost instantaneously, a non-equilibrium solution of PAA is formed. Within about 30 seconds to about five minutes, the amount of hydrogen peroxide and acetyl precursor that are converted into peracetic acid is maximized. When triacetin is used as the acetyl precursor and assuming all three acetyl groups are reacted, about 40.9% to about 85.7% of the triacetin is converted into peracetic acid, and the percent of hydrogen peroxide remaining is about 0.078% to about 1.88%. The reaction medium may optionally be sampled at various times after the addition of the aqueous source of alkali metal or earth alkali metal hydroxide to determine the time required to maximize the amount of hydrogen peroxide and acetyl precursor that are converted into peracetic acid.

[0021] The non-equilibrium solutions of PAA that are formed comprise PAA, unreacted hydrogen peroxide, unreacted acetyl precursor, the product of the perhydrolysis reaction of the acetyl precursor, the aqueous source of alkali metal or earth alkali metal hydroxide, and water. The peracetic acid solutions are alkaline, having a pH of about 11.2 to about 13.37. The reaction is remarkably fast, proceeds with a high conversion of the acetyl precursor into PAA. This method produces solutions with a high level of PAA, from about 1% to about 7.1%.

[0022] The PAA solution is introduced to the receiving water at the point-of-use. It may be introduced immediately, or stabilized with the addition of a source of acid and used throughout a working day. The receiving water may be water used in the dairy, food, and beverage processing industries for clean-in-place pipeline and equipment cleaning; for fruit and

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 254

vegetable washing; and in the treatment of meat, poultry, and seafood products. The receiving water may also be cooling water, oil and gas process water, or municipal wastewater. Other uses include slime and biofilm removal in papermaking processes.

[0023] This method addresses one or more problems of the known prior art. The method is easy to perform, inexpensive to operate, and requires only basic and common equipment. The method is safe, in that it does not isolate pure PAA, and there is no possibility of a catastrophic event due to an equipment failure, such as over-pressurization or explosions. When triacetin is used as the acetyl precursor, it is inexpensive, non-toxic, safe, non-corrosive, non-irritating, non-flammable, sanctioned as Generally Recognized as Safe (GRAS) by the FDA, and converted quickly and with a high conversion rate into PAA. The method does not require the use of perhydrolase enzymes, acetic acid, or acetic anhydride, all of which suffer from the aforementioned limitations and problems. The method generates a PAA product that does not contain ammonium hydroxide. The method can be performed to generate a PAA product in a continuous or intermittent fashion. Further, the method allows the end-user the choice of utilizing the on site generated PAA immediately or later over the course of a working day.

[0024] In another embodiment, a freely-flowable, solid peroxygen composition for use in laundry bleaching and stain removal is provided. The solid composition comprises a liquid acetyl precursor, a water-soluble solid source of hydrogen peroxide, and a water-soluble solid source of alkalinity. The liquid acetyl precursor is preferably triacetin The composition produces peracetic acid upon being introduced to water. Upon dissolution, the solid hydrogen peroxide source releases hydrogen peroxide and the solid source of alkalinity dissolves to increase the pH, resulting in the formation of peracetic acid from the reaction of the hydrogen peroxide and the acetyl precursor.

[0025] The solid composition is used as a bleaching agent and a stain remover for the treatment of articles such as fabrics, dentures, textile garments, and equipment used in the food and beverage industry. The solid composition is advantageous in that it does not give rise to an undesirable PAA odor upon storage, contains an acetyl precursor that efficiently utilizes the acetyl groups it contains, and has a high solubility in cool temperature water which quickly and efficiently produces PAA without the need for elevated water temperatures. Moreover, the acetyl precursor used in making the solid composition may also be used in preparing the liquid compositions described in section 3 above, streamlining manufacturing practices by using the same acetyl precursor as an ingredient in liquid as well as solid compositions.

[0026] Surprisingly, this freely-flowable, solid composition includes a liquid acetyl precursor, triacetin. In addition, it is surprising that this composition does not produce a strong odor of peracetic acid during storage.

[0027] In another embodiment, a method of preparing the freely-flowable, solid peroxygen composition for use in laundry bleaching and stain removal is provided.

BRIEF DESCRIPTION OF THE DRAWING

[0028] Figure 1 is a schematic representation of an example of a system that may be used to continuously or intermittently generate PAA for on a site having a point-of-use of peracetic acid In another embodiment, a freely-flowable, solid peroxygen composition for use in laundry bleaching and stain removal is provided according to an embodiment.

DETAILED DESCRIPTION OF THE INVENTION

[0029] **1. Definitions**

[0030] The terms "PAA" and "peracetic acid" mean peroxyacetic acid or peracetic acid, and/or the conjugate base of peracetic acid (the peracetate ion).

[0031] The terms "percent" and "%" mean weight percent, except when referring to the percent converted.

[0032] The term "receiving water" means the water that is being treated.

[0033] The term "point-of-use" means the location where the peracetic acid enters the receiving water.

[0034] **2. Experimental Methods**

[0035] PAA and hydrogen peroxide in solution were determined using the ceric sulfate-sodium thiosulfate method. The method involves adding a known weight of sample containing the PAA and hydrogen peroxide (or dilution) to a beaker containing 50 ml of chilled 0.9 N sulfuric acid. Using a transfer pipette, 1-2 grams is accurately weighed to a sample cup and reverse osmosis (RO) or deionized water is added to provide a workable volume. Five drops of ferroin indicator is then added with stirring, and the sample is then titrated with 0.1 N ceric sulfate until the sample turns from purple to blue. The volume of ceric sulfate required in mL is recorded. Then, one or two small scoops of potassium iodide are added to the sample cup, which turns the solution dark brown. The sample is then titrated with 0.1 N sodium thiosulfate to discharge the brown coloration and form a pale straw coloration. Then, 10-15 drops of 0.5% starch indicator solution is introduced and the sample turns blue-black. The sodium thiosulfate is then added dropwise until the color transitions to a bright orange. The volume of sodium thiosulfate in mL was recorded. The percent hydrogen peroxide and the percent PAA are calculated as follows:

$$\% \text{ hydrogen peroxide} = \frac{\text{mL 0.1 N ceric sulfate} \times 0.17}{\text{wt. sample}}$$

$$\% \text{ PAA} = \frac{\text{mL 0.1 N sodium thiosulfate x 0.38}}{\text{wt. sample}}$$

[0036] For kinetic runs which involved measuring the PAA and hydrogen peroxide in samples at one, three, and five minute intervals after adding the reactants together, the generation reaction was quenched by adding a sample of the reaction medium to the sulfuric acid. This halted the generation reaction and stabilized the PAA and hydrogen peroxide to elevated pH degradation reactions. This permitted the samples to be taken at the appropriate time interval (one, three, and five minutes), and analyzed later.

[0037] In circumstances where low concentrations of PAA were used, the modified DPD method (U.S. patent no. 7,651,724) was employed. This analytical technique is based on a modified DPD (N,N-diethyl-*p*-phenylenediamine) colorimetric method accepted by the EPA for measuring total chlorine in drinking water and wastewater. It relies on the ability of PAA to behave like chlorine in that it rapidly and quantitatively oxidizes iodide ion (I^-) into iodine (I_2) that reacts with a color indicator (DPD), which turns the solution a shade of pink, the intensity of which is proportional to the concentration of the PAA. A colorimeter is used that is programmed to measure the intensity (absorbance) of the pink coloration and display the result in terms of ppm as Cl_2. A calculation converts this number into the ppm as PAA, based on the weight ratio of PAA to Cl_2 (76/71 = 1.07).

[0038] Hydrogen peroxide does not interfere with the measurement for PAA provided the analysis is completed within 30 seconds of introducing the DPD reagent. In order for the hydrogen peroxide to be measured, it must be activated by addition of a sodium molybdate catalyst and then given time (six minutes) to react with the I^- ion to liberate I_2. Upon addition of the DPD indicator, the intensity of the pink coloration measured by the colorimeter is now the

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 258

sum of the PAA and hydrogen peroxide concentrations expressed as ppm Cl_2. After subtracting the ppm reading obtained earlier for the contribution due to PAA, a calculation is then used to convert this number into ppm as hydrogen peroxide, and is based on the weight ratio of hydrogen peroxide to Cl_2 (34/71 = 0.479).

[0039] **3. Liquid Compositions for Generating Non-Equilibrium Solutions of PAA On a Site Having a Point-of-Use**

[0040] In an embodiment, liquid compositions for generating non-equilibrium solutions of PAA on a site having a point-of-use of peracetic acid are provided. These solutions are referred to as "hydrogen peroxide-acetyl precursor solutions." These solutions comprise aqueous hydrogen peroxide, a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide, a trace amount of peracetic acid, and water.

[0041] The hydrogen peroxide-acetyl precursor solutions are prepared by the following steps.

[0042] (a) Introducing a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide to a solution of aqueous hydrogen peroxide.

[0043] Triacetin is a preferable liquid acetyl precursor and 50% hydrogen peroxide is a preferable solution of aqueous hydrogen peroxide. The triacetin is preferably added to the 50% hydrogen peroxide at room temperature. Alternatively, 70% hydrogen peroxide can be used, but it is not widely available and requires special handling and transportation. Given that the solubility of triacetin in water is only 7% at 25°C, triacetin is unexpectedly highly soluble in 50% hydrogen peroxide. It solubilizes without an exotherm (temperature increase).

[0044] The mole ratio of hydrogen peroxide:triacetin is about 2.98:1 to about 12.84:1.

[0045] (b) Allowing the acetyl precursor and the aqueous hydrogen peroxide to mix to form a hydrogen peroxide-acetyl precursor solution.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 259

[0046] The solution is mixed until a homogenous solution has been formed. The solution is allowed to mix by diffusion or by using a mixing device that is suitable for mixing liquids together. For example, 50% hydrogen peroxide can be introduced to a batch tank equipped with an overhead agitator blade. Triacetin can then be introduced to the 50% hydrogen peroxide when the agitator is in motion so that the components are thoroughly mixed.

[0047] The solution that is formed is a hydrogen peroxide-acetyl precursor solution, which also includes varying amounts of water, depending on the formulation used. When triacetin is used as the liquid acetyl precursor, the solution that is formed is a hydrogen peroxide-triacetin solution. One such hydrogen peroxide-triacetin solution comprises about 23% to about 40% hydrogen peroxide (from 50% aqueous hydrogen peroxide), about 20% to about 52% triacetin, water, and a trace amount of PAA that is formed within the first day of preparing the hydrogen peroxide-acetyl precursor solution. The pH is about 1.46 to about 2.2 and no deliberate attempt is made to adjust the pH further.

[0048] A preferable hydrogen peroxide-triacetin solution comprises about 27.15% hydrogen peroxide (from 50% aqueous hydrogen peroxide), about 45.67% triacetin, water, and a trace amount of PAA that is formed within the first day of preparing the hydrogen peroxide-acetyl precursor solution. The mole ratio of hydrogen peroxide:triacetin is about 3.8:1.

[0049] The hydrogen peroxide-acetyl precursor solutions prepared by this method may be used to generate non-equilibrium solutions of PAA on a site having a point-of-use of peracetic acid, in the methods described in section 4 below. The hydrogen peroxide-acetyl precursor solutions may be transported in any container suitable for transporting liquids, such as plastic tote bins of 275-330 gallons, drums of 15-55 gallons, five-gallon pails, one-gallon jugs, or other containers.

[0050] Example 1

[0051] Triacetin (83.05 g) was added to 50% hydrogen peroxide solution (75 g) to form 158.05 g of a mixture. There was no evolution of gas indicating the hydrogen peroxide had decomposed to oxygen, nor was there any exotherm indicating that a chemical reaction had occurred. The solution did not turn oily or cloudy but remained clear. The solution was calculated to comprise 23.73% hydrogen peroxide and 52.55% triacetin, with the balance being water, and had a measured pH of 2.2. The mole ratio of hydrogen peroxide to triacetin was calculated to be 2.98:1. Titration of the solution immediately upon preparation yielded 24.1% hydrogen peroxide, which is within experimental error of the calculated amount of hydrogen peroxide.

[0052] This experiment showed that triacetin is remarkably soluble in 50% hydrogen peroxide. The solubility of triacetin was found to be at least 52.55%. This is surprising, given that the solubility of triacetin in water is only 7% at 25°C.

[0053] In order to test the stability of the mixture, the amount of hydrogen peroxide remaining and the amount of PAA generated was tracked for several months. The mixture was held at ambient temperature away from sources of light. Table I summarizes the data.

[0054] Table I

Day #	% Hydrogen Peroxide Remaining	% PAA Generated
1	23.79	0.00
29	23.32	1.28
57	22.56	2.36
92	21.06	4.22
120	19.54	6.05
134	18.57	6.87

[0055] Table I shows that although there was a steady depletion in hydrogen peroxide, it was accompanied by an increase in PAA. By the end of the 134-day study, the composition had

lost 5.22% hydrogen peroxide. Had all of the depleted hydrogen peroxide gone towards the generation of PAA, 11.67% PAA would have been generated. Because 6.87% PAA was generated, unaccounted losses of hydrogen peroxide amounted to 2.15%. This loss of hydrogen peroxide was surprisingly small given that hydrogen peroxide is often used to destroy organic compounds by oxidation and the composition originally contained 52.55% of triacetin, an organic compound.

[0056] Example 2

[0057] A formulation containing hydrogen peroxide and triacetin in a mole ratio of 12.84:1 was prepared by adding triacetin (100.0 g) to 50% hydrogen peroxide (400.0 g) so that the mixture was 40% hydrogen peroxide and 20% triacetin, with the balance being water. The pH of the solution was 1.46 and the pH of a 1:100 dilution was 3.69. To accelerate storage characteristics, the sample was placed in an incubator set for 86-87° F. Table II shows the percent of hydrogen peroxide remaining and the percent of PAA generated over a period of more than six months.

[0058] Table II

Days of Study	% Hydrogen Peroxide Remaining	% PAA Generated
1	40.21	0.004
33	38.02	3.499
54	35.5	5.992
96	29.27	8.36
127	25.05	6.66
173	18.49	4.43
201	15.67	3.51

[0059] Table II indicates that after 96 days, the generation of PAA maximized at 8.36% and corresponded to a loss of 10.94% hydrogen peroxide. Had all of the depleted hydrogen

peroxide gone toward the generation of PAA, 24.45% PAA would have been generated. Because only 8.36% PAA was generated, unaccounted losses of hydrogen peroxide amounted to 7.2%.

[0060] Example 3

[0061] A formulation containing hydrogen peroxide and triacetin in a mole ratio of 5.8:1 was prepared by adding triacetin (37.5008 g) to 50% hydrogen peroxide (65.2504 g) so that the mixture was 31.75% hydrogen peroxide and 36.5% triacetin, with the balance being water. The pH of the solution was 1.57 and the pH of a 1:100 dilution was 5.17. To accelerate degradation, the sample was placed in an incubator set for 86-87° F. Table III shows the percent of hydrogen peroxide remaining and the percent of PAA generated over a period of six days.

[0062] Table III

Days of Study	% Hydrogen Peroxide Remaining	% PAA Generated
1	31.72	0.33
6	31.63	0.716

[0063] In this study, after six days, the mixture had lost only 0.09% hydrogen peroxide, yet had generated an additional 0.386% PAA. Had all the loss of hydrogen peroxide been due to the formation of PAA, only an additional 0.201% would have been generated. It is clear that the analytical methods employed for solutions that are high in hydrogen peroxide but low in PAA are subject to detection limit errors.

[0064] Example 4

[0065] A formulation containing hydrogen peroxide and triacetin in a mole ratio of 3.2:1 was prepared by adding triacetin (35.0 g) to 50% hydrogen peroxide (35.0 g) so that the mixture was 25% hydrogen peroxide and 50% triacetin, with the balance being water. The pH of the solution was 1.66 and the pH of a 1:100 dilution was 4.09. To accelerate degradation, the sample

was placed in an incubator set for 86-87° F. Table IV shows the percent of hydrogen peroxide remaining and the percent of PAA generated over a period of 22 days.

[0066] Table IV

Days of Study	% Hydrogen Peroxide Remaining	% PAA Generated
1	25	0.62
8	24.51	1
15	24.17	1.17
22	23.68	1.14

[0067] Table IV indicates that after 15 days, the generation of PAA maximized at 1.17% and corresponded to a loss of 0.83% hydrogen peroxide. Had all of the depleted hydrogen peroxide gone toward the generation of PAA, 1.86% PAA would have been generated. Because only 1.17% PAA was generated, unaccounted losses of hydrogen peroxide amounted to 0.31%.

[0068] Example 5

[0069] A formulation containing hydrogen peroxide and triacetin in a mole ratio of 4.8:1 was prepared by adding triacetin (37.50 g) to 50% hydrogen peroxide (56.25 g) so that the mixture was 30% hydrogen peroxide and 40% triacetin, with the balance being water. The pH of the solution was 1.67 and the pH of a 1:100 dilution was 4.62. To accelerate degradation, the sample was placed in an incubator set for 86-87° F. Table V shows the percent of hydrogen peroxide remaining and the percent of PAA generated over a period of 43 days.

[0070] Table V

Days of Study	% Hydrogen Peroxide Remaining	% PAA Generated
1	30.08	0.38
8	29.85	0.784
15	29.63	1.22
22	29.37	1.71
29	28.76	2.26
36	28.67	2.78
43	28.31	3.41

[0071] Table V shows that although there was a steady depletion in hydrogen peroxide, it was accompanied by the associative increase of PAA. At the end of the 43-day study, the composition had lost 1.77% hydrogen peroxide. Had all of the depleted hydrogen peroxide gone toward the generation of PAA, 3.96% PAA would have been generated. Because only 3.41% PAA was generated, unaccounted losses of hydrogen peroxide amounted to 0.24%.

[0072] Example 6

[0073] A formulation containing hydrogen peroxide and triacetin in a mole ratio of 6.42:1 was prepared by adding triacetin (25.0007 g) to 50% hydrogen peroxide (50.0007 g) so that the mixture was 33.33% hydrogen peroxide and 33.33% triacetin, with the balance being water. The pH of the solution was 1.56 and the pH of a 1:100 dilution was 5.15. To accelerate degradation, the sample was placed in an incubator set for 86-87° F. Table VI shows the percent of hydrogen peroxide remaining and the percent of PAA generated over a period of 36 days.

[0074] Table VI

Days of Study	% Hydrogen Peroxide Remaining	% PAA Generated
1	33.13	0.81
8	32.88	1.35
15	32.61	1.88
22	31.69	2.58
29	31.75	3.03
36	31.29	3.28

[0075] Table VI shows that although there was a steady depletion in hydrogen peroxide, it was accompanied by an associative increase of PAA. At the end of the 36-day study, the composition had lost 1.84% hydrogen peroxide. Had all of the depleted hydrogen peroxide gone toward the generation of PAA, 4.11% PAA would have been generated. Because only 3.28% PAA was generated, unaccounted losses of hydrogen peroxide amounted to 0.37%.

[0076] Example 7

[0077] A 30-gallon batch of 50% hydrogen peroxide and triacetin was prepared by blending 137 lbs triacetin with 163 lbs 50% hydrogen peroxide so that the mixture was 27.15% hydrogen peroxide and 45.67% triacetin, with the balance being water. Thus, the mole ratio of hydrogen peroxide:triacetin was 3.8:1. The mixture was stored in an opaque drum in a non-climate controlled environment. On storage, the mixture slowly formed PAA in the container. Since this reaction of hydrogen peroxide to PAA does not represent a destructive loss of total peroxygen, to determine the true stability of the hydrogen peroxide, both the hydrogen peroxide and the peracetic acid generated must be quantified and reported as total peroxygen recovered.

[0078] After 295 days of storage, the mixture was analyzed for total peroxygen recovered (expressed as hydrogen peroxide) to determine the percent loss of peroxygen. Using the ceric sulfate–iodometric titration method, the PAA generated and the hydrogen peroxide remaining were measured. The total peroxygen recovered after 295 days and the theoretical initial concentrations are shown in Table VII. All peroxygen is expressed as % hydrogen peroxide.

[0079] Table VII

	Initial Theoretical %	% (after 295 days)
Hydrogen Peroxide Recovered	27.17	15.20
PAA formed	0	15.57
Hydrogen Peroxide Reacted to form PAA	0	6.97
Total Recovered Hydrogen Peroxide	27.17	22.17
Total Hydrogen Peroxide Unproductive Loss		5.00

[0080] After 295 days, 22.17% of the total peroxygen was recovered as either titratable hydrogen peroxide or hydrogen peroxide reacted to form PAA. To determine the stability of the peroxygen in the mixture, the total recovered hydrogen peroxide after 295 days (22.17%) was

subtracted from the total recovered hydrogen peroxide of the initial theoretical value (27.17%). The result, 5%, is the loss of peroxygen (expressed as hydrogen peroxide) after 295 days of storage in a non-climate controlled environment.

4. Methods of Generating Non-Equilibrium PAA On Site at the Point-of-Use

[0081] Methods of continuously or intermittently generating non-equilibrium solutions of PAA on a site having a point-of-use of PAA for use as a disinfectant or sanitizer, using a source of water that is an aqueous stream or by a batch process using water in a container, are provided.

[0082] In one embodiment, a method of continuously or intermittently generating non-equilibrium solutions of PAA on a site having a point-of-use, using a source of water that is an aqueous stream, comprises the following steps.

[0083] (a) Providing water.

[0084] Flowing water is provided on a site having a point-of-use of peracetic acid.

[0085] The water may be flowing in, for example, a pipe, a flume, a canal, or other types of aqueous streams. The water pressure should be regulated and the flow rate should be monitored or measured. Any suitable flow meter may be used, such as a rotameter, a magnetic flow meter, an ultrasonic flow meter, a Doppler flow meter, a differential-pressure flow meter, a turbine flow meter, or a Coriolis flow meter.

[0086] The water should be softened, deionized, or of sufficient low hardness that it will not precipitate calcium salts when the alkali metal or earth alkali metal hydroxide is introduced in step (d).

[0087] (b) Introducing a hydrogen peroxide-acetyl precursor solution to the water.

[0088] A hydrogen peroxide-acetyl precursor solution is provided on the site having the point-of-use of the PAA. The hydrogen peroxide-acetyl precursor solution may be prepared by the steps set forth in section 3 above. The hydrogen peroxide-acetyl precursor solution may be

prepared off site and then transported to the site having the point-of-use, or the acetyl precursor and the aqueous hydrogen peroxide may be transported to the site having the point-of-use and used to prepare the hydrogen peroxide-acetyl precursor solution on the site.

[0089] A preferable liquid acetyl precursor is triacetin. When triacetin is used, a hydrogen peroxide-triacetin solution is introduced.

[0090] The hydrogen peroxide-acetyl precursor solution is introduced to the flowing water in an amount such that the hydrogen peroxide-acetyl precursor solution is about 5.6% to about 22.5% of the total.

[0091] The hydrogen peroxide-acetyl precursor solution is pumped from its container into the aqueous water stream, for example, through an injection quill mounted on the pipe. Any suitable pump capable of overcoming the pressure of the water flowing in the pipe may be used. Examples include a solenoid-driven or air-driven diaphragm pump or a peristaltic pump. The rate at which the hydrogen peroxide-acetyl precursor solution is pumped into the flowing water is governed by a controller that is interfaced to a flow meter that is measuring the flow of the water. In this way, the rate at which the hydrogen peroxide-acetyl precursor solution is pumped may be matched to the flow of the water in the aqueous stream. If the flow of the water slows, the rate at which the hydrogen peroxide-acetyl precursor solution is pumped should slow accordingly. If the flow of the water stops, the hydrogen peroxide-acetyl precursor pump should stop.

[0092] As an alternative to step (b), the liquid acetyl precursor and the solution of aqueous hydrogen peroxide may be introduced to the water separately, either simultaneously or sequentially. If they are introduced sequentially, either one may be added first. If the liquid acetyl precursor and the aqueous hydrogen peroxide are introduced separately, rather than as an hydrogen peroxide-acetyl precursor solution, then in step (c) the liquid acetyl precursor and the aqueous hydrogen peroxide are mixed with the water to form a mixture.

[0093] (c) Mixing the hydrogen peroxide-acetyl precursor solution and the water to form a mixture.

[0094] Any mixing device suitable for mixing liquids may be used. An example is a static mixer located just after the point that the hydrogen peroxide-acetyl precursor solution is introduced to the flowing water. One type of static mixer utilizes a non-moving element such as a series of baffles. As the mixture flows through the static mixer under the motive force of the flowing water, the non-moving element divides the flow several times to provide radial mixing. Another type of static mixer utilizes a series of obstructions, such as column packing or glass beads, provided there is a low differential pressure drop across the mixer. The obstructions provide for turbulent mixing of the hydrogen peroxide-acetyl precursor solution and the flowing water. The mixing should yield a homogeneous solution with no concentration gradients before the next step is performed. The velocity of the water will determine the time it takes to complete the mixing and the efficiency of the mixing. For example, with ¾" pipe, a static mixer of ¾" diameter and 6" long, and a velocity of about 1 gal/min., mixing should be accomplished in less than about one second.

[0095] (d) Adding an aqueous source of an alkali metal or earth alkali metal hydroxide to the mixture.

[0096] An aqueous source of an alkali metal or earth alkali metal hydroxide is provided on the site having the point-of-use. A preferable aqueous source of an alkali metal hydroxide is sodium hydroxide, and 50% sodium hydroxide is most preferable. Other suitable alkali metal hydroxides include 45% potassium hydroxide.

[0097] Sufficient 50% NaOH is added to the flowing mixture such that the amount of sodium hydroxide is about 1.82% to about 7.28% of the total amount. When the acetyl precursor is triacetin, a preferred mole ratio of NaOH: hydrogen peroxide:triacetin is about 4.2:3.8:1.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 269

[0098] The 50% NaOH solution is added to the mixture by pumping it from its container with a suitable pumping device and into the mixture through an injection quill mounted on the pipe. Any suitable pump capable of overcoming the hydraulic pressure of the pipe may be used. Examples include a solenoid-driven or air-driven diaphragm pump or a peristaltic pump.

[0099] The rate at which the 50% NaOH solution is pumped into the pipe is governed by the same controller that is interfaced to both the flow meter that is measuring the flow of the mixture and the pump controlling the rate of introduction of the hydrogen peroxide-acetyl precursor solution. In this way, the rate at which the 50% NaOH solution is introduced may be matched to both the flow of the mixture and the rate of introducing the hydrogen peroxide-acetyl precursor solution. If the flow of the mixture slows for any reason, the rate at which the 50% NaOH solution is pumped should slow accordingly. If the flow of the mixture stops, the 50% NaOH pump should stop as well.

[00100] Step (d) may be performed after step (c), or it may be performed simultaneously with step (b).

[00101] (e) Forming a reaction medium comprising a non-equilibrium solution of peracetic acid.

[00102] The reaction medium that is formed in this step almost instantaneously forms a non-equilibrium solution of PAA. The hydrogen peroxide reacts with the acetyl precursor to form peracetic acid. Depending upon the temperature of the water, the efficiency of mixing, and the mole ratio of NaOH:hydrogen peroxide:acetyl precursor employed, the amount of hydrogen peroxide and acetyl precursor that are converted into PAA is maximized within about 30 seconds to about five minutes.

[00103] The non-equilibrium solutions of PAA prepared by this method comprise PAA, unreacted hydrogen peroxide, unreacted acetyl precursor, the product of the perhydrolysis

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 270

reaction of the acetyl precursor, the aqueous source of alkali metal or earth alkali metal hydroxide, and water. When the acetyl precursors is triacetin, the product of the perhydrolysis reaction is 1, 2, 3-propanetriol (glycerine).

[00104] This method may also include an optional step after step (e) of sampling the reaction medium at various times after the addition of the aqueous source of alkali metal or earth alkali metal hydroxide to determine the time required under the existing conditions to maximize the amount of hydrogen peroxide and acetyl precursor that are converted into PAA. This may be accomplished by directing the flow of the reaction medium through a series of residence chambers equipped with sampling ports. The residence chambers are designed to be of sufficient volume such that a certain amount of time has elapsed since the introduction of the 50% NaOH. Thus, at any given flow rate in the pipe, the first residence chamber is of a volume such that 30 seconds have elapsed since the introduction of 50% NaOH, one minute has elapsed by the time the flow reaches the sampling port immediately after the second residence chamber, and additional time elapses by the time the flow reaches the remaining sampling ports. Up to four residence chambers and sampling ports may be placed in series such as this to provide the user with about 30 seconds to five minutes of residence time after the introduction of the 50% NaOH. Once the flow of the reaction medium has been established, samples are drawn from all four sampling ports associated with the residence chambers and analyzed for peracetic acid. The sample which registers the highest amount of peracetic acid is deemed to be drawn from the sampling port associated with the residence chamber corresponding to the time of maximum conversion of the acetyl precursor into peracetic acid. At this point, the entire flow of reaction medium is directed through the sampling point of maximum conversion of acetyl precursor and to the point-of-use.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 271

[00105] In another embodiment, a method of continuously or intermittently generating a non-equilibrium solution of PAA on a site having a the point-of-use in a batch process comprises the following steps:

[00106] (a) Providing water.

[00107] A container of water, such as a mixing tank or other vessel, is provided on a site having a point-of-use of peracetic acid. The water should be softened, deionized, or of sufficient low hardness that it will not precipitate calcium salts when the alkali metal or earth alkali metal hydroxide is introduced in step (d).

[00108] (b) Introducing a hydrogen peroxide-acetyl precursor solution to the water.

[00109] A hydrogen peroxide-acetyl precursor solution is provided on the site having the point-of-use of the PAA. The hydrogen peroxide-acetyl precursor solution may be prepared by the steps set forth in section 3 above. The hydrogen peroxide-acetyl precursor solution may be prepared off site and then transported to the site having the point-of-use, or the acetyl precursor and the aqueous hydrogen peroxide may be transported to the site having the point-of-use and used to prepare the hydrogen peroxide-acetyl precursor solution on the site.

[00110] A preferable liquid acetyl precursor is triacetin. When triacetin is used, a hydrogen peroxide-triacetin solution is introduced.

[00111] The hydrogen peroxide-acetyl precursor solution is introduced to the water in an amount such that the hydrogen peroxide-acetyl precursor solution is about 5.6% to about 22.5% of the total.

[00112] The hydrogen peroxide-acetyl precursor solution is pumped from its container into the container of water through an injection quill mounted on the side of the container of water. Any suitable pump may be used. Examples include a solenoid-driven or air-driven diaphragm pump or a peristaltic pump.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 272

[00113] As an alternative to step (b), the liquid acetyl precursor and the solution of aqueous hydrogen peroxide may be introduced to the water separately, either simultaneously or sequentially. If they are introduced sequentially, either one may be added first. If the liquid acetyl precursor and the aqueous hydrogen peroxide are introduced separately, rather than as an hydrogen peroxide-acetyl precursor solution, then in step (c) the liquid acetyl precursor and the aqueous hydrogen peroxide are mixed with the water to form a mixture.

[00114] (c) Mixing the hydrogen peroxide-acetyl precursor solution and the water to form a mixture.

[00115] Any mixing device suitable for mixing liquids may be used. An example is an overhead stirrer, such as an agitator blade. The container of water is equipped with a baffle to assist the process of mixing. The mixing should yield a homogeneous solution with no concentration gradients before the next step is performed.

[00116] (d) Adding an aqueous source of an alkali metal or earth alkali metal hydroxide to the mixture.

[00117] An aqueous source of an alkali metal or earth alkali metal hydroxide is provided on the site having the point-of-use. A preferable aqueous source of an alkali metal hydroxide is sodium hydroxide, and 50% sodium hydroxide is most preferable. Other suitable alkali metal hydroxides include 45% potassium hydroxide.

[00118] Sufficient 50% NaOH is added to the mixture such that the amount of sodium hydroxide is about 1.82% to about 7.28% of the total amount. When the acetyl precursor is triacetin, a preferred mole ratio of NaOH: hydrogen peroxide:triacetin is about 4.2:3.8:1.

[00119] The 50% NaOH solution is added to the mixture by pumping it from its container with a suitable pumping device and into the mixture through an injection quill mounted on the

side of the container of water. Any suitable pump may be used. Examples include a solenoid-driven or air-driven diaphragm pump or a peristaltic pump.

[00120] Step (d) may be performed after step (c), or it may be performed simultaneously with step (b).

[00121] (e) Forming a reaction medium comprising a non-equilibrium solution of peracetic acid.

[00122] The reaction medium that is formed in this step almost instantaneously forms a non-equilibrium solution of PAA. The hydrogen peroxide reacts with the acetyl precursor to form peracetic acid. Depending upon the temperature of the water, the efficiency of mixing, and the mole ratio of NaOH:hydrogen peroxide:acetyl precursor employed, the amount of hydrogen peroxide and acetyl precursor that are converted into PAA is maximized within about 30 seconds to about five minutes.

[00123] The non-equilibrium solutions of PAA prepared by this method comprise PAA, unreacted hydrogen peroxide, unreacted acetyl precursor, the product of the perhydrolysis reaction of the acetyl precursor, the aqueous source of alkali metal or earth alkali metal hydroxide, and water. When the acetyl precursors is triacetin, the product of the perhydrolysis reaction is 1, 2, 3-propanetriol (glycerine).

[00124] While not wishing to be bound by theory, it is believed that under elevated pH conditions created by the addition of a source of alkali metal hydroxide or earth alkali metal hydroxide, hydrogen peroxide dissociates according to the following equation:

$$H_2O_2 = H^+ + HO_2^-$$

[00125] The perhydroxyl anion (HO_2^-) then affects nucleophilic substitution reactions on the carbonyl groups of the acetyl precursor in a perhydrolysis reaction to form peracetic acid and the product of the perhydroloysis reaction of the acetyl precursor. When the acetyl precursor is

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 274

triacetin and all three acetyl groups are reacted, then the product of the perhydrolysis reaction is 1, 2, 3-propanetriol (glycerine).

[00126] In these methods, the perhydrolysis reaction is rapid and the maximum amount of PAA is generated within about 30 seconds to about five minutes at ambient temperature. The methods efficiently utilize the acetyl precursor and the source of hydrogen peroxide. When triacetin is used, assuming all three acetyl groups are reacted, about 40.9% to about 85.7% of the triacetin is converted into PAA. The percent of hydrogen peroxide remaining is about 0.078% to about 1.88%.

[00127] The non-equilibrium solutions of PAA prepared by these methods have several unique characteristics. The PAA solutions have high levels of PAA, from about 1% to about 7.1%. In addition, the PAA solutions are alkaline, having a pH of about 11.2 to about 13.37.

[00128] The non-equilibrium solutions of PAA may be immediately introduced to the receiving water at the point-of-use. Alternatively, the solutions may be stabilized by halting the decomposition of the PAA by adding a source of acid to lower the elevated pH of the reaction medium caused by the addition of an alkali metal or earth alkali metal hydroxide, and to provide neutral to mildly acid pH conditions to stabilize the PAA to elevated pH degradation. The acid-stabilized PAA solutions can then be stored and used at the point-of-use as required throughout a working day.

[00129] The non-equilibrium PAA solutions produced by these methods can be advantageously used wherever traditional equilibrium solutions of PAA are used. Thus, the PAA solutions may be used as a disinfectant and sanitizer in the dairy, food, and beverage processing industries for clean-in-place pipeline and equipment cleaning; for fruit and vegetable washing; and in the treatment of meat, poultry, and seafood products. These PAA solutions may also be

used in the treatment of cooling water, oil and gas process water, and municipal wastewater. Other uses include slime and biofilm removal in papermaking processes.

[00130] For both of the above methods, steps (a) through (e) may be performed on a continuous or intermittent basis. In a continuous basis, the steps are performed under conditions of steady state, and the PAA solution is produced at the same rate as a function of time. However, intermittent performing of steps (a) through (e) is possible if the demand for the PAA solution drops for any reason (e.g., change in working shift or the target level of PAA in the receiving water has been achieved), in which case, steps (a) through (e) may be discontinued and resumed when the demand increases.

[00131] Example 8

[00132] Tests were performed using about one liter of reverse osmosis (RO) or softened water which was buffered to an alkaline pH. The buffering media included 0.1 and 0.2 M Na_2CO_3 solutions, in addition to 0.1 and 0.2 M NaOH solutions. Sufficient buffering media was added to the water in order to achieve the desired pH. The amount of hydrogen peroxide (introduced as 50% hydrogen peroxide) and triacetin used in the tests is summarized in Table VIII. The reactants were introduced to the solution in one of three ways: simultaneously (referred to in Table VIII as "double"), sequentially (triacetin followed shortly by hydrogen peroxide), or by mixing the hydrogen peroxide and triacetin together and adding them in a single charge (referred to in Table VIII as "mixed"). All testing was performed at ambient temperature as the one-liter beaker was stirred with a magnetic stir bar. Using the ceric sulfate–iodometric titration method, the percent of PAA generated and the percent of hydrogen peroxide remaining were measured five minutes after introduction of the reactants to the buffer. The percent of the triacetin acetyl donor converted to PAA was calculated, assuming all three acetyl groups were available for perhydrolysis.

[00133] Table VIII

Test #	Moles Hydrogen Peroxide/ Mole Triacetin	Type of Addition (Double, Sequential or Mixed)	pH of Buffer	Hydrogen Peroxide Used (Wt., g)	Triacetin Used (Wt., g)	% PAA Generated	% Hydrogen Peroxide Remaining	% Triacetin Converted to PAA
1	4.99	Double	10.50	8.60	5.53	0.170	0.329	29.6%
2	5.47	Double	10.50	8.60	5.04	0.178	0.333	33.9%
3	5.45	Double	10.80	8.61	5.07	0.192	0.329	36.4%
4	5.68	Double	11.00	8.87	5.01	0.201	0.322	38.6%
5	5.72	Double	11.00	9.13	5.12	0.068	0.416	12.8%
6	5.49	Double	12.42	8.60	5.02	0.169	0.306	32.4%
7	5.59	Double	12.91	8.60	4.93	0.320	0.265	62.4%
8	5.53	Double	12.80	8.69	5.04	0.335	0.273	63.9%
9	25.0	Double	12.65	9.03	1.16	0.104	0.413	85.9%
10	5.26	Double	12.60	8.70	5.30	0.298	0.247	54.1%
11	5.52	Sequential	12.83	8.68	5.04	0.276	0.248	52.4%
12	5.47	Sequential	12.81	17.11	10.03	0.120	0.371	11.4%
13	28.8	Mixed	11.12	8.74	0.973	0.039	0.398	38.9%
14	28.8	Mixed	11.99	8.75	0.974	0.038	0.374	37.9%
15	28.8	Mixed	13.02	8.69	0.967	0.055	0.367	55.2%
16	28.8	Mixed	7.91	8.70	0.968	0.024	0.435	23.7%
17	28.8	Mixed	11.22	8.76	0.975	0.029	0.309	28.4%
18	28.8	Mixed	12.07	8.68	0.966	0.028	0.311	27.7%
19	28.8	Mixed	13.22	8.72	0.971	0.026	0.321	25.6%
19 dup	25.2	Mixed	12.97	8.77	1.12	0.031	0.249	26.5%
20	25.2	Mixed	12.98	9.08	1.16	0.066	0.393	54.5%
20 dup	25.2	Mixed	13.00	9.10	1.16	0.074	0.409	61.0%
21	25.2	Mixed	13.02	9.10	1.16	0.02	0.261	16.5%
21 dup	25.2	Mixed	12.99	9.12	1.16	0.017	0.376	14.0%
22	16.0	Mixed	12.99	5.80	1.16	0.070	0.246	57.7%
23	16.0	Mixed	13.05	5.79	1.16	0.013	0.189	10.7%
24	16.0	Mixed	12.55	5.78	1.16	0.031	0.234	25.6%
25	16.0	Mixed	12.49	5.80	1.16	0.013	0.144	10.7%
26	16.0	Mixed	12.01	5.85	1.17	0.016	0.259	13.1%
27	16.0	Mixed	12.05	5.82	1.16	0.011	0.080	9.0%
28	16.0	Mixed	10.50	0.601	0.120	0.00077	0.028	6.1%
29	16.0	Mixed	10.97	0.595	0.119	0.00023	0.021	1.8%
30	16.0	Mixed	10.50	0.614	0.123	0.00012	0.019	0.9%
32	16.0	Mixed	10.97	0.595	0.119	0.00035	0.018	2.8%

[00134] Table VIII shows that the amount of PAA generated was independent of the method of introducing the triacetin and hydrogen peroxide to the buffer solutions. It can be seen that the pH of the buffer had a significant effect on the percent of the triacetin that was converted into PAA. Only when the pH was above 12 was a meaningful percent of the triacetin converted into PAA.

[00135] Example 9

[00136] A mixture of triacetin and hydrogen peroxide was prepared by blending 50% hydrogen peroxide (63.4%) and triacetin (36.6%). Thus, the mole ratio of hydrogen peroxide:triacetin was 5.57:1. The mixture (13.68 g) was added to soft water such that the final solution contained 5 g/L of triacetin and had a pH of 4.1. Then, in successive experiments, sufficient 50% NaOH was added to the beaker so that the mole ratio of NaOH:TA was varied from 3:1 (obtained by introducing 5.49 g of 50% NaOH) to 8:1 (obtained by introducing 14.68 g of 50% NaOH). Using the ceric sulfate–iodometric titration method, the percent of PAA generated and the percent of hydrogen peroxide remaining were measured over the next 20 minutes. The method was performed in duplicate for each sample point. The averages of the results for the 6:1 mole ratio of NaOH:TA are shown in Table IX.

[00137] Table IX

Time (min)	% PAA Generated	% Hydrogen Peroxide Remaining	% Triacetin Converted to PAA (3 acetyls)
0	0.015	0.437	2.9
1	0.275	0.298	53.1
3	0.312	0.274	60.2
5	0.326	0.258	62.9
11	0.302	0.233	58.3
21	0.246	0.199	47.5

[00138] It can be seen that even before the introduction of 50% NaOH, some PAA was present in solution as a result of being generated in the diluted mixture of the two components.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 278

Upon addition of the NaOH, PAA was immediately generated, with the maximum amount of 0.326% occurring at five minutes, corresponding to a yield of 62.9% assuming all three acetyl groups of triacetin were available for perhydrolysis.

[00139] This exercise was repeated for mole ratios of NaOH:triacetin ranging from 3:1 to 8:1. Table X summarizes the next set of data and shows the maximum percent of PAA generated, the time after the addition of NaOH that it took to reach the maximum percent of PAA generated, the pH after the addition of the NaOH, the percent of hydrogen peroxide remaining at the time of the maximum percent of PAA, and the calculated percent of triacetin converted to PAA assuming that all three acetyl groups were available for perhydrolysis.

[00140] Table X

Mole ratio NaOH:TA	Time at Max. PAA (min)	Max % PAA Generated	% Hydrogen Peroxide Remaining	% Triacetin Converted to PAA (3 acetyls)	pH
3:1	3	0.229	0.291	43.8	11.2
4:1	6	0.285	0.251	54.8	11.3
6:1	5	0.326	0.258	62.9	11.6
8:1	3	0.335	0.271	64.7	12.2

[00141] It can be seen that the amount of PAA generated, and hence the conversion of triacetin into PAA, increased with the increasing mole ratio of NaOH:TA. For all four mole ratios employed, the maximum amount of PAA was generated between three and six minutes. The optimum mole ratio of NaOH:TA was 6:1 as it resulted in an efficient utilization of triacetin converted into PAA, and because the pH of the resulting reaction medium would have less impact on the pH of the receiving water than the higher pH of the reaction medium resulting from the 8:1 mole ratio.

[00142] Example 10

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 279

[00143] A series of experiments was then performed in which the mole ratio of NaOH:TA was fixed at 8:1 and the mole ratio of hydrogen peroxide:triacetin was varied from 2:1 to 8:1. Triacetin (5 g) was added to about 965 mL of softened water along with 50.7% hydrogen peroxide in successive tests (3.06 g for the 2:1 mole ratio; 6.19 g for the 4:1 mole ratio; 9.23 g for the 6:1 mole ratio; and 12.32 g for the 8:1 mole ratio) to yield a solution with a pH of about 4.8-5.5. The volume of the mixture was adjusted to 990 mL with softened water. With mixing, 50% NaOH (14.67 g) was introduced. Using the ceric sulfate–iodometric titration method, the percent of PAA generated and the percent of hydrogen peroxide remaining were measured over the next 20 minutes. The method was performed in duplicate for each sample point. The averages of the results for the kinetic run employing the mole ratio of 8:6:1 NaOH:hydrogen peroxide:TA are shown in Table XI.

[00144] Table XI

Time (min)	% PAA Generated	% Hydrogen Peroxide Remaining	% Triacetin Converted to PAA (3 acetyls)
1	0.331	0.317	63.8
3	0.330	0.303	63.6
5	0.319	0.303	61.5
10	0.300	0.295	57.8
20	0.256	0.274	49.3

[00145] Upon addition of the NaOH, PAA was immediately generated, with the maximum amount of 0.331% occurring after just one minute, corresponding to a calculated conversion of triacetin into PAA of 63.8%, assuming that all three acetyl groups of triacetin were available for perhydrolysis.

[00146] This exercise was repeated for mole ratios of hydrogen peroxide:triacetin ranging from 2:1 to 6:1. Table XII summarizes the data and shows the maximum percent of PAA generated, the time after the addition of NaOH that it took to reach the maximum percent of PAA

generated, the pH after the addition of the NaOH, the percent of hydrogen peroxide remaining at the time of the maximum percent of PAA, and the calculated percent of triacetin converted to PAA assuming that all three acetyl groups were available for perhydrolysis.

[00147] Table XII

Mole Ratio Hydrogen Peroxide:Triacetin	Time at Max. PAA (min)	Max % PAA Generated	% Hydrogen Peroxide Remaining	% Triacetin Converted to PAA (3 acetyls)	pH
2:1	3	0.214	0.079	40.9	12.6
4:1	1	0.272	0.195	51.9	12.4
6:1	1	0.331	0.317	63.8	12.3
8:1	3	0.374	0.445	72.0	11.9

[00148] It can be seen that the amount of PAA generated, and hence the conversion of triacetin into PAA, increased with the increasing mole ratio of hydrogen peroxide:triacetin. For all four mole ratios employed, the maximum amount of PAA was generated between one and three minutes. The optimum mole ratio of hydrogen peroxide:triacetin was 8:1 as it resulted in the most efficient utilization of triacetin converted into PAA.

[00149] Example 11

[00150] A further series of experiments was performed in which the mole ratio of hydrogen peroxide to triacetin was fixed at 4:1 and the molar ratio of NaOH to triacetin was varied from 3:1 to 8:1. Triacetin (5 g) was added to around 975 mL of softened water along with 50.7% hydrogen peroxide (6.18 g) to yield a solution with a pH of 4.8 to 5.3. With mixing, 50% NaOH was introduced in successive tests (5.51 g for the 3:1 mole ratio; 7.30 g for the 4:1 mole ratio; 11.03 g for the 6:1 mole ratio; and 14.67 g for the 8:1 mole ratio). The volume of the mixture was adjusted to 1000 mL with softened water. Using the ceric sulfate–iodometric titration method, the percent of PAA generated and the percent of hydrogen peroxide remaining were measured over the next 20 minutes. The method was performed in duplicate for each

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 281

sample point. The averages of the results for the kinetic run employing the mole ratio of NaOH:hydrogen peroxide:triacetin of 4:4:1 are shown in Table XIII.

[00151] Table XIII

Time (min)	% PAA Generated	% Hydrogen Peroxide Remaining	% Triacetin Converted to PAA (3 acetyls)
1	0.247	0.207	47.3
3	0.280	0.178	53.6
5	0.292	0.167	55.9
10	0.267	0.142	51.1
20	0.229	0.111	43.8

[00152] Upon addition of the NaOH, PAA was immediately generated, with the maximum amount of 0.292% occurring after five minutes, corresponding, to a calculated conversion of 55.9% triacetin into PAA assuming that all three acetyl groups of triacetin were available for perhydrolysis.

[00153] This exercise was repeated for mole ratios of NaOH:TA ranging from 3:1 to 8:1. Table XIV summarizes the data and records the maximum percent of PAA generated, the time after the addition of NaOH that it took to reach the maximum percent of PAA generated, the pH after the addition of the NaOH, the percent of hydrogen peroxide remaining at the time of the maximum percent of PAA, and the calculated percent of triacetin converted to PAA assuming that all three acetyl groups were available for perhydrolysis.

[00154] Table XIV

Mole Ratio NaOH:TA	Time at Max. PAA (min)	Max % PAA Generated	% Hydrogen Peroxide Remaining	% Triacetin Converted to PAA (3 acetyls)	pH
3:1	3	0.246	0.202	47.2	11.3
4:1	5	0.292	0.167	55.9	11.6
6:1	3	0.290	0.181	55.6	12.2
8:1	3	0.272	0.195	51.9	12.4

[00155] It can be seen that the amount of PAA generated maximized when the mole ratio of NaOH:hydrogen peroxide:triacetin was 4:4:1. The optimum mole ratio of NaOH:hydrogen peroxide:triacetin was 4:4:1 as it resulted in an efficient utilization of triacetin converted into PAA, and because the pH of the resulting reaction medium would have less impact on the pH of the receiving water than the higher pH of the reaction medium resulting from the 4:6:1 mole ratio of NaOH:hydrogen peroxide:triacetin. For all four mole ratios employed, the maximum amount of PAA was generated between three and five minutes.

[00156] Example 12

[00157] In the first test, a mixture of triacetin and hydrogen peroxide was prepared by blending 50% hydrogen peroxide (54.24%) and triacetin (45.76%). Thus, the mole ratio of hydrogen peroxide:triacetin was 3.65:1. The mixture (51.22 g) was dissolved in soft water (911.9 g) in a one-liter beaker to yield a solution with a pH of 6.47. Then, 50% NaOH (36.47 g) was introduced with stirring. Thus, the mole ratio of the combined mixture of NaOH:hydrogen peroxide:triacetin was 4.2:3.8:1. The pH of the resulting solution initially measured 12.1. Using the ceric sulfate–iodometric titration method, the PAA generated and the hydrogen peroxide remaining were measured over the next 10 minutes. It was noticed that the sample temperature rose immediately upon addition of the 50% NaOH.

[00158] In the second test, the first test was repeated, except that the water was chilled soft water.

[00159] In the third test, the first test was repeated using three times the original amount of hydrogen peroxide:triacetin mixture and three times the original amount of 50% NaOH. The mole ratio of the combined mixture of NaOH:hydrogen peroxide:triacetin remained the same as before, at 4.2:3.8:1. The hydrogen peroxide and triacetin mixture (153.96 g) was introduced to chilled soft water (735.6 g) in a one-liter beaker to yield a solution with an initial pH of 5.14.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 283

Then, 50% NaOH (111.21 g) was introduced. Using the ceric sulfate–iodometric titration method, the PAA generated and the hydrogen peroxide remaining were measured over the next 10 minutes.

[00160] In the fourth test, the first test was repeated using four times the original amount of hydrogen peroxide:triacetin mixture and four times the original amount of 50% NaOH. The mole ratio of the combined mixture of NaOH:hydrogen peroxide:triacetin remained the same as before, at 4.2:3.8:1. The hydrogen peroxide and triacetin mixture (204.7 g) was introduced to chilled soft water (647.5 g) in a one-liter beaker to yield a solution with an initial pH of 6.32. Then, 50% NaOH (155.4 g) was introduced. Using the ceric sulfate–iodometric titration method, the PAA generated and the hydrogen peroxide remaining were measured over the next 10 minutes.

[00161] Table XV summarizes the results obtained for the four tests and shows the initial and final solution temperatures, the pH of the solution after the addition of the 50% NaOH, the maximum percent of PAA generated, the time of maximum PAA generation, and the percent of hydrogen peroxide remaining.

[00162] Table XV

Test #	Initial Temp. (°F)	Final Temp. (°F)	Final pH	Max. % PAA Generated (time, min)	% Hydrogen Peroxide Remaining
1	NM	NM	12.14	1.71 (1)	0.58
2	38	50	12.67	2.1 (4)	0.43
3	44	88	12.77	6.3 (1)	1.18
4	34	92	13.17	7.2 (1)	1.88

NM = not measured

[00163] Table XVI shows the percent of hydrogen peroxide converted overall, the percent of hydrogen peroxide converted to PAA, and the percent of triacetin converted to PAA

(assuming that all three acetyl groups on triacetin are available for conversion to PAA) for each of the tests in Table XV.

[00164] Table XVI

Test #	% Hydrogen Peroxide Converted Overall	% Hydrogen Peroxide Converted to PAA (at maximum conversion time)	% Triacetin Converted to PAA (3 acetyls)
1	67.8	88.1	69.7
2	68.8	94.4	85.8
3	71.6	94.3	85.7
4	66.1	88.1	73.8

[00165] The data in Tables XV and XVI indicate that far higher amounts of PAA are possible if the 50% sodium hydroxide solution is the last component of the mixture to be introduced. Further, up to 7.1% PAA was generated, although this solution got hot despite chilling the source water. Generation of the 6.3% PAA solution was very efficient because it represented a high 85.7% utilization of triacetin converted into PAA. There was clearly a linear relationship between Test 2, which generated 2.1% PAA, and Test 3, which utilized three times more of the reactants and generated 6.3% PAA. The data in Table XV indicate that the time of maximum conversion of triacetin was between one and four minutes. Thereafter, the amount of PAA in solution is reduced because it undergoes high pH degradation slowly over the following 10 minutes.

[00166] Example 13

[00167] Fig. 1 is a schematic representation of an example of a system 10 that was used to perform an embodiment of one of the methods described above to prepare a non-equilibrium solution of PAA on a site having a point-of-use. Triacetin was used as the acetyl precursor and 50% sodium hydroxide was used as the aqueous source of an alkali metal hydroxide.

[00168] A container 120 of a hydrogen peroxide-acetyl precursor solution, which was a hydrogen peroxide-triacetin solution, and a container 140 of 50% sodium hydroxide were each equipped with chemical delivery diaphragm pumps 115 and 135, respectively. Inlet water 90, which was softened, was provided from a water source on the site having the point-of-use. Inlet water 90 was directed through a pressure regulator 100 and flow meter 105, then into a section of pipe where the hydrogen peroxide-triacetin solution was introduced through injection quill 110. Mixing was accomplished using static mixer 125. Then, the sodium hydroxide solution was added through injection quill 130 to form a reaction medium.

[00169] The hydrogen peroxide-triacetin solution and the sodium hydroxide solution may be added in a sequential manner as described, where the hydrogen peroxide-triacetin solution was added first, or they may be added to the water simultaneously through a "T" fitting placed before static mixer 125. If a T fitting is used, the hydrogen peroxide- triacetin solution and the 50% sodium hydroxide solution are introduced to opposite ends of the T fitting and the mixture is injected into the pipe of water. In other embodiments, the hydrogen peroxide and triacetin may be added separately, or sequentially, with either one first, or simultaneously, with the sodium hydroxide added either simultaneously with, or after, the hydrogen peroxide and triacetin.

[00170] The reaction medium was introduced to a residence chamber 145 which provided reaction time and contained a packing material to promote mixing. Residence chamber 145 was designed to be of a volume such that at a total flow rate of one gallon per minute, by the time the reaction medium reached sampling port 160, 30 seconds had elapsed since the sodium hydroxide solution had been added. A pH probe 155 monitored the pH of the mixture.

[00171] A controller 150 was interfaced to the flow meter 105 of the inlet water 90, and also to the chemical delivery diaphragm pumps 115 and 135. The controller 150 monitored the

rate of the inlet water 90 and governed the rate at which the hydrogen peroxide-triacetin solution and the NaOH solution were introduced. If the flow of inlet water 90 decreased because of lower PAA requirements at the point-of-use 195, the rates at which the hydrogen peroxide-triacetin solution and the NaOH solution were pumped decreased accordingly. If the flow of inlet water 90 increased because of higher PAA requirements at the point-of-use 195, the rates at which the hydrogen peroxide-triacetin solution and the NaOH solution were pumped increased accordingly. If the flow of inlet water 90 stopped, pumps 115 and 135 stopped. Thus, the generation of PAA was both continuous and intermittent, and was tailored to the PAA requirements at the point-of-use.

[00172] The rate of the reaction between the hydrogen peroxide and the triacetin to form PAA is dependent upon the temperature of inlet water 90. If the temperature of inlet water 90 is high (for example, about 70°F), the maximum conversion of triacetin into PAA may occur after 30 seconds, in which case the entire reaction medium was directed to the point-of-use 195. However, if the temperature of inlet water 90 is low (for example, about 32°F), longer reaction times may be necessary to maximize the conversion of triacetin into PAA. Then, the reaction medium was directed through one or more residence chambers 165, 175, and 185 which also contained a packing material to promote turbulence and cause thorough mixing. Residence chambers 165, 175, and 185 were designed to be of volumes such that at a total flow rate of one gallon per minute, the reaction medium reached sampling port 170 in one minute, sampling port 180 in two minutes, and sampling port 190 in five minutes, to permit sampling at different time intervals.

[00173] Thus, depending on the temperature of the inlet water, the time to achieve the maximum conversion of hydrogen peroxide and triacetin into PAA was determined by sampling and analyzing the solution at sample ports 160, 170, 180, and 190. The entire flow was then

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 287

directed from the sampling port with the highest amount of PAA to the point-of-use 195. In practice, the PAA generated from the reaction of hydrogen peroxide with triacetin is typically diluted at the point-of-use 195.

[00174] Point-of-use 195 may be recirculating cooling water; municipal wastewater; poultry chill tank water; water used to sanitize meat, poultry, or seafood products; fruit and vegetable rinse water; or water used to clean and sanitize equipment used in the dairy, food, or beverage processing industries.

[00175] Example 14

[00176] Referring again to Fig. 1, a 55-gallon drum container 120 of a hydrogen peroxide-triacetin solution was prepared by mixing triacetin (251.5 lbs) with 50% hydrogen peroxide (298.4 lbs). The resulting 550 lbs of hydrogen peroxide-triacetin solution had a specific gravity of 1.19 g/mL (10 lbs/gal) and contained 54.3% hydrogen peroxide and 45.7% triacetin. Thus, the mole ratio of hydrogen peroxide:triacetin was 3.8:1. The apparatus depicted in Fig. 1 was used to continuously and intermittently prepare an approximately 1% PAA solution.

[00177] Softened local city water was directed through pressure regulator 100 at a flow rate of one gallon per minute as measured by flow meter 105. The container 120 of hydrogen peroxide-triacetin solution was equipped with a draw down tube so that the flow rate of the mixture could be measured. Diaphragm pump 115 injected the hydrogen peroxide-triacetin solution through injection quill 110. The hydrogen peroxide-triacetin solution was then mixed with the softened water using static mixer 125. A container 140 of 50% NaOH was also equipped with a draw down tube to measure the flow pumped by diaphragm pump 135 into injection quill 130.

[00178] The percent of PAA generated was measured by quenching samples drawn through the sampling ports in mineral acid, followed by use of the ceric sulfate–iodometric

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 288

titration method. Table XVII summarizes the results of several trials where it was sought to maximize the conversion of triacetin into PAA and minimize the amount of 50% NaOH used.

[00179] Table XVII

Trial #	Sample Port	% PAA Generated	% Triacetin Converted to PAA	Hydrogen Peroxide-Triacetin Mix Flow Rate (mL/min)	NaOH Flow Rate (mL/min)	pH (PAA solution)
1	160	1.083	65.42	115.73	112.11	~13
2	170	1.073	64.82	115.73	112.11	13.19
3	160	0.955	57.32	116.79	122.12	13.37
4	160	1.058	63.39	116.79	114.93	13.11
5	160	1.061	63.3	116.79	98.1	12.9
6	160	1.102	68.96	110.82	85.01	12.91
7	170	1.055	55.59	132.64	99.77	12.95
8	160	0.978	59.91	115.5	74	12.62
9	180	0.936	56.7	114.25	78	12.64

[00180] It can be seen that the amount of PAA generated, and hence the conversion of triacetin into PAA, increased with the increasing flow rate of NaOH. For this mole ratio of hydrogen peroxide:triacetin of 3.8:1, the maximum amount of PAA was generated between 30 seconds (sample port 160) and two minutes (sample port 180) from the time the NaOH was added at injection quill 130. The flow rate of 74-78 mL/min of 50% NaOH was the optimum flow rate as it resulted in an efficient utilization of triacetin converted into PAA, consumed only a moderate amount of 50% NaOH, and had a lower pH that would have less impact on the pH of the receiving water.

[00181] Example 15

[00182] *E. coli* O157:H7 bacteria (ATCC 35150) was cultured in nutrient broth (Sigma, St. Louis, MO) by incubation for two days at 35°C. The bacteria were separated from the nutrient broth by centrifugation and carefully resuspended in two liters of sterile phosphate buffer, which was then split into two one-liter test solutions.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 289

[00183] *Salmonella* typhimurium bacteria (ATCC 14028) was cultured in nutrient broth (Sigma, St. Louis, MO) by incubation for two days at 35°C. The bacteria were separated from the nutrient broth by centrifugation and carefully resuspended in two liters of sterile phosphate buffer, which was then split into two one-liter test solutions.

[00184] The amount of *E. coli* O157:H7 and *Salmonella typhimurium* bacteria were measured by serial dilution and plating on 3M *E. coli* plates and 3M *Enterobacteriaceae* Petrifilms, respectively.

[00185] A 1000 ppm stock of PAA was made by weighing 0.6386 g of Perasan MP-2 (5.83% hydrogen peroxide and 15.66% PAA) and adding water up to 100 g. Perasan MP-2 is an equilibrium product of PAA (Enviro Tech Chemical Services, Inc., Modesto, California). Side-by-side, one of the *E. coli* and one of the *Salmonella* test solutions were treated with a nominal dose of 1.0 ppm PAA by adding one mL of the 1000 ppm PAA stock solution to each sample. After one minute, approximately 100 mL of each test solution was removed, and sodium thiosulfate (0.5 g) was added to neutralize the PAA and hydrogen peroxide oxidants. After five minutes, sodium thiosulfate (0.5 g) was added to the remaining test solution to neutralize the PAA and hydrogen peroxide in the rest of the test solutions. The amount of viable *E. coli* O157:H7 and *Salmonella typhimurium* bacteria remaining in the test solutions at the one-minute and five-minute contact times were measured by serial dilution and plating on 3M *E. coli* Petrifilms and 3M *Enterobacteriaceae* Petrifilms, respectively.

[00186] A 1% solution of PAA was prepared by combining 30.90 g of a mixture of 50% hydrogen peroxide and triacetin (54.22% hydrogen peroxide and 45.78% triacetin) with 929.4 g of water, and then adding 50% NaOH (40.53 g). The PAA solution had a pH of 12.79. The mole ratio of this mixture was 3.8:7.8:1 NaOH:hydrogen peroxide:triacetin. One minute after preparation, the second one-liter *E. coli* solution and the second one-liter *Salmonella* solution

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 290

were treated with a nominal dose of 1.0 ppm PAA by adding 0.10 g of the 1% PAA solution to each sample. The test solution contact times, neutralization, and plating procedures were replicated for those that employed PAA from Perasan MP-2.

[00187] All 3M *E. coli* Pertrifilms and 3M *Enterobacteriaceae* Petrifilms were incubated at 35°C for 24 hours. After incubation, the plates were enumerated.

[00188] Table XVIII shows the microbiological results of the *E. coli* O157:H7 test solutions before treatment with PAA, one minute after the samples were dosed with a nominal 1.0 ppm PAA, and five minutes after being dosed with PAA. The *E. coli* test solution started with $\log_{10}$ 6.99 CFU/mL prior to being treated with 1.0 ppm of PAA from Perasan MP-2 or with 1 ppm of PAA from the 1% PAA solution.

[00189] The *E. coli* test solution treated with 1.0 ppm PAA from Perasan MP-2 contained a $\log_{10}$ 6.74 CFU/mL after one minute. This corresponds to 43.48% reduction. After five minutes, $\log_{10}$ 6.34 CFU/mL remained (77.50% reduction). The *E. coli* solution treated with a nominal 1.0 ppm PAA from the 1% PAA solution contained a $\log_{10}$ 6.78 CFU/mL after one minute and 6.63 CFU/mL after five minutes, respectively, corresponding to 38.02% and 56.12% reductions, respectively.

[00190] Table XVIII

***E. coli* O157:H7**

Description	$\log_{10}$ CFU/ml remaining	$\log_{10}$ reduction	% reduction
Control	6.99	N/A	N/A
Perasan MP-2 (1 min)	6.74	0.25	43.48
Perasan MP-2 (5 min)	6.34	0.65	77.50
1% PAA solution (1 min)	6.78	0.21	38.02
1% PAA solution (5 min)	6.63	0.36	56.12

[00191] Table XIX shows the microbiological results of the *Salmonella typhimurium* test solutions before treatment with PAA, one minute after the samples were dosed with a nominal 1.0 ppm PAA, and five minutes after being dosed with PAA. The *Salmonella* test solution started with $\log_{10}$ 7.07 CFU/mL prior to being treated with PAA from Perasan MP-2 or with the 1% PAA solution.

[00192] The *Salmonella* solution treated with a nominal 1.0 ppm PAA from Perasan MP-2 contained a $\log_{10}$ 1.76 CFU/mL after one minute and 0.70 CFU/mL after five minutes, corresponding to >99.999% reduction at both contact times. The *Salmonella* test solution treated with 1.0 ppm PAA from the 1% PAA solution contained a $\log_{10}$ 6.69 CFU/mL after one minute. This corresponds to 58.31% reduction. After five minutes, $\log_{10}$ 4.95 CFU/mL remained (99.24% reduction).

[00193] Table XIX

Salmonella typhimurium

Description	$\log_{10}$ CFU/ml remaining	$\log_{10}$ reduction	% reduction
Control	7.07	N/A	N/A
Perasan MP-2 (1 min)	1.76	5.31	99.9995
Perasan MP-2 (5 min)	0.70	6.37	>99.9999
1% PAA solution (1 min)	6.69	0.38	58.31
1% PAA solution (5 min)	4.95	2.12	99.24

[00194] The data in tables XVIII and XIX demonstrate that the 1% PAA had antimicrobial efficacy. After five minutes, the efficacy of this PAA was 99.24%, about equal to that of the Perasan MP-2, which was > 99.9999%. The difference in efficacy at one minute was likely not of statistical significance, given that the comparison was only at the one-minute interval.

[00195] **5. Solid Compositions for Bleaching and Stain Removal**

[00196] A freely-flowable, solid peroxygen bleaching and stain removal composition comprises a liquid acetyl precursor, a water-soluble solid source of hydrogen peroxide, and a water-soluble solid source of alkalinity. A preferable liquid acetyl precursor is triacetin. The water soluble solid source of hydrogen peroxide is preferably sodium percarbonate, although sodium perborate monohydrate or sodium perborate tetrahydrate may be used. The water-soluble solid source of alkalinity acts as a pH control agent, and may be an alkali metal or earth alkali metal bicarbonate, carbonate, sesquicarbonate, borate, silicate, or hydroxide. Examples include sodium bicarbonate, sodium carbonate, sodium sesquicarbonate, sodium borate, sodium borate decahydrate (borax), sodium metasilicate, and sodium hydroxide.

[00197] In an embodiment, the composition comprises about 0.99% to about 8.45% triacetin, about 13% to about 54% sodium percarbonate, and about 24% to about 44% solid source of alkalinity.

[00198] The composition may optionally contain other components to improve performance. These components may prevent soil redeposition, sequester water hardness, increase dispercency, and lower surface tension.

[00199] Metal ions present in the bleaching medium can have a tendency to deposit on the substrates being bleached. Therefore, the solid bleaching composition may optionally contain a metal chelating agent such as a polyacrylate, a phosphonate, a maleic acid, a salt of ethylenediaminetetraacetic acid, a salt of nitrilotriacetic acid, or a salt of gluconic acid.

[00200] Surfactants reduce the surface tension of the bleaching medium and enhance the process of cleaning the soiled article. Surfactants also disperse the soil particles removed from the article and keep them suspended. Therefore, the solid bleaching composition may optionally contain a surfactant, such as an anionic, cationic, amphoteric, or non-ionic surfactant.

[00201] The solid bleaching composition may also optionally contain a solid zeolite, such as sodium zeolite, which acts to capture calcium and magnesium ions that may be present in the bleaching medium that would otherwise interact with an anionic surfactant, causing the surfactant to precipitate and removing it from the bleaching medium.

[00202] The composition may also optionally contain an inert, solid filler, such as anhydrous sodium sulfate, sodium sulfate decahydrate, or sodium chloride. The filler increases the total ionic strength of the aqueous phase, but imparts no chemical properties to the bleaching medium.

[00203] To make the solid peroxygen bleaching and stain removal composition, the water soluble solid source of hydrogen peroxide, the water-soluble solid source of alkalinity, any chelating agent, any sufactant, and any filler are blended with the liquid triacetin to form a solid bleaching composition. The components may be added in any order. Any blending equipment may be used. Suitable examples of equipment include a ribbon and paddle blender, a V and double-cone blender, a Nauta screw mixer, and a rotating cement mixer. Alternatively, the ingredients may be blended by milling using a pulveriser mill, a ball mill, a hammer mill, a pin mill, an air mill, or a roller mill. Blending is performed for sufficient time to create a homongenous mixture. The mixture is a freely-flowable solid which is readily discharged from the blender.

[00204] Example 16

[00205] A series of tests were performed to determine whether triacetin, a liquid at room temperature, could be blended with a solid source of hydrogen peroxide to form a solid bleaching and stain removal composition that did not clump or turn into a sticky, non-flowable mass. The components listed in Table XX were mixed together to form a solid peroxygen bleach precursor.

[00206] Table XX

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 294

Component	%
Sodium carbonate, anhydrous	26.3
Sodium percarbonate	58.9
Sodium sulfate decahydrate	13.8
Surfactant (60% sodium dodecylbenzene sulfonate)	1.0
Total	100

[00207] This solid peroxygen bleach precursor was then blended with incrementally increasing amounts of liquid triacetin. At each addition, the product was examined for flowability and for the odor of PAA. Table XXI summarizes the findings when up to 9.1g of liquid triacetin was blended into 100 g of the solid peroxygen bleach precursor set forth above.

[00208] Table XXI

Wt. of triacetin added to solid peroxygen bleach precursor (g)	Freely-flowable solid or sticky and clumping	Odor of PAA
1	Freely- flowable solid	None
2	Freely- flowable solid	None
3	Freely- flowable solid	None
4	Freely- flowable solid	None
5	Freely- flowable solid	None
6	Freely- flowable solid	None
7	Freely- flowable solid	None
8	Freely- flowable solid	None
8.45	Freely-flowable solid	None
9	Sticky and clumping	None
9.1	Sticky and clumping	None

[00209] Surprisingly, even though triacetin is a liquid, the solid peroxygen bleach precursor (100 g) could be blended with up to 8.45g of the triacetin to form a freely-flowable solid composition, without becoming a sticky, non-flowable product which would not pour easily or would become a solid mass upon storage inside a container.

[00210] The solid peroxygen bleaching and stain removal composition was calculated to contain the following percentage of components, listed in Table XXII.

[00211] Table XXII

Component	%
Sodium carbonate, anhydrous	24.14
Sodium percarbonate	53.90
Sodium sulfate decahydrate	12.56
Surfactant (90% sodium dodecylbenzene sulfonate)	0.95
Triacetin	8.45
Total	100

[00212] Another unexpected result was that after storing the composition for over one year at ambient temperature, the composition still had not developed an odor of PAA.

[00213] These surprising results are in contrast to the current belief that a liquid acetyl precursor, such as triacetin, could not be utilized with a solid source of hydrogen peroxide in a non-chlorine peroxygen bleaching and stain removal composition, for at least two reasons. First, when a non-chlorine peroxygen bleaching composition is used in residential and commercial laundering applications, the product must be a freely-flowable solid. Typically, the acetyl precursor in a non-chlorinated peroxygen bleach is present in amounts up to 10%. It was believed that blending a liquid at this level with the other dry components of the laundry bleach would create a sticky, clumping mass, rather than a freely-flowable solid, and would therefore not be acceptable to the user. Second, it was assumed that a liquid acetyl precursor would interact with the solid source of hydrogen peroxide and any free water or water of crystallization associated with other components, and thus form PAA in the product during storage, before being introduced to the aqueous bleaching medium. The high volatility and strong odor of the PAA would be unacceptable to the user of such a product.

[00214] Example 17

[00215] Two solid peroxygen bleaching and stain removal compositions were prepared with the components listed in Table XXIII.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 296

[00216] Table XXIII

Components of Composition A	%	Charge Weights, g
Premix 1		
Sodium Percarbonate	13	195
NANSA HS 90	1.5	22.5
Sodium Metasilicate (Anhydrous)	19.5	292.5
Sodium Sulfate (Anhydrous)	41	615
Triacetin	4	60
Premix 2		
Mineral Oil	1	15
Sodium Hydroxide Beads	4	60
Soda Ash	16	240

Components of Composition B	%	Charge Weights, g
Premix 1		
Sodium Percarbonate	13	195
NANSA HS 90	1.5	22.5
Sodium Metasilicate (Anhydrous)	19.5	292.5
Sodium Sulfate (Anhydrous)	43	645
Triacetin	4	60
Premix 2		
Mineral Oil	1	15
Sodium Hydroxide Beads	2	30
Soda Ash	16	240

[00217] In both cases, Premix 1 was prepared by kneading the NANSA HS 90 (a sodium dodecylbenzenesulfonate surfactant) with the sodium sulfate. The sodium sulfate helped break up the sticky surfactant efficiently. Then, the sodium percarbonate, the sodium metasilicate, and the triacetin were added and mixed by hand.

[00218] In both cases, Premix 2 was prepared by mixing the sodium hydroxide beads with the mineral oil to afford a well-coated mixture, with some free-standing mineral oil remaining. Soda ash was blended in portions to take up the excess liquid and to provide a free-flowing solid mixture.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 297

[00219] Premix 2 was blended in portions into Premix 1, and the final solid composition was mixed well by hand.

[00220] Both compositions A and B, which were held in uncovered bowls at ambient temperature after preparation, exhibited slow weight gain over time, most likely due to absorbance of water from the air. Each composition had gained 2.4% of its initial weight over a period of three days.

[00221] Neither composition exhibited significant exothermic behavior. However, composition A was hotter at the end of preparation and cooled more slowly than composition B. The temperature of composition A was 85°F immediately after preparation, rose to 88°F over the next ten minutes, and then fell slowly to 74°F. The temperature of composition B was 80°F immediately after preparation, rose to 81°F over the next twenty minutes, and then fell slowly to 65°F.

[00222] The solid peroxygen bleaching and stain removal composition described above may be used as follows.

[00223] First, the solid peroxygen, composition is introduced to an aqueous medium that is used for bleaching or stain removal of at least one article contained within the aqueous medium. For bleaching of laundry articles, about 5g of bleaching composition is introduced for every liter of water used in the bleaching cycle. For home use, the bleaching composition can be added manually at the start of the wash. For commercial laundry systems, the bleaching composition may be introduced just before the bleaching cycle, toward the end of the wash and following the soil removal cycle. In most commercial and residential laundry machines, bleaching cycles are typically about 10-15 minutes.

[00224] Second, the composition is allowed to dissolve and react to form the bleaching medium containing PAA. The solid source of hydrogen peroxide, such as sodium percarbonate,

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 298

and the solid source of alkalinity, such as sodium hydroxide, dissolve in the laundry water and cause the pH of the water to increase to above about 10.5.

[00225] While not wishing to be bound by theory, it is believed that under elevated pH conditions, hydrogen peroxide dissociates according to the following equation:

$$H_2O_2 = H^+ + HO_2^-$$

[00226] The perhydroxyl anion (HO_2^-) then effects nucleophilic substitution reactions on the carbonyl groups of triacetin, in a perhydrolysis reaction, to form PAA and 1,2,3-propanetriol (glycerine). The laundry water would also contain unreacted hydrogen peroxide, unreacted triacetin, and sodium hydroxide.

[00227] Third, the aqueous solution of PAA and the unreacted hydrogen peroxide are mixed for sufficient time to effect bleaching or stain removal of the articles contained within the aqueous medium. Both commercial and residential bleaching cycles are about 10-15 minutes.

[00228] Fourth, the article is rinsed with fresh water so that it becomes substantially free of PAA and the unreacted hydrogen peroxide, the glycerine, the unreacted triacetin, and the sodium hydroxide. Generally, for a laundered article, the washing machine is programmed to empty the bleaching medium and replace it with fresh water. The machine can agitate the articles with the rinse water to enhance the rinsing process.

[00229] Fifth, the article is allowed to dry. Any suitable means of drying the bleached articles may be employed. This includes the use of centrifugal forces to mechanically dewater the articles prior to introducing the wet articles to another machine before the articles are tumbled in a stream of hot air. Alternatively, the articles may be allowed to air dry without the use of externally-applied heat.

[00230] Example 18

[00231] Laundry swatches were made by cutting a tea towel into 50 equal 5 x 4 inch sheets. They were then separated into seven groups of seven swatches. Six of the groups were stained and the seventh group was left unstained for comparison purposes. Five of the groups that were stained were stained by soaking them in one of the following: black tea, black coffee, red wine, blood (pork), and acetone-extracted chlorophyll. The sixth group of swatches was stained by rubbing them on green grass. After allowing the stained swatches to dry, and before challenging the stains, the swatches were set aside for two months to allow the stains to set in the fabric.

[00232] A solid peroxygen bleaching and stain removal composition (200 g) was prepared by blending sodium percarbonate (104.0 g), triacetin (8.00 g), soda ash (80.01 g), and sodium hydroxide beads (8.00 g). The final product was a freely-flowable solid.

[00233] The composition was tested using 1:100 dilution at both 75°F and 104°F. The initial pH was measured and the concentrations of PAA and hydrogen peroxide were evaluated using the method of U.S. patent no. 7,651,724. At each temperature, the composition (1.0 g) was weighed out into a glass beaker (100 mL). To the beaker, city water (99 mL) was added while mixing on a stir plate. The pH and PAA generation profile was then monitored over the next 10-13 minutes to model the times of a typical low temperature and high temperature bleaching cycle. For city water at 75°F, the initial pH measured 11.2 and the PAA measured highest at 10.5 minutes (123 ppm PAA and 1594 ppm hydrogen peroxide). The test with city water at 104°F had the same initial pH of 11.2, but the PAA measured highest at 5.5 minutes (133 ppm PAA and 1494 ppm H_2O_2). Table XXIV shows the amount of PAA generated and the amount of hydrogen peroxide remaining over time at 75°F at a pH of 11.2. Table XXV shows the amount of PAA generated and the amount of hydrogen peroxide remaining over time at 104°F at a pH of 11.2.

[00234] Table XXIV

Time (min)	ppm PAA	ppm Hydrogen Peroxide
1	61	1717
3	106	1673
5.2	113	1694
7.3	121	1571
10.5	123	1594
13.5	120	1547

[00235] Table XXV

Time (min)	ppm PAA	ppm Hydrogen Peroxide
0.5	72	1569
2.8	125	1426
5.5	133	1494
7.8	122	1427
10.3	119	1405

[00236] The stain removal ability of the composition was determined by comparing treated swatches to control swatches (swatches washed in just city water for the same amount of time and at elevated temperature) and non-stained swatches. The description of the swatches is set forth in Table XXVI. Three stained swatches were used for each test. The composition (10.0 g) was weighed into a beaker (2000 mL). To this beaker a measured amount of hard water (990.0 g) was added at ambient temperature (64°F). The swatches were added to the solution and agitated by mixing with a plastic utensil for 10 minutes to simulate a laundry bleaching cycle. After 10 minutes, the wash water was discarded and a water rinse was performed by adding fresh city water (1000.0 g) to the swatches and agitating for two minutes using the same plastic utensil. The swatches were immediately removed from the beaker after rinsing, wrung out by hand, and laid to dry. These steps were then repeated using water at an elevated temperature (120°F).

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 301

[00237] A control swatch was obtained by taking one swatch at a time from each stain group and washing in city water at an elevated temperature (120°F) for 10 minutes in the same manner as the treated swatches. After the wash, the swatches were immediately removed, wrung out by hand, and laid to dry.

[00238] Table XXVI

Type of Swatches	Description
Treated Swatches	Swatches subjected to bleaching for 10 minutes using bleaching formulation with triacetin and a 2-minute rinse with hard water
Control Swatches	Swatches subjected to only an elevated temperature (120°F) hard water wash for 10 minutes
Non-Stained Swatches	Non-altered swatches

[00239] The bleaching ability of the test swatches was obtained by visual comparison of the treated swatches to the control swatches (treated with water only) and the non-stained swatches. The scale of bleaching ability of the composition was rated on a scale of 0 to 10, with 0 representing no apparent bleaching or stain removal properties of the swatches compared to the control and 10 representing bleaching of swatches to the original color (i.e., identical to the non-stained swatches). Three individuals rated the bleaching ability of the triacetin-containing formulation on the swatches independently. The average ratings from the three individuals are shown in Table XXVII.

[00240] Table XXVII

Type of Stain	Bleaching Formula at 64°F	Bleaching Formula at 120°F
Black Tea	5	8
Black Coffee	2	8
Red Wine	3	7
Blood (pork)	3	3
Extracted chlorophyll	0	0
Grass Stains	0	1

[00241] It can be seen that, in general, the composition displayed enhanced stain removal properties at elevated temperature. Excellent stain removal properties were obtained for black tea and black coffee, and more moderate performance with red wine and blood. The composition had virtually no effect on grass stains or the chlorophyll pigment that was acetone-extracted from green grass.

[00242] The invention has been described above with the reference to the preferred embodiments. Those skilled in the art may envision other embodiments and variations of the invention that fall within the scope of the claims.

Claims

We claim:

1. A hydrogen peroxide-acetyl precursor solution, comprising:

    a. aqueous hydrogen peroxide;

    b. a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide;

    c. a trace amount of peracetic acid; and

    d. water.

2. The solution of claim 1, wherein said liquid acetyl precursor is triacetin.

3. The solution of claim 2, wherein said aqueous hydrogen peroxide is about 23% to about 40% and said triacetin is about 20% to about 53%, and further wherein the mole ratio of said hydrogen peroxide to said triacetin is about 2.98:1 to about 12.84:1.

4. The solution of claim 3, wherein said aqueous hydrogen peroxide is about 27% and said triacetin is about 46%, and further wherein said mole ratio of said hydrogen peroxide to said triacetin is about 3.8:1.

5. A method of preparing a hydrogen peroxide-acetyl precursor solution, comprising:

    a. introducing a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide to a solution of aqueous hydrogen peroxide; and

    b. allowing the liquid acetyl precursor and the solution of aqueous hydrogen peroxide to mix to form a hydrogen peroxide-acetyl precursor solution.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 304

6. The composition of claim 5, wherein the liquid acetyl precursor is triacetin.

7. A method of generating a non-equilibrium solution of peracetic acid, comprising:

a. providing water;

b. introducing a hydrogen peroxide-acetyl precursor solution to the water;

c. mixing the hydrogen peroxide-acetyl precursor solution and the water to form a mixture;

d. adding an aqueous source of an alkali metal or earth alkali metal hydroxide to the mixture; and

e. forming a reaction medium comprising a non-equilibrium solution of peracetic acid.

8. The method of claim 7, further comprising, prior to step (b), a step of providing the hydrogen peroxide-acetyl precursor solution comprising: introducing a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide to a solution of aqueous hydrogen peroxide; and allowing the liquid acetyl precursor and the solution of aqueous hydrogen peroxide to mix to form the hydrogen peroxide-acetyl precursor solution.

9. The method of claim 8, wherein the liquid acetyl precursor is triacetin defining a hydrogen peroxide-triacetin solution.

10. The method of claim 9, wherein the hydrogen peroxide-triacetin solution has a mole ratio of hydrogen peroxide to triacetin of about 2.98:1 to about 12.84:1.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 305

11. The method of claim 7, wherein the provided water is an aqueous stream.

12. The method of claim 7, wherein the provided water is contained in a mixing tank or other vessel.

13. The method of claim 9, wherein the aqueous source of the alkali metal or earth alkali metal hydroxide is sodium hydroxide.

14. The method of claim 13, wherein the sodium hydroxide is about 1.82% to about 7.28%.

15. The method of claim 7, wherein step (d) is performed simultaneously with step (b).

16. The method of claim 7, further comprising allowing the reaction medium sufficient time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid.

17. The method of claim 16, wherein the time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid is about 30 seconds to about five minutes.

18. The method of claim 17, further comprising, after step (e), a step of sampling the reaction medium to determine the time required to maximize the amount of hydrogen peroxide and acetyl precursor that are converted into peracetic acid.

19. The method of claim 16, wherein the acetyl precursor is triacetin and the percent of triacetin that is converted into peracetic acid is about 40.9% to about 85.7%.

20. The method of claim 14, wherein the mole ratio of the sodium hydroxide to the hydrogen peroxide to the triacetin is about 4.2:3.8:1.

21. The method of claim 7, wherein steps (a) through (e) are performed on a continuous basis.

22. The method of claim 7, wherein steps (a) through (e) are performed on an intermittent basis.

23. The method of claim 7, wherein the peracetic acid solution is for immediate use.

24. The method of claim 7, further comprising, after step (e), a step of adding a source of acid to stabilize the non-equilibrium solution of peracetic acid for storing and using throughout a working day.

25. The method of claim 7, wherein the peracetic acid solution is prepared on a site having a point-of-use.

26. A method of generating a non-equilibrium solution of peracetic acid for use on a site having a point-of-use of peracetic acid, comprising:

a. providing water on a site;

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 307

b. providing a hydrogen peroxide-acetyl precursor solution on the site having a point-of-use;

c. introducing the hydrogen peroxide-acetyl precursor solution to the water;

d. mixing the hydrogen peroxide-acetyl precursor solution and the water to form a mixture;

e. providing an aqueous source of an alkali metal or earth alkali metal hydroxide on the site having the point-of-use;

f. adding the aqueous source of the alkali metal or earth alkali metal hydroxide to the mixture; and

g. forming a reaction medium comprising a non-equilibrium solution of peracetic acid for use at the point-of-use of peracetic acid.

27. The method of claim 26, further comprising, prior to step (b), a step of providing the hydrogen peroxide-acetyl precursor solution comprising: introducing a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide to a solution of aqueous hydrogen peroxide; and allowing the liquid acetyl precursor and the solution of aqueous hydrogen peroxide to mix to form the hydrogen peroxide-acetyl precursor solution.

28. The method of claim 8, wherein the liquid acetyl precursor is triacetin defining a hydrogen peroxide-triacetin solution.

29. The method of claim 28, wherein the hydrogen peroxide-triacetin solution has a mole ratio of hydrogen peroxide to triacetin of about 2.98:1 to about 12.84:1.

30. The method of claim 26, wherein the provided water is an aqueous stream.

31. The method of claim 26, wherein the provided water is contained in a mixing tank or other vessel.

32. The method of claim 28, wherein the aqueous source of the alkali metal or earth alkali metal hydroxide is sodium hydroxide.

33. The method of claim 32, wherein the sodium hydroxide is about 1.82% to about 7.28%.

34. The method of claim 26, wherein step (d) is performed simultaneously with step (b).

35. The method of claim 26, further comprising allowing the reaction medium sufficient time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid.

36. The method of claim 35, wherein the time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid is about 30 seconds to about five minutes.

37. The method of claim 36, further comprising, after step (e), a step of sampling the reaction medium to determine the time required to maximize the amount of hydrogen peroxide and acetyl precursor that are converted into peracetic acid.

38. The method of claim 35, wherein the acetyl precursor is triacetin and the percent of triacetin that is converted into peracetic acid is about 40.9% to about 85.7%.

39. The method of claim 33, wherein the mole ratio of the sodium hydroxide to the hydrogen peroxide to the triacetin is about 4.2:3.8:1.

40. The method of claim 26, wherein steps (a) through (e) are performed on a continuous basis.

41. The method of claim 26, wherein steps (a) through (e) are performed on an intermittent basis.

42. The method of claim 26, wherein the peracetic acid solution is for immediate use.

43. The method of claim 26, further comprising, after step (e), a step of adding a source of acid to stabilize the non-equilibrium solution of peracetic acid for storing and using throughout a working day.

44. The method of claim 26, wherein the peracetic acid solution is prepared on a site having a point-of-use.

45. A non-equilibrium solution of peracetic acid made by the method of claim 7 for use as a disinfectant or sanitizer.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 310

46. The solution of claim 45 for clean-in-place pipeline and equipment cleaning.

47. The solution of claim 45 for use in washing fruits and vegetables.

48. The solution of claim 45 for use in the treatment of meat, poultry, and seafood.

49. A method for sanitizing a surface, which comprises generating a non-equilibrium solution of peracetic acid comprising:

peracetic acid, hydrogen peroxide, triacetin, 1,2,3-propanetriol, a source of an alkali metal or earth alkali metal hydroxide, and water.

50. A non-equilibrium solution of peracetic acid, comprising:

a. peracetic acid;

b. hydrogen peroxide;

c. triacetin;

d. 1,2,3-propanetriol;

e. an aqueous source of an alkali metal or earth alkali metal hydroxide; and

f. water.

51. The solution of claim 50, wherein said solution has a pH of about 11.2 to about 13.37.

52. The solution of claim 50, wherein said peracetic acid is about 1% to about 7.1%.

53. A method of generating a non-equilibrium solution of peracetic acid, comprising:

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 311

a. providing water;

b. introducing a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide and aqueous hydrogen peroxide to the water;

c. mixing the liquid acetyl precursor and the aqueous hydrogen peroxide with the water to form a mixture;

d. adding an aqueous source of an alkali metal or earth alkali metal hydroxide to the mixture; and

e. forming a reaction medium comprising a non-equilibrium solution of peracetic acid.

54. The method of claim 53, wherein the liquid acetyl precursor is triacetin defining a hydrogen peroxide-triacetin solution.

55. The method of claim 53, wherein the liquid acetyl precursor and the aqueous hydrogen peroxide are introduced simultaneously.

56. The method of claim 53, wherein the liquid acetyl precursor and the aqueous hydrogen peroxide are introduced sequentially with either one first.

57. The method of claim 53, wherein the provided water is an aqueous stream.

58. The method of claim 53, wherein the provided water is contained in a mixing tank or other vessel.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 312

59. The method of claim 54, wherein the aqueous source of the alkali metal or earth alkali metal hydroxide is sodium hydroxide.

60. The method of claim 59, wherein the sodium hydroxide is about 1.82% to about 7.28%.

61. The method of claim 53, wherein step (d) is performed simultaneously with step (b).

62. The method of claim 53, further comprising allowing the reaction medium sufficient time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid.

63. The method of claim 62, wherein the time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid is about 30 seconds to about five minutes.

64. The method of claim 63, wherein the acetyl precursor is triacetin and the percent of triacetin that is converted into peracetic acid is about 40.9% to about 85.7%.

65. The method of claim 60, wherein the mole ratio of the sodium hydroxide to the hydrogen peroxide to the triacetin is about 4.2:3.8:1.

66. The method of claim 53, wherein said steps (a) through (e) are performed on a continuous basis.

67. The method of claim 53, wherein said steps (a) through (e) are performed on an intermittent basis.

68. A method of generating a non-equilibrium solution of peracetic acid on a site having a point-of-use, comprising:

a. providing water on a site;

b. providing a liquid acetyl precursor that is soluble in aqueous hydrogen peroxide and aqueous hydrogen peroxide on the site having a point-of-use;

c. introducing the liquid acetyl precursor and the aqueous hydrogen peroxide to the water;

d. mixing the aqueous hydrogen peroxide and the liquid acetyl precursor with the water to form a mixture;

e. providing an aqueous source of an alkali metal or earth alkali metal hydroxide water on the site having the point-of-use;

f. adding the aqueous source of the alkali metal or earth alkali metal hydroxide to the mixture; and

g. forming a reaction medium comprising a non-equilibrium solution of peracetic acid for use at the point-of-use.

69. The method of claim 68, wherein the liquid acetyl precursor is triacetin.

70. The method of claim 68, wherein the aqueous source of the alkali metal or earth alkali metal hydroxide is sodium hydroxide.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 314

71. The method of claim 70, wherein the sodium hydroxide is about 1.82% to about 7.28%.

72. The method of claim 68, further comprising allowing the reaction medium sufficient time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid.

73. The method of claim 72, wherein the time to maximize the conversion of the hydrogen peroxide and the acetyl precursor into peracetic acid is about 30 seconds to about five minutes.

74. The method of claim 68, further comprising, after step (g), a step of sampling the reaction medium to determine the time required to maximize the amount of hydrogen peroxide and acetyl precursor that are converted into peracetic acid.

75. The method of claim 72, wherein the acetyl precursor is triacetin and the percent of triacetin that is converted into peracetic acid is about 40.9% to about 85.7%.

76. The method of claim 71, wherein the mole ratio of the sodium hydroxide to the hydrogen peroxide to the triacetin is about 4.2:3.8:1.

77. An on site non-equilibrium peracetic acid generation system, comprising:

a first container comprising a first solution wherein said first solution comprises:

aqueous hydrogen peroxide;

a liquid acetyl precursor that is soluble in said aqueous hydrogen peroxide;

a trace amount of peracetic acid; and

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 315

water;

a second container comprising a second solution wherein said second solution comprises:

an aqueous source of an alkali metal or earth alkali metal hydroxide; and

means for mixing the first solution, water, and the second solution to generate a non-equilibrium peracetic acid solution.

78. A freely-flowable solid composition, comprising:

a. a liquid acetyl precursor;

b. a water-soluble solid source of hydrogen peroxide; and

c. a water-soluble solid source of alkalinity.

79. The composition of claim 78, wherein said liquid acetyl precursor is triacetin.

80. The composition of claim 79, wherein said triacetin is about 0.99% to about 8.45%.

81. The composition of claim 78, wherein said solid source of hydrogen peroxide is sodium percarbonate and is about 13% to about 54% of the total.

82. The composition of claim 78, wherein said solid source of alkalinity is about 24% to about 44% of the total.

83. A method of making a solid composition for bleaching and stain removal, comprising:

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 316

forming a homogenous freely-flowable solid by blending a liquid acetyl precursor, a water-soluble solid source of hydrogen peroxide, and a water-soluble solid source of alkalinity.

84. The method of claim 83, wherein the liquid acetyl precursor is triacetin.

85. The method of claim 84, wherein the triacetin is about 0.99% to about 8.45%.

86. The method of claim 83, wherein the solid source of hydrogen peroxide is about 13% to about 54%.

87. The composition of claim 83, wherein the solid source of alkalinity is about 24% to about 44% of the total.

88. The method of claim 83, further comprising adding a metal chelating agent.

89. The method of claim 83, further comprising adding a surfactant.

90. The method of claim 83, further comprising adding a compound to sequester water hardness.

91. The method of claim 83, further comprising adding an inert solid filler.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 317

Abstract

Methods and compositions for the generation of a peroxyacetic acid sanitizer in proximity to the point-of-use are disclosed. These methods comprise introducing a hydrogen peroxide-acetyl precursor solution to water, mixing, and then adding an aqueous source of a alkali metal or earth alkali metal hydroxide. Triacetin is a preferred acetyl precursor and is converted rapidly and with a high conversion rate into peracetic acid. These methods produce solutions with a high level of peracetic acid. Methods for preparing the hydrogen peroxide-acetyl precursor solution are also provided. Also disclosed are solid compositions comprising a liquid acetyl precursor, a water-soluble source of hydrogen peroxide, and a water-soluble source of alkalinity. The solid composition is a freely-flowable solid that is used as a bleaching agent and a stain remover for the treatment of articles such as fabrics, dentures, textile garments, and equipment used in the food and beverage industry.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 318

1/1



195
190
155
pH
160
145
140
135
130
165
170
125
120
115
110
185
150
105
100
175
180
90
10

FIG. 1

Exp. Mail EV 419585747 US

Practitioner's Docket No. 8568/17669 **PATENT**

COMBINED DECLARATION AND POWER OF ATTORNEY

(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL, CONTINUATION, OR C-I-P)

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is of the following type:

(check one applicable item below)

☒ original.

☐ design.

NOTE: With the exception of a supplemental oath or declaration submitted in a reissue, a supplemental oath or declaration is not treated as an amendment under 37 CFR 1.312 (Amendments after allowance). M.P.E.P. § 714.16, 7th Edition.

☐ supplemental.

NOTE: If the declaration is for an International Application being filed as a divisional, continuation or continuation-in-part application, do not check next item; check appropriate one of last three items.

☐ national stage of PCT.

NOTE: If one of the following 3 items apply, then complete and also attach ADDED PAGES FOR DIVISIONAL, CONTINUATION OR C-I-P.

NOTE: See 37 C.F.R. § 1.63(d) (continued prosecution application) for use of a prior nonprovisional application declaration in the continuation or divisional application being filed on behalf of the same or fewer of the inventors named in the prior application.

☐ divisional.

☐ continuation.

NOTE: Where an application discloses and claims subject matter not disclosed in the prior application, or a continuation or divisional application names an inventor not named in the prior application, a continuation-in-part application must be filed under 37 C.F.R. § 1.53(b) (application filing requirements — nonprovisional application).

☐ continuation-in-part (C-I-P).

INVENTORSHIP IDENTIFICATION

WARNING: If the inventors are each not the inventors of all the claims, an explanation of the facts, including the ownership of all the claims at the time the last claimed invention was made, should be submitted.

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor *(if only one name is listed below)* or an original, first and joint inventor *(if plural names are listed below)* of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

Methods and Compositions for the Generation of Peracetic Acid On Site at the Point-of-Use

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 320

SPECIFICATION IDENTIFICATION

the specification of which:

(complete (a), (b), or (c))

(a) ☒ is attached hereto.

NOTE: "The following combinations of information supplied in an oath or declaration filed on the application filing date with a specification are acceptable as minimums for identifying a specification and compliance with any one of the items below will be accepted as complying with the identification requirement of 37 CFR 1.63:

"(1) name of inventor(s), and reference to an attached specification which is both attached to the oath or declaration at the time of execution and submitted with the oath or declaration on filing;

"(2) name of inventor(s), and attorney docket number which was on the specification as filed; or

"(3) name of inventor(s), and title which was on the specification as filed."

Notice of July 13, 1995 (1177 O.G. 60).

(b) ☐ was filed on _____, as ☐ Serial No. 0 /_____

and was amended on _____ *(if applicable).*

NOTE: Amendments filed after the original papers are deposited with the PTO that contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 C.F.R. § 1.67.

NOTE: "The following combinations of information supplied in an oath or declaration filed after the filing date are acceptable as minimums for identifying a specification and compliance with any one of the items below will be accepted as complying with the identification requirement of 37 CFR 1.63:

"(A) application number (consisting of the series code and the serial number, e.g., 08/123,456);

"(B) serial number and filing date;

"(C) attorney docket number which was on the specification as filed;

"(D) title which was on the specification as filed and reference to an attached specification which is both attached to the oath or declaration at the time of execution and submitted with the oath or declaration; or

"(E) title which was on the specification as filed and accompanied by a cover letter accurately identifying the application for which it was intended by either the application number (consisting of the series code and the serial number, e.g., 08/123,456), or serial number and filing date. Absent any statement(s) to the contrary, it will be presumed that the application filed in the PTO is the application which the inventor(s) executed by signing the oath or declaration."

M.P.E.P. § 601.01(a), 7th Ed.

(c) ☐ was described and claimed in PCT International Application No. _____, filed on _____ and as amended under PCT Article 19 on _____ *(if any).*

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 321

SUPPLEMENTAL DECLARATION (37 C.F.R. § 1.67(b))

(complete the following where a supplemental declaration is being submitted)

☐ I hereby declare that the subject matter of the

☐ attached amendment

☐ amendment filed on _____

was part of my/our invention and was invented before the filing date of the original application, above-identified, for such invention.

ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, § 1.56,

(also check the following items, if desired)

☒ and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and

☐ In compliance with this duty, there is attached an information disclosure statement, in accordance with 37 C.F.R. § 1.98.

PRIORITY CLAIM (35 U.S.C. §§ 119(a)-(d), (f) 172, and 365(a) and (b))

NOTE: 37 C.F.R. § 1.55 Claim for foreign priority.

"(a) An applicant in a nonprovisional application may claim the benefit of the filing date of one or more prior foreign applications under the conditions specified in 35 U.S.C. 119(a) through (d) and (f), 172, and 365(a) and (b).

(1)(i) In an original application filed under 35 U.S.C. 111(a), the claim for priority must be presented during the pendency of the application, and within the later of four months from the actual filing date of the application or sixteen months from the filing date of the prior foreign application This time period is not extendable. The claim must identify the foreign application for which priority is claimed, as well as any foreign application for the same subject matter and having a filing date before that of the application for which priority is claimed, by specifying the application number, country (or intellectual property authority), day, month, and year of its filing. The time period in this paragraph does not apply to an application for a design patent.

(ii) In an application that entered the national stage from an international application after compliance with 35 U.S.C. 371, the claim for priority must be made during the pendency of the application and within the time limit set forth in the PCT and the Regulations under the PCT."

(2) The claim for priority and the certified copy of the foreign application specified in 35 U.S.C. 119(b) or PCT Rule 17 must, in any event, be filed before the patent is granted. If the claim for priority or the certified copy of the foreign application is filed after the date the issue fee is paid, it must be accompanied by the processing fee set forth in § 1.17(i), but the patent will not include the priority claim unless corrected by a certificate of correction under 35 U.S.C. 255 and § 1.323

I hereby claim foreign priority benefits under Title 35, United States Code, §§ 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 322

(complete (d) or (e))

(d) ☒ no such applications have been filed.

(e) ☐ such applications have been filed as follows.

NOTE: Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119(a)-(d)

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 37 USC 119
			☐ YES NO ☐
			☐ YES NO ☐
			☐ YES NO ☐
			☐ YES NO ☐
			☐ YES NO ☐

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)
(35 U.S.C. § 119(e))

NOTE: 35 U.S.C. 119(e)(1) requires that a nonprovisional application be filed within twelve months of the filing date of the provisional application for the nonprovisional application to claim the benefit of the filing date of the provisional application. Under 35 U.S.C. 21(b) and 119(e)(3), if this twelve-month period expires on a non-business day, it is extended to expire on the next business day.

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER	FILING DATE
_____ /_____	_____
_____ /_____	_____
_____ /_____	_____

CLAIM FOR BENEFIT OF EARLIER US/PCT APPLICATION(S) UNDER 35 U.S.C. § 120

☐ The claim for the benefit of any such applications are set forth in the attached ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR CONTINUATION-IN PART (C-I-P) APPLICATION.

ALL FOREIGN APPLICATION(S), *IF ANY*, FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

_____

_____

_____

NOTE: If the application filed more than 12 months from the filing date of this application is a PCT filing forming the basis for this application entering the United States as (1) the national stage, or (2) a continuation, divisional, or continuation-in-part, then also complete ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR C-I-P APPLICATION for benefit of the prior U.S. or PCT application(s) under 35 U.S.C. § 120.

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

(list name and registration number)

Audrey A. Millemann (Reg. No. 44,942)

(check the following item, if applicable)

☐ I hereby appoint the practitioner(s) associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

☐ Attached, as part of this declaration and power of attorney, is the authorization of the above-named practitioner(s) to accept and follow instructions from my representative(s).

NOTE: "Special care should be taken in continuation or divisional applications to ensure that any change of correspondence address in a prior application is reflected in the continuation or divisional application. For example, where a copy of the oath or declaration from the prior application is submitted for a continuation or divisional application filed under 37 CFR 1.53(b) and the copy of the oath or declaration from the prior application designates an old correspondence address, the Office may not recognize, in the continuation or divisional application, the change of correspondence address made during the prosecution of the prior application. Applicant is required to identify the change of correspondence address in the continuation or divisional application to ensure that communications from the Office are mailed to the current correspondence address. 37 CFR 1.63(d)(4)." § 601.03, M.P.E.P., 7th Edition.

SEND CORRESPONDENCE TO	**DIRECT TELEPHONE CALLS TO:** *(Name and telephone number)*
☒ Address Audrey A. Millemann Weintraub Genshlea Chediak 400 Capitol Mall, 11th Floor Sacramento, CA 95814	Audrey A. Millemann (916) 558-6033
☐ Customer Number _____	

(complete the following if applicable)

Since this filing is a ☐ continuation ☐ divisional there is attached hereto a Change of Correspondence Address so that there will be no question as to where the PTO should direct all correspondence.

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 324

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

NOTE: Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other documents.

NOTE: Each inventor must be identified by full name, including the family name, and at least one given name without abbreviation together with any other given name or initial, and by his/her residence, post office address and country of citizenship. 37 CFR § 1.63(a)(3).

NOTE: Inventors may execute separate declarations/oaths provided each declaration/oath sets forth all the inventors. Section 1.63(a)(3) requires that a declaration/oath, inter alia, identify each inventor and prohibits the execution of separate declarations/oaths which each sets forth only the name of the executing inventor. 62 Fed. Reg. 53,131, 53,142, October 10, 1997.

WARNING: MPEP, § 409.03(b), 8th Edition: "Where an application is executed by one other than the inventor, the declaration required by 37 CFR 1.63 must state the full name, residence, post office address, and citizenship of the nonsigning inventor. Also, the title or position of the person signing must be stated if signing on behalf of a corporation under 37 CFR 1.47(b)."

Full name of sole or first inventor

Michael (GIVEN NAME) S. (MIDDLE INITIAL OR NAME) Harvey (FAMILY OR LAST NAME)

Inventor's signature Michael S Harvey

Date March 22 2011 **Country of Citizenship** U.S.

Residence Modesto, California

Post Office Address 712 Faust Road
Modesto, California 95358

Full name of second joint inventor, if any

Jonathan (GIVEN NAME) N. (MIDDLE INITIAL OR NAME) Howarth. (FAMILY OR LAST NAME)

Inventor's signature Jonathan N. Howarth

Date March 22 2011 **Country of Citizenship** G.B.

Residence Modesto, California

Post Office Address 1848 Scenic Drive
Modesto, California 95355

Full name of third joint inventor, if any

(GIVEN NAME) (MIDDLE INITIAL OR NAME) (FAMILY OR LAST NAME)

Inventor's signature

Date **Country of Citizenship**

Residence

Post Office Address

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 325

(check proper box(es) for any of the following added page(s) that form a part of this declaration)

☐ **Signature** for fourth and subsequent joint inventors. *Number of pages added* _____

• • •

☐ **Signature** by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor. ***Number of pages added*** _____.

• • •

☐ **Signature** for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. ***Number of pages added*** _____

• • •

☐ Added page for **signature** by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time. (37 CFR 1.47)

• • •

☐ Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (C-I-P) application.

☐ Number of pages added _____

• • •

☐ Authorization of practitioner(s) to accept and follow instructions from representative.

• • •

(if no further pages form a part of this Declaration, then end this Declaration with this page and check the following item)

☒ **This declaration ends with this page.**

Petitioner's Exhibit 1018
Clean Chemistry v. EnviroTech
IPR2025-01471 – Page 326

PATENT APPLICATION SERIAL NO._____

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

03/25/2011 MBELETE1 00000056 501176 13065553

01 FC:2011	165.00	DA
02 FC:2111	270.00	DA
03 FC:2311	110.00	DA
04 FC:2201	880.00	DA
05 FC:2202	1846.00	DA

PTO-1556
(5/87)

*U.S. Government Printing Office: 2002- 489-267/69033